Assessment Of Risk For Colorectal Cancer

ASSESSMENT OF RISK FOR COLORECTAL CANCER

FIELD OF THE INVENTION

This invention relates to prediction of the susceptibility of an individual to colorectal cancer. Basis for the prediction lies in relating an individual's genetic makeup, as through molecular analysis, to the genetic makeup of a population of individuals.

BACKGROUND

During the course of evolution, spontaneous mutations arise in the genomes of organisms. Variations in genomic DNA sequences are created continuously at a rate of about 100 new base changes per individual (Kondrashov, 1995; Crow, 1995). These germ-line changes may produce an evolutionary advantage and be retained in the population, or they may be deleterious and ultimately eliminated, hi many cases, equilibrium between multiple germline forms of a sequence is established within a population if reproductive ability of individuals containing either polymorphism is not affected. Over time, significant numbers of mutations have accumulated within the human population that may be observed to varying extents in geographically separated groups based upon the presence of common ancestors.

Colorectal cancer is the third most common cancer and the third most common cause of death from cancer for both men and women. Colorectal cancer is responsible for more deaths that are not due primarily to tobacco use than any other type of cancer and inflicts a huge financial burden. Early detection of some human tumors such as uterine cervical cancer has dramatically reduced mortality from this condition (Herzog, 2003). Early detection of colorectal cancer can reasonably be expected to prevent death from this condition by identifying patients at risk for the disease, or those with the disease in an early stage and allow life saving intervention. A validated genetic test for colorectal cancer predisposition will have clinical utility, allowing prevention of cancer mortality through targeted screening programs. There are good reasons to expect that at least some of the genetic risks of common disease is due to common variants - for example, based on evolutionary arguments, and the fact that most human genetic variation is common. Although approximately 20% of colorectal cancers have a familial component with relatives exhibiting a doubling of risk (Carstensen et al, 1996), less than 5% of colorectal cancer is explained by rare, highly penetrant genetic syndromes such as APC and HNPCC (de Leon et al, 1999). Familial colorectal cancer occurring in patterns inconsistent with classical inherited syndromes suggests that variation in genome sequence plays a major role in determining individual risk to colorectal cancer. These genetic causes appear complex due to a variety of reasons such as genetic heterogeneity, incomplete penetrance, phenocopies and variation in exposures to environmental co-factors etc. There is little insight into the genetic or environmental determinants of almost 90% of cases of human colorectal carcinoma (Lynch and de La, 2003).

Although common human genetic variation is limited compared to other species, it remains impractical to discover and test every one of the estimated 10,000,000 common genotype variants (Sachidanandam et al, 2001) as predictors of disease risk. Genotypic complexity is reduced through linkage disequilibrium that exists across long segments of the human genome with restriction in the diversity of haplotypes observed (Daly et al, 2001 ; Rioux et al , 2001 ; Liu et al, 2004). That is, single nucleotide polymorphisms found at specific locations within the human genome are inherited in conjunction with nucleotides that can be polymorphic that are physically located near by. In European genomes, allelic association between pairs of markers typically extends over 10-50k, although there is tremendous variability in the magnitude of association observed at any given distance (Clark et al, 1998; Kikuchi et al, 2003; Dunning et al, 2000; Abecasis et al, 2001). Genome-wide data (Gabriel et al, 2002; Reich et al, 2001; Dawson et al, 2002) supports the generality of this description as well as its application across populations. This confirms that measurement of single nucleotide polymorphisms at sites in tight linkage disequilibrium with adjacent genomic regions can provide information about the presence of diversity not just at sites actually measured, but also about large areas of the adjacent genome.

Numerous types of polymorphisms exist and are created when DNA sequences are either inserted or deleted from the genome. Another source of sequence variation results from the presence of repeated sequences in the genome variously termed short tandem repeats (STR), variable number of tandem repeats (VNTR), short sequence repeats (SSR) or microsatellites. These repeats commonly are comprised of 1 to 5 base pairs. Polymorphism occurs due to variation in the number of repeated sequences found at a particular locus.

The most common form of genomic variability are single nucleotide polymorphisms or SNPs. SNPs account for as much as 90% of human DNA polymorphism (Collins et al, 1998). SNPs are single base pair positions in genomic DNA at which different sequence alternatives (genotypes) exist in a population. By common definition, the least frequent allele occurs at least 1 % of the time. These nucleotide substitutions may be a transition, which is the substitution of one purine by another purine or the substitution of one pyrimidine by another, or they may be transversions in which a purine is replaced by a pyrimidine or vice versa.

Typically SNPs are observed in about 1 in 1000 base pairs (Wang et al, 1998; Taillon-Miller et al, 1999). The frequency of SNPs varies with the type and location of the change. Specifically, two-thirds of the substitutions involve the C <→ T (G <→ A) type, which may occur due to 5-methylcytosine deamination reactions that occur commonly. SNPs occur at a much higher frequency in non-coding regions than they do in coding regions.

SUMMARY OF THE INVENTION

It has been discovered that polymorphic variations in a number of loci in human genomic DNA are associated with susceptibility to colorectal cancer. This invention thus includes methods for identifying a subject at risk of colorectal and/or determining risk of colorectal cancer in a subject, which comprise detecting the presence or absence of one or more polymorphic variations associated with colorectal cancer in a nucleic acid sample from the subject. In a specific embodiment, this invention relates to identifying an individual who is at altered risk for developing colorectal cancer based on the presence of specific genotypes defined by 230 single nucleotide polymorphism (SNPs), observed alone or in combination.

Through large scale genotyping studies on 2,198 blood samples from patients with colorectal cancer and 2,124 control samples from unaffected individuals we have identified 230 polymorphic markers found in 85 genes which are found more frequently in patients with colorectal cancer than in those without this disease. These markers, or those in close linkage disequilibrium, may change the composition, function or abundance of the elements of cellular constituents resulting in a predisposition to colorectal cancer. Measuring these markers in individuals who do not ostensibly have colorectal cancer will identify those at heightened risk for the subsequent development of colorectal cancer, providing benefit for, but not limited to, individuals, insurers, care givers and employers. Genes containing colorectal cancer-associated polymorphic markers that we have identified and genes found in linkage disequilibrium with these that we have identified are valuable targets for the development of therapeutics that inhibit or augment the activity of ihe gene products uf these genes for therapeutic use in, but not restricted to, colorectal cancer. Information obtained from the detection of SNPs associated with colorectal cancer is of great value in the treatment and prevention of this condition. Accordingly, one aspect of the present invention provides a method for diagnosing a genetic predisposition to colorectal cancer in a subject, comprising obtaining a sample containing at least one polynucleotide from the subject and analyzing the polynucleotide to detect the genetic polymorphism wherein the presence or absence of the polymorphism is associated with an altered susceptibility to developing colorectal cancer. In one embodiment, one or more of the 230 polymorphisms found distributed among 85 genes that we have identified may be used.

Another aspect of the present invention provides an isolated nucleic acid sequence comprising at least 16 contiguous nucleotides or their complements found in the genomic sequences of the 85 genes adjacent to and including the 230 polymorphic sites the inventors have identified to be associated with colorectal cancer.

Yet another aspect of the invention provides a method for treating colorectal cancer comprising obtaining a sample of biological material containing at least one polynucleotide from the subject, analyzing the polynucleotides to detect the presence of at least one polymorphism associated with colorectal cancer and treating the subject in such a way as to counteract the effect of any such polymorphism detected.

Still another aspect of the invention provides a method for the prophylactic treatment of a subject identified with a genetic predisposition to colorectal cancer identified through the measurement of all or some of the 230 polymorphic SNP markers described in Tables 1 to 230.

Further scope of the applicability of the present invention will become apparent from the detailed description provided below. It should be understood however, that the following detailed description and examples, while indicating preferred embodiments of the invention, are given by way of illustration only, since various changes and modification within the spirit and scope of the invention will become apparent to those skilled in the art from the following detailed description.

Tables 1 to 230 report the result of a genotyping analysis of 4,322 samples by measuring 385,562 single nucleotide polymorphisms in peripheral blood DNA from 2,128 subjects (1,059 cases with colorectal cancer and 1,069 age matched individuals undiseased at the time of testing), and validating the identified CRC-associated alleles by using peripheral blood DNA from a second and third, different, group of 2,194 subjects (687 and 452 cases, respectively, with colorectal cancer and 688 and 367 age matched individuals undiseased, respectively, at the time of testing).

DETAILED DESCRIPTION OF THE INVENTION

It has been discovered that polymorphic variants in a number of sequences, SEQ ID NOs: 1 to 5618 are associated with an altered risk of developing colorectal cancer in subjects. The present invention thus provides SNPs associated with colorectal cancer, nucleic acid molecules containing SNPs, methods and reagents for the detection of the SNPs disclosed herein, uses of these SNPs for the development of detection reagents, and assays or kits that utilize such reagents. The colorectal cancer-associated SNPs disclosed herein are useful for diagnosing, screening for, and evaluating predisposition to colorectal cancer and related pathologies in humans. Furthermore, such SNPs and their encoded products are useful targets for the development of therapeutic agents.

A large number of colorectal cancer-associated SNPs have been identified by genotyping DNA from 4,322 individuals, 2,198 of these individuals having been previously diagnosed with colorectal cancer and 2,124 being "control" or individuals thought to be free of colorectal cancer.

The present invention thus provides individual SNPs associated with colorectal cancer, genomic sequences (SEQ ID NOs:5619 to 5703) containing SNPs, and transcript sequences amino acid sequences. The invention includes methods of detecting these polymorphisms in a test sample, methods of determining the risk of an individual of having or developing colorectal cancer, methods of screening for compounds useful for treating di&oidCiV associated with a variant gene/protein such as colorectal cancer, compounds identified by these screening methods, methods of using the disclosed SNPs to select a treatment strategy, methods of treating a disorder associated with a variant gene/protein (i.e., therapeutic methods), and methods of using the SNPs of the present invention for human identification.

When the presence in the genome of an individual of a particular base, e.g., adenine, at a particular location in the genome correlates with an increased probability of that individual contracting colorectal cancer vis-a-vis a population not having that base at that location in the genome, that individual is said to be at "increased risk" of contracting colorectal cancer, i.e., to have an increased susceptibility. In certain cases, this effect can be a "dominant" effect in which case such increased probability exists when the base is present in one or the other or both alleles of the individual. In certain cases, the effect can be said to be "recessive", in which case such increased probability exists only when the base is present in both alleles of the individual.

When the presence in the genome of an individual of a particular base, e.g., adenine, at a particular location in the genome decreases the probability of that individual contracting colorectal cancer vis-a-vis a population not having that base at that location in the genome, that individual is said to be at "decreased risk" of contracting colorectal cancer, i.e., to have a decreased susceptibility. Such an allele is sometimes referred to in the art as being "protective". As with increased risk, it is also possible for a decreased risk to be characterized as dominant or recessive.

An "altered risk" means either an increased or a decreased risk.

The genetic analysis detailed below linked colorectal cancer with SNPs in the human genome. A SNP is a particular type of polymorphic site, a polymorphic site being a region in a nucleic acid sequence at which two or more alternative nucleotides are observed in a significant number of individuals from a population. A polymorphic site may be a nucleotide sequence of two or more nucleotides, an inserted nucleotide or nucleotide sequence, a deleted nucleotide or nucleotide sequence, or a microsatellite, for example. A polymorphic site that is two or more nucleotides in length may be 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 or more, 20 or more, 30 or more, 50 or more, 75 or more, 100 or more, 500 or more, or about 1000 nucleotides in length, where all or some of the nucleotide sequences differ within the region. Each of the specific polymorphic sites found in SEQ ID NOs:5619 to 5703 is a "single nucleotide polymorphism" or a "SNP."

Where there are two, three, or four alternative nucleotide sequences at a polymorphic site, each nucleotide sequence is referred to as a "polymorphic variant" or "nucleic acid variant." Where two polymorphic variants exist, for example, the polymorphic variant represented in a majority of samples from a population is sometimes referred to as a "prevalent allele" and the polymorphic variant that is less prevalently represented is sometimes referred to as an "uncommon allele." AP individual who possesses two prevalent alleles or two uncommon alleles is "homozygous" with respect to the polymorphism, and an individual who possesses one prevalent allele and one uncommon allele is "heterozygous" with respect to the polymorphism. Individuals who are homozygous with respect to one allele are sometimes predisposed to a different phenotype as compared to individuals who are heterozygous or homozygous with respect to another allele.

A genotype or polymorphic variant may also be expressed in terms of a "haplotype," which refers to the identity of two or more polymorphic variants occurring within genomic DNA on the same strand of DNA. For example, two SNPs may exist within a gene where each SNP position may include a cytosine variation or an adenine variation. Certain individuals in a population may carry an allele (heterozygous) or two alleles (homozygous) having the gene with a cytosine at each SNP position. As the two cytosines corresponding to each SNP in the gene travel together on one or both alleles in these individuals, the individuals can be characterized as having a cytosine/cytosine haplotype with respect to the two SNPs in the gene.

A "phenotype" is a trait which can be compared between individuals, such as presence or absence of a condition, for example, occurrence of colorectal cancer.

Polymorphic variants are often reported without any determination of whether the variant is represented in a significant fraction of a population. Some reported variants are sequencing errors and/or not biologically relevant. Thus, it is often not known whether a reported polymorphic variant is statistically significant or biologically relevant until the presence of the variant is detected in a population of individuals and the frequency of the variant is determined.

A polymorphic variant may be detected on either or both strands of a double-stranded nucleic acid. Also, a polymorphic variant may be located within an inϋon or exon of a gene or within a portion of a regulatory region such as a promoter, a 5' untranslated region (UTR), a 3' UTR, and in DNA (e.g., genomic DNA (gDNA) and complementary DNA (cDNA)), RNA (e.g., mRNA, tRNA, and rRNA), or a polypeptide. Polymorphic variations may or may not result in detectable differences in gene expression, polypeptide structure, or polypeptide function.

In our genetic analysis associating colorectal cancer with the polymorphic variants set forth in the tables, samples from individuals having been diagnosed with colorectal cancer and individuals not having cancer were allelotyped and genotyped. The allele frequency for each polymorphic variant among cases and controls was determined. These allele frequencies were compared in cases and controls, or combinations. Particular SNPs were thus found to be associated with colorectal cancer when genotype and haplotype frequency differences calculated between case and control pools were established to be statistically significant.

As mentioned above, polymorphic variants can travel together. Such variants are said to be in "linkage disequilibrium" so that heritable elements e.g., alleles that have a tendency to be inherited together instead of being inherited independently by random assortment are in linkage disequilibrium. Alleles are randomly assorted or inherited independently of each other if the frequency of the two alleles together is the product of the frequencies of the two alleles individually. For example, if two alleles at different polymorphic sites are present in 50% of the chromosomes in a population, then they would be said to assort randomly if the two alleles are present together on 25% of the chromosomes in the population. A higher percentage would mean that the two alleles are linked. For example, a first polymorphic site Pl having two alleles, e.g. A and C~each appearing in 50% of the individuals in a given population, is said to be in linkage disequilibrium with a second polymorphic site P2 having two alleles e.g. G and T~each appearing in 50% of the individuals in a given population, if particular combinations of alleles are observed in individuals at a frequency greater than 25% (if the polymorphic sites are not linked, then one would expect a 50% chance of an individual having A at Pl and a 50% chance of having G at P2 thus leading to a 25% chance of having the combination of A at Pl and G at P2 together). Heritable elements that are in linkage disequilibrium are said to be "linked" or "genetically linked" to each other.

One can see that in the case of a group of SNPs that are in linkage disequilibrium with each other, knowledge of the existence of all such SNPs in a particular individual generally provides redundant information. Thus, when identifying an individual who has an altered risk for developing colorectal cancer according to this invention, it is necessary to detect only one SNP of such a group of SNPs associated with an altered risk of developing colorectal cancer.

It has been shown that each SNP in the genomic sequences identified as SEQ ID NOs:5619 to 5703 is associated with the occurrence of colorectal cancer. Thus, featured herein are methods for identifying a risk of colorectal cancer in a subject, which includes detecting the presence or absence of one or more of the SNPs described herein in a human nucleic acid sample.

Three different analyses were performed for each marker: (a) a test of trend across the 3 genotypes (Sasieni et al. 1997); (b) a dominant model where the homozygous genotype for allele "B" is combined with the prevalent heterozygote genotype; and (c) a recessive model where the homozygous genotype for allele "A" is combined with the heterozygous genotype. Using permutation analysis, the empirical p-value for the maximum of these three test statistics was calculated. Odds ratios measuring the strength of the association are also reported for the model corresponding to the largest of the three test statistics.

Pertinent results for each SNP are summarized in the tables: Chromosomal number and position- using the International Human Genome Sequencing Consortium build 35 (http://www.ncbi.nlm.nih.gov/genome/seq/) as made available by the National Center for Biotechnology Information (NCBI), National Library of Medicine, Building 38A, Bethesda, Maryland 20894 U.S.A., gene marker name-using the nomenclature of the NCBI dbSNP (http://www.ncbi.nlm.nih.gov/SNP/) and gene name-using the unigene naming convention. Under the "Case Flag" the number 1 designates Cases and the number 0 designates Controls. The identity of the base designated "A" in the analysis is indicated where I = A (adenine), 2 = C (cytosine), 3 = G (guanine) and 4 = T (thymidine). "B" indicates the polymorphic allele. AA, AB, BB are the counts of the number of individuals with the given genotype, by cases/controls. For dominant models, an odds ratio measuring the increase in risk associated with one or two copies of allele B is calculated. For recessive models, an odds ratio associated with exactly two copies of allele B is calculated. For the trend models, the Mantel-Haenszel odds ratio showing the increase in risk with each additional copy of allele B is calculated.

It has been discovered that each polymorphic variation in the genomic sequences identified as SEQ ID NOs:5619 to 5703 is associated with the occurrence of colorectal cancer. Thus, featured herein are methods for identifying a risk of colorectal cancer in a subject, which comprises detecting the presence or absence of one or more of the polymorphic variations described herein in a human nucleic acid sample. The polymorphic variation, SNP, are detailed in the tables.

Methods for determining whether a subject is susceptible to, i.e., at risk of colorectal cancer are provided herein. These methods include detecting the presence or absence of one or more polymorphic variations, i.e., SNPs, associated with colorectal cancer in a sample from a subject.

SNPs can be associated with a disease state in humans or in animals. The association can be direct, as in conditions where the substitution of a base results in alteration of the protein coding sequence of a gene which contributes directly to the pathophysiology of the condition. Common examples of this include diseases such °s sickle cell anemia and cystic fibrosis. The association can be indirect when the SNP plays no role in the disease, but is located close to the defective gene such that there is a strong association between the presence of the SNP and the disease state. Because of the high frequency of SNPs within the genome, there is a greater probability that a SNP will be linked to a genetic locus of interest than other types of genetic markers.

Disease-associated SNPs can occur in coding and non-coding regions of the genome. When located in the coding region altered function of the ensuing protein sequence may occur. If it occurs in the regulatory region of a gene it may affect expression of the protein. If the protein is involved in protecting the body against pathological conditions this can result in disease susceptibility.

Numerous methods exist for the measurement of specific SNP genotypes. Individuals carrying mutations in one or more SNPs of the present invention may be detected at the DNA level by a variety of techniques. Nucleic acids for diagnosis may be obtained from a patient's cells, such as from blood, urine, saliva, tissue biopsy and autopsy material.

The genomic DNA may be used directly for detection or may be amplified enzymatically by using PCR prior to analysis (Saiki et al, 1986). RNA or cDNA may also be used in the same ways. As an example, PCR primers complementary to the nucleic acid of one or more SNPs of the present invention can be used to identify and analyze the presence or absence of the SNP. For example, deletions and insertions can be detected by a change in size of the amplified product in comparison to the normal genotype. Point mutations can be identified by hybridizing amplified DNA to radiolabeled SNP RNA of the present invention or alternatively, radiolabeled SNP antisense DNA sequences of the present invention. Perfectly matched sequences can be distinguished from mismatched duplexes by RNase A digestion or by differences in melting temperatures.

Sequence differences between a reference gene and genes having mutations also may be revealed by direct DNA sequencing. In addition, cloned DNA segments may be employed as probes to detect specific DNA segments. The sensitivity of such methods can be greatly enhanced by appropriate use of PCR or another amplification method. For example, a sequencing primer is used with double-stranded PCR product or a single-stranded template molecule generated by a modified PCR. The sequence determination is performed by conventional procedures with radiolabeled nucleotide or by automatic sequencing procedures with fluorescent-tags.

Genetic testing based on DNA sequence differences may be achieved by detection of alteration in electrophoretic mobility of DNA fragments in gels, with or without denaturing agents. Small sequence deletions and insertions can be visualized by high resolution gel electrophoresis. DNA fragments of different sequences may be distinguished on denaturing formamide gradient gels in which the mobilities of different DNA fragments are retarded in the gel at different positions according to their specific melting or partial melting temperatures (Myers et al, 1985).

Sequence changes at specific locations also may be revealed by nuclease protection assays, such as RNase and Sl protection or the chemical cleavage method (Cotton et al, 1988).

Thus, *he detection ofa-speeifk DNA sequence may be achieved by methods which include, but are not limited to, hybridization, RNase protection, chemical cleavage, direct DNA sequencing or the use of restriction enzymes, (e.g., restriction fragment length polymorphisms ("RFLP") and Southern blotting of genomic DNA).

In addition to more conventional gel-electrophoresis and DNA sequencing, mutations also can be detected by in situ analysis.

Genetic mutations can be identified by hybridizing a sample and control nucleic acids, e.g., DNA or RNA, to high density arrays containing hundreds or thousands of oligonucleotide probes (Cronin et al, 1996; Kozal et al, 1996). For example, genetic mutations can be identified in two-dimensional arrays containing light-generated DNA probes as described in Cronin et al., supra. Briefly, a first hybridization array of probes can be used to scan through long stretches of DNA in a sample and control to identify base changes between the sequences by making linear arrays of sequential overlapping probes. This step allows the identification of point mutations. This step is followed by a second hybridization array that allows the characterization of specific mutations by using smaller, specialized probe arrays complementary to all variants or mutations detected. Each mutation array is composed of parallel probe sets, one complementary to the wild-type gene and the other complementary to the mutant gene. Specific mutations can also be determined through direct sequencing of one or both strands of DNA using dideoxy nucleotide chain termination chemistry, electrophoresis through a semi-solid matrix and fluorescent or radioactive chain length detection techniques. Further mutation detection techniques may involve differential susceptibility of the polymorphic double strand to restriction endonuclease digestion, or altered electrophoretic gel mobility of single or double stranded gene fragments containing one polymorphic form. Other techniques to detect specific DNA polymorphisms or mutation may involve evaluation of the structural characteristics at the site of polymorphism using nuclear magnetic resonance or x- ray diffraction techniques.

These genetic tests are useful for prognosing and/or diagnosing colorectal cancer and often are useful for determining whether an individual is at an increased or decreased risk of developing or having colorectal cancer.

Thus, the invention includes a method for identifying a subject at risk of colorectal cancer, which includes detecting in a nucleic acid sample from the subject the presence or absence of a SNP associated with colorectal cancer at a polymorphic site in a nucleotide sequence identified as SEQ ID NOs: 1 to 5703 .

Results from prognostic tests may be combined with other test results to diagnose colorectal cancer. For example, prognostic results may be gathered, a patient sample may be ordered based on a determined predisposition to colorectal cancer, the patient sample analyzed, and the results of the analysis may be utilized to diagnose colorectal cancer. Also colorectal cancer diagnostic methods can be developed from studies used to generate prognostic/diagnostic methods in which populations are stratified into subpopulations having different progressions of colorectal cancer. In another embodiment, prognostic results may be gathered; a patient's risk factors for developing colorectal cancer analyzed (e.g., age, family history); and a patient sample may be ordered based on a determined predisposition to colorectal cancer. In an alternative embodiment, the results from predisposition analyses may be combined with other test results indicative of colorectal cancer, which were previously, concurrently, or subsequently gathered with respect to the predisposition testing. In these embodiments, the combination of the prognostic test results with other test results can be probative of colorectal cancer, and the combination can be utilized as a colorectal cancer diagnostic.

Risk of colorectal cancer sometimes is expressed as a probability, such as an odds ratio, percentage, or risk factor. The risk is based upon the presence or absence of one or more of the SNP variants described herein, and also may be based in part upon phenotypic traits of the individual being tested. Methods for calculating risk based upon patient data are well known (Agresti, 2001). Allelotyping and genotyping analyses may be carried out in populations other than those exemplified herein to enhance the predictive power of the prognostic method. These further analyses are executed in view of the exemplified procedures described herein, and may be based upon the same polymorphic variations or additional polymorphic variations. Risk determinations for colorectal cancer are useful in a variety of applications. In one embodiment, colorectal cancer risk determinations are used by clinicians to direct appropriate detection, preventative and treatment procedures to subjects who most require these. In another embodiment, colorectal cancer risk determinations are used by health insurers for preparing actuarial tables and for calculating insurance premiums.

The nucleic acid sample typically is isolated from a biological sample obtained from a subject. For example, nucleic acid can be isolated from blood, saliva, sputum, urine, cell scrapings, and biopsy tissue.JThe nucleic acid sample can be isolated from a biological sample using standard techniques. The nucleic acid sample may be isolated from the subject and then directly utilized in a method for determining the presence of a polymorphic variant, or alternatively, the sample may be isolated and then stored (e.g., frozen) for a period of time before being subjected to analysis.

The presence or absence of a polymorphic variant is determined using one or both chromosomal complements represented in the nucleic acid sample. Determining the presence or absence of a polymorphic variant in both chromosomal complements represented in a nucleic acid sample is useful for determining the zygosity of an individual for the polymorphic variant (i.e.. whether the individual is homozygous or heterozygous for the polymorphic variant). Any oligonucleotide-based diagnostic may be utilized to determine whether a sample includes the presence or absence of a polymorphic variant in a sample. For example, primer extension methods, ligase sequence determination methods (e.g., U.S. Pat. Nos. 5,679,524 and 5,952,174, and WO 01/27326), mismatch sequence determination methods (e.g., U.S. Pat. Nos. 5,851,770; 5,958,692; 6,110,684; and 6,183,958), microarray sequence determination methods, restriction fragment length polymorphism (RFLP), single strand conformation polymorphism detection (SSCP) (e.g., U.S. Pat, Nos. 5,89] ,6^5 and 6,013,499), PCR-based assays (e.g., TAQMAN™ PCR System (Applied Biosystems)), and nucleotide sequencing methods may be used. Oligonucleotide extension methods typically involve providing a pair of oligonucleotide primers in a polymerase chain reaction (PCR) or in other nucleic acid amplification methods for the purpose of amplifying a region from the nucleic acid sample that comprises the polymorphic variation. One oligonucleotide primer is complementary to a region 3' of the polymorphism and the other is complementary to a region 5' of the polymorphism. A PCR primer pair may be used in methods disclosed in U.S. Pat. Nos. 4,683,195; 4,683,202, 4,965,188; 5,656,493; 5,998,143; 6,140,054; WO 01/27327; and WO 01/27329 for example. PCR primer pairs may also be used in any commercially available machines that perform PCR, such as any of the GENEAMP™, systems available from Applied Biosystems. Also, those of ordinary skill in the art will be able to design oligonucleotide primers based upon the nucleotide sequences set forth in SEQ ID NOs: 1 to 5703.

Also provided is an extension oligonucleotide that hybridizes to the amplified fragment adjacent to the polymorphic variation. An adjacent fragment refers to the 3' end of the extension oligonucleotide being often 1 nucleotide from the 5' end of the polymorphic site, and sometimes 2, 3, 4, 5, 6, 7, 8, 9, or 10 nucleotides from the 5' end of the polymorphic site, in the nucleic acid when the extension oligonucleotide is hybridized to the nucleic acid. The extension oligonucleotide then is extended by one or more nucleotides, and the number and/or type of nucleotides that are added to the extension oligonucleotide determine whether the polymorphic variant is present. Oligonucleotide extension methods are disclosed, for example, in U.S. Pat. Nos. 4,656,127; 4,851,331; 5,679,524; 5,834,189; 5,876,934; 5,908,755; 5,912,118; 5,976,802; 5,981,186; 6,004,744; 6,013,431; 6,017,702; 6,046,005; 6,087,095; 6,210,891; and WO 01/20039. Oligonucleotide extension methods using mass spectrometry are described, for example, in U.S. Pat. Nos. 5,547,835; 5,605,798; 5,691,141; 5,849,542; 5,869,242; 5,928,906; 6,043,031; and 6,194,144. Multiple extension oligonucleotides may be utilized in one reaction, which is referred to as multiplexing.

A microarray can be utilized for determining whether a SNP is present or absent in a nucleic acid sample. A microarray may include any oligonucleotides described herein, and methods for making and using oligonucleotide microarrays suitable for diagnostic use are disclosed in U.S. Pat. Nos. 5,492,806; 5,525,464; 5,589,330: 5.695.940; 5,849,483; 6,018,041; 6,045,996; 6,136,541; 6,142,681; 6,156,501; 6,197,506; 6,223,127; 6,225,625; 6,229,911; 6,239,273; WO 00/52625; WO 01/25485; and WO 01/29259. The microarray typically comprises a solid support and the oligonucleotides may be linked to this solid support by covalent bonds or by non-covalent interactions. The oligonucleotides may also be linked to the solid support directly or by a spacer molecule. A microar^ay may comprise one or more oligonucleotides complementary to a SNP set forth in the tables.

A kit also may be utilized for determining whether a polymorphic variant is present or absent in a nucleic acid sample. A kit can include one or more pairs of oligonucleotide primers useful for amplifying a fragment of a nucleotide sequence of interest, where the fragment includes a polymorphic site. The kit sometimes comprises a polymerizing agent, for example, a thermostable nucleic acid polymerase such as one disclosed in U.S. Pat. Nos. 4,889,818 or 6,077,664. Also, the kit often comprises an elongation oligonucleotide that hybridizes to the nucleotide sequence in a nucleic acid sample adjacent to the polymorphic site. Where the kit includes an elongation oligonucleotide, it can also include chain elongating nucleotides, such as dATP, dTTP, dGTP, dCTP, and dITP, including analogs of dATP, dTTP, dGTP, dCTP and dlTP, provided that such analogs are substrates for a thermo-stable nucleic acid polymerase -and can be incorporated into a nucleic acid chain elongated from the extension oligonucleotide. Along with chain elongating nucleotides would be one or more chain terminating nucleotides such as ddATP, ddTTP, ddGTP, ddCTP. The kit can include one or more oligonucleotide primer pairs, a polymerizing agent, chain elongating nucleotides, at least one elongation oligonucleotide, and one or more chain terminating nucleotides. Kits optionally include buffers, vials, microtiter plates, and instructions for use.

An individual identified as being susceptible to colorectal cancer may be heterozygous or homozygous with respect to the allele associated with an increased risk of colorectal cancer, as indicated in the tables. A subject homozygous for an allele associated with an increased risk of colorectal cancer is at a comparatively high risk of colorectal cpnrer as far as that SNP is concerned whether or not the allelic effect has been determined to be dominant or recessive. A subject who is heterozygous for an allele associated with an increased risk of colorectal cancer, in which the allelic effect is recessive would likely be at a comparatively reduced risk of colorectal cancer predicted by that SNP.

Individuals carrying mutations in one or more SNP of the present invention may be detected at the protein level by a variety of techniques. Cells suitable for diagnosis may be obtained from a patient's blood, urine, saliva, tissue biopsy and autopsy material.

Also featured are methods for determining risk of colorectal cancer and/or identifying a subject at risk of colorectal cancer by contacting a polypeptide or protein encoded by a nucleotide sequence from a subject with an antibody that specifically binds to an epitope associated with an altered, usually increased risk of colorectal cancer in the polypeptide.

Isolated Nucleic Acids

Oligonucleotides can be linked to a second moiety, which can be another nucleic acid molecule to provide, for example, a tail sequence (e.g., a polyadenosine tail), an adapter sequence (e.g., phage M13 universal tail sequence), etc. Alternatively, the moiety might be one that facilitates linkage to a solid support or a detectable label, e.g., a radioactive label, a fluorescent label, a chemiluminescent label, a paramagnetic label, etc.

Nucleic acid sequences shown in the tables can be used for diagnostic purposes for detection and control of polypeptide expression. Also, oligonucleotide sequences such as antisense

RNA, small-interfering RNA (siRNA) and DNA molecules and ribozymes that function to — inhibit translation of ^ polypeptide are part of this invention.

Antisense RNA and DNA molecules, siRNA and^ ribozymes can be prepared by known methods. These include techniques for chemically synthesizing oligodeoxyribonucleotides such as solid phase phosphoramidite chemical synthesis. Alternatively, RNA molecules may be generated by in vitro and in vivo transcription of DNA sequences encoding the antisense RNA molecule. Such DNA sequences can be incorporated into vectors which incorporate suitable RNA polymerase promoters such as the T7 or SP6 polymerase promoters, or antisense cDNA constructs that synthesize antisense RNA constitutively or inducibly, depending on the promoter used, can be introduced stably into cell lines.

DNA encoding a polypeptide can also be used in the diagnosis of colorectal cancer, resulting from aberrant expression of a target gene. For example, the nucleic acid sequence can be used in hybridization assays of biopsies or autopsies to diagnose abnormalities of expression or function (e.g., Southern or Northern blot analysis, in situ hybridization assays).

Expression of a polypeptide during embryonic development can also be determined using nucleic acid encoding the polypeptide, particularly production of a functionally impaired polypeptide mat is the cause of colorectal cancer. In situ hybridizations using a polypeptide as a probe can be employed to predict problems related to colorectal cancer. Administration of human active polypeptide, recombinantly produced can be used to treat disease states related to functionally impaired polypeptide. Alternatively, gene therapy approaches may be employed to remedy deficiencies of functional polypeptide or to replace or compete with a dysfunctional polypeptide.

Included as part of this invention are nucleic acid vectors, often expression vectors, which contain a nucleotide sequence set forth in the tables. A vector is a nucleic acid molecule capable of transporting another nucleic acid to which it has been linked and can include a plasmid, cosmid, or viral vector. The vector can be capable of autonomous replication or it can integrate into a host DNA. Viral vectors may include replication defective retroviruses, adenoviruses and adeno-associated viruses for example.

A vector can include a nucleotide sequence from the tables in a form suitable for expression of an encoded protein or nucleic acid in a host cell. The recombinant expression vector generally includes one or more regulatory sequences operatively linked to the nucleic acid sequence to be expressed. A regulatory sequence includes promoters, enhancers and other expression control elements (e.g., polyadenylation signals). Regulatory sequences include those that direct constitutive expression of a nucleotide sequence, as well as tissue-specific regulatory and/or inducible sequences. The design of the expression vector can depend on such factors as the choice of the host cell to be transformed, the level of expression of polypeptide desired, etc. Expression vectors can be introduced into host cells to produce the desired polypeptides, including fusion polypeptides.

Recombinant expression vectors can be designed for expression of polypeptides in prokaryotic or eukaryotic cells. For example, the polypeptides can be expressed in E. coli, insect cells (e.g., using baculovirus expression vectors), yeast cells, or mammalian cells. Suitable host cells are discussed further by Goeddel (Goeddel, 1990). A recombinant expression vector can also be transcribed and translated in vitro, for example using T7 promoter regulatory sequences and T7 polymerase.

Expression of polypeptides in prokaryotes can be carried out in E. coli with vectors containing constitutive or inducible promoters directing the expression of either fusion or non-fusion polypeptides. Fusion vectors add a number of amino acids to a polypeptide. Such fusion vectors typically serve to increase expression of recombinant polypeptide, to increase the solubility of the recombinant polypeptide and/or to aid in the purification of the recombinant polypeptide by acting as a ligand during purification. Often, a proteolytic cleavage site is introduced at the junction of the fusion moiety and the recombinant polypeptide to enable separation of the recombinant polypeptide from the fusion moiety after purification of the fusion polypeptide. Such enzymes, and their cognate recognition sequences, include Factor Xa, thrombin and enterokinase. Typical fusion expression vectors include pGEX (Pharmacia Biotech Inc; (Smith & Johnson, 1988)), pMAL (New England Biolabs, Beverly, Mass.) and pRIT5 (Pharmacia, Piscataway, NJ.) which fuse glutathione S-transferase (GST), maltose E binding polypeptide, or polypeptide A, respectively, to the target recombinant polypeptide.

Purified fusion polypeptides can be used in screening assays and to generate antibodies specific for polypeptides. In a therapeutic embodiment, fusion polypeptide expressed in a retroviral expression vector can be used to infect bone marrow cells that are subsequently transplanted into irradiated recipients. The pathology of the subject recipient is then examined after sufficient time has passed.

Expressing a polypeptide in host bacteria with an impaired capacity to proteolytically cleave the recombinant polypeptide can be used to maximize recombinant polypeptide expression (Gottesman, 1990). The nucleotide sequence of the nucleic acid to be inserted into an expression vector can be changed so that the individual codons for each amino acid are those preferentially utilized in E. coli (Wada et ah, 1992).

When used in mammalian cells, the expression vector's control functions are often provided by viral regulatory elements. For example, commonly used promoters are derived from polyoma, Adenovirus 2, cytomegalovirus and Simian Virus 40. Recombinant mammalian expression vectors can be capable of directing expression of the nucleic acid in a particular cell type (e.g., tissue-specific regulatory elements are used to express the nucleic acid). Examples of suitable tissue-specific promoters include an albumin promoter (Pinkert et ah, 1987), lymphoid-specific promoters (Calame and Eaton, 1988) , promoters of immunoglobulins (Banerji et ah, 1983; Queen and Baltimore, 1983), neuron-specific promoters (Byrne and Ruddle, 1989), pancreas-specific promoters (Edlund et ah, 1985), and mammary gland-specific promoters (e.g., milk whey promoter; U.S. Pat. No. 4,873,316 and European Application Publication No. 264,166). Developmentally-regulated promoters are sometimes utilized, for example, the murine hox promoters (Kessel and Grass, 1990) and the .alpha.-fetopolypeptide promoter (Camper and Tilghman, 1989).

A nucleic acid from one of the tables might be cloned into an expression vector in an antisense orientation. Regulatory sequences (e.g., viral promoters and/or enhancers) operatively linked to a nucleic acid cloned in the antisence orientation can be chosen for directing constitutive, tissue specific or cell type specific expression of antisense RNA in a variety of cell types. Antisense expression vectors can be in the form of a recombinant plasmid, phagemid or attenuated virus.

The invention includes host cells having a nucleotide sequence from the tables within a recombinant expression vector or a fragment of such a sequence, which facilitate homologous recombination into a specific site of the host cell genome. Terms such as host cell and recombinant host cell refer not only to the particular subject cell but also to the progeny of a cell. Because certain modifications may occur in succeeding generations due to either mutation or environmental influences, such progeny may not, in fact, be identical to the parent cell. A host cell can be any prokaryotic or eukaryotic cell. For example, a polypeptide can be expressed in bacterial cells such as E. coli, insect cells, yeast or mammalian cells (such as Chinese hamster ovary cells (CHO) or COS cells).

Vectors can be introduced into host cells via conventional transformation or transfection techniques. The terms transformation and transfection refer to a variety of techniques known for introducing foreign nucleic acid (e.g., DNA) into a host cell, including calcium phosphate or calcium chloride co-precipitation, transduction/infection, DΕAΕ-dextran-mediated transfection, lipofection, or electroporation.

A host cell can be used to produce a polypeptide. Accordingly, methods for producing a polypeptide using the host cells are included as part of this invention. Such a method can include culturing host cells into which a recombinant expression vector encoding a polypeptide has been introduced in a suitable medium such that the polypeptide is produced. The method can further include isolating the polypeptide from the medium or the host cell.

The invention also includes cells or purified preparations of cells which include a transgene from the tables, or which otherwise mis-express a polypeptide. Cell preparations can consist of human or non-human cells, e.g., rodent cells, e.g., mouse or rat cells, rabbit cells, or pig ceils. The transgene can be mis-expressed, e.g., over-expressed or under-expressed. In other embodiments, the cell or cells include a gene which misexpresses an endogenous polypeptide (e.g., expression of a gene is disrupted, also known as a knockout). Such cells can serve as a model for studying disorders which are related to mutated or mis-expressed alleles or for use in drug screening. Also provided are human cells (e.g., hematopoietic stem cells) transformed with a nucleic acid from the tables.

The invention includes cells or a purified preparation thereof (e.g., human cells) in which an endogenous nucleic acid from the tables is under the control of a regulatory sequence that does not normally control the expression of the endogenous gene corresponding to the sequence. The expression characteristics of an endogenous gene within a cell (e.g., a cell line or microorganism) can be modified by inserting a heterologous DNA regulatory element into the genome of the cell such that the inserted regulatory element is operably linked to the corresponding endogenous gene. For example, an endogenous corresponding gene (e.g., a gene which is transcriptionally silent, not normally expressed, or expressed only at very low levels) may be activated by inserting a regulatory element which is capable of promoting the expression of a normally expressed gene product in that cell. Techniques such as targeted homologous recombinations, can be used to insert the heterologous DNA as described in, e.g., Chappel, U.S. Pat. No. 5,272,071; WO 91/06667, published on May 16, 1991.

Non-human transgenic animals that express a heterologous polypeptide (e.g., expressed from a nucleic acid from the tables) can be generated. Such animals are useful for studying the function and/or activity of a polypeptide and for identifying and/or evaluating modulators of the activity of the nucleic acids and encoded polypeptides. A transgenic animal is a non- human animal such as a mammal (e.g., a non-human primate such as chimpanzee, baboon, or macaque; an ungulate such as an equine, bovine, or caprine; or a rodent such as a rat, a mouse, or an Israeli sand rat), a bird (e.g., a chicken or a turkey), an amphibian (e.g., a frog, salamander, or newt), or an insect (e.g., Drosophila in which one or more of the cells of the animal includes a transgene. A transgene is exogenous DNA or a rearrangement (e.g., a deletion of endogenous chromosomal DNA) that is often integrated into or occurs in the genome of cells in a transgenic animal. A transgene can direct expression of an encoded gene product in one or more cell types or tissues of the transgenic animal. Thus, a transgenic animal can be one in which an endogenous nucleic acid homologous to a nucleic acid from the tables has been altered by homologous recombination between the endogenous gene and an exogenous DNA molecule introduced into a cell of the animal (e.g., an , embryonic cell of the animal) prior to development of the animal.

Intronic sequences and polyadenylation signals can also be included in the transgene to increase expression efficiency of the transgene. One or more tissue-specific regulatory sequences can be operably linked to a nucleotide sequence from the tables to direct expression of an encoded polypeptide to particular cells. A transgenic founder animal can be identified based upon the presence of the nucleotide sequence in its genome and/or expression of encoded mRNA in tissues or cells of the animals. A transgenic founder animal can then be used to breed additional animals carrying the transgene. Moreover, transgenic animals carrying a nucleotide sequence can further be bred to other transgenic animals carrying other transgenes.

Polypeptides can be expressed in transgenic animals or plants by introducing a nucleic acid encoding the polypeptide into the genome of an animal. In certain embodiments the nucleic acid is placed under the control of a tissue specific promoter, e.g., a milk or egg specific promoter, and recovered from the milk or eggs produced by the animal. Also included is a population of cells from a transgenic animal.

Isolated polypeptides encoded by a nucleotide sequence from the tables can be synthesized. Isolated polypeptides include both the full-length polypeptide and the mature polypeptide (i.e., the polypeptide minus the signal sequence or propeptide domain). An isolated, or purified, polypeptide or protein is substantially free of cellular material or other contaminating proteins from the cell or tissue source from which the protein is derived, or is substantially free from chemical precursors or other chemicals when chemically synthesized. Substantially free means a preparation of a polypeptide having less than about 5% (by dry weight) of contaminating protein, or of chemical precursors or non-target chemicals. When the desired polypeptide is recombinantly produced, it is typically substantially free of culture medium, specifically, where culture medium represents less than about 10% of the polypeptide preparation.

Also, polypeptides may exist as chimeric or fusion polypeptides. As used herein, a "target chimeric polypeptide" or "target fusion polypeptide" includes a target polypeptide linked to a different polypeptide. The target polypeptide in the fusion polypeptide can correspond to an entire or nearly entire polypeptide as it exists in nature or a fragment thereof. The other polypeptide can be fused to the N-terminus or C-terminus of the target polypeptide.

Fusion polypeptides can include a moiety having high affinity for a ligand. For example, the fusion polypeptide can be a GST-target fusion polypeptide in which the target sequences are fused to the C-terminus of the GST sequences, or a polyhistidine-target fusion polypeptide in which the target polypeptide is fused at the N- or C-terminus to a string of histidine residues. Such fusion polypeptides can facilitate purification of recombinant target polypeptide. Expression vectors are commercially available that already encode a fusion moiety (e.g., a GST polypeptide), and a nucleotide sequence from the tables, or a substantially identical nucleotide sequence thereof, can be cloned into an expression vector such that the fusion moiety is linked in-frame to the target polypeptide. Further, the fusion polypeptide can be a target polypeptide containing a heterologous signal sequence at its N-terminus. In certain host cells (e.g., mammalian host cells), expression, secretion, cellular internalization, and cellular localization of a target polypeptide can be increased through use of a heterologous signal sequence. Fusion polypeptides can also include all or a part of a serum polypeptide (e.g., an IgG constant region or human serum albumin).

Target polypeptides can be incorporated into pharmaceutical compositions and administered _ _ to a subject these polypeptides can be used to affect the bioavailability of a substrate of the polypeptide and may effectively increase polypeptide biological activity in a cell. Target fusion polypeptides may be useful therapeutically for the treatment of disorders caused by, for example, (i) aberrant modification or mutation of a gene encoding a polypeptide; (ii) mis-regulation of the gene encoding the polypeptide; and (iii) aberrant post-translational modification of a polypeptide. Also, target polypeptides can be used as immunogens to produce anti-target antibodies in a subject, to purify the polypeptide ligands or binding partners, and in screening assays to identify molecules which inhibit or enhance the interaction of a polypeptide with a substrate.

Polypeptides can be differentially modified during or after translation, e.g., by glycosylation, acetylation, phosphorylation, amidation, derivatization by known protecting/blocking groups, proteolytic cleavage, linkage to an antibody molecule or other cellular ligand, etc. Any known modification including specific chemical cleavage by cyanogen bromide, trypsin, chymotrypsin, papain, V8 protease, NaBH4; acetylation, formylation, oxidation, reduction; metabolic synthesis in the presence of tunicamycin; etc. may be used. Additional post- translational modifications include, for example, N-linked or O-linked carbohydrate chains, processing of N-terminal or C-terminal ends), attachment of chemical moieties to the amino acid backbone, chemical modifications of N-Iinked or O-linked carbohydrate chains, and addition or deletion of an N-terminal methionine residue as a result of prokaryotic host cell expression. The polypeptide fragments may also be modified with a detectable label, such as an enzymatic, fluorescent, isotopic or affinity label to allow for detection and isolation of the polypeptide.

Chemically modified derivatives of polypeptides that can provide additional advantages such as increased solubility, stability and circulating time of the polypeptide, or decreased immunogenicity (see e.g., U.S. Pat. No. 4,179,337) are also part of this invention. The chemical moieties for derivitization may be selected from water soluble polymers such as polyethylene glycol, ethylene glycol/propylene glycol copolymers, carboxymethylcellulose, dextran, polyvinyl alcohol and the like. The polypeptides may be modified at random positions within the molecule, or at predetermined positions within the molecule and may include one, two, three or more attached chemical moieties.

The polymer may be of any molecular weight, and may be branched or unbranched. For polyethylene glycol, the molecular weight often is between about 1 kDa and about 100 kDa for ease in handling and manufacturing. Other sizes may be used, depending on the desired therapeutic profile (e.g., the duration of sustained release desired, the effects, if any on biological activity, the ease in handling, the degree or lack of antigenicity and other known effects of the polyethylene glycol to a therapeutic protein or analog).

The polymers can be attached to the polypeptide with consideration of effects on functional or antigenic domains of the polypeptide. There are a number of attachment methods available to those skilled in the art (e.g., EP 0401 384 (coupling PEG to G-CSF) and Malik et al. (Malik et al, 1992) For example, polyethylene glycol may be covalently bound through amino acid residues via a reactive group, such as a free amino or carboxyl group. Reactive groups are those to which an activated polyethylene glycol molecule may be bound. The amino acid residues having a free amino group may include lysine residues and the N-terminal amino acid residues; those having a free carboxyl group may include aspartic acid residues, glutamic acid residues and the C-terminal amino acid residue. Sulfhydryl groups may also be used as a reactive group for attaching the polyethylene glycol molecules. For therapeutic purposes, the attachment sometimes is at an amino group, such as attachment at the N-terminus or lysine group.

Proteins can be chemically modified at the N-terminus. Using polyethylene glycol, for example, one may select from a variety of polyethylene glycol molecules (by molecular weight, branching, and the like), the proportion of polyethylene glycol molecules to protein (polypeptide) molecules in the reaction mix, the type of pegylation reaction to be performed, and the method of obtaining the selected N-terminally pegylated protein. The method of obtaining the N-terminally pegylated preparation (i.e., separating this moiety from other monopegylated moieties if necessary) may be by purification of the N-terminally pegylated material from a population of pegylated protein molecules. Selective proteins chemically modified at the N-terminus may be accomplished by reductive alkylation, which exploits differential reactivity of different types of primary amino groups (lysine versus the N- terminal) available for derivatization in a particular protein. Under the appropriate reaction conditions, substantially selective derivatization of the protein at the N-terminus with a carbonyl group containing polymer is achievable.

Applications of Prognostic and Diagnostic Results to Pharmacogenomic Methods

Pharmacogenomics is a discipline that involves tailoring a treatment for a subject according to the subject's genotype. For example, based upon the outcome of a prognostic test, a clinician or physician may target pertinent information and preventative or therapeutic treatments to a subject who would be benefited by the information or treatment and avoid directing such information and treatments to a subject who would not be benefited (e.g., the treatment has no therapeutic effect and/or the subject experiences adverse side effects). As therapeutic approaches for colorectal cancer continue to evolve and improve, the goal of treatments for colorectal cancer related disorders is to intervene even before clinical signs manifest themselves. Thus, genetic markers associated with susceptibility to colorectal cancer prove useful for early diagnosis, prevention and treatment of colorectal cancer.

The following is an example of a pharmacogenomic embodiment. A particular treatment regimen can exert a differential effect depending upon the subject's genotype. Where a candidate therapeutic exhibits a significant beneficial interaction with a prevalent allele and a comparatively weak interaction with an uncommon allele (e.g., an order of magnitude or greater difference in the interaction), such a therapeutic typically would not be administered to a subject genotyped as being homozygous for the uncommon allele, and sometimes not administered to a subject genotyped as being heterozygous for the uncommon allele. In another example, where a candidate therapeutic is not significantly toxic when administered to subjects who are homozygous for a prevalent allele but is comparatively toxic when administered to subjects heterozygous or homozygous for an uncommon allele, the candidate therapeutic is not typically administered to subjects who are genotyped as being heterozygous or homozygous with respect to the uncommon allele.

Methods of the invention are applicable to pharmacogenomic methods for detecting, preventing, alleviating and/or treating colorectal cancer. For example, a nucleic acid sample from an individual may be subjected to a genetic test. Where one or more SNPs associated with increased risk of colorectal cancer are identified in a subject, information for detecting, preventing or treating colorectal cancer and/or one or more colorectal cancer detection, prevention and/or treatment regimens then may be directed to and/or prescribed to that subject.

In certain embodiments, a detection, preventative and/or treatment regimen is specifically prescribed and/or administered to individuals who will most benefit from it based upon their risk of developing colorectal cancer assessed by the methods described herein. Methods are thus provided for identifying a subject at risk of colorectal cancer and then prescribing a detection, therapeutic, or preventative regimen to individuals identified as being at increased risk of colorectal cancer. Thus, certain embodiments are directed to methods for treating colorectal cancer in a subject, reducing risk of colorectal cancer in a subject, or early detection of colorectal cancer in a subject, which comprise: detecting the presence or absence of a SNP associated with colorectal cancer in a nucleotide sequence set forth in SEQ ID NOs: 1 to 5703, and prescribing or administering a colorectal cancer treatment regimen, preventative regimen and/or detection regimen to a subject from whom the sample originated where the presence of one or more SNPs associated with colorectal cancer are detected in the nucleotide sequence. In these methods, genetic results may be utilized in with other test results to diagnose colorectal cancer as described above.

The use of certain colorectal cancer treatments are known in the art, and include surgery, chemotherapy and/or radiation therapy. Any of the treatments may be used in combination to treat or prevent colorectal cancer (e.g., surgery followed by radiation therapy or chemotherapy).

Pharmacogenomic methods also may be used to analyze and predict a response to a colorectal cancer treatment or a drug. For example, if pharmacogenomic analysis indicates a likelihood that an individual will respond positively to a colorectal cancer treatment with a particular drug, the drug may be administered to the individual. Conversely, if the analysis indicates that an individual is likely to respond negatively to treatment with a particular drug, an alternative course of treatment may be prescribed. A negative response may be defined as either the absence of an efficacious response or the presence of toxic side effects. The response to a therapeutic treatment can be predicted in a background study in which subjects in any of the following populations are genotyped: a population that responds favorably to a treatment regimen, a population that does not respond significantly to a treatment regimen, and a population that responds adversely to a treatment regiment (e.g., exhibits one or more side effects). These populations are provided as examples and other populations and subpopulations may be analyzed. Based upon the results of these analyses, a subject is genotyped to predict whether he or she will respond favorably to a treatment regimen, not respond significantly to a treatment regimen, or respond adversely to a treatment regimen.

The methods described herein also are applicable to clinical drug trials. One or more SNPs indicative of response to an agent for treating colorectal cancer or to side effects to an agent for treating colorectal cancer may be identified. Thereafter, potential participants in clinical trials of such an agent may be screened to identify those individuals most likely to respond favorably to the drug and exclude those likely to experience side effects. In that way, the effectiveness of drug treatment may be measured in individuals who respond positively to the drug, without lowering the measurement as a result of the inclusion of individuals who are unlikely to respond positively in the study and without risking undesirable safety problems.

Thus, another embodiment is a method of selecting an individual for inclusion in a clinical trial of a treatment or drug comprising the steps of: (a) obtaining a nucleic acid sample from an individual; (b) determining the identity of a polymorphic variant, e.g., SNP which is associated with a positive response to the treatment or the drug, or at least one SNP which is associated with a negative response to the treatment or the drug in the nucleic acid sample, and (c) including the individual in the clinical trial if the nucleic acid sample contains the SNP associated with a positive response to the treatment or the drug or if the nucleic acid sample lacks said SNP associated with a negative response to the treatment or the drug. The SNP may be in a sequence selected individually or in any combination from those disclosed in the tables. Step (c) can also include administering the drug or the treatment to the individual if the nucleic acid sample contains the SNP associated with a positive response to the treatment or the drug and the nucleic acid sample lacks the SNP associated with a negative response to the treatment or the drug. Compositions Comprising Colorectal Cancer-Directed Molecules

The invention includes a composition made up of a colorectal cancer cell and one or more molecules specifically directed and targeted to a nucleic acid comprising a nucleotide sequence shown in the tables, or a polypeptide encoded thereby. Such directed molecules include, but are not limited to, a compound that binds to a nucleic acid or a polypeptide; a RNAi or siRNA molecule having a strand complementary to a nucleotide sequence; an antisense nucleic acid complementary to an RNA encoded by a DNA sequence; a ribozyme that hybridizes to a nucleotide sequence; a nucleic acid aptamer that specifically binds a polypeptide; and an antibody that specifically binds to a polypeptide or binds to a nucleic acid. In specific embodiments, the colorectal cancer directed molecule interacts with a nucleic acid or polypeptide variant associated with colorectal cancer.

Compounds

Compounds can be obtained using any of numerous approaches in combinatorial library methods known in the art, including: biological libraries; peptoid libraries (libraries of molecules having the functionalities of peptides, but with a novel, non-peptide backbone which are resistant to enzymatic degradation but which nevertheless remain bioactive (Zuckermann et al, 1994). Biological library and peptoid library approaches are typically limited to peptide libraries, while the other approaches are applicable to peptide, non-peptide oligomer or small molecule libraries of compounds (Lam, 1997). Examples of methods for synthesizing molecular libraries are described, for example, in DeWitt et al. (DeWitt et al, 1993), Erb et al. (Erb et al, 1994), Zuckermann et al (Zuckermann et al, 1994), Cho et al. (Cho et al, 1993) and Gallop et al. (Gallop et al, 1994).

Libraries of compounds may be presented in solution (Houghten et al, 1992), or on beads (Lam et al, 1991), chips (Fodor et al, 1993), bacteria or spores (Ladner, U.S. Pat. No. 5,223,409), plasmids (Cull et al, 1992) or on phage (Scott and Smith, 1990; Devlin et al, 1990; Cwirla et al, 1990; Felici et al, 1991).

A compound sometimes alters expression and sometimes alters activity of a target polypeptide and may be a small molecule. Small molecules include peptides, peptidomimetics (e.g., peptoids), amino acids, amino acid analogs, polynucleotides, polynucleotide analogs, nucleotides, nucleotide analogs, organic or inorganic compounds (i.e., including heteroorganic and organometallic compounds) having a molecular weight less than about 10,000 grams per mole, organic or inorganic compounds having a molecular weight less than about 5,000 grams per mole, organic or inorganic compounds having a molecular weight less than about 1,000 grams per mole, organic or inorganic compounds having a molecular weight less than about 500 grams per mole, and salts, esters, and other pharmaceutically acceptable forms of such compounds.

An antisense nucleic acid refers to a nucleotide sequence complementary to a sense nucleic acid encoding a polypeptide, e.g., complementary to the, coding strand of a double-stranded cDNA molecule or complementary to an mRNA sequence. The antisense nucleic acid can be complementary to an entire coding strand in a nucleic acid molecule having a sequence of one of SEQ ID NOs:5619 to 5703, or to a portion thereof. In another embodiment, the antisense nucleic acid molecule is antisense to a non-coding region of the coding strand of a nucleotide sequence, e.g., 5' and 3' untranslated regions.

An antisense nucleic acid can be designed such that it is complementary to the entire coding region of an mRNA encoded by a nucleotide sequence of interest, and often the antisense nucleic acid is an oligonucleotide antisense to only a portion of a coding or non-coding region of the mRNA. For example, the antisense oligonucleotide can be complementary to the region surrounding the translation start site of the mRNA, e.g., between the -10 and +10 regions of the target gene nucleotide (SNP) sequence of interest. An antisense oligonucleotide can be, for example, about 7, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, or more nucleotides in length. The antisense nucleic acids, which include the ribozymes described below, can be designed to target a nucleotide sequence in any of SEQ ID NOs: 5619 to 5703. Uncommon alleles and prevalent alleles can be targeted, and those associated with an increased risk of colorectal cancer are often designed, tested, and administered to subjects.

An antisense nucleic acid can be constructed using chemical synthesis and enzymatic ligation reactions using standard procedures. For example, an antisense nucleic acid molecule can be chemically synthesized using naturally occurring nucleotides or variously modified nucleotides designed to increase the biological stability of the molecules or to increase the physical stability of the duplex formed between the antisense and sense nucleic acids, e.g., phosphorothioate derivatives and acridine substituted nucleotides can be used. Antisense nucleic acid also can be produced biologically using an expression vector into which a nucleic acid has been subcloned in an antisense orientation (i.e., RNA transcribed from the inserted nucleic acid will be of an antisense orientation to a target nucleic acid of interest. When utilized as therapeutics, antisense nucleic acids typically are administered to a subject (e.g., by direct injection at a tissue site) or generated in situ such that they hybridize with or bind to cellular mRNA and/or genomic DNA encoding a polypeptide and thereby inhibit expression of the polypeptide, for example, by inhibiting transcription and/or translation. Alternatively, antisense nucleic acid molecules can be modified to target selected cells and then are administered systemically. For systemic administration, antisense molecules can be modified such that they specifically bind to receptors or antigens expressed on a selected cell surface, for example, by linking antisense nucleic acid molecules to peptides or antibodies which bind to cell surface receptors or antigens. Antisense nucleic acid molecules can also be delivered to cells using vectors. Sufficient intracellular concentrations of antisense molecules are achieved by incorporating a strong promoter, such as a pol II or pol III promoter, in the vector construct.

Antisense nucleic acid molecules sometimes are anomeric nucleic acid molecules (Gautier et al, 1987). Antisense nucleic acid molecules can also comprise a 2'-o-methylribonucleotide (Inoue et al, 1987a) or a chimeric RNA-DNA analogue (Inoue et al, 1987b). Antisense nucleic acids sometimes are composed of DNA or peptide nucleic acid (PNA).

In another embodiment, an antisense nucleic acid is a ribozyme. A ribozyme having specificity for a target nucleotide sequence can include one or more sequences complementary to such a nucleotide sequence, and a sequence having a known catalytic region responsible for mRNA cleavage (see e.g., U.S. Pat. No. 5,093,246 or Haselhoff and Gerlach (Haseloff and Gerlach, 1988). For example, a derivative of a Tetrahymena L- 19 IVS RNA is sometimes utilized in which the nucleotide sequence of the f«rtiv#» site is complementary to the nucleotide sequence to be cleaved in a mRNA (see e.g., Cech et al, U.S. Pat. No. 4,987,071; and Cech et al, U.S. Pat. No. 5,116,742). Also, target mRNA sequences can be used to select a catalytic RNA having a specific ribonuclease activity from a pool of RNA molecules (Bartel and Szostak, 1993).

Colorectal cancer directed molecules include in certain embodiments nucleic acids that can form triple helix structures with a target nucleotide sequence, especially one that includes a regulatory region that controls expression of a polypeptide. Gene expression can be inhibited by targeting nucleotide sequences complementary to the regulatory region of a target nucleotide sequence (e.g., promoter and/or enhancers) to form triple helical structures that prevent transcription of a gene in target cells (Helene, 1991; Helene et al, 1992; Maher, III, 1992). Potential sequences that can be targeted for triple helix formation can be increased by creating a switchback nucleic acid molecule. Switchback molecules are synthesized in an alternating 5'-3',3'-5' manner, such that they base pair with first one strand of a duplex and then the other, eliminating the necessity for a sizeable stretch of either purines or pyrimidines to be present on one strand of a duplex.

Colorectal cancer directed molecules include RNAi and siRNA nucleic acids. Gene expression may be inhibited by the introduction of double-stranded RNA (dsRNA), which induces potent and specific gene silencing, a phenomenon called RNA interference or RNAi. See, e.g., Fire et al, U.S. Pat. No. 6,506,559; Tuschl et al, PCT International Publication No. WO 01/75164; Kay et al, PCT International Publication No. WO O3/O1O18OA1; or Bosher J M, Labouesse (Bosher and Labouesse, 2000). This process has been improved by decreasing the size of the double-stranded RNA to 20-24 base pairs (to create small-interfering RNAs or siRNAs) that switched off genes in mammalian cells without initiating an acute phase response, i.e., a host defense mechanism that often results in cell death (Caplen et al, 2001a; Elbashir et al, 2002). There is increasing evidence of post-transcriptional gene silencing by RNA interference (RNAi) for inhibiting targeted expression in mammalian cells at the mRNA level, in human cells. There is additional evidence of effective methods for inhibiting the proliferation and migration of tumor cells in human patients, and for inhibiting metastatic cancer development (see, e.g., U.S. patent application No. US2001000993183; Caplen et al. (Caplen et al, 2001b), Abderrahman et al. (Abderrahmani et al, 2001).

An siRNA or RNAi is a nucleic acid that forms a double stranded RNA and has the ability to reduce or inhibit expression of a gene or target σene when the siRNA. is delivered to or expressed in the same cell as the gene or target gene. siRNA is short double-stranded RNA formed by the complementary strands. Complementary portions of the siRNA that hybridize to form the double stranded molecule often have substantial or complete identity to the target molecule sequence. In one embodiment, an siRNA is a nucleic acid that has substantial or complete identity to a target gene and forms a double stranded siRNA.

When designing the siRNA molecules, the targeted region often is selected from a given DNA sequence beginning 50 to 100 nucleotides downstream of the start codon. See, e.g., Elbashir et al (Elbashir et al, 2002). Initially, 5' or 3' UTRs and regions nearby the start codon were avoided assuming that UTR-binding proteins and/or translation initiation complexes may interfere with binding of the siRNP or RISC endonuclease complex. Sometimes regions of the target 23 nucleotides in length conforming to the sequence motif AA (N19)TT (N, an nucleotide), and regions with approximately 30% to 70% G/C-content (often about 50% G/C- content) often are selected. If no suitable sequences are found, the search often is extended using the motif NA (N2 1). The sequence of the sense siRNA sometimes corresponds to (N19) TT or N21 (position 3 to 23 of the 23-nt motif), respectively. In the latter case, the 3' end of the sense siRNA often is converted to TT. The rationale for this sequence conversion is to generate a symmetric duplex with respect to the sequence composition of the sense and antisense 3' overhangs. The antisense siRNA is synthesized as the complement to position 1 to 21 of the 23-nt motif. Because position 1 of the 23-nt motif is not recognized sequence- specifically by the antisense siRNA, the 3'-most nucleotide residue of the antisense siRNA can be chosen deliberately. However, the penultimate nucleotide of the antisense siRNA (complementary to position 2 of the 23-nt motif) often is complementary to the targeted sequence. For simplifying chemical synthesis, TT often is utilized. siRNAs corresponding to the target motif NAR (Nl 7) YNN, where R is purine (A,G) and Y is pyrimidine (C,U), often are selected. Respective 21 nucleotide sense and antisense siRNAs often begin with a purine nucleotide and can also be expressed from pol III expression vectors without a change in targeting site. Expression of RNAs from pol III promoters can be more efficient when the first transcribed nucleotide is a purine.

The sequence of the siRNA can correspond to the full length target gene, or a subsequence thereof. Often, the siRNA is about 15 to about 50 nucleotides in length (e.g., each complementary sequence of the double stranded siRNA is 15 to 50 nucleotides in length, and the double stranded siRNA is about 15 to 50 base pairs in length, sometimes about 20 to 30 nucleotides in length or about 20 to 25 nucleotides in length, e.g., 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 nucleotides in length. The siRNA sometimes is about 21 nucleotides in length. Methods of using siRNA are known in the art, and specific siRNA molecules may be purchased from a number of companies including Dharmacon Research, Inc.

Antisense, ribozyme, RNAi and siRNA nucleic acids can be altered to form modified nucleic acid molecules. The nucleic acids can be altered at base moieties, sugar moieties or phosphate backbone moieties to improve stability, hybridization, or solubility of the molecule. For example, the deoxyribose phosphate backbone of nucleic acid molecules can be modified to generate peptide nucleic acids (see Hyrup et al, Bioorganic & Medicinal Chemistry 4 (1): 5- 23 (1996)). A peptide nucleic acid, or PNA, refers to a nucleic acid mimic such as a DNA mimic, in which the deoxyribose phosphate backbone is replaced by a pseudopeptide backbone and only the four natural nucleobases are retained. The neutral backbone of a PNA can allow for specific hybridization to DNA and RNA under conditions of low ionic strength. Synthesis of PNA oligomers can be performed using standard solid phase peptide synthesis protocols as described, for example, in Hyrup et al (Hyrup and Nielsen, 1996), and Perry- O'Keefe et al. (Abderrahrnani et al. , 2001 ).

PNA nucleic acids can be used in prognostic, diagnostic, and therapeutic applications. For example, PNAs can be used as anti-sense or anti-gene agents for sequence-specific modulation of gene expression by, for example, inducing transcription or translation arrest or inhibiting replication. PNA nucleic acid molecules can also be used in the analysis of SNPs in a gene, (e.g., by PNA-directed PCR clamping); as artificial restriction enzymes when used in combination with other enzymes, (e.g., Sl nucleases (Hyrup and Nielsen, 1996) or as probes or primers for DNA sequencing or hybridization (Hyrup and Nielsen, 1996; Perry-O'Keefe et al, 1996).

In other embodiments, oligonucleotides may include other appended groups such as peptides (e.g., for targeting host cell receptors in vivo), or agents facilitating transport across cell membranes (see e.g., Letsinger et al. (Letsinger et al., 1989); Lemaitre et al. (Lemaitre et al., 1987) and PCT Publication No. W088/09810) or the blood-brain barrier (see, e.g., PCT Publication No. W089/10134). In addition, oligonucleotides can be modified with hybridization-triggered cleavage agents (van der Krol et al, 1988) or intercalating agents (Zon, 1988). To this end, the oligonucleotide may be conjugated to another molecule, (e.g., a peptide, hybridization triggered cross-linking agent, transport agent, or hybridization- triggered cleavage agent).

Also included as part of this invention are molecular beacon oligonucleotide primer and probe molecules having one or more regions complementary to a target nucleotide sequence, two complementary regions one having a fluorophore and one a quencher such that the molecular beacon is useful for quantifying the presence of the nucleic acid in a sample. Molecular beacon nucleic acids are described, for example, in Lizardi et al, U.S. Pat. No. 5,854,033; Nazarenko et al, U.S. Pat. No. 5,866,336, and Livak et al, U.S. Pat. No. 5,876,930.

Antibodies

An immunogen typically is used to prepare antibodies by immunizing a suitable subject, (e.g., rabbit, goat, mouse or other mammal). An appropriate immunogenic preparation can contain, for example, recombinantly expressed chemically synthesized polypeptide. The preparation can further include an adjuvant, such as Freund's complete or incomplete adjuvant, or a similar immunostimulatory agent. Amino acid polymorphisms can be detected using antibodies specific for the altered epitope by western analysis after the electrophoresis of denatured proteins. Protein polymorphism can also be detected using fluorescently identified antibodies which bind to specific polymorphic epitopes and detected in whole cells using fluorescence activated cell sorting techniques (FACS). Polymorphic protein sequence may also be determined by NMR spectroscopy or by x-ray diffraction studies. Further, determination of polymorphic sites in proteins may be accomplished by observing differential cleavage by specific or non specific proteases.

An antibody is an immunoglobulin molecule or immunologically active portion thereof, i.e., an antigen-binding portion. Examples of immunologically active portions of immunoglobulin molecules include F(ab) and F(ab')2 fragments which can be generated by treating the antibody with an enzyme such as pepsin. An antibody can be polyclonal, monoclonal, or recombinant (e.g., a chimeric or humanized), fully human, non-human (e.g., murine), or a single chain antibody. An antibody may have effector function and can fix complement, and is sometimes coupled to a toxin or imaging agent.

A full-length polypeptide or antigenic peptide fragment encoded by a target nucleotide sequence can be used as an immunogen or can be used to identify antibodies made with other immunogens, e.g., cells, membrane preparations, and the like. An antigenic peptide often includes at least 8 amino acid residues of the amino acid sequences encoded by a nucleotide sequence of one of SEQ ID NOs:5619 to 5703, and encompasses an epitope. Antigenic peptides sometimes include 10 or more amino acids, 15 or more amino acids, 20 or more amino acids, or 30 or more amino acids. Hydrophilic and hydrophobic fragments of polypeptides sometimes are used as immunogens.

Epitopes encompassed by the antigenic peptide are regions located on the surface of the polypeptide (e.g., hydrophilic regions) as well as regions with high antigenicity. For example, an Emini surface probability analysis of the human polypeptide sequence can be used to indicate the regions that have a particularly high probability of being localized to the surface of the polypeptide and are thus likely to constitute surface residues useful for targeting antibody production. The antibody may bind an epitope on any domain or region on polypeptides for use in the invention. Also, chimeric, humanized, and completely human antibodies are useful for applications which include repeated administration to subjects. Chimeric and humanized monoclonal antibodies, comprising both human and non-human portions, can be made using standard recombinant DNA techniques. Such chimeric and humanized monoclonal antibodies can be produced by recombinant DNA techniques, for example using methods described in Robinson et al, PCT International Publication No. WO 87/02671; Akira, et al, European Patent Application 184,187; Taniguchi, M., European Patent Application 171,496; Morrison et al, European Patent Application 173,494; Neuberger et al, PCT International Publication No. WO 86/01533; Cabilly et al, U.S. Pat. No. 4,816,567; Cabilly et al, European Patent Application 125,023; (Better et al, 1988; Liu et al, 1987a; Liu et al, 1987b; Sun et al, 1987; Nishimura et al, 1987; Wood et al, 1985; Shaw et al, 1988; Morrison, 1985; Verhoeyen et al, 1988; Beidler et al, 1988) and Winter, U.S. Pat. No. 5,225,539.

Completely human antibodies can be particularly desirable for therapeutic treatment of human patients. Such antibodies can be produced using transgenic mice that are incapable of expressing endogenous immunoglobulin heavy and light chains genes, but which can express human heavy and light chain genes. See, for example, Lonberg and Huszar (Lonberg and Huszar, 1995) and U.S. Pat. Nos. 5,625,126; 5,633,425; 5,569,825; 5,661,016; and 5,545,806. In addition, companies such as Abgenix, Inc. (Fremont, Calif.) and Medarex, Inc. (Princeton, N.J.), can be engaged to provide human antibodies directed against a selected antigen. Completely human antibodies that recognize a selected epitope also can be generated using guided selection. In this approach a selected non-human monoclonal antibody (e.g., a murine antibody) is used to guide the selection of a completely human antibody recognizing the same epitope. This technology is described for example by Jespers et al (Jespers et al, 1994).

An antibody can be a single chain antibody. A single chain antibody (scFV) can be engineered (see, e.g., Colcher et al. (Colcher et al, 1999) and Reiter (Reiter and Pastan, 1996). Single chain antibodies can be dimerized or multimerized to generate multivalent antibodies having specificities for different epitopes of the same target polypeptide.

Antibodies also may be selected or modified so that they exhibit reduced or no ability to bind an Fc receptor. For example, an antibody may be an isotype or subtype, fragment or other mutant, which does not support binding to an Fc receptor (e.g., it has a mutagenized or deleted Fc receptor binding region). Also, an antibody (or fragment thereof) may be conjugated to a therapeutic moiety such as a cytotoxin, a therapeutic agent or a radioactive metal ion. A cytotoxin or cytotoxic agent includes any agent that is detrimental to cells. Examples include taxol, cytochalasin B, gramicidin D, ethidium bromide, emetine, mitomycin, etoposide, tenoposide, vincristine, vinblastine, colchicin, doxorubicin, daunorubicin, dihydroxy anthracin dione, mitoxantrone, mithramycin, actinomycin D, 1 dehydrotestosterone, glucocorticoids, procaine, tetracaine, lidocaine, propranolol, and puromycin and analogs or homologs thereof. Therapeutic agents include antimetabolites (e.g., methotrexate, 6-mercaptopurine, 6-thioguanine, cytarabine, 5- fluorouracil decarbazine), alkylating agents (e.g., mechlorethamine, thiotepa chlorambucil, melphalan, carmustine (BCNU) and lomustine (CCNU), cyclophosphamide, busulfan, dibromomannitol, streptozotocin, mitomycin C, and cis-dichlorodiamine platinum (II) (DDP) cisplatin), anthracyclines (e.g., daunorubicin (formerly daunomycin) and doxorubicin), antibiotics (e.g., dactinomycin (formerly actinomycin), bleomycin, mithramycin, and anthramycin (AMC)), and anti-mitotic agents (e.g., vincristine and vinblastine).

Antibody conjugates can be used for modifying a given biological response. For example, the drug moiety may be a protein or polypeptide possessing a desired biological activity. Such proteins may include, for example, a toxin such as abrin, ricin A, pseudomonas exotoxin, or diphtheria toxin; a polypeptide such as tumor necrosis factor, γ-interferon, α-interferon, nerve growth factor, platelet derived growth factor, tissue plasminogen activator; or, biological response modifiers such as, for example, lymphokines, interleukin-1 ("IL-I"), interleukin-2 ("IL-2"), interleukin-6 ("IL-6"), granulocyte macrophage colony stimulating factor ("GM- CSF"), granulocyte colony stimulating factor ("G-CSF"), or other growth factors. Also, an antibody can be conjugated to a second antibody to form an antibody heteroconjugate as described by Segal in U.S. Pat. No. 4,676,980, for example.

An antibody (e.g., monoclonal antibody) can be used to isolate target polypeptides by standard techniques, such as affinity chromatography or immunoprecipitation. Moreover, an antibody can be used to detect a target polypeptide (e.g., in a cellular lysate or cell supernatant) in order to evaluate the abundance and pattern of expression of the polypeptide. Antibodies can be used diagnostically to monitor polypeptide levels in tissue as part of a clinical testing procedure, e.g., to determine the efficacy of a given treatment regimen.

Detection can be facilitated by coupling (i.e., physically linking) the antibody to a detectable substance. Examples of detectable substances include various enzymes, prosthetic groups, fluorescent materials, luminescent materials, bioluminescent materials, and radioactive materials. Examples of suitable enzymes include horseradish peroxidase, alkaline phosphatase, β-galactosidase, or acetylcholinesterase; examples of suitable prosthetic group complexes include streptavidin/biotin and avidin/biotin; examples of suitable fluorescent materials include umbelliferone, fluorescein, fluorescein isothiocyanate, rhodamine, dichlorotriazinylamine fluorescein, dansyl chloride or phycoerythrin; an example of a luminescent material includes luminol; examples of bioluminescent materials include luciferase, luciferin, and aequorin, and examples of suitable radioactive material include 125I, .1311, 35S or 3H. Also, an antibody can be utilized as a test molecule for determining whether it can treat colorectal cancer, and as a therapeutic for administration to a subject for treating colorectal cancer.

An antibody can be made by immunizing with a purified antigen, or a fragment thereof, a membrane associated antigen, tissues, e.g., crude tissue preparations, whole cells, preferably living cells, lysed cells, or cell fractions.

Included as part of this invention are antibodies which bind only a native polypeptide, only denatured or otherwise non-native polypeptide, or which bind both, as well as those having linear or conformational epitopes. Conformational epitopes sometimes can be identified by selecting antibodies that bind to native but not denatured polypeptide. Also featured are antibodies that specifically bind to a polypeptide variant associated with colorectal cancer.

Screening Assays

The invention includes methods for identifying a candidate therapeutic for treating colorectal cancer. The methods include contacting a test molecule with a target molecule in a system. A target molecule is a nucleic acid molecule having a sequence of any of SEQ ID NOs: 1 to 5703, or a fragment thereof, or a polypeptide encoded by the nucleic acid molecules of SEQ ID NOs:5619 to 5703. The method also includes determining the presence or absence of an interaction between the test molecule and the target molecule, where the presence of an interaction between the test molecule and the nucleic acid or polypeptide identifies the test molecule as a candidate colorectal cancer therapeutic. The interaction between the test molecule and the target molecule may be quantified.

Test molecules and candidate therapeutics include compounds, antisense nucleic acids, siRNA molecules, ribozymes, polypeptides or proteins encoded by target nucleic acids, and immunotherapeutics (e.g., antibodies and HLA-presented polypeptide fragments). A test molecule or candidate therapeutic may act as a modulator of target molecule concentration or target molecule function in a system. A modulator may agonize (i.e., up-regulates) or antagonize (i.e., down-regulates) a target molecule concentration partially or completely in a system by affecting such cellular functions as DNA replication and/or DNA processing (e.g., DNA methylation or DNA repair), RNA transcription and/or RNA processing (e.g., removal of intronic sequences and/or translocation of spliced mRNA from the nucleus), polypeptide production (e.g., translation of the polypeptide from mRNA), and/or polypeptide post- translational modification (e.g., glycosylation, phosphorylation, and proteolysis of pro- polypeptides). A modulator may also agonize or antagonize a biological function of a target molecule partially or completely, where the function may include adopting a certain structural conformation, interacting with one or more binding partners, ligand binding, catalysis (e.g., phosphorylation, dephosphorylation, hydrolysis, methylation, and isomerization), and an effect upon a cellular event (e.g., effecting progression of colorectal cancer).

According to an aspect of this invention a system, i.e., a cell free in vitro environment and a cell-based environment such as a collection of cells, a tissue, an organ, or an organism, is contacted with a test molecule in a variety of manners, including adding molecules in solution and allowing them to interact with one another by diffusion, cell injection, and any administration routes in an animal. An interaction refers to an effect of a test molecule on test molecule, where the effect sometimes is binding between the test molecule and the target molecule, and sometimes is an observable change in cells, tissue, or organism.

There are known methods for detecting the presence or absence of interaction between a test molecule and a target molecule. For example, titrametric, acidimetric, radiometric, NMR, monolayer, polarographic, spectrophotometric, fluorescent, and ESR assays probative of a target molecule interaction may be utilized.

Test molecule/target molecule interactions can be detected and/or quantified using known assays. For example, an interaction can be determined by labeling the test molecule and/or the target molecule, where the label is covalently or non-covalently attached to the test molecule or target molecule. The label is sometimes a radioactive molecule such as 1251, 1311, 35S or 3H, which can be detected by direct counting of radio-emission or by scintillation counting. Also, enzymatic labels such as horseradish peroxidase, alkaline phosphatase, or luciferase may be utilized where the enzymatic label can be detected by determining conversion of an appropriate substrate to product, hi addition, presence or absence of an interaction can be determined without labeling. For example, a microphysiometer (e.g., Cytosensor) is an analytical instrument that measures the rate at which a cell acidifies its environment using a light-addressable potentiometric sensor (LAPS). Changes in this acidification rate can be used as an indication of an interaction between a test molecule and target molecule (McConnell et al, 1992).

In cell-based systems, cells typically include a nucleic acid from SEQ ID NOs: 1 to 5703 or a polypeptide encoded by the nucleic acid molecules from SEQ ID NOs:5619 to 5703, and are often of mammalian origin, although the cell can be of any origin. Whole cells, cell homogenates, and cell fractions (e.g., cell membrane fractions) can be subjected to analysis. Where interactions between a test molecule with a target polypeptide are monitored, soluble and/or membrane bound forms of the polypeptide may be utilized. Where membrane-bound forms of the polypeptide are used, it may be desirable to utilize a solubilizing agent. Examples of such solubilizing agents include non-ionic detergents such as n-octylglucoside, n- dodecylglucoside, n-dodecylmaltoside, octanoyl-N-methylglucamide, decanoyl-N- methylglucamide, Triton™X-100, Triton™ X-114, etc.

An interaction between a test molecule and target molecule also can be detected by monitoring fluorescence energy transfer (FET) (see, e.g., Lakowicz et al, U.S. Pat. No. 5,631,169; Stavrianopoulos et al, U.S. Pat. No. 4,868,103). A fluorophore label on a first, donor molecule is selected such that its emitted fluorescent energy will be absorbed by a fluorescent label on a second, acceptor molecule, which in turn is able to fluoresce due to the absorbed energy. Alternately, the donor polypeptide molecule may simply utilize the natural fluorescent energy of tryptophan residues. Labels are chosen that emit different wavelengths of light, such that the acceptor molecule label may be differentiated from that of the donor. Since the efficiency of energy transfer between the labels is related to the distance separating the molecules, the spatial relationship between the molecules can be assessed. In a situation in which binding occurs between the molecules, the fluorescent emission of the acceptor molecule label in the assay should be maximal. An FET binding event can be conveniently measured through standard fluorometric detection means well known in the art (e.g., using a fluorimeter).

In another embodiment, determining the presence or absence of an interaction between a test molecule and a target molecule can be effected by monitoring surface plasmon resonance (Sjolander and Urbaniczky, 1991; Szabo et al, 1995). Surface plasmon resonance (SPR) or biomolecular interaction analysis (BIA) can be utilized to detect biospecific interactions in real time, without labeling any of the interactants (e.g., BIAcore). Changes in the mass at the binding surface (indicative of a binding event) result in alterations of the refractive index of light near the surface (the optical phenomenon of surface plasmon resonance, resulting in a detectable signal which can be used as an indication of real-time reactions between biological molecules.

In another embodiment, the target molecule or test molecules are anchored to a solid phase, facilitating the detection of target molecule/test molecule complexes and separation of the complexes from free, uncomplexed molecules. The target molecule or test molecule is immobilized to the solid support. In one embodiment, the target molecule is anchored to a solid surface, and the test molecule, which is not anchored, can be labeled, either directly or indirectly, with detectable labels.

It may be desirable to immobilize a target molecule, an anti-target molecule antibody, and/or test molecules to facilitate separation of target molecule/test molecule complexes from uncomplexed forms, as well as to accommodate automation of the assay. The attachment between a test molecule and/or target molecule and the solid support may be covalent or non- covalent (see, e.g., U.S. Pat. No. 6,022,688 for non-covalent attachments). The solid support may be one or more surfaces of the system, such as one or more surfaces in each well of a microtiter plate, a surface of a silicon wafer, a surface of a bead (Lam et ai, 1991) that is optionally linked to another solid support, or a channel in a microfluidic device, for example. Types of solid supports, linker molecules for covalent and non-covalent attachments to solid supports, and methods for immobilizing nucleic acids and other molecules to solid supports are known (see, e.g., U.S. Pat. Nos. 6,261,776; 5,900,481; 6,133,436; and 6,022,688; and WIPO publication WO 01/18234).

In one embodiment, a target molecule may be immobilized to surfaces via biotin and streptavidin. For example, a biotinylated polypeptide can be prepared from biotin-NHS (N- hydroxysuccinimide, e.g., biotinylation kit, Pierce Chemicals, Rockford, 111.), and immobilized in the wells of streptavidin-coated 96 well plates (Pierce Chemical). In another embodiment, a target polypeptide can be prepared as a fusion polypeptide. For example, glutathione-S-transferase/-polypeptide fusion can be adsorbed onto glutathione sepharose beads (Sigma Chemical, St. Louis, Mo.) or glutathione derivatized microtiter plates, which are then combined with a test molecule under conditions conducive to complex formation (e.g., at physiological conditions for salt and pH). Following incubation, the beads or microtiter plate wells are washed to remove any unbound components, or the matrix is immobilized in the case of beads, and complex formation is determined directly or indirectly as described above. Alternatively, the complexes can be dissociated from the matrix, and the level of target molecule binding or activity is determined using standard techniques.

In one embodiment, the non-immobilized component is added to the coated surface containing the anchored component. After the reaction is complete, unreacted components are removed (e.g., by washing) under conditions such that a significant percentage of complexes formed will remain immobilized to the solid surface. The detection of complexes anchored on the solid surface can be accomplished in a number of manners. Where the previously non- immobilized component is pre-labeled, the detection of label immobilized on the surface indicates that complexes were formed. Where the previously non-immobilized component is not pre-labeled, an indirect label can be used to detect complexes anchored on the surface, e.g., by adding a labeled antibody specific for the immobilized component, where the antibody, in turn, can be directly labeled or indirectly labeled with, e.g., a labeled anti-Ig antibody.

In another embodiment, an assay is performed utilizing antibodies that specifically bind a target molecule or test molecule but do not interfere with binding of the target molecule to the test molecule. Such antibodies can be linked to a solid support, and unbound target molecule may be immobilized by antibody conjugation. Methods for detecting such complexes, in addition to those described above for the GST-immobilized complexes, include immunodetection of complexes using antibodies reactive with the target molecule, as well as enzyme-linked assays which rely on detecting an enzymatic activity associated with the target molecule.

Cell free assays also can be conducted in a liquid phase. In such an assay, reaction products are separated from unreacted components, by known techniques, including: differential centrifugation (Rivas and Minton, 1993); electrophoresis (1999) and immunoprecipitation (1999). Media and chromatographic techniques are known (Heegaard, 1998; Hage and Tweed, 1997). Further, fluorescence energy transfer may also be conveniently utilized to detect binding without further purification of the complex from solution. In another embodiment, modulators of target molecule expression are identified. For example, a cell or cell free mixture is contacted with a candidate compound and the expression of target mRNA or polypeptide is evaluated relative to the level of expression of target mRNA or polypeptide in the absence of the candidate compound. When expression of target mRNA or polypeptide is greater in the presence of the candidate compound than in its absence, the candidate compound is identified as an agonist of target mRNA or polypeptide expression. Alternatively, when expression of target mRNA or polypeptide is less (e.g., less with statistical significance) in the presence of the candidate compound than in its absence, the candidate compound is identified as an antagonist or inhibitor of target mRNA or polypeptide expression. The level of target mRNA or polypeptide expression can be determined by methods described herein.

In another embodiment, binding partners that interact with a target molecule are detected. The target molecules can interact with one or more cellular or extra-cellular macromolecules, such as polypeptides in vivo, and these interacting molecules or binding partners. Binding partners can agonize or antagonize target molecule biological activity. Also, test molecules that agonize or antagonize interactions between target molecules and binding partners can be useful as therapeutic molecules as they can up-regulate or down-regulated target molecule activity in vivo and thereby treat colorectal cancer.

Binding partners of target molecules can be identified by known methods. For example, binding partners may be identified by lysing cells and analyzing cell lysates by electrophoretic techniques. Alternatively, a two-hybrid assay or three-hybrid assay can be utilized (Zervos et al., 1993; Madura et al, 1993; Bartel et al, 1993; Iwabuchi et al, 1993): see also, e.g., U.S. Pat. No. 5,283,317 and Brent WO94/10300. A two-hybrid system is based on the modular nature of most transcription factors, which consist of separable DNA-binding and activation domains. The assay often utilizes two different DNA constructs. In one construct, a nucleic acid from one of SEQ ID NOs:5619 to 5703, sometimes referred to as the bait, is fused to a gene encoding the DNA binding domain of a known transcription factor (e.g., GAL-4). In another construct, a DNA sequence from a library of DNA sequences that encodes a potential binding partner, sometimes referred to as the prey, is fused to a gene that encodes an activation domain of the known transcription factor. Sometimes, a target nucleic acid can be fused to the activation domain. If the bait and the prey molecules interact in vivo, the DNA- binding and activation domains of the transcription factor are brought into close proximity.

This proximity allows transcription of a reporter gene (e.g., lacZ) which is operably linked to a transcriptional regulatory site responsive to the transcription factor. Expression of the reporter gene can be detected and cell colonies containing the functional transcription factor can be isolated and used to identify the potential binding partner.

In an embodiment for identifying test molecules that antagonize or agonize complex formation between target molecules and binding partners, a reaction mixture containing the target molecule and the binding partner is prepared, under conditions and for a time sufficient to allow complex formation. The reaction mixture often is provided in the presence or absence of the test molecule. The test molecule can be included initially in the reaction mixture, or can be added at a time subsequent to the addition of the target molecule and its binding partner. Control reaction mixtures are incubated without the test molecule or with a placebo.

Formation of any complexes between the target molecule and the binding partner then is detected. Decreased formation of a complex in the reaction mixture containing test molecule as compared to in a control reaction mixture indicates that the molecule antagonizes target molecule/binding partner complex formation. Alternatively, increased formation of a complex in the reaction mixture containing test molecule as compared to in a control reaction mixture, indicates that the molecule agonizes target molecule/binding partner complex formation, hi another embodiment, complex formation of target molecule/binding partner can be compared to complex formation of mutant target molecule/binding partner (e.g., amino acid modifications in a target polypeptide). Such a comparison can be important in those cases where it is desirable to identify test molecules that modulate interactions of mutant but not non-mutated target gene products.

The assays can be conducted in a heterogeneous or homogeneous format. In heterogeneous assays, a target molecule and/or the binding partner are immobilized to a solid phase, and complexes are detected on the solid phase at the end of the reaction. In homogeneous assays, the entire reaction is carried out in a liquid phase. In either approach, the order of addition of reactants can be varied to obtain different information about the molecules being tested. For example, test compounds that agonize target molecule/binding partner interactions can be identified by conducting the reaction in the presence of the test molecule in a competition format. Alternatively, test molecules that agonize preformed complexes, e.g., molecules with higher binding constants that displace one of the components from the complex, can be tested by adding the test compound to the reaction mixture after complexes have been formed. In a heterogeneous assay, the target molecule or the binding partner is anchored onto a solid surface (e.g., a microtiter plate), while the non-anchored species is labeled, either directly or indirectly. The anchored molecule can be immobilized by non-covalent or covalent attachments. Alternatively, an immobilized antibody specific for the molecule to be anchored can be used to anchor the molecule to the solid surface. The partner of the immobilized species is exposed to the coated surface with or without the test molecule. After the reaction is complete, unreacted components are removed (e.g., by washing) such that a significant portion of any complexes formed will remain immobilized on the solid surface. Where the non-immobilized species is pre-labeled, the detection of label immobilized on the surface is indicative of complex. Where the non-immobilized species is not pre-labeled, an indirect label can be used to detect complexes anchored to the surface; e.g., by using a labeled antibody specific for the initially non-immobilized species. Depending upon the order of addition of reaction components, test compounds that inhibit complex formation or that disrupt preformed complexes can be detected.

The reaction can be conducted in a liquid phase in the presence or absence of test molecule, where the reaction products are separated from unreacted components, and the complexes are detected (e.g., using an immobilized antibody specific for one of the binding components to anchor any complexes formed in solution, and a labeled antibody specific for the other partner to detect anchored complexes). Again, depending upon the order of addition of reactants to the liquid phase, test compounds that inhibit complex or that disrupt preformed complexes can be identified.

hi an alternate embodiment, a homogeneous assay can be utilized. For example, a preformed complex of the target gene product and the interactive cellular or extra-cellular binding partner-product is prepared. One or both of the target molecule or binding partner is labeled, and the signal generated by the label(s) is quenched upon complex formation (e.g., U.S. Pat. No. 4,109,496 that-utilizes this approach for immunoassays). Addition of a test molecule that competes with and displaces one of the species from the preformed complex will result in the generation of a signal above background, hi this way, test substances that disrupt target molecule/binding partner complexes can be identified. Identification of Candidate Therapeutics

Candidate therapeutics for treating colorectal cancer are identified from a group of test molecules that interact with a target molecule. Test molecules are normally ranked according to the degree with which they modulate (e.g., agonize or antagonize) a function associated with the target molecule (e.g., DNA replication and/or processing, RNA transcription and/or processing, polypeptide production and/or processing, and/or biological function/activity), and then top ranking modulators are selected. Also, pharmacogenomic information can determine the rank of a modulator. The top 10% of ranked test molecules often are selected for further testing as candidate therapeutics, and sometimes the top 15%, 20%, or 25% of ranked test molecules are selected for further testing as candidate therapeutics. Candidate therapeutics typically are formulated for administration to a subject.

Therapeutic Formulations

Formulations and pharmaceutical compositions typically include in combination with a pharmaceutically acceptable carrier one or more target molecule modulators. The modulator often is a test molecule identified as having an interaction with a target molecule by a screening method. The modulator may be a compound, an antisense nucleic acid, a ribozyme, an antibody, or a binding partner. Also, formulations may include a polypeptide combination with a pharmaceutically acceptable carrier.

A pharmaceutically acceptable carrier includes solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like, compatible with pharmaceutical administration. See for example, Remington's Pharmaceutical Sciences (2005). Supplementary active compounds can also be incorporated into the compositions. Pharmaceutical compositions can be included in a container, pack, or dispenser together with instructions for administration.

A pharmaceutical composition typically is formulated to be compatible with its intended route of administration. Examples of routes of administration include parenteral, e.g., intravenous, intradermal, subcutaneous, oral (e.g., inhalation), transdermal (topical), transmucosal, and rectal administrations Solutions or suspensions used for parenteral, intradermal, or subcutaneous application can include the following components: a sterile diluent such as water for injection, saline solution, fixed oils, polyethylene glycols, glycerin, propylene glycol or other synthetic solvents; antibacterial agents such as benzyl alcohol or methyl parabens; antioxidants such as ascorbic acid or sodium bisulfite; chelating agents such as ethylenediaminetetraacetic acid; buffers such as acetates, citrates or phosphates and agents for the adjustment of tonicity such as sodium chloride or dextrose. pH can be adjusted with acids or bases, such as hydrochloric acid or sodium hydroxide. The parenteral preparation can be enclosed in ampoules, disposable syringes or multiple dose vials made of glass or plastic.

Oral compositions generally include an inert diluent or an edible carrier. For the purpose of oral therapeutic administration, the active compound can be incorporated with excipients and used in the form of tablets, troches, or capsules, e.g., gelatin capsules. Oral compositions can also be prepared using a fluid carrier for use as a mouthwash. Pharmaceutically compatible binding agents, and/or adjuvant materials can be included as part of the composition. The tablets, pills, capsules, troches and the like can contain any of the following ingredients, or compounds of a similar nature: a binder such as microcrystalline cellulose, gum tragacanth or gelatin; an excipient such as starch or lactose, a disintegrating agent such as alginic acid, Primogel, or corn starch; a lubricant such as magnesium stearate; a glidant such as colloidal silicon dioxide; a sweetening agent such as sucrose or saccharin; or a flavoring agent such as peppermint, methyl salicylate, or orange flavoring.

Pharmaceutical compositions suitable for injectable use include sterile aqueous solutions (where water soluble) or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersion. For intravenous administration, suitable carriers include physiological saline, bacteriostatic water, Cremophor EL™ (BASF, Parsippany, NJ.) or phosphate buffered saline (PBS). The composition must be sterile and should be fluid to the extent that easy syringability exists. It should be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms such as bacteria and fungi. The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyethylene glycol, and the like), and suitable mixtures thereof. The proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants. Prevention of the action of microorganisms can be achieved by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, ascorbic acid, thimerosal, and the like. In many cases, it will be preferable to include isotonic agents, for example, sugars, polyalcohols such as mannitol or sorbitol, and/or sodium chloride in the composition.

Prolonged absorption of the injectable compositions can be brought about by including in the composition an agent which delays absorption, for example, aluminum monostearate and gelatin.

Sterile injectable solutions can be prepared by incorporating the active compound in the required amount in an appropriate solvent with one or a combination of ingredients enumerated above, as required, followed by filtered sterilization. Generally, dispersions are prepared by incorporating the active compound into a sterile vehicle which contains a basic dispersion medium and the required other ingredients from those enumerated above, hi the case of sterile powders for the preparation of sterile injectable solutions, the methods of preparation often utilized are vacuum drying and freeze-drying which yields a powder of the active ingredient plus any additional desired ingredient from a previously sterile-filtered solution thereof.

Systemic administration might be by transmucosal or transdermal means. For transmucosal or transdermal administration, penetrants appropriate to the barrier to be permeated are used in the formulation. Such penetrants are generally known in the art, and include, for example, for transmucosal administration, detergents, bile salts, and fusidic acid derivatives. Transmucosal administration can be accomplished through the use of nasal sprays or suppositories. For transdermal administration, the active compounds are formulated into ointments, salves, gels, or creams as generally known in the art. Molecules can also be prepared in the form of suppositories (e.g., with conventional suppository bases such as cocoa butter and other glycerides) or retention enemas for rectal delivery.

hi one embodiment, active molecules are prepared with carriers that will protect the compound against rapid elimination from the body, such as a controlled release formulation, including implants and microencapsulated delivery systems. Biodegradable, biocompatible polymers can be used, such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters, and polylactic acid. Methods for preparation of such formulations will be apparent to those skilled in the art. Materials can also be obtained commercially from Alza Corporation and Nova Pharmaceuticals, Inc. Liposomal suspensions (including liposomes targeted to infected cells with monoclonal antibodies to viral antigens) can also be used as pharmaceutically acceptable carriers. These can be prepared according to methods known to those skilled in the art, for example, as described in U.S. Pat. No. 4,522,811. It is advantageous to formulate oral or parenteral compositions in dosage unit form for ease of administration and uniformity of dosage. Each unit containing a predetermined quantity of active compound is calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier.

Toxicity and therapeutic efficacy of such compounds can be determined by standard pharmaceutical procedures in cell cultures or experimental animals, e.g., for determining the LD50 (the dose lethal to 50% of the population) and the ED.sub.50 (the dose therapeutically effective in 50% of the population). The dose ratio between toxic and therapeutic effects is the therapeutic index and it can be expressed as the ratio LD50/ED50. Molecules which exhibit high therapeutic indices often are utilized. While molecules that exhibit toxic side effects may be used, care should be taken to design a delivery system that targets sueh compounds to the site of affected tissue in order to minimize potential damage to uninfected cells and, thereby, reduce side effects.

The data obtained from the cell culture assays and animal studies can be used in formulating a range of dosage for use in humans. The dosage of such molecules typically lies within a range of circulating concentrations that include the ED50 with little or no toxicity. The dosage may vary within this range depending upon the dosage form employed and the route of administration utilized. For any molecules used in methods described herein, the therapeutically effective dose can be estimated initially from cell culture assays. A dose may be formulated in animal models to achieve a circulating plasma concentration range that includes the IC.sub.50 (i.e., the concentration of the test compound which achieves a half- maximal inhibition of symptoms) as determined in cell culture. Such information can be used to more accurately determine useful doses in humans. Levels in plasma may be measured, for example, by high performance liquid chromatography.

As defined herein, a therapeutically effective amount of protein or polypeptide (i.e., an effective dosage) ranges from about 0.001 to 30 mg/kg body weight, sometimes about 0.01 to 25 mg/kg body weight, often about 0.1 to 20 mg/kg body weight, and more often about 1 to 10 mg/kg, 2 to 9 mg/kg, 3 to 8 mg/kg, 4 to 7 mg/kg, or 5 to 6 mg/kg body weight. The protein or polypeptide can be administered one time per week for between about 1 to 10 weeks, sometimes between 2 to 8 weeks, often between about 3 to 7 weeks, and more often for about 4, 5, or 6 weeks. The skilled artisan will appreciate that certain factors may influence the dosage and timing required to effectively treat a subject, including but not limited to the severity of the disease or disorder, previous treatments, the general health and/or age of the subject, and other diseases present. Moreover, treatment of a subject with a therapeutically effective amount of a protein, polypeptide, or antibody can include a single treatment or, can include a series of treatments.

For antibodies, a dosage of 0.1 mg/kg of body weight (generally 10 mg/kg to 20 mg/kg) is often utilized. If the antibody is to act in the brain, a dosage of 50 mg/kg to 100 mg/kg is often appropriate. Generally, partially human antibodies and fully human antibodies have a longer half-life within the human body than other antibodies. Accordingly, lower dosage and less frequent administration is often possible. Modifications such as lipidation can be used to stabilize antibodies and to enhance uptake and tissue penetration (e.g., into the brain). A method for lipidation of antibodies is described by Cruikshank et al. (Cruikshank et al, 1997).

Antibody conjugates can be used for modifying a given biological response, the drug moiety is not to be construed as limited to classical chemical therapeutic agents. For example, the drug moiety may be a protein or polypeptide possessing a desired biological activity. Such proteins may include, for example, a toxin such as abrin, ricin A, pseudomonas exotoxin, or diphtheria toxin; a polypeptide such as tumor necrosis factor, alpha-interferon, beta- interferon, nerve growth factor, platelet derived growth factor, tissue plasminogen activator; or, biological response modifiers such as, for example, lymphokines, interleukin-1 ("IL-I"), interleukin-2 ("IL-2"), interleukin-6 ("IL-6"), granulocyte macrophage colony stimulating factor ("GM-CSF"), granulocyte colony stimulating factor ("G-CSF"), or other growth factors. Alternatively, an antibody can be conjugate to a se^nH antibody to fom an antibody heteroconjugate as described by Segal in U.S. Pat. No. 4,676,980.

For compounds, exemplary doses include milligram or microgram amounts of the compound per kilogram of subject or sample weight, for example, about 1 microgram per kilogram to about 500 milligrams per kilogram, about 100 micrograms per kilogram to about 5 milligrams per kilogram, or about 1 microgram per kilogram to about 50 micrograms per kilogram. It is understood that appropriate doses of a small molecule depend upon the potency of the small molecule with respect to the expression or activity to be modulated. When one or more of these small molecules is to be administered to an animal (e.g., a human) in order to modulate expression or activity of a polypeptide or nucleic acid described herein, a physician, veterinarian, or researcher may, for example, prescribe a relatively low dose at first, subsequently increasing the dose until an appropriate response is obtained. In addition, it is understood that the specific dose level for any particular animal subject will depend upon a variety of factors including the activity of the specific compound employed, the age, body weight, general health, gender, and diet of the subject, the time of administration, the route of administration, the rate of excretion, any drug combination, and the degree of expression or activity to be modulated.

With regard to nucleic acid formulations, gene therapy vectors can be delivered to a subject by, for example, intravenous injection, local administration (see, e.g., U.S. Pat. No. 5,328,470) or by stereotactic injection (Chen et al, 1994). Pharmaceutical preparations of gene therapy vectors can include a gene therapy vector in an acceptable diluent, or can comprise a slow release matrix in which the gene delivery vehicle is imbedded. Alternatively, where the complete gene delivery vector can be produced intact from recombinant cells (e.g., retroviral vectors) the pharmaceutical preparation can include one or more cells which produce the gene delivery system. Examples of gene delivery vectors are described herein.

Therapeutic Methods

A therapeutic formulation described above can be administered to a subject in need of a therapeutic for treating colorectal cancer. Therapeutic formulations can be administered by any of the paths described herein. With regard to both prophylactic and therapeutic methods of treatment, such treatments may be specifically tailored or modified, based on knowledge obtained from pharmacogenomic analyses described herein.

A treatment is the application or administration of a therapeutic formulation to a subject, or application or administration of a therapeutic agent to an isolated tissue or cell line from a subject with the purpose to cure, heal, alleviate, relieve, alter, remedy, ameliorate, improve or affect colorectal cancer, symptoms of colorectal cancer or a predisposition towards colorectal cancer. A therapeutic formulation includes small molecules, peptides, antibodies, ribozymes and antisense oligonucleotides. Administration of a therapeutic formulation can occur prior to the manifestation of symptoms characteristic of colorectal cancer, such that the cancer is prevented or delayed in its progression. The appropriate therapeutic composition can be determined based on screening assays described herein.

As discussed, successful treatment of colorectal cancer can be brought about by techniques that serve to agonize target molecule expression or function, or alternatively, antagonize target molecule expression or function. These techniques include administration of modulators that include, but are not limited to, small organic or inorganic molecules; antibodies (including, for example, polyclonal, monoclonal, humanized, anti-idiotypic, chimeric or single chain antibodies, and FAb, F(ab')2 and FAb expression library fragments, scFV molecules, and epitope-binding fragments thereof); and peptides, phosphopeptides, or polypeptides.

Further, antisense and ribozyme molecules that inhibit expression of the target gene can also be used to reduce the level of target gene expression, thus effectively reducing the level of target gene activity. Still further, triple helix molecules can be utilized in reducing the level of target gene activity. Antisense, ribozyme and triple helix molecules are discussed above. It is possible that the use of antisense, ribozyme, and/or triple helix molecules to reduce or inhibit mutant gene expression can also reduce or inhibit the transcription (triple helix) and/or translation (antisense, ribozyme) of mRNA produced by normal target gene alleles, such that the concentration of normal target gene product present can be lower than is necessary for a normal phenotype. In such cases, nucleic acid molecules that encode and express target gene polypeptides exhibiting normal target gene activity can be introduced into cells via gene therapy method. Alternatively, in instances in that the target gene encodes an extra-cellular polypeptide, it can be preferable to co-administer normal target gene polypeptide into the cell or tissue in order to maintain the requisite level of cellular or tissue target gene activity.

Another method by which nucleic acid molecules may be utilized in treating or preventing colorectal cancer is use of aptamer molecules specific for target molecules. Aptamers are nucleic acid molecules having a tertiary structure which permits them to specifically bind to ligands (Osborne et al, 1997; Patel, 1997).

Yet another method of utilizing nucleic acid molecules for colorectal cancer treatment is gene therapy, which can also be referred to as allele therapy. The invention thus includes a gene therapy method for treating colorectal cancer in a subject, which includes contacting one or more cells in the subject or from the subject with a nucleic acid having a first nucleotide sequence. Genomic DNA in the subject includes a second nucleotide sequence having one or more SNPs associated with colorectal cancer. The first and second nucleotide sequences typically are substantially identical to one another, and the first nucleotide sequence comprises fewer SNPs associated with colorectal cancer than the second nucleotide sequence. The first nucleotide sequence may comprise a gene sequence that encodes a full-length polypeptide or a fragment thereof. The subject is often a human. Allels therapy methods often are utilized in conjunction with a method of first determining whether a subject has genomic DNA that includes SNPs associated with colorectal cancer.

Another allele therapy is a method which comprises contacting one or more cells in the subject or from the subject with a polypeptide encoded by a nucleic acid having a first nucleotide sequence. Genomic DNA in the subject includes a second nucleotide sequence having one or more SNPs associated with colorectal cancer. The first and second nucleotide sequences typically are substantially identical to one another, and the first nucleotide sequence includes fewer SNPs associated with colorectal cancer than the second nucleotide sequence. The first nucleotide sequence may include a gene sequence that encodes a full- length polypeptide or a fragment thereof. The subject is usually a human.

For antibody-based therapies, antibodies can be generated that are both specific for target molecules and that reduce target molecule activity. Such antibodies may be administered in instances where antagonizing a target molecule function is appropriate for the treatment of colorectal cancer.

In circumstances where stimulating antibody production in an animal or a human subject by injection with a target molecule is harmful to the subject, it is possible to generate an immune response against the target molecule by use of anti-idiotypic antibodies (Herlyn and Birebent, 1999; Bhattacharya-Chatterjee and Foon, 1998). Introducing an anti-idiotypic antibody to a mammal or human subject often stimulates production of anti-anti-idiotypic antibodies, which typically are specific to the target molecule. Vaccines directed to colorectal cancer also may be generated in this fashion.

In instances where the target molecule is intracellular and whole antibodies are used, internalizing antibodies often are utilized. Lipofectin or liposomes can be used to deliver the antibody or a fragment of the Fab region that binds to the target antigen into cells. Where fragments of the antibody are used, the smallest inhibitory fragment that binds to the target antigen often is utilized. For example, peptides having an amino acid sequence corresponding to the Fv region of the antibody can be used. Alternatively, single chain neutralizing antibodies that bind to intracellular target antigens can also be administered. Such single chain antibodies can be administered, for example, by expressing nucleotide sequences encoding single-chain antibodies within the target cell population (Marasco et al., 1993). Modulators can be administered to a patient at therapeutically effective doses to treat colorectal cancer. A therapeutically effective dose refers to an amount of the modulator sufficient to result in amelioration of symptoms of colorectal cancer. Toxicity and therapeutic efficacy of modulators can be determined by standard pharmaceutical procedures in cell cultures or experimental animals, e.g., for determining the LD50 (the dose lethal to 50% of the population) and the ED50 (the dose therapeutically effective in 50% of the population). The dose ratio between toxic and therapeutic effects is the therapeutic index and it can be expressed as the ratio LDsc/EDso- Modulators that exhibit large therapeutic indices often are utilized. While modulators that exhibit toxic side effects can be used, care should be taken to design a delivery system that targets such molecules to the site of affected tissue in order to minimize potential damage to uninfected cells, thereby reducing side effects.

Data obtained from cell culture assays and animal studies can be used in formulating a range of dosagesior use-in humans. The dosage of such compounds typically lies within a range of circulating concentrations that include the ED50 with little or no toxicity. The dosage can vary within this range depending upon the dosage form employed and the route of administration utilized. The therapeutically effective dose can be estimated initially from cell culture assays. A dose can be formulated in animal models to achieve a circulating plasma concentration range that includes the IC50 (i.e., the concentration of the test compound that achieves a half- maximal inhibition of symptoms) as determined in cell culture. Such information can be used to more accurately determine useful doses in humans. Levels in plasma can be measured, for example, by high performance liquid chromatography.

Another example of effective dose determination for an individual is the πWϋty to directly assay levels of "free" and "bound" compound in the serum of the test subject. Such assays may utilize antibody mimics and/or "biosensors" that have been created through molecular imprinting techniques. Molecules that modulate target molecule activity are used as a template, or "imprinting molecule", to spatially organize polymerizable monomers prior to their polymerization with catalytic reagents. The subsequent removal of the imprinted molecule leaves a polymer matrix which contains a repeated "negative image" of the compound and is able to selectively rebind the molecule under biological assay conditions. A detailed review of this technique can be seen in Ansell et al. (Ansell et al., 1996). Such "imprinted" affinity matrixes are amenable to ligand-binding assays, whereby the immobilized monoclonal antibody component is replaced by an appropriately imprinted matrix. An example of the use of such matrixes in this way can be seen in Vlatakis, et al. (Vlatakis et al, 1993). Through the use of isotope-labeling, the "free" concentration of compound which modulates target molecule expression or activity readily can be monitored and used in calculations of IC50. Such "imprinted" affinity matrixes can also be designed to include fluorescent groups whose photon-emitting properties measurably change upon local and selective binding of target compound. These changes readily can be assayed in real time using appropriate fiberoptic devices, in turn allowing the dose in a test subject to be quickly optimized based on its individual IC50.

The examples set forth below are intended to illustrate but not limit the invention.

Genomic DNA samples from patients aged 25-74 and patients with both familial and sporadic CRC with family and unrelated ethnically matched controls were studied. We identified CRC- associated alleles by measuring 385,562 single nucleotide polymorphisms in peripheral blood DNA from 2,128 subjects (1,059 cases with colorectal cancer and 1,069 age matched individuals undiseased at the time of testing), and validating the identified CRC-associated alleles by using peripheral blood DNA from a second and third, different, group of 2,194 subjects (687 and 452 cases, respectively, with colorectal cancer and 688 and 367 age matched individuals undiseased, respectively, at the time of testing). Patients with clinically documented well characterized inherited colorectal cancer syndromes such as Familial Adenomatous Polyposis (FAP) or Hereditary Non Polyposis Colorectal Cancer were excluded from our analysis. Single nucleotide polymorphisms were selected to maximize measurement of genomic variability by choosing these markers that were in the greatest degree of linkage disequilibrium with neighboring SNPs. This was determined by calculating correlation coefficients (r2) with successive neighboring SNPs at eβrh site of polymorphism until an arbitrary cut off of 0.8 was observed. Marker SNPs selected for measurement were in linkage disequilibrium with a maximal number of adjacent SNPs, thus providing an economical method for measuring diversity over a large portion of the genome.

Single Nucleotide Polymorphisms selected for study were derived from the International Haplotype Mapping Project (http://www.hapmap.org) August 2004 release, information about which is available from the National Institutes of Health, National Institutes of Health (NIH; http://www.nih.gov/), 9000 Rockville Pike, Bethesda, Maryland 20892. The SNPs were analyzed on DNA from our control and study population using the Affymetrix GeneChip® Human Mapping 500K Array Set platform (http://www.affymetrix.com, Affymetrix, Inc., 3380 Central Expressway, Santa Clara, CA 95051). The SNPs for the Affymetrix GeneChip® Human Mapping 500K Array Set platforms were selected as to cover the entire genome, but the SNPs were preferentially selected in genie regions present on Nspl and Styl restriction fragments varying in length from about 200 base pairs to about 1100 base pairs. Data was stored and organized using the Nanuq informatics environment of the McGiIl University and Genome Quebec Innovation Centre (http://www.genomequebec.mcgill.ca/; McGiIl University and Genome Quebec Innovation Centre, 740, Docteur Penfleld Avenue, Montreal, Quebec H3A 1 A4). Allele frequencies found within DNA from patients with colorectal cancer and those without this disease were compared using the univariate Mantel-Haenszel Chi-Square statistic.

The inventors of the present invention have discovered single base pair polymorphisms that are present in a highly significant percentage of the genetic DNA of individuals affected with colorectal cancer while only present in a smaller percentage of individuals who are not known to be affected by the disease.

Example 1 For individuals with colorectal cancer, the distribution of polymorphic alleles at position 5652680 of chromosome 1 was different from those without colorectal cancer (Table 1). The dominant test for risk associated with carrying the G allele had an empirical p-value based on permutation analysis of 0.005204, and the corresponding dominant odds ratio is 1.467 (Table 1). These data further suggest that this marker is associated with colorectal cancer risk and that the G allele at position 5652680 of chromosome 1 is associated with an increased risk of developing colorectal cancer.

Table IA indicates SNPs found to be in strong linkage disequilibrium with rsl763322. To generate this list, correlation coefficients (r2) were calculated between the index SNP and all neighboring SNPs cited in the June 2006 HapMap data set release. An r2 cut off of 0.50 was selected for inclusion as evidence for strong genetic linkage, i.e., a "strong linkage disequilibrium.

Example 2

For individuals with colorectal cancer, the distribution of polymorphic alleles at position 17391832 of chromosome 1, found within the PADI4 gene, was different from those without colorectal cancer (Table 2). The trend test for risk associated with carrying the C allele had an empirical p-value of 0.006108 based on permutation analysis, and the corresponding Mantel- Haenszel odds ratio for trend is 1.349 (Table 2). These data further suggest that this marker, located within the PADI4 gene, is associated with colorectal cancer risk and that the C allele at position 17391832 of chromosome 1 is associated with an increased risk of developing colorectal cancer.

Table 2 A indicates SNPs found to be in strong linkage disequilibrium with rs2147333. To generate this list, correlation coefficients (r2) were calculated between the index SNP and all neighboring SNPs cited in the June 2006 HapMap data set release. An r2 cut off of 0.50 was selected for inclusion as evidence for strong genetic linkage, i.e., a "strong linkage disequilibrium.

Example 3

For individuals with colorectal cancer, the distribution of polymorphic alleles at position 18512119 of chromosome 1 was different from those without colorectal cancer (Table 3). The trend test for risk associated with carrying the A allele had an empirical p-value of 0.000118 based on permutation analysis, and the corresponding Mantel-Haenszel odds ratio for trend is

1.291 (Table 3). These data further suggest that this marker is associated with colorectal cancer risk and that the A allele at position 18512119 of chromosome 1 is associated with an increased risk of developing colorectal cancer.

Table 3A indicates SNPs found to be in ctrong linkage disequilibrium with rsl 1261011. To generate this list, correlation coefficients (r2) were calculated between the index SNP and all neighboring SNPs cited in the June 2006 HapMap data set release. An r2 cut off of 0.50 was selected for inclusion as evidence for strong genetic linkage, i.e., a "strong linkage disequilibrium.

Example 4

For individuals with colorectal cancer, the distribution of polymorphic alleles at position 20628809 of chromosome 1 was different from those without colorectal cancer (Table 4). The dominant test for risk associated with carrying the A allele had an empirical p-value based on permutation analysis of 0.051552, and the corresponding dominant odds ratio is 1.451 (Table 4). These data further suggest that this marker is associated with colorectal cancer risk and that the A allele at position 20628809 of chromosome 1 is associated with an increased risk of developing colorectal cancer.

Table 4A indicates SNPs found to be in strong linkage disequilibrium with rs7545658. To generate this list, correlation coefficients (r2) were calculated between the index SNP and all neighboring SNPs cited in the June 2006 HapMap data set release. An r2 cut off of 0.50 was selected for inclusion as evidence for strong genetic linkage, i.e., a "strong linkage disequilibrium.

Example 5

For individuals with colorectal cancer, the distribution of polymorphic alleles at position 20901973 of chromosome 1, found within the EIF4G3 gene, was different from those without colorectal cancer (Table 5). The recessive test for risk associated with carrying the A allele had an empirical p-value of 0.006048 based on permutation analysis, and the corresponding recessive odds ratio is 1.359 (Table 5). These data further suggest that this marker, located within the EIF4G3 gene, is associated with colorectal cancer risk and that the A allele at position 20901973 of chromosome 1 is associated with an increased risk of developing colorectal cancer.

Table 5A indicates SNPs found to be in strong linkage disequilibrium with rs4654874. To generate this list, correlation coefficients (r2) were calculated between the index SNP and all neighboring SNPs cited in the June 2006 HapMap data set release. An r2 cut off of 0.50 was selected for inclusion as evidence for strong genetic linkage, i.e., a "strong linkage disequilibrium.

Example 6

For individuals with colorectal cancer, the distribution of polymorphic alleles at position 22090399 of chromosome 1 was different from those without colorectal cancer (Table 6). The trend test for risk associated with carrying the G allele had an empirical p- value of 0.001626 based on permutation analysis, and the corresponding Mantel-Haenszel odds ratio for trend is 1.262 (Table 6). These data further suggest that this marker is associated with colorectal cancer risk and that the G allele at position 22090399 of chromosome 1 is associated with an increased risk of developing colorectal cancer.

Table 6A indicates SNPs found to be in strong linkage disequilibrium with rs3117048. To generate this list, correlation coefficients (r2) were calculated between the index SNP and all neighboring SNPs cited in the June 2006 FapMap da*a set release. An r? cut off of 0.50 wub selected for inclusion as evidence for strong genetic linkage, i.e., a "strong linkage disequilibrium.

Table 6A Linked SNPs

SNP Position on chrl SEQ ID NO

Example 7

For individuals with colorectal cancer, the distribution of polymorphic alleles at position 33676444 of chromosome 1, found within the CSMD2 gene, was different from those without colorectal cancer (Table 7). The recessive test for risk associated with carrying the C allele had an empirical p-value of 0.000364 based on permutation analysis, and the corresponding recessive odds ratio is 1.426 (Table 7). These data further suggest that this marker, located within the CSMD2 gene, is associated with colorectal cancer risk and that the C allele at position 33676444 of chromosome 1 is associated with an increased risk of developing colorectal cancer.

Table 7A indicates SNPs found to be in strong linkage disequilibrium with rs 1773026. To generate this list, correlation coefficients (r2) were calculated between the index SNP and all neighboring SNPs cited in the June 2006 HapMap data set release. An r2 cut off of 0.50 was selected for inclusion as evidence for strong genetic linkage, i.e., a "strong linkage disequilibrium.

Example 8

For individuals with colorectal cancer, the distribution of polymorphic alleles at position 40781063 of chromosome 1, found within the RIMS3 gene, was different from those without colorectal cancer (Table 8). The recessive test for risk associated with carrying the A allele had an empirical p-value of 0.001402 based υn permutation analysis, and the corresponding recessive odds ratio is 3.527 (Table 8). These data further suggest that this marker, located within the RIMS3 gene, is associated with colorectal cancer risk and that the A allele at position 40781063 of chromosome 1 is associated with an increased risk of developing colorectal cancer.

E 754 217 24

Table 8A indicates SNPs found to be in strong linkage disequilibrium with rs 1333827. To generate this list, correlation coefficients (r2) were calculated between the index SNP and all neighboring SNPs cited in the June 2006 HapMap data set release. An r2 cut off of 0.50 was selected for inclusion as evidence for strong genetic linkage, i.e., a "strong linkage disequilibrium.

Example 9

For individuals with colorectal cancer, the distribution of polymorphic alleles at position 82422197 of chromosome 1 was different from those without colorectal cancer (Table 9). The recessive test for risk associated with carrying the A allele had an empirical p-value of

0.004479 based on permutation analysis, and the corresponding recessive odds ratio is 1.397

(Table 9). These data further suggest that this marker is associated with colorectal cancer risk and that the A allele at position 82422197 of chromosome 1 is associated with an increased risk of developing colorectal cancer.

Table 9A indicates SNPs found to be in strong linkage disequilibrium with rs7555416. To generate this list, correlation coefficients (r2) were calculated between the index SNP and all neighboring SNPs cited in the June 2006 HapMap data set release. An r2 cut off of 0.50 was selected for inclusion as evidence for strong genetic linkage, i.e., a "strong linkage disequilibrium.

Example 10

For individuals with colorectal cancer, the distribution of polymorphic alleles at position 95494480 of chromosome 1 was different from those without colorectal cancer (Table 10). The recessive test for risk associated with carrying the T allele had an empirical p-value of 0.002715 based on permutation analysis, and the corresponding recessive odds ratio is 1.395 (Table 10). These data further suggest that this marker is associated with colorectal cancer risk and that the T allele at position 95494480 of chromosome 1 is associated with an increased risk of developing colorectal cancer.

Table 1OA indicates SNPs found to be in strong linkage disequilibrium with rs 17113360. To generate this list, correlation coefficients (r2) were calculated between the index SNP and all neighboring SNPs cited in the June 2006 HapMap data set release. An r2 cut off of 0.50 was selected for inclusion as evidence for strong genetic linkage, i.e., a "strong linkage disequilibrium.

Table 1OA Linked SNPs

SNP Position on chrl SEQ ID NO

Example 11

For individuals with colorectal cancer, the distribution of polymorphic alleles at position 118562981 of chromosome 1 was different from those without colorectal cancer (Table 11). The trend test for risk associated with carrying the C allele had an empirical p-value of 0.005399 based on permutation analysis, and the corresponding Mantel-Haenszel odds ratio for trend is 1.237 (Table 11). These data further suggest that this marker is associated with colorectal cancer risk and that the C allele at position 118562981 of chromosome 1 is associated with an increased risk of developing colorectal cancer.

Table HA indicates SNPs found to be in strong linkage disequilibrium with rsl 1578232. To generate this list, correlation coefficients (r2) were calculated between the index SNP and all neighboring SNPs cited in the June 2006 HapMap data set release. An r2 cut off of 0.50 was selected for inclusion as evidence for strong genetic linkage, i.e., a "strong linkage disequilibrium.

Example 12

For individuals with colorectal cancer, the distribution of polymorphic alleles at position 143043494 of chromosome 1, found within the FLJ25124 gene, was different from those without colorectal cancer (Table 12). The recessive test for risk associated with carrying the C allele had an empirical p- value of 0.001269 based on permutation analysis, and the corresponding recessive odds ratio is 1.567 (Table 12). These data further suggest that this marker, located within the FLJ25124 gene, is associated with colorectal cancer risk and that the C allele at position 143043494 of chromosome 1 is associated with an increased risk of developing colorectal cancer.

Table 12A indicates SNPs found to be in strong linkage disequilibrium with rsl2125340. To generate this list, correlation coefficients (r2) were calculated between the index SNP and all neighboring SNPs cited in the June 2006 HapMap data set release. An r2 cut off of 0.50 was selected for inclusion as evidence for strong genetic linkage, i.e., a "strong linkage disequilibrium.

Example 13

For individuals with colorectal cancer, the distribution of polymorphic alleles at position 154420450 of chromosome 1, found within the LOC391105 gene, was different from those without colorectal cancer (Table 13). The recessive test for risk associated with carrying the T allele had an empirical p-value of 0.001106 based on permutation analysis, and the corresponding recessive odds ratio is 1.342 (Table 13). These data further suggest that this marker, located within the LOC391105 gene, is associated with colorectal cancer risk and that the T allele at position 154420450 of chromosome 1 is associated with an increased risk of developing colorectal cancer.

Table 13A indicates SNPs found to be in strong linkage disequilibrium with rs2758688. To generate this list, correlation coefficients (r2) were calculated between the index SNP and all neighboring SNPs cited in the June 2006 HapMap data set release. An r2 cut off of 0.50 was selected for inclusion as evidence for strong genetic linkage, i.e., a "strong linkage disequilibrium.

Example 14

For individuals with colorectal cancer, the distribution of polymorphic alleles at position 166408144 of chromosome 1, found within the SELL gene, was different from those without colorectal cancer (Table 14). The recessive test for risk associated with carrying the G allele had an empirical p- value of 0.063371 based on permutation analysis, and the corresponding recessive odds ratio is 1.330 (Table 14). These data further suggest that this marker, located within the SELL gene, is associated with colorectal cancer risk and that the G allele at position 166408144 of chromosome 1 is associated with an increased risk of developing colorectal cancer.

Table 14A indicates SNPs found to be in strong linkage disequilibrium with rs3177980. To generate this list, correlation coefficients (r2) were calculated between the index SNP and all neighboring SNPs cited in the June 2006 HapMap data set release. An r2 cut off of 0.50 was selected for inclusion as evidence for strong genetic linkage, i.e., a "strong linkage disequilibrium.

Example 15

For individuals with colorectal cancer, the distribution of polymorphic alleles at position 182256575 of chromosome 1 was different from those without colorectal cancer (Table 15). The dominant test for risk associated with carrying the G allele had an empirical p-value based on permutation analysis of 0.009853, and the corresponding dominant odds ratio is 1.441 (Table 15). These data further suggest that this marker is associated with colorectal cancer risk and that the G allele at position 182256575 of chromosome 1 is associated with an increased risk of developing colorectal cancer.

Table 15A indicates SNPs found to be in strong linkage disequilibrium with rs 1321999. To generate this list, correlation coefficients (r2) were calculated between the index SNP and all neighboring SNPs cited in the June 2006 HapMap data set release. An r2 cut off of 0.50 was selected for inclusion as evidence for strong genetic linkage, i.e., a "strong linkage disequilibrium.

Example 16

For individuals with colorectal cancer, the distribution of polymorphic alleles at position 187260102 of chromosome 1 was different from those without colorectal cancer (Table 16). The trend test for risk associated with carrying the C allele had an empirical p-value of 0.000492 based on permutation analysis, and the corresponding Mantel-Haenszel odds ratio for trend is 1.377 (Table 16). These data further suggest that this marker is associated with colorectal cancer risk and that the C allele at position 187260102 of chromosome 1 is associated with an increased risk of developing colorectal cancer.

Table 16A indicates SNPs found to be in strong linkage disequilibrium with rs 1501501. To generate this list, correlation coefficients (r2) were calculated between the index SNP and all neighboring SNPs cited in the June 2006 HapMap data set release. An r2 cut off of 0.50 was selected for inclusion as evidence for strong genetic linkage, i.e., a "strong linkage disequilibrium.

Example 17

For individuals with colorectal cancer, the distribution of polymorphic alleles at position 200680317 of chromosome 1 was different from those without colorectal cancer (Table 17). The trend test for risk associated with carrying the G allele had an empirical p-value of 0.009365 based on permutation analysis, and the corresponding Mantel-Haenszel odds ratio for trend is 1.226 (Table 17). These data further suggest that this marker is associated with colorectal cancer risk and that the G allele at position 200680317 of chromosome 1 is associated with an increased risk of developing colorectal cancer.

Table 17A indicates SNPs found to be in strong linkage disequilibrium with rsl2408223. To generate this list, correlation coefficients (r2) were calculated between the index SNP and all neighboring SNPs cited in the June 2006 HapMap data set release. An r2 cut off of 0.50 was selected for inclusion as evidence for strong genetic linkage, i.e., a "strong linkage disequilibrium.

Example 18

For individuals with colorectal cancer, the distribution of polymorphic alleles at position 211276776 of chromosome 1 was different from those without colorectal cancer (Table 18). The recessive test for risk associated with carrying the T allele had an empirical p-value of 0.001597 based on permutation analysis, and the corresponding recessive odds ratio is 1.361 (Table 18). These data further suggest that this marker is associated with colorectal cancer risk and that the T allele at position 211276776 of chromosome 1 is associated with an increased risk of developing colorectal cancer.

Table 18A indicates SNPs found to be in strong linkage disequilibrium with rs335554. To generate this list, correlation coefficients (r2) were calculated between the index SNP and all neighboring SNPs cited in the June 2006 HapMap data set release. An r2 cut off of 0.50 was selected for inclusion as evidence for strong genetic linkage, i.e., a "strong linkage disequilibrium.

Example 19

For individuals with colorectal cancer, the distribution of polymorphic alleles at position 214640087 of chromosome 1 was different from those without colorectal cancer (Table 19). The recessive test for risk associated with carrying the T allele had an empirical p-value of 0.001243 based on permutation analysis, and the corresponding recessive odds ratio is 1.377 (Table 19). These data further suggest that this marker is associated with colorectal cancer risk and that the T allele at position 214640087 of chromosome 1 is associated with an increased risk of developing colorectal cancer.

Table 19A indicates SNPs found to be in strong linkage disequilibrium with rs 10863373. To generate this list, correlation coefficients (r2) were calculated between the index SNP and all neighboring SNPs cited in the June 2006 HapMap data set release. An r2 cut off of 0.50 was selected for inclusion as evidence for strong genetic linkage, i.e., a "strong linkage disequilibrium.

Example 20

For individuals with colorectal cancer, the distribution of polymorphic alleles at position 228779667 of chromosome 1 was different from those without colorectal cancer (Table 20). The trend test for risk associated with carrying the G allele had an empirical p-value of 0.00338 based on permutation analysis, and the corresponding Mantel-Haenszel odds ratio for trend is 1.207 (Table 20). These data further suggest that this marker is associated with colorectal cancer risk and that the G allele at position 228779667 of chromosome 1 is associated with an increased risk of developing colorectal cancer.

Table 2OA indicates SNPs found to be in strong linkage disequilibrium with rs789367. To generate this list, correlation coefficients (r2) were calculated between the index SNP and all neighboring SNPs cited in the June 2006 HapMap data set release. An r2 cut off of 0.50 was selected for inclusion as evidence for strong genetic linkage, i.e., a "strong linkage disequilibrium.

Example 21

For individuals with colorectal cancer, the distribution of polymorphic alleles at position 228798840 of chromosome 1 was different from those without colorectal cancer (Table 21). The trend test for risk associated with carrying the G allele had an empirical p-value of 0.001512 based on permutation analysis, and the corresponding Mantel-Haenszel odds ratio for trend is 1.239 (Table 21). These data further suggest that this marker is associated with colorectal cancer risk and that the G allele at position 228798840 of chromosome 1 is associated with an increased risk of developing colorectal cancer.

Table 21 A indicates SNPs found to be in strong linkage disequilibrium with rs586510. To generate this list, correlation coefficients (r2) were calculated between the index SNP and all neighboring SNPs cited in the June 2006 HapMap data set release. An r2 cut off of 0.50 was selected for inclusion as evidence for strong genetic linkage, i.e., a "strong linkage disequilibrium.

Example 22 For individuals with colorectal cancer, the distribution of polymorphic alleles at position 229775255 of chromosome 1, found within the KIAA 1804 gene, was different from those without colorectal cancer (Table 22). The trend test for risk associated with carrying the G allele had an empirical p- value of 0.001743 based on permutation analysis, and the corresponding Mantel -Haenszel odds ratio for trend is 1.276 (Table 22). These data further suggest that this marker, located within the KIAA 1804 gene, is associated with colorectal cancer risk and that the G allele at position 229775255 of chromosome 1 is associated with an increased risk of developing colorectal cancer.

Table 22A indicates SNPs found to be in strong linkage disequilibrium with rs 1294302. To generate this list, correlation coefficients (r2) were calculated between the index SNP and all neighboring SNPs cited in the June 2006 HapMap data set release. An r2 cut off of 0.50 was selected for inclusion as evidence for strong genetic linkage, i.e., a "strong linkage disequilibrium.

Example 23

For individuals with colorectal cancer, the distribution of polymorphic alleles at position 236665853 of chromosome 1, found within the FMN2 gene, was different from those without colorectal cancer (Table 23). The trend test for risk associated with carrying the C allele had an empirical p-value of 0.007535 based on permutation analysis, and the corresponding Mantel-Haenszel odds ratio for trend is 1.351 (Table 23). These data further suggest that this marker, located within the FMN2 gene, is associated with colorectal cancer risk and that the C allele at position 236665853 of chromosome 1 is associated with an increased risk of developing colorectal cancer.

Table 23A indicates SNPs found to be in strong linkage disequilibrium with rs7542728. To generate this list, correlation coefficients (r2) were calculated between the index SNP and all neighboring SNPs cited in the June 2006 HapMap data set release. An r2 cut off of 0.50 was selected for inclusion as evidence for strong genetic linkage, i.e., a "strong linkage disequilibrium.

Table 23A Linked SNPs

SNP r2 Position on chrl SEQ ID NO rs7542728 - 236665853 550

Example 24

For individuals with colorectal cancer, the distribution of polymorphic alleles at position 2143625 of chromosome 2, found within the MYTlL gene, was different from those without colorectal cancer (Table 24). The dominant test for risk associated with carrying the T allele had an empirical p-value based on permutation analysis of 0.002046, and the corresponding dominant odds ratio is 1.422 (Table 24). These data further suggest that this marker, located within the MYTlL gene, is associated with colorectal cancer risk and that the T allele at position 2143625 of chromosome 2 is associated with an increased risk of developing colorectal cancer.

Table 24A indicates SNPs found to be in strong linkage disequilibrium with rsl7338512. To generate this list, correlation coefficients (r2) were calculated between the index SNP and all neighboring SNPs cited in the June 2006 HapMap data set release. An r2 cut off of 0.50 was selected for inclusion as evidence for strong genetic linkage, i.e., a "strong linkage disequilibrium.

Example 25

For individuals with colorectal cancer, the distribution of polymorphic alleles at position 6817511 of chromosome 2 was different from those without colorectal cancer (Table 25). The dominant test for risk associated with carrying the G allele had an empirical p-value based on permutation analysis of 0.006141, and the corresponding dominant odds ratio is 1.320 (Table 25). These data further suggest that this marker is associated with colorectal cancer risk and that the G allele at position 6817511 of chromosome 2 is associated with an increased risk of developing colorectal cancer.

Table 25 A indicates SNPs found to be in strong linkage disequilibrium with rs3O8O19. To generate this list, correlation coefficients (r2) were calculated between the index SNP and all neighboring SNPs cited in the June 2006 HapMap data set release. An r2 cut off of 0.50 was selected for inclusion as evidence for strong genetic linkage, i.e., a "strong linkage disequilibrium.

Example 26

For individuals with colorectal cancer, the distribution of polymorphic alleles at position 10449016 of chromosome 2, found within the HPCALl gene, was different from those without colorectal cancer (Table 26). The dominant test for risk associated with carrying the C allele had an empirical p-value based on permutation analysis of 0.004781, and the corresponding dominant odds ratio is 1.324 (Table 26). These data further suggest that this marker, located within the HPCALl gene, is associated with colorectal cancer risk and that the C allele at position 10449016 of chromosome 2 is associated with an increased risk of developing colorectal cancer.

Table 26A indicates SNPs found to be in strong linkage disequilibrium with rs 1974677. To generate this list, correlation coefficients (r2) were calculated between the index SNP and all neighboring SNPs cited in the June 2006 HapMap data set release. An r2 cut off of 0.50 was selected for inclusion as evidence for strong genetic linkage, i.e., a "strong linkage disequilibrium.

Example 27

For individuals with colorectal cancer, the distribution of polymorphic alleles at position 14819616 of chromosome 2 was different fiom iliusc williout colorectal cancer (Table 21). The recessive test for risk associated with carrying the G allele had an empirical p-value of 0.002257 based on permutation analysis, and the corresponding recessive odds ratio is 1.315 (Table 27). These data further suggest that this marker is associated with colorectal cancer risk and that the G allele at position 1-4819616 of chromosome 2 is associated with an increased risk of developing colorectal cancer.

Table 27A indicates SNPs found to be in strong linkage disequilibrium with rs4670019. To generate this list, correlation coefficients (r2) were calculated between the index SNP and all neighboring SNPs cited in the June 2006 HapMap data set release. An r2 cut off of 0.50 was selected for inclusion as evidence for strong genetic linkage, i.e., a "strong linkage disequilibrium.

Example 28

For individuals with colorectal cancer, the distribution of polymorphic alleles at position 16429905 of chromosome 2, found within the LOC391353 gene, was different from those without colorectal cancer (Table 28). The trend test for risk associated v.ith carrying the G allele had an empirical p-value of 0.000839 based on permutation analysis, and the corresponding Mantel-Haenszel odds ratio for trend is 1.256 (Table 28). These data further suggest that this marker, located within the LOC391353 gene, is associated with colorectal cancer risk and that the G allele at position 16429905 of chromosome 2 is associated with an increased risk of developing colorectal cancer.

Table 28A indicates SNPs found to be in strong linkage disequilibrium with rs340779. To generate this list, correlation coefficients (r2) were calculated between the index SNP and all neighboring SNPs cited in the June 2006 HapMap data set release. An r2 cut off of 0.50 was selected for inclusion as evidence for strong genetic linkage, i.e., a "strong linkage disequilibrium.

Example 29

For individuals with colorectal cancer, the distribution of polymorphic alleles at position 16465684 of chromosome 2 was different from those without colorectal cancer (Table 29). The recessive test for risk associated with carrying the G allele had an empirical p-value of 0.005471 based on permutation analysis, and the corresponding recessive odds ratio is 1.378 (Table 29). These data further suggest that this marker is associated with colorectal cancer risk and that the G allele at position 16465684 of chromosome 2 is associated with an increased risk of developing colorectal cancer.

Table 29A indicates SNPs found to be in strong linkage disequilibrium with rs919432. To generate this list, correlation coefficients (r2) were calculated between the index SNP and all neighboring SNPs cited in the June 2006 HapMap data set release. An iΞtut off of ύ.5X) was selected for inclusion as evidence for strong genetic linkage, i.e., a "strong linkage disequilibrium.

Example 30

For individuals with colorectal cancer, the distribution of polymorphic alleles at position 19207725 of chromosome 2, found within the LOC388927 gene, was different from those without colorectal cancer (Table 30). The recessive test for risk associated with carrying the A allele had an empirical p-value of 0.002328 based on permutation analysis, and the corresponding recessive odds ratio is 1.469 (Table 30). These data further suggest that this marker, located within the LOC388927 gene, is associated with colorectal cancer risk and that the A allele at position 19207725 of chromosome 2 is associated with an increased risk of developing colorectal cancer.

Table 30A indicates SNPs found to be in strong linkage disequilibrium with rs 11694107. To generate this list, correlation coefficients (r2) were calculated between the index SNP and all neighboring SNPs cited in the June 2006 HapMap data set release. An r2 cut off of 0.50 was selected for inclusion as evidence for strong genetic linkage, i.e., a "strong linkage disequilibrium.

Example 31

For individuals with colorectal cancer, the distribution of polymorphic alleles at position 45108790 of chromosome 2 was different from those without colorectal cancer (Table 31). The dominant test for risk associated with carrying the A allele had an empirical p-value based on permutation analysis of 0.007796, and the corresponding dominant odds ratio is 1.274 (Table 31). These data further suggest that this marker is associated with colorectal cancer risk and that the A allele at position 45108790 of chromosome 2 is associated with an increased risk of developing colorectal cancer.

Table 31A indicates SNPs found to be in strong linkage disequilibrium with rsl63503. To generate this list, correlation coefficients (r2) were calculated between the index SNP and all neighboring SNPs cited in the June 2006 HapMap data set release. An r2 cut off of 0.50 was selected for inclusion as evidence for strong genetic linkage, i.e., a "strong linkage disequilibrium.

Example 32 For individuals with colorectal cancer, the distribution of polymorphic alleles at position 49180455 of chromosome 2, found within the FSHR gene, was different from those without colorectal cancer (Table 32). The recessive test for risk associated with carrying the A allele had an empirical p-value of 0.000124 based on permutation analysis, and the corresponding recessive odds ratio is 1.609 (Table 32). These data further suggest that this marker, located within the FSHR gene, is associated with colorectal cancer risk and that the A allele at position 49180455 of chromosome 2 is associated with an increased risk of developing colorectal cancer.

Table 32A indicates SNPs found to be in strong linkage disequilibrium with rs 10865238. To generate this list, correlation coefficients (r2) were calculated between the index SNP and all neighboring SNPs cited in the June 2006 HapMap data set release. An r2 cut off of 0.50 was selected for inclusion as evidence for strong genetic linkage, i.e., a "strong linkage disequilibrium.

Example 33

For individuals with colorectal cancer, the distribution of polymorphic alleles at position 51310020 of chromosome 2 was different from those without colorectal cancer (Table 33). The dominant test for risk associated with carrying the C allele had an empirical p-value based on permutation analysis of 0.002806, and the corresponding dominant odds ratio is 1.805 (Table 33). These data further suggest that this marker is associated with colorectal cancer risk and that the C allele at position 51310020 of chromosome 2 is associated with an increased risk of developing colorectal cancer.

Table 33A indicates SNPs found to be in strong linkage disequilibrium with rslO49O155. To generate this list, correlation coefficients (r2) were calculated between the index SNP and all neighboring SNPs cited in the June 2006 HapMap data set release. An r2 cut off of 0.50 was selected for inclusion as evidence for strong genetic linkage, i.e., a "strong linkage disequilibrium.

Example 34

For individuals with colorectal cancer, the distribution of polymorphic alleles at position 51663024 of chromosome 2 was different from those without colorectal cancer (Table 34). The recessive test for risk associated with carrying the T allele had an empirical p-value of 0.001612 based on permutation analysis, and the corresponding recessive odds ratio is 3.159 (Table 34). These data further suggest that this marker is associated with colorectal cancer risk and that the T allele at position 51663024 of chromosome 2 is associated with an increased risk of developing colorectal cancer.

Table 34A indicates SNPs found to be in strong linkage disequilibrium with rs 1406421. To generate this list, correlation coefficients (r2) were calculated between the index SNP and all neighboring SNPs cited in the June 2006 HapMap data set release. An r2 cut off of 0.50 was selected for inclusion as evidence for strong genetic linkage, i.e., a "strong linkage disequilibrium.

Example 35

For individuals with colorectal cancer, the distribution of polymorphic alleles at position 51848463 of chromosome 2 was different from those without colorectal cancer (Table 35). The trend test for risk associated with carrying the C allele had an empirical p-value of 0.011173 based on permutation analysis, and the corresponding Mantel-Haenszel odds ratio for trend is 1.235 (Table 35). These data further suggest that this marker is associated with colorectal cancer risk and that the C allele at position 51848463 of chromosome 2 is associated with an increased risk of developing colorectal cancer.

Table 35 A indicates SNPs found to be in strong linkage disequilibrium with rs9309219. To generate this list, correlation coefficients (r2) were calculated between the index SNP and all neighboring SNPs cited in the June 2006 HapMap data set release. An r2 cut off of 0.50 was selected for inclusion as evidence for strong genetic linkage, i.e., a "strong linkage disequilibrium.

Example 36

For individuals with colorectal cancer, the distribution of polymorphic alleles at position 54634922 of chromosome 2, found within the LOC442016 gene, was different from those without colorectal cancer (Table 36). The dominant test for risk associated with carrying the T allele had an empirical p-value based on permutation analysis of 0.000238, and the corresponding dominant odds ratio is 2.414 (Table 36). These data further suggest that this marker, located within the LOC442016 gene, is associated with colorectal cancer risk and that the T allele at position 54634922 of chromosome 2 is associated with an increased risk of developing colorectal cancer.

Table 36A indicates SNPs found to be in strong linkage disequilibrium with rs 10496032. To generate this list, correlation coefficients (r2) were calculated between the index SNP and all neighboring SNPs cited in the June 2006 HapMap data set release. An r2 cut off of 0.50 was selected for inclusion as evidence for strong genetic linkage, i.e., a "strong linkage disequilibrium.

Example 37

For individuals with colorectal cancer, the distribution of polymorphic alleles at position 57735950 of chromosome 2 was different from those without colorectal cancer (Table 37). The recessive test for risk associated with carrying the G allele had an empirical p-value of 0.005533 based on permutation analysis, and the corresponding recessive odds ratio is 1.316 (Table 37). These data further suggest that this marker is associated with colorectal cancer risk and that the G allele at position 57735950 of chromosome 2 is associated with an increased risk of developing colorectal cancer.

Table 37A indicates SNPs found to be in strong linkage disequilibrium with rs 13014264. To generate this list, correlation coefficients (r2) were calculated between the index SNP and all neighboring SNPs cited in the June 2006 HapMap data set release. An r2 cut off of 0.50 was selected for inclusion as evidence for strong genetic linkage, i.e., a "strong linkage disequilibrium.

Example 38

For individuals with colorectal cancer, the distribution of polymorphic alleles at position 59457067 of chromosome 2 was different from those without colorectal cancer (Table 38). The dominant test for risk associated with carrying the T allele had an empirical p-value based on permutation analysis of 0.002361, and the corresponding dominant odds ratio is 1.540 (Table 38). These data further suggest that this marker is associated with colorectal cancer risk and that the T allele at position 59457067 of chromosome 2 is associated with an increased risk of developing colorectal cancer.

Table 38A indicates SNPs found to be in strong linkage disequilibrium with rs 17643867. To generate this list, correlation coefficients (r2) were calculated between the index SNP and all neighboring SNPs cited in the June 2006 HapMap data set release. An r2 cut off of 0.50 was selected for inclusion as evidence for strong genetic linkage, i.e., a "strong linkage disequilibrium.

Example 39

For individuals with colorectal cancer, the distribution of polymorphic alleles at position 66217596 of chromosome 2, found within the LOC440867 gene, was different from those without colorectal cancer (Table 39). The dominant test for risk associated with carrying the G allele had an empirical p-value based on permutation analysis of 0.002887, and the corresponding dominant odds ratio is 1.426 (Table 39). These data further suggest that this marker, located within the LOC440867 gene, is associated with colorectal cancer risk and that the G allele at position 66217596 of chromosome 2 is associated with an increased risk of developing colorectal cancer.

Table 39A indicates SNPs found to be in strong linkage disequilibrium with rsl3409331. To generate this list, correlation coefficients (x1) were calculated between the index SNP and all neighboring SNPs cited in the June 2006 HapMap data set release. An r2 cut off of 0.50 was selected for inclusion as evidence for strong genetic linkage, i.e., a "strong linkage disequilibrium.

Example 40

For individuals with colorectal cancer, the distribution of polymorphic alleles at position 76605013 of chromosome 2 was different from those without colorectal cancer (Table 40). The trend test for risk associated with carrying the C allele had an empirical p-value of 0.002652 based on permutation analysis, and the corresponding Mantel-Haenszel odds ratio for trend is 1.304 (Table 40). These data further suggest that this marker is associated with colorectal cancer risk and that the C allele at position 76605013 of chromosome 2 is associated with an increased risk of developing colorectal cancer.

Table 4OA indicates SNPs found to be in strong linkage disequilibrium with rsl7012735. To generate this list, correlation coefficients (r2) were calculated between the index SNP and all neighboring SNPs cited in the June 2006 HapMap data set release. An r2 cut off of 0.50 was selected for inclusion as evidence for strong genetic linkage, i.e., a "strong linkage disequilibrium.

Example 41

For individuals with colorectal cancer, the distribution of polymorphic alleles at position 79514895 of chromosome 2 was different from those without colorectal cancer (Table 41). The recessive test for risk associated with carrying the C allele had an empirical p-value of 0.007206 based on permutation analysis, and the corresponding recessive odds ratio is 1.275 (Table 41). These data further suggest that this marker is associated with colorectal cancer risk and that the C allele at position 79514895 of chromosome 2 is associated with an increased risk of developing colorectal cancer.

Table 41 A indicates SNPs found to be in strong linkage disequilibrium with rs7595284. To generate this list, correlation coefficients (r2) were calculated between the index SNP and all neighboring SNPs cited in the June 2006 HapMap data set release. An r2 cut off of 0.50 was selected for inclusion as evidence for strong genetic linkage, i.e., a "strong linkage disequilibrium.

Example 42

For individuals with colorectal cancer, the distribution of polymorphic alleles at position 101444879 of chromosome 2, found within the CREG2 gene, was different from those without colorectal cancer (Table 42). The dominant test for risk associated with carrying the G allele had an empirical p-value based on permutation analysis of 0.001748, and the corresponding dominant odds ratio is 1.629 (Table 42). These data further suggest that this marker, located within the CREG2 gene, is associated with colorectal cancer risk and that the G allele at position 101444879 of chromosome 2 is associated with an increased risk of developing colorectal cancer.

Table 42A indicates SNPs found to be in strong linkage disequilibrium with rs3923053. To generate this list, correlation coefficients (r2) were calculated between the index SNP and all neighboring SNPs cited in the June 2006 HapMap data set release. An r2 cut off of 0.50 was selected for inclusion as evidence for strong genetic linkage, i.e., a "strong linkage disequilibrium.

Example 43

For individuals with colorectal cancer, the distribution of polymorphic alleles at position 102001205 of chromosome 2 was different from those without colorectal cancer (Table 43). The dominant test for risk associated with carrying the G allele had an empirical p-value based on permutation analysis of 0.00342, and the corresponding dominant odds ratio is 1.667 (Table 43). These data further suggest that this inaiκei is associated witn colorectal cancer risk and that the G allele at position 102001205 of chromosome 2 is associated with an increased risk of developing colorectal cancer.

Table 43A indicates SNPs found to be in strong linkage disequilibrium with rs2214890. To generate this list, correlation coefficients (r2) were calculated between the index SNP and all neighboring SNPs cited in the June 2006 HapMap data set release. An r2 cut off of 0.50 was selected for inclusion as evidence for strong genetic linkage, i.e., a "strong linkage disequilibrium.

Example 44

For individuals with colorectal cancer, the distribution of polymorphic alleles at position 117009893 of chromosome 2 was different from those without colorectal cancer (Table 44). The trend test for risk associated with carrying the T allele had an empirical p-value of 0.002858 based on permutation analysis, and the corresponding Mantel-Haenszel odds ratio for trend is 1.347 (Table 44). These data further suggest that this marker is associated with colorectal cancer risk and that the T allele at position 117009893 of chromosome 2 is associated with an increased risk of developing colorectal cancer.

Table 44A indicates SNPs found to be in strong linkage disequilibrium with rslO496519. To generate this list, correlation coefficients (r2) were calculated between the index SNP and all neighboring SNPs cited in the June 2006 HapMap data set release. An r2 cut off of 0.50 was selected for inclusion as evidence for strong genetic linkage, i.e., a "strong linkage disequilibrium.

Table 44A Linked SNPs

Example 45

For individuals with colorectal cancer, the distribution of polymorphic alleles at position 136925001 of chromosome 2 was different from those without colorectal cancer (Table 45). The trend test for risk associated with carrying the C allele had an empirical p-value of 0.006875 based on permutation analysis, and the corresponding Mantel-Haenszel odds ratio for trend is 1.220 (Table 45). These data further suggest that this marker is associated with colorectal cancer risk and that the C allele at position 136925001 of chromosome 2 is associated with an increased risk of developing colorectal cancer.

- U l - Table 45 A indicates SNPs found to be in strong linkage disequilibrium with rs 12614381. To generate this list, correlation coefficients (r2) were calculated between the index SNP and all neighboring SNPs cited in the June 2006 HapMap data set release. An r2 cut off of 0.50 was selected for inclusion as evidence for strong genetic linkage, i.e., a "strong linkage disequilibrium.

Example 46

For individuals with colorectal cancer, the distribution of polymorphic alleles at position 148316634 of chromosome 2 was different from those without colorectal cancer (Table 46).

The recessive test for risk associated with carrying the A allele had an empirical p-value of

0.004417 based on permutation analysis, and the corresponding recessive odds ratio is 1.294

(Table 46). These data further suggest that this marker is associated with colorectal cancer risk and that the A allele at position 148316634 of chromosome 2 is associated with an increased risk of developing colorectal cancer.

Table 46A indicates SNPs found to be in strong linkage disequilibrium with rs 1881569. To generate this list, correlation coefficients (r2) were calculated between the index SNP and all neighboring SNPs cited in the June 2006 HapMap data set release. An r2 cut off of 0.50 was selected for inclusion as evidence for strong genetic linkage, i.e., a "strong linkage disequilibrium.

Example 47

For individuals with colorectal cancer, the distribution of polymorphic alleles at position 166084924 of chromosome 2 was different from those without colorectal cancer (Table 47).

The trend test for risk associated with carrying the G allele had an empirical p-value of 0.00117 based on permutation analysis, and the corresponding Mantel-Haenszel odds ratio for trend is 1.249 (Table 47). These data further suggest that this marker is associated with colorectal cancer risk and that the G allele at position 166084924 of chromosome 2 is associated with an increased risk of developing colorectal cancer.

Table 47A indicates SNPs found to be in strong linkage disequilibrium with rs2082366. To generate this list, correlation coefficients (r2) were calculated between the index SNP and all neighboring SNPs cited in the June 2006 HapMap data set release. An r2 cut off of 0.50 was selected for inclusion as evidence for strong genetic linkage, i.e., a "strong linkage disequilibrium.

Example 48

For individuals with colorectal cancer, the distribution of polymorphic alleles at position 166402463 of chromosome 2 was different from those without colorectal cancer (Table 48). The recessive test for risk associated with carrying the C allele had an empirical p-value of 0.000712 based on permutation analysis, and the corresponding recessive odds ratio is 1.418 (Table 48). These data further suggest that this marker is associated with colorectal cancer risk and that the C allele at position 166402463 of chromosome 2 is associated with an increased risk of developing colorectal cancer.

Table 48A indicates SNPs found to be in strong linkage disequilibrium with rs 12185748. To generate this list, correlation coefficients (r2) were calculated between the index SNP and all neighboring SNPs cited in the June 2006 HapMap data set release. An r2 cut off of 0.50 was selected for inclusion as evidence for strong genetic linkage, i.e., a "strong linkage disequilibrium.

Example 49

For individuals with colorectal cancer, the distribution of polymorphic alleles at position 182938657 of chromosome 2, found within the PDElA gene, was different from those without colorectal cancer (Table 49). The trend test for risk associated with carrying the G allele had an empirical p- value of 0.002501 based on permutation analysis, and the corresponding Mantel-Haenszel odds ratio for trend is 1.271 (Table 49). These data further suggest that this marker, located within the PDElA gene, is associated with colorectal cancer risk and that the G allele at position 182938657 of chromosome 2 is associated with an increased risk of developing colorectal cancer.

Table 49A indicates SNPs found to be in strong linkage disequilibrium with rs4666828. To generate this list, correlation coefficients (r2) were calculated between the index SNP and all neighboring SNPs cited in the June 2006 HapMap data set release. An r2 cut off of 0.50 was selected for inclusion as evidence for strong genetic linkage, i.e., a "strong linkage disequilibrium.

Example 50

For individuals with colorectal cancer, the distribution of polymorphic alleles at position 186817077 of chromosome 2 was different from those without colorectal cancer (Table 50). The recessive test for risk associated with carrying the C allele had an empirical p-value of 0.003843 based on permutation analysis, and the corresponding recessive odds ratio is 2.152 (Table 50). These data further suggest that this marker is associated with colorectal cancer risk and that the C allele at position 186817077 of chromosome 2 is associated with an increased risk of developing colorectal cancer.

Table 50A indicates SNPs found to be in strong linkage disequilibrium with rs4264536. To generate this list, correlation coefficients (r2) were calculated between the index SNP and all neighboring SNPs cited in the June 2006 HapMap data set release. An r2 cut off of 0.50 was selected for inclusion as evidence for strong genetic linkage, i.e., a "strong linkage disequilibrium.

Example 51 For individuals with colorectal cancer, the distribution of polymorphic alleles at position 190205948 of chromosome 2 was different from those without colorectal cancer (Table 51). The recessive test for risk associated with carrying the T allele had an empirical p-value of 0.001635 based on permutation analysis, and the corresponding recessive odds ratio is 1.501 (Table 51). These data further suggest that this marker is associated with colorectal cancer risk and that the T allele at position 190205948 of chromosome 2 is associated with an increased risk of developing colorectal cancer.

Table 51 A indicates SNPs found to be in strong linkage disequilibrium with rs 1371469. To generate this list, correlation coefficients (r2) were calculated between the index SNP and all neighboring SNPs cited in the June 2006 HapMap data set release. An r2 cut off of 0.50 was selected for inclusion as evidence for strong genetic linkage, i.e., a "strong linkage disequilibrium.

Example 52

For individuals with colorectal cancer, the distribution of polymorphic alleles at position 192530205 of chromosome 2, found within the SDPR gene, was different from those without colorectal cancer (Table 52). The dominant test for risk associated with carrying the G allele had an empirical p-value based on permutation analysis of 0.00171, and the corresponding dominant odds ratio is 2.017 (Table 52). These data further suggest that this marker, located within the SDPR gene, is associated with colorectal cancer risk and that the G allele at position 192530205 of chromosome 2 is associated with an increased risk of developing colorectal cancer.

Table 52A indicates SNPs found to be in strong linkage disequilibrium with rs4280394. To generate this list, correlation coefficients (r2) were calculated between the index SNP and all neighboring SNPs cited in the June 2006 HapMap data set release. An r2 cut off of 0.50 was selected for inclusion as evidence for strong genetic linkage, i.e., a "strong linkage disequilibrium.

Table 52A Linked SNPs

SNP r2 Position on chr2 SEQ ID NO rs4280394 - 192530205 1530

Example 53

For individuals with colorectal cancer, the distribution of polymorphic alleles at position 201062851 of chromosome 2, found within the DNAPTP6 gene, was different from those without colorectal cancer (Table 53). The dominant test for risk associated with carrying the G allele had an empirical p-value based on permutation analysis of 0.017416, and the corresponding dominant odds ratio is 1.356 (Table 53). These data further suggest that this marker, located within the DNAPTP6 gene, is associated with colorectal cancer risk and that the G allele at position 201062851 of chromosome 2 is associated with an increased risk of developing colorectal cancer.

Table 53 A indicates SNPs found to be in strong linkage disequilibrium with rs 10497857. To generate this list, correlation coefficients (r2) were calculated between the index SNP and all neighboring SNPs cited in the June 2006 HapMap data set release. An r2 cut off of 0.50 was selected for inclusion as evidence for strong genetic linkage, i.e., a "strong linkage disequilibrium.

Example 54

For individuals with colorectal cancer, the distribution of polymorphic alleles at position 201393474 of chromosome 2 was different from those without colorectal cancer (Table 54). The dominant test for risk associated with carrying the G allele had an empirical p-value based on permutation analysis of 0.009524, and the corresponding dominant odds ratio is 1.348 (Table 54). These data further suggest that this marker is associated with colorectal cancer risk and that the G allele at position 201393474 of chromosome 2 is associated with an increased risk of developing colorectal cancer.

Table 54A indicates SNPs found to be in strong linkage disequilibrium with rs2540053. To generate this list, correlation coefficients (r2) were calculated between the index SNP and all neighboring SNPs cited in the June 2006 HapMap data set release. An r2 cut off of 0.50 was selected for inclusion as evidence for strong genetic linkage, i.e., a "strong linkage disequilibrium.

Example 55

For individuals with colorectal cancer, the distribution of polymorphic alleles at position 15985480 of chromosome 3 was different from those without colorectal cancer (Table 55). The dominant test for risk associated with carrying the T allele had an empirical p- value based on permutation analysis of 0.066835, and the corresponding dominant odds ratio is 1.199 (Table 55). These data further suggest that this marker is associated with colorectal cancer risk and that the T allele at position 15985480 of chromosome 3 is associated with an increased risk of developing colorectal cancer.

Table 55A indicates SNPs found to be in strong linkage disequilibrium with rsl0510444. To generate this list, correlation coefficients (r2) were calculated between the index SNP and all neighboring SNPs cited in the June 2006 HapMap data set release. An r2 cut off of 0.50 was selected for inclusion as evidence for strong genetic linkage, i.e., a "strong linkage disequilibrium.

Example 56

For individuals with colorectal cancer, the distribution of polymorphic alleles at position 25139810 of chromosome 3 was different from those without colorectal cancer (Table 56). The trend test for risk associated with carrying the G allele had an empirical p-value of 0.01185 based on permutation analysis, and the corresponding Mantel-Haenszel odds ratio for trend is 1.247 (Table 56). These data further suggest that this marker is associated with colorectal cancer risk and that the G allele at position 25139810 of chromosome 3 is associated with an increased risk of developing colorectal cancer.

Table 56 A indicates SNPs found to be in strong linkage disequilibrium with rs 17516853. To generate this list, correlation coefficients (r2) were calculated between the index SNP and all neighboring SNPs cited in the June 2006 HapMap data set release. An r2 cut off of 0.50 was selected for inclusion as evidence for strong genetic linkage, i.e., a "strong linkage disequilibrium.

rs321519 0.521 25182177 1590

Example 57

For individuals with colorectal cancer, the distribution of polymorphic alleles at position 25170688 of chromosome 3 was different from those without colorectal cancer (Table 57). The trend test for risk associated with carrying the G allele had an empirical p-value of 0.00084 based on permutation analysis, and the corresponding Mantel-Haenszel odds ratio for trend is 1.384 (Table 57). These data further suggest that this marker is associated with colorectal cancer risk and that the G allele at position 25170688 of chromosome 3 is associated with an increased risk of developing colorectal cancer.

Table 57 A indicates SNPs found to be in strong linkage disequilibrium with rs 17517792. To generate this list, correlation coefficients (r2) were calculated between the index SNP and all neighboring SNPs cited in the June 2006 HapMap data set release. An r2 cut off of 0.50 was selected for inclusion as evidence for strong genetic linkage, i.e., a "strong linkage disequilibrium.

Example 58

For individuals with colorectal cancer, the distribution of polymorphic alleles at position 32134166 of chromosome 3, found within the KIAA0089 gene, was different from those without colorectal cancer (Table 58). The trend test for risk associated with carrying the C allele had an empirical p-value of 0.000558 based en permutation analysis, and the corresponding Mantel-Haenszel odds ratio for trend is 1.254 (Table 58). These data further suggest that this marker, located within the KIAA0089 gene, is associated with colorectal cancer risk and that the C allele at position 32134166 of chromosome 3 is associated with an increased risk of developing colorectal cancer.

158 1 459 I 328 |

Table 58A indicates SNPs found to be in strong linkage disequilibrium with rs6762236. To generate this list, correlation coefficients (r2) were calculated between the index SNP and all neighboring SNPs cited in the June 2006 HapMap data set release. An r2 cut off of 0.50 was selected for inclusion as evidence for strong genetic linkage, i.e., a "strong linkage disequilibrium.

Example 59

For individuals with colorectal cancer, the distribution of polymorphic alleles at position 36561025 of chromosome 3, found within the STAC gene, was different from those without colorectal cancer (Table 59). The recessive test for risk associated with carrying the G allele had an empirical p- value of 0.001917 based on permutation analysis, and the corresponding recessive odds ratio is 1.356 (Table 59). These data further suggest that this marker, located within the STAC gene, is associated with colorectal cancer risk and that the G allele at position 36561025 of chromosome 3 is associated with an increased risk of developing colorectal cancer.

Table 59A indicates SNPs found to be in strong linkage disequilibrium with rs6781630. To generate this list, correlation coefficients (r2) were calculated between the index SNP and all neighboring SNPs cited in the June 2006 HapMap data set release. An r2 cut off of 0.50 was selected for inclusion as evidence for strong genetic linkage, i.e., a "strong linkage disequilibrium.

Example 60

For individuals with colorectal cancer, the distribution of polymorphic alleles at position 95541430 of chromosome 3 was different from those without colorectal cancer (Table 60). The dominant test for risk associated with carrying the T allele had an empirical p-value based on permutation analysis of 0.001442, and the corresponding dominant odds ratio is 2.019 (Table 60). These data further suggest that this marker is associated with colorectal cancer risk and that the T allele at position 95541430 of chromosome 3 is associated with an increased risk of developing colorectal cancer.

Table 60A indicates SNPs found to be in strong linkage disequilibrium with rsl 907645. To generate this list, correlation coefficients (r2) were calculated between the index SNP and all neighboring SNPs cited in the June 2006 HapMap data set release. An r2 cut off of 0.50 was selected for inclusion as evidence for strong genetic linkage, i.e., a "strong linkage disequilibrium.

Example 61

For individuals with colorectal cancer, the distribution of polymorphic alleles at position 112941527 of chromosome 3, found within the FLJ31579 gene, was different from those without colorectal cancer (Table 61). The dominant test for risk associated with carrying the C allele had an empirical p- value based on permutation analysis of 0.010941, and the corresponding dominant odds ratio is 1.322 (Table 61). These data further suggest that this marker, located within the FLJ31579 gene, is associated with colorectal cancer risk and that the C allele at position 112941527 of chromosome 3 is associated with an increased risk of developing colorectal cancer.

Table 61 A indicates SNPs found to be in strong linkage disequilibrium with rs6788543. To generate this list, correlation coefficients (r2) were calculated between the index SNP and all neighboring SNPs cited in the June 2006 HapMap data set release. An r2 cut off of 0.50 was selected for inclusion as evidence for strong genetic linkage, i.e., a "strong linkage disequilibrium.

Example 62

For individuals with colorectal cancer, the distribution of polymorphic alleles at position 115129347 of chromosome 3, found within the DKFZp434C0328 gene, was different from those without colorectal cancer (Table 62). The dominant test for risk associated with carrying the C allele had an empirical p-value based on permutation analysis of 0.001539, and the corresponding dominant odds ratio is 1.669 (Table 62). These data further suggest that this marker, located within the DKFZp434C0328 gene, is associated with colorectal cancer risk and that the C allele at position 115129347 of chromosome 3 is associated with an increased risk of developing colorectal cancer.

1 Table 62 1

Table 62A indicates SNPs found to be in strong linkage disequilibrium with rs4422272. To generate this list, correlation coefficients (r2) were calculated between the index SNP and all neighboring SNPs cited in the June 2006 HapMap data set release. An r2 cut off of 0.50 was selected for inclusion as evidence for strong genetic linkage, i.e., a "strong linkage disequilibrium.

Example 63

For individuals with colorectal cancer, the distribution of polymorphic alleles at position 119908152 of chromosome 3 was different from those without colorectal cancer (Table 63).

The dominant test for risk associated with carrying the T allele had an empirical p- value based on permutation analysis of 0.002706. and the corresponding dominant odds ratio is 1.356

(Table 63). These data further suggest that this marker is associated with colorectal cancer risk and that the T allele at position 119908152 of chromosome 3 is associated with an increased risk of developing colorectal cancer.

Table 63 A indicates SNPs found to be in strong linkage disequilibrium with rs 1566414. To generate this list, correlation coefficients (r2) were calculated between the index SNP and all neighboring SNPs cited in the June 2006 HapMap data set release. An r2 cut off of 0.50 was selected for inclusion as evidence for strong genetic linkage, i.e., a "strong linkage disequilibrium.

Example 64

For individuals with colorectal cancer, the distribution of polymorphic alleles at position 135305323 of chromosome 3 was different from those without colorectal cancer (Table 64). The trend test for risk associated with carrying the C allele had an empirical p-value of 0.030773 based on permutation analysis, and the corresponding Mantel-Haenszel odds ratio for trend is 1.309 (Table 64). These data further suggest that this marker is associated with colorectal cancer risk and that the C allele at position 135305323 of chromosome 3 is associated with an increased risk of developing colorectal cancer.

Table 64A indicates SNPs found to be in strong linkage disequilibrium with rsl 3074310. To generate this list, correlation coefficients (r2) were calculated between the index SNP and all neighboring SNPs cited in the June 2006 HapMap data set release. An r2 cut off of 0.50 was selected for inclusion as evidence for strong genetic linkage, i.e., a "strong linkage disequilibrium.

Example 65

For individuals with colorectal cancer, the distribution of polymorphic alleles at position 150158635 of chromosome 3 was different from those without colorectal cancer (Table 65). The trend test for risk associated with carrying the A allele had an empirical p-value of 0.003457 based on permutation analysis, and the corresponding Mantel-Haenszel odds ratio for trend is 1.355 (Table 65). These data further suggest that this marker is associated with colorectal cancer risk and that the A allele at position 150158635 of chromosome 3 is associated with an increased risk of developing colorectal cancer.

Table 65 A indicates SNPs found to be in strong linkage disequilibrium with rs 12492507. To generate this list, correlation coefficients (r2) were calculated between the index SNP and all neighboring SNPs cited in the June 2006 HapMap data set release. An r2 cut off of 0.50 was selected for inclusion as evidence for strong genetic linkage, i.e., a "strong linkage disequilibrium.

Example 66

For individuals with colorectal cancer, the distribution of polymorphic alleles at position 171033461 of chromosome 3, found within the LOC344657 gene, was different from those without colorectal cancer (Table 66). The dominant test for risk associated with parrying the G allele had an empirical p-value based on permutation analysis of 0.00833, and the corresponding dominant odds ratio is 1.397 (Table 66). These data further suggest that this marker, located within the LOC344657 gene, is associated with colorectal cancer risk and that the G allele at position 171033461 of chromosome 3 is associated with an increased risk of developing colorectal cancer.

Table 66A indicates SNPs found to be in strong linkage disequilibrium with rsl2486767. To generate this list, correlation coefficients (r2) were calculated between the index SNP and all neighboring SNPs cited in the June 2006 HapMap data set release. An r2 cut off of 0.50 was selected for inclusion as evidence for strong genetic linkage, i.e., a "strong linkage disequilibrium.

Example 67

For individuals with colorectal cancer, the distribution of polymorphic alleles at position 185078886 of chromosome 3, found within the PSARL gene, was different from those without colorectal cancer (Table 67). The recessive test for risk associated with carrying the T allele had an empirical p-value of 0.000417 based on permutation analysis, and the corresponding recessive odds ratio is 1.472 (Table 67). These data further suggest that this marker, located within the PSARL gene, is associated with colorectal cancer risk and that the T allele at position 185078886 of chromosome 3 is associated with an increased risk of developing colorectal cancer.

Table 67A indicates SNPs found to be in strong linkage disequilibrium with rs7644746. To generate this list, correlation coefficients (r2) were calculated between the index SNP and all neighboring SNPs cited in the June 2006 HapMap data set release. An r2 cut off of 0.50 was selected for inclusion as evidence for strong genetic linkage, i.e., a "strong linkage disequilibrium.

Example 68

For individuals with colorectal cancer, the distribution of polymorphic alleles at position 189622331 of chromosome 3, found within the LPP gene, was different from those without colorectal cancer (Table 68). The trend test for risk associated with carrying the G allele had an empirical p-value of 0.016373 based on permutation analysis, and the corresponding Mantel-Haenszel odds ratio for trend is 1.174 (Table 68). These data further suggest that this marker, located within the LPP gene, is associated with colorectal cancer risk and that the G allele at position 189622331 of chromosome 3 is associated with an increased risk of developing colorectal cancer.

Table 68 A indicates SNPs found to be in strong linkage disequilibrium with rs6789800. To generate this list, correlation coefficients (r2) were calculated between the index SNP and all neighboring SNPs cited in the June 2006 HapMap data set release. An r2 cut off of 0.50 was selected for inclusion as evidence for strong genetic linkage, i.e., a "strong linkage disequilibrium.

rs7621433 0.959 189651573 1953

Example 69

For individuals with colorectal cancer, the distribution of polymorphic alleles at position 17011072 of chromosome 4 was different from those without colorectal cancer (Table 69). The trend test for risk associated with carrying the C allele had an empirical p-value of 0.004052 based on permutation analysis, and the corresponding Mantel-Haenszel odds ratio for trend is 1.227 (Table 69). These data further suggest that this marker is associated with colorectal cancer risk and that the C allele at position 17011072 of chromosome 4 is associated with an increased risk of developing colorectal cancer.

Table 69A indicates SNPs found to be in strong linkage disequilibrium with rs 16894896. To generate this list, correlation coefficients (r2) were calculated between the index SNP and all neighboring SNPs cited in the June 2006 HapMap data set release. An r2 cut off of 0.50 was selected for inclusion as evidence for strong genetic linkage, i.e., a "strong linkage disequilibrium.

Example 70

For individuals with colorectal cancer, the distribution of polymorphic alleles at position 84526533 of chromosome 4, found within the LOC391674 gene, was different from those without colorectal cancer (Table 70). The dominant test for risk associated with carrying the A allele had an empirical p-value based on permutation analysis of 0.007788, and the corresponding dominant odds ratio is 1.998 (Table 70). These data further suggest that this marker, located within the LOC391674 gene, is associated with colorectal cancer risk and that the A allele at position 84526533 of chromosome 4 is associated with an increased risk of developing colorectal cancer.

Table 70A indicates SNPs found to be in strong linkage disequilibrium with rs 10031382. To generate this list, correlation coefficients (r2) were calculated between the index SNP and all neighboring SNPs cited in the June 2006 HapMap data set release. An r2 cut off of 0.50 was selected for inclusion as evidence for strong genetic linkage, i.e., a "strong linkage disequilibrium.

Example 71

For individuals with colorectal cancer, the distribution of polymorphic alleles at position 96582519 of chromosome 4, found within the UNC5C gene, was different from those without colorectal cancer (Table 71). The dominant test for risk associated with carrying the G allele had an empirical p-value based on permutation analysis of 0.007659, and the corresponding dominant odds ratio is 1.407 (Table 71). These data further suggest that this marker, located within the UNC5C gene, is associated with colorectal cancer risk and that the G allele at position 96582519 of chromosome 4 is associated with an increased risk of developing colorectal cancer. 1 Table 71 I

Table 71 A indicates SNPs found to be in strong linkage disequilibrium with rs 10049501. To generate this list, correlation coefficients (r2) were calculated between the index SNP and all neighboring SNPs cited in the June 2006 HapMap data set release. An r2 cut off of 0.50 was selected for inclusion as evidence for strong genetic linkage, i.e., a "strong linkage disequilibrium.

Example 72

For individuals with colorectal cancer, the distribution of polymorphic alleles at position 99867911 of chromosome 4, found within the TM4SF9 gene, was different fτπi those without colorectal cancer (Table 72). The trend test for risk associated with carrying the G allele had an empirical p-value of 0.008867 based on permutation analysis, and the corresponding Mantel-Haenszel odds ratio for trend is 1.204 (Table 72). These data further suggest that this marker, located within the TM4SF9 gene, is associated with colorectal cancer risk and that the G allele at position 99867911 of chromosome 4 is associated with an increased risk of developing colorectal cancer.

Table 72A indicates SNPs found to be in strong linkage disequilibrium with rs4699354. To generate this list, correlation coefficients (r2) were calculated between the index SNP and all neighboring SNPs cited in the June 2006 HapMap data set release. An r2 cut off of 0.50 was selected for inclusion as evidence for strong genetic linkage, i.e., a "strong linkage disequilibrium.

Example 73

For individuals with colorectal cancer, the distribution of polymorphic alleles at position 126409942 of chromosome 4 was different from those without colorectal cancer (Table 73). The dominant test for risk associated with carrying the T allele had an empirical p-value based on permutation analysis of 0.011165, and the corresponding dominant odds ratio is 1.263 (Table 73). These data further suggest that this marker is associated with colorectal cancer risk and that the T allele at position 126409942 of chromosome 4 is associated with an increased risk of developing colorectal cancer.

Table 73 A indicates SNPs found to be in strong linkage disequilibrium with rs4602510. To generate this list, correlation coefficients (r2) were calculated between the index SNP and all neighboring SNPs cited in the June 2006 HapMap data set release. An r2 cut off of 0.50 was selected for inclusion as evidence for strong genetic linkage, i.e., a "strong linkage disequilibrium.

Example 74

For individuals with colorectal cancer, the distribution of polymorphic alleles at position 136887132 of chromosome 4 was different from those without colorectal cancer (Table 74). The trend test for risk associated with carrying the A allele had an empirical p-value of 0.001659 based on permutation analysis, and the corresponding Mantel-Haenszel odds ratio for trend is 1.368 (Table 74). These data further suggest that this marker is associated with colorectal cancer risk and that the A allele at position 136887132 of chromosome 4 is associated with an increased risk of developing colorectal cancer.

Table 74A indicates SNPs found to be in strong linkage disequilibrium with rsl 3119704. To generate this list, correlation coefficients (r2) were calculated between the index SNP and all neighboring SNPs cited in the June 2006 HapMap data set release. An r2 cut off of 0.50 was selected for inclusion as evidence for strong genetic linkage, i.e., a "strong linkage disequilibrium.

Example 75

For individuals with colorectal cancer, the distribution of polymorphic alleles at position 141745922 of chromosome 4, found within the LOC152586 gene, was different from those without colorectal cancer (Table 75). The recessive test for risk associated with carrying the C allele had an empirical p- value of 0.000871 based on permutation analysis, and the corresponding recessive odds ratio is 1.457 (Table 75). These data further suggest that this marker, located within the LOC 152586 gene, is associated with colorectal cancer risk and that the C allele at position 141745922 of chromosome 4 is associated with an increased risk of developing colorectal cancer.

Table 75A indicates SNPs found to be in strong linkage disequilibrium with rs 1431346. To generate this list, correlation coefficients (r2) were calculated between the index SNP and all neighboring SNPs cited in the June 2006 HapMap data set release. An r2 cut off of 0.50 was selected for inclusion as evidence for strong genetic linkage, i.e., a "strong linkage disequilibrium.

Example 76

For individuals with colorectal cancer, the distribution of polymorphic alleles at position 174207198 of chromosome 4, found within the LOC442117 gene, was different from those without colorectal cancer (Table 76). The recessive test for risk associated with carrying the G allele had an empirical p-value of 0.006454 based on permutation analysis, and the corresponding recessive odds ratio is 1.298 (Table 76). These data further suggest that this marker, located within the LOC442117 gene, is associated with colorectal cancer risk and that the G allele at position 174207198 of chromosome 4 is associated with an increased risk of developing colorectal cancer.

Table 76 A indicates SNPs found to be in strong linkage disequilibrium with rs2610201. To generate this list, correlation coefficients (r2) were calculated between the index SNP and all neighboring SNPs cited in the June 2006 HapMap data set release. An r2 cut off of 0.50 was selected for inclusion as evidence for strong genetic linkage, i.e., a "strong linkage disequilibrium.

Example 77

For individuals with colorectal cancer, the distribution of polymorphic alleles at position 33086350 of chromosome 5 was different from those without colorectal cancer (Table 77). The dominant test for risk associated with carrying the G allele had an empirical p-value based on permutation analysis of 0.008186, and the corresponding dominant odds ratio is 1.332 (Table 77). These data further suggest that this marker is associated with colorectal cancer risk and that the G allele at position 33086350 of chromosome 5 is associated with an increased risk of developing colorectal cancer.

Table 77 A indicates SNPs found to be in strong linkage disequilibrium with rs3909867. To generate this list, correlation coefficients (r2) were calculated between the index SNP and all neighboring SNPs cited in the June 2006 HapMap data set release. An r2 cut off of 0.50 was selected for inclusion as evidence for strong genetic linkage, i.e., a "strong linkage disequilibrium.

Example 78

For individuals with colorectal cancer, the distribution of polymorphic alleles at position 34830429 of chromosome 5, found within the RAI14 gene, was different from those without colorectal cancer (Table 78). The recessive test for risk associated with carrying the A allele had an empirical p- value of 0.001639 based on permutation analysis, and the corresponding recessive odds ratio is 3.515 (Table 78). These data further suggest that this marker, located within the RAI14 gene, is associated with colorectal cancer risk and that the A allele at position 34830429 of chromosome 5 is associated with an increased risk of developing colorectal cancer.

Table 78A indicates SNPs found to be in strong linkage disequilibrium with rsl0045171. To generate this list, correlation coefficients (r2) were calculated between the index SNP and all neighboring SNPs cited in the June 2006 HapMap data set release. An r2 cut off of 0.50 was selected for inclusion as evidence for strong genetic linkage, i.e., a "strong linkage disequilibrium.

Example 79 For individuals with colorectal cancer, the distribution of polymorphic alleles at position 53419665 of chromosome 5, found within the ARFRP2 gene, was different from those without colorectal cancer (Table 79). The dominant test for risk associated with carrying fhe A allele had an empirical p- value based on permutation analysis of 0.00013, and the corresponding dominant odds ratio is 1.663 (Table 79). These data further suggest that this marker, located within the ARFRP2 gene, is associated with colorectal cancer risk and that the A allele at position 53419665 of chromosome 5 is associated with an increased risk of developing colorectal cancer.

Table 79A indicates SNPs found to be in strong linkage disequilibrium with rs448666. To generate this list, correlation coefficients (r2) were calculated between the index SNP and all neighboring SNPs cited in the June 2006 HapMap data set release. An r2 cut off of 0.50 was selected for inclusion as evidence for strong genetic linkage, i.e., a "strong linkage disequilibrium.

Example 80

For individuals with colorectal cancer, the distribution of polymorphic alleles at position 53708606 of chromosome 5 was different from those without colorectal cancer (Table 80).

The dominant test for risk associated with carrying the C allele had an empirical p-value based on permutation analysis of 0.011736, and the corresponding dominant odds ratio is

1.271 (Table 80). These data further suggest that this marker is associated with colorectal cancer risk and that the C allele at position 53708606 of chromosome 5 is associated with an increased risk of developing colorectal cancer.

Table 8OA indicates SNPs found to be in strong linkage disequilibrium with rsl2515791. To generate this list, correlation coefficients (r2) were calculated between the index SNP and all neighboring SNPs cited in the June 2006 HapMap data set release. An r2 cut off of 0.50 was selected for inclusion as evidence for strong genetic linkage, i.e., a "strong linkage disequilibrium.

Example 81

For individuals with colorectal cancer, the distribution of polymorphic alleles at position 88045349 of chromosome 5 was different from those without colorectal cancer (Table 81). The dominant test for risk associated with carrying the G allele had an empirical p-value based on permutation analysis of 0.000934, and the corresponding dominant odds ratio is 1.355 (Table 81). These data further suggest that this marker is associated with colorectal cancer risk and that the G allele at position 88045349 of chromosome 5 is associated with an increased risk of developing colorectal cancer. I Table 81 1

Table 81A indicates SNPs found to be in strong linkage disequilibrium with rs254778. To generate this list, correlation coefficients (r2) were calculated between the index SNP and all neighboring SNPs cited in the June 2006 HapMap data set release. An r2 cut off of 0.50 was selected for inclusion as evidence for strong genetic linkage, i.e., a "strong linkage disequilibrium.

Example 82

For individuals with colorectal cancer, the distribution of polymorphic alleles at position 94655931 of chromosome 5 was different from those without colorectal cancer (Table 82). The dominant test for risk associated with carrying the T allele had an empirical p- value based on permutation analysis of 0.000386, and the corresponding dominant odds ratio is 2.342 (Table 82). These data further suggest that this marker is associated with colorectal cancer risk and that the T allele at position 94655931 of chromosome 5 is associated with an increased risk of developing colorectal cancer.

Table 82A indicates SNPs found to be in strong linkage disequilibrium with rs26396. To generate this list, correlation coefficients (r2) were calculated between the index SNP and all neighboring SNPs cited in the June 2006 HapMap data set release. An r2 cut off of 0.50 was selected for inclusion as evidence for strong genetic linkage, i.e., a "strong linkage disequilibrium.

Example 83

For individuals with colorectal cancer, the distribution of polymorphic alleles at position 98722748 of chromosome 5 was different from those without colorectal cancer (Table 83). The recessive test for risk associated with carrying the A allele had an empirical p-value of 0.005064 based on permutation analysis, and the corresponding recessive odds ratio is 1.313 (Table 83). These data further suggest that this marker is associated with colorectal cancer risk and that the A allele at position 98722748 of chromosome 5 is associated with an increased risk of developing colorectal cancer.

Table 83 A indicates SNPs found to be in strong linkage disequilibrium with rs6892901. To generate this list, correlation coefficients (r2) were calculated between the index SNP and all neighboring SNPs cited in the June 2006 HapMap data set release. An r2 cut off of 0.50 was selected for inclusion as evidence for strong genetic linkage, i.e., a "strong linkage disequilibrium.

Example 84

For individuals with colorectal cancer, the distribution of polymorphic alleles at position 100014052 of chromosome 5 was different from those without colorectal cancer (Table 84). The dominant test for risk associated with carrying the C allele had an empirical p-value based on permutation analysis of 0.005392, and the corresponding dominant odds ratio is 1.328 (Table 84). These data further suggest that this marker is associated with colorertal cancer risk and that the C allele at position 100014052 of chromosome 5 is associated with an increased risk of developing colorectal cancer.

Table 84 rs no. 6880868

Table 84A indicates SNPs found to be in strong linkage disequilibrium with rs6880868. To generate this list, correlation coefficients (r2) were calculated between the index SNP and all neighboring SNPs cited in the June 2006 HapMap data set release. An r2 cut off of 0.50 was selected for inclusion as evidence for strong genetic linkage, i.e., a "strong linkage disequilibrium.

Example 85

For individuals with colorectal cancer, the distribution of polymorphic alleles at position 106741517 of chromosome 5 was different from those without colorectal cancer (Table 85). The dominant test for risk associated with carrying the G allele had an empirical p-value based on permutation analysis of 0.027033, and the corresponding dominant odds ratio is 1.211 (Table 85). These data further suggest that this marker is associated with colorectal cancer risk and that the G allele at position 106741517 of chromosome 5 is associated with an increased risk of developing colorectal cancer.

Table 85A indicates SNPs found to be in strong linkage disequilibrium with rs365807. To generate this list, correlation coefficients (r2) were calculated between the index SNP and all neighboring SNPs cited in the June 2006 HapMap data set release. An r2 cut off of 0.50 was selected for inclusion as evidence for strong genetic linkage, i.e., a "strong linkage disequilibrium.

Example 86

For individuals with colorectal cancer, the distribution of polymorphic alleles at position 113516722 of chromosome 5 was different from those without colorectal cancer (Table 86). The recessive test for risk associated with carrying the G allele had an empirical p-value of 0.002529 based on permutation analysis, and the corresponding recessive odds ratio is 1.384 (Table 86). These data further suggest that this marker is associated with colorectal cancer risk and that the G allele at position 113516722 of chromosome 5 is associated with an increased risk of developing colorectal cancer.

Table 86A indicates SNPs found to be in strong linkage disequilibrium with rsl 7350454. To generate this list, correlation coefficients (r2) were calculated between the index SNP and all neighboring SNPs cited in the June 2006 HapMap data set release. An r2 cut off of 0.50 was selected for inclusion as evidence for strong genetic linkage, i.e., a "strong linkage disequilibrium.

Example 87

For individuals with colorectal cancer, the distribution of polymorphic alleles at position 114745898 of chromosome 5 was different from those without colorectal cancer (Table 87). The recessive test for risk associated with carrying the G allele had an empirical p-value of 0.001657 based on permutation analysis, and the corresponding recessive odds ratio is 1.829 (Table 87). These data further suggest that this marker is associated with colorectal cancer risk and that the G allele at position 114745898 of chromosome 5 is associated with an increased risk of developing colorectal cancer.

Table 87A indicates SNPs found to be in strong linkage disequilibrium with rs 1455850. To generate this list, correlation coefficients (r2) were calculated between the index SNP and all neighboring SNPs cited in the June 2006 HapMap data set release. An r2 cut off of 0.50 was selected for inclusion as evidence for strong genetic linkage, i.e., a "strong linkage disequilibrium.

Example 88

For individuals with colorectal cancer, the distribution of polymorphic alleles at position 128997514 of chromosome 5, found within the ADAMTS 19 gene, was different from those without colorectal cancer (Table 88). The recessive test for risk associated with carrying the G allele had an empirical p-value of 0.009425 based on permutation analysis, and the corresponding recessive odds ratio is 1.364 (Table 88). These data further suggest that this marker, located within the ADAMTS 19 gene, is associated with colorectal cancer risk and that the G allele at position 128997514 of chromosome 5 is associated with an increased risk of developing colorectal cancer.

Table 88A indicates SNPs found to be in strong linkage disequilibrium with rs3909548. To generate this list, correlation coefficients (r2) were calculated between the index SNP and all neighboring SNPs cited in the June 2006 HapMap data set release. An r2 cut off of 0.50 was selected for inclusion as evidence for strong genetic linkage, i.e., a "strong linkage disequilibrium.

Example 89 For individuals with colorectal cancer, the distribution of polymorphic alleles at position 145262302 of chromosome 5 was different from those without colorectal cancer (Table 89). The trend test for risk associated with carrying the A allele had an empirical p-value of 0.002925 based on permutation analysis, and the corresponding Mantel-Haenszel odds ratio for trend is 1.41 (Table 89). These data further suggest that this marker is associated with colorectal cancer risk and that the A allele at position 145262302 of chromosome 5 is associated with an increased risk of developing colorectal cancer.

Table 89A indicates SNPs found to be in strong linkage disequilibrium with rs4913050. To generate this list, correlation coefficients (r2) were calculated between the index SNP and all neighboring SNPs cited in the June 2006 HapMap data set release. An r2 cut off of 0.50 was selected for inclusion as evidence for strong genetic linkage, i.e., a "strong linkage disequilibrium.

Example 90

For individuals with colorectal cancer, the distribution of polymorphic alleles at position 153344333 of chromosome 5 was different from those without colorectal cancer (Table 90). The dominant test for risk associated with carrying the G allele had an empirical p-value based on permutation analysis of 0.003318, and the corresponding dominant odds ratio is 1.497 (Table 90). These data further suggest that this marker is associated with colorectal cancer risk and that the G allele at position 153344333 of chromosome 5 is associated with an increased risk of developing colorectal cancer.

Table 9OA indicates SNPs found to be in strong linkage disequilibrium with rs375232. To generate this list, correlation coefficients (r2) were calculated between the index SNP and all neighboring SNPs cited in the June 2006 HapMap data set release. An r2 cut off of 0.50 was selected for inclusion as evidence for strong genetic linkage, i.e., a "strong linkage disequilibrium.

Example 91

For individuals with colorectal cancer, the distribution of polymorphic alleles at position 155797045 of chromosome 5, found within the SGCD gene, was different from those without colorectal cancer (Table 91). The dominant test for risk associated with carrying the C allele had an empirical p-value based on permutation analysis of 0.000968, and the corresponding dominant odds ratio is 3.556 (Table 91). These data further suggest that this marker, located within the SGCD gene, is associated with colorectal cancer risk and that the C allele at position 155797045 of chromosome 5 is associated with an increased risk of developing colorectal cancer.

Table 91A indicates SNPs found to be in strong linkage disequilibrium with rsl7053557. To generate this list, correlation coefficients (r2) were calculated between the index SNP and all neighboring SNPs cited in the June 2006 HapMap data set release. An r2 cut off of 0.50 was selected for inclusion as evidence for strong genetic linkage, i.e., a "strong linkage disequilibrium.

Example 92

For individuals with colorectal cancer, the distribution of polymorphic alleles at position 166726668 of chromosome 5, found within the LOC 134541 gene, was different from those without colorectal cancer (Table 92). The dominant test for risk associated with carrying the

A allele had an empirical p-value based on permutation analysis of 0.000473, and the corresponding dominant odds ratio is 12.493 (Table 92). These data further suggest that this marker, located within the LOC 134541 gene, is associated with colorectal cancer risk and that the A allele at position 166726668 of chromosome 5 is associated with an increased risk of developing colorectal cancer.

Table 92A indicates SNPs found to be in strong linkage disequilibrium with rs 10516032. To generate this list, correlation coefficients (r2) were calculated between the index SNP and all neighboring SNPs cited in the June 2006 HapMap data set release. An r2 cut off of 0.50 was selected for inclusion as evidence for strong genetic linkage, i.e., a "strong linkage disequilibrium.

Table 92A Linked SNPs

SNP r2 Position on chr5 SEQ ID NO rs 10516032 - 166726668 2709

Example 93

For individuals with colorectal cancer, the distribution of polymorphic alleles at position 172412942 of chromosome 5 was different from those without colorectal cancer (Table 93).

The dominant test for risk associated with carrying the C allele had an empirical p-value based on permutation analysis of 0.000974, and the corresponding dominant odds ratio is

1.353 (Table 93). These data further suggest that this marker is associated with colorectal cancer risk and that the C allele at position 172412942 of chromosome 5 is associated with an increased risk of developing colorectal cancer.

Table 93 A indicates SNPs found to be in strong linkage disequilibrium with rs251253. To generate this list, correlation coefficients (r2) were calculated between the index SNP and all neighboring SNPs cited in the June 2006 HapMap data set release. An r2 cut off of 0.50 was selected for inclusion as evidence for strong genetic linkage, i.e., a "strong linkage disequilibrium.

Table 93A Linked SNPs

Example 94

For individuals with colorectal cancer, the distribution of polymorphic alleles at position 3445838 of chromosome 6 was different from those without colorectal cancer (Table 94). The dominant test for risk associated with carrying the A allele had an empirical p-value based on permutation analysis of 0.002472, and the corresponding dominant odds ratio is 1.326 (Table 94). These data further suggest that this marker is associated with colorectal cancer risk and that the A allele at position 3445838 of chromosome 6 is associated with an increased risk of developing colorectal cancer.

Table 94 A indicates SNPs found to be in strong linkage disequilibrium witb isό93"8454. To generate this list, correlation coefficients (r2) were calculated between the index SNP and all neighboring SNPs cited in the June 2006 HapMap data set release. An r2 cut off of 0.50 was selected for inclusion as evidence for strong genetic linkage, i.e., a "strong linkage disequilibrium.

Example 95

For individuals with colorectal cancer, the distribution of polymorphic alleles at position 8944645 of chromosome 6 was different from those without colorectal cancer (Table 95). The recessive test for risk associated with carrying the G allele had an empirical p-value of

0.004674 based on permutation analysis, and the corresponding recessive odds ratio is 1.348

(Table 95). These data further suggest that this marker is associated with colorectal cancer risk and that the G allele at position 8944645 of chromosome 6 is associated with an increased risk of developing colorectal cancer.

Table 95A indicates SNPs found to be in strong linkage disequilibrium with rs2327112. To generate this list, correlation coefficients (r2) were calculated between the index SNP and all neighboring SNPs cited in the June 2006 HapMap data set release. An r2 cut off of 0.50 was selected for inclusion as evidence for strong genetic linkage, i.e., a "strong linkage disequilibrium.

Example 96 For individuals with colorectal cancer, the distribution of polymorphic alleles at position 10970876 of chromosome 6 was different from those without colorectal cancer (Table 96). The dominant test for risk associated with carrying the G allele had an empirical p-value based on permutation analysis of 0.00059, and the corresponding dominant odds ratio is 1.512 (Table 96). These data further suggest that this marker is associated with colorectal cancer risk and that the G allele at position 10970876 of chromosome 6 is associated with an increased risk of developing colorectal cancer.

Table 96A indicates SNPs found to be in strong linkage disequilibrium with rs 1233846. To generate this list, correlation coefficients (r2) were calculated between the index SNP and all neighboring SNPs cited in the June 2006 HapMap data set release. An r2 cut off of 0.50 was selected for inclusion as evidence for strong genetic linkage, i.e., a "strong linkage disequilibrium.

Example 97

For individuals with colorectal cancer, the distribution of polymorphic alleles at position 12403489 of chromosome 6, found within the EDNl gene, was different from those without colorectal cancer (Table 97). The trend test for risk associated with carrying the G allele had an empirical p-value of 0.000746 based on permutation analysis, and the corresponding Mantel-Haenszel odds ratio for trend is 1.269 (Table 97). These data further suggest that this marker, located within the EDNl gene, is associated with colorectal cancer risk and that the G allele at position 12403489 of chromosome 6 is associated with an increased risk of developing colorectal cancer.

Table 97A indicates SNPs found to be in strong linkage disequilibrium with rs 1626492. To generate this list, correlation coefficients (r2) were calculated between the index SNP and all neighboring SNPs cited in the June 2006 HapMap data set release. An r2 cut off of 0.50 was selected for inclusion as evidence for strong genetic linkage, i.e., a "strong linkage disequilibrium.

Table 97A Linked SNPs

SNP r2 Position on chr6 SEQ ID NO rs 1626492 - 12403489 2760

Example 98

For individuals with colorectal cancer, the distribution of polymorphic alleles at position 12517402 of chromosome 6 was different from those without colorectal cancer (Table 98). The recessive test for risk associated with carrying the C allele had an empirical p-value of 0.000928 based on permutation analysis, and the corresponding recessive odds ratio is 1.353 (Table 98). These data further suggest that this marker is associated with colorectal cancer risk and that the C allele at position 12517402 of chromosome 6 is associated with an increased risk of developing colorectal cancer.

Table 98 A indicates SNPs found to be in strong linkage disequilibrium with rs 12216318. To generate this list, correlation coefficients (r2) were calculated between the index SNP and all neighboring SNPs cited in the June 2006 HapMap data set release. An r2 cut off of 0.50 was selected for inclusion as evidence for strong genetic linkage, i.e., a "strong linkage disequilibrium.

Example 99

For individuals with colorectal cancer, the distribution of polymorphic alleles at position 20099425 of chromosome 6, found within the LOC442165 gene, was different from those without colorectal cancer (Table 99). The dominant test for risk associated with carrying the T allele had an empirical p-value based on permutation analysis of 0.007512, and the corresponding dominant odds ratio is 1.861 (Table 99). These data further suggest that this marker, located within the LOC442165 gene, is associated with colorectal cancer risk and that the T allele at position 20099425 of chromosome 6 is associated with an increased risk of developing colorectal cancer.

Table 99A indicates SNPs found to be in strong linkage disequilibrium with rs9295456. To generate this list, correlation coefficients (r2) were calculated between the index SNP and all neighboring SNPs cited in the June 2006 HapMap data set release. An r2 cut off of 0.50 was selected for inclusion as evidence for strong genetic linkage, i.e., a "strong linkage disequilibrium.

Example 100 For individuals with colorectal cancer, the distribution of polymorphic alleles at position 23527622 of chromosome 6 was different from these without colorectal cancel (Table 100). The dominant test for risk associated with carrying the A allele had an empirical p-value based on permutation analysis of 0.001047, and the corresponding dominant odds ratio is 2.585 (Table 100). These data further suggest that this marker is associated with colorectal cancer risk and that the A allele at position 23527622 of chromosome 6 is associated with an increased risk of developing colorectal cancer.

Table IOOA indicates SNPs found to be in strong linkage disequilibrium with rs943068. To generate this list, correlation coefficients (r2) were calculated between the index SNP and all neighboring SNPs cited in the June 2006 HapMap data set release. An r2 cut off of 0.50 was selected for inclusion as evidence for strong genetic linkage, i.e., a "strong linkage disequilibrium.

Example 101

For individuals with colorectal cancer, the distribution of polymorphic alleles at position 39396512 of chromosome 6, found within the KCNK 16 gene, was different from those without colorectal cancer (Table 101). The recessive test fcr risk associated with carrying the A allele had an empirical p-value of 0.004541 based on permutation analysis, and the corresponding recessive odds ratio is 1.418 (Table 101). These data further suggest that this marker, located within the KCNK 16 gene, is associated with colorectal cancer risk and that the A allele at position 39396512 of chromosome 6 is associated with an increased risk of developing colorectal cancer.

Table 101 A indicates SNPs found to be in strong linkage disequilibrium with rs4714237. To generate this list, correlation coefficients (r2) were calculated between the index SNP and all neighboring SNPs cited in the June 2006 HapMap data set release. An r2 cut off of 0.50 was selected for inclusion as evidence for strong genetic linkage, i.e., a "strong linkage disequilibrium.

Example 102

For individuals with colorectal cancer, the distribution of polymorphic alleles at position 50379448 of chromosome 6 was different from those without colorectal cancer (Table 102). The trend test for risk associated with carrying the A allele had an empirical p-value of 0.001558 based on permutation analysis, and the corresponding Mantel-Haenszel odds ratio for trend is 1.228 (Table 102). These data further suggest that this marker is associated with colorectal cancer risk and that the A allele at position 50379448 of chromosome 6 is associated with an increased risk of developing colorectal cancer.

Table 102A indicates SNPs found to be in strong linkage disequilibrium with rs7766954. To generate this list, correlation coefficients (r2) were calculated between the index SNP and all neighboring SNPs cited in the June 2006 HapMap data set release. An r2 cut off of 0.50 was selected for inclusion as evidence for strong genetic linkage, i.e., a "strong linkage disequilibrium.

Example 103

For individuals with colorectal cancer, the distribution of polymorphic alleles at position 83067321 of chromosome 6 was different from those without colorectal cancer (Table 103). The dominant test for risk associated with carrying the C allele had an empirical p-value based on permutation analysis of 0.000387, and the corresponding dominant odds ratio is 1.381 (Table 103). These data further suggest that this marker is associated with colorectal cancer risk and that the C allele at position 83067321 of chromosome 6 is associated with an increased risk of developing colorectal cancer.

Table 103 A indicates SNPs found to be in strong linkage disequilibrium with rs507500. To generate this list, correlation coefficients (r2) were calculated between the index SNP and all neighboring SNPs cited in the June 2006 HapMap data set release. An r2 cut off of 0.50 was selected for inclusion as evidence for strong genetic linkage, i.e., a "strong linkage disequilibrium.

Example 104

For individuals with colorectal cancer, the distribution of polymorphic alleles at position 83146661 of chromosome 6 was different from those without colorectal cancer (Table 104). The dominant test for risk associated with carrying the G allele had an empirical p-value based on permutation analysis of 0.000135, and the corresponding dominant odds ratio is 1.422 (IaDIe 104). These data further suggest that this marker is associated with colorectal cancer risk and that the G allele at position 83146661 of chromosome 6 is associated with an increased risk of developing colorectal cancer.

Table 104A indicates SNPs found to be in strong linkage disequilibrium with rs932614. To generate this list, correlation coefficients (r2) were calculated between the index SNP and all neighboring SNPs cited in the June 2006 HapMap data set release. An r2 cut off of 0.50 was selected for inclusion as evidence for strong genetic linkage, i.e., a "strong linkage disequilibrium.

rs9361923 0.925 83172329 2904

Example 105

For individuals with colorectal cancer, the distribution of polymorphic alleles at position 93587421 of chromosome 6 was different from those without colorectal cancer (Table 105). The dominant test for risk associated with carrying the C allele had an empirical p-value based on permutation analysis of 0.003475, and the corresponding dominant odds ratio is 1.317 (Table 105). These data further suggest that this marker is associated with colorectal cancer risk and that the C allele at position 93587421 of chromosome 6 is associated with an increased risk of developing colorectal cancer.

Table 105 A indicates SNPs found to be in strong linkage disequilibrium with rs9452134. To generate this list, correlation coefficients (r2) were calculated between the index SNP and all neighboring SNPs cited in the June 2006 HapMap data set release. An r2 cut off of 0.50 was selected for inclusion as evidence for strong genetic linkage, i.e., a "strong linkage disequilibrium.

Example 106

For individuals with colorectal cancer, the distribution of polymorphic alleles at position 129880427 of chromosome 6 was different from those without colorectal cancer (Table 106). The trend test for risk associated with carrying the A allele had an empirical p-value of 0.002908 based on permutation analysis, and the corresponding Mantel-Haenszel odds ratio for trend is 1.363 (Table 106). These data further suggest that this marker is associated with colorectal cancer risk and that the A allele at position 129880427 of chromosome 6 is associated with an increased risk of developing colorectal cancer.

Table 106A indicates SNPs found to be in strong linkage disequilibrium with rs 17753229. TQ generate this list, correlation coefficients (r2) were calculated between the index SNP and all neighboring SNPs cited in the June 2006 HapMap data set release. An r2 cut off of 0.50 was selected for inclusion as evidence for strong genetic linkage, i.e., a "strong linkage disequilibrium.

Example 107

For individuals with colorectal cancer, the distribution of polymorphic alleles at position 131751505 of chromosome 6 was different from those without colorectal cancer (Table 107). The dominant test for risk associated with carrying the C allele had an empirical p-value based on permutation analysis of 0.000155, and the corresponding dominant odds ratio is 1.423 (Table 107). These data further suggest that this marker is associated wiih colorectal cancer risk and that the C allele at position 131751505 of chromosome 6 is associated with an increased risk of developing colorectal cancer.

Table 107A indicates SNPs found to be in strong linkage disequilibrium with rs6933778. To generate this list, correlation coefficients (r2) were calculated between the index SNP and all neighboring SNPs cited in the June 2006 HapMap data set release. An r2 cut off of 0.50 was selected for inclusion as evidence for strong genetic linkage, i.e., a "strong linkage disequilibrium.

Example 108

For individuals with colorectal cancer, the distribution of polymorphic alleles at position 133771457 of chromosome 6, found within the EYA4 gene, was different from those without colorectal cancer (Table 108). The trend test for risk associated with carrying the T allele had an empirical p- value of 0.004718 based on permutation analysis, and the corresponding Mantel-Haenszel odds ratio for trend is 1.28 (Table 108). These data further suggest that this marker, located within the EY A4 gene, is associated with colorectal cancer risk and that the T allele at position 133771457 of chromosome 6 is associated with an increased risk of developing colorectal cancer.

Table 108A indicates SNPs found to be in strong linkage disequilibrium with rsl336533. To generate this list, correlation coefficients (r2) were calculated between the index SNP and all neighboring SNPs cited in the June 2006 HapMap data set release. An r2 cut off of 0.50 was selected for inclusion as evidence for strong genetic linkage, i.e., a "strong linkage disequilibrium.

Table 108A Linked SNPs

SNP r2 Position on chr6 SEQ ID NO rsl336533 - 133771457 3011

Example 109

For individuals with colorectal cancer, the distribution of polymorphic alleles at position 158382054 of chromosome 6, found within the SYNJ2 gene, was different from those without colorectal cancer (Table 109). The dominant test for risk associated with carrying the A allele had an empirical p-value based on permutation analysis of 2.8e-O5, and the corresponding dominant odds ratio is 1.636 (Table 109). These data further suggest that this marker, located within the SYNJ2 gene, is associated with colorectal cancer risk and that the A allele at position 158382054 of chromosome 6 is associated with an increased risk of developing colorectal cancer.

Table 109A indicates SNPs found to be in strong linkage disequilibrium with rs9459057. To generate this list, correlation coefficients (r2) were calculated between the index SNP and all neighboring SNPs cited in the June 2006 HapMap data set release. An r2 cut off of 0.50 was selected for inclusion as evidence for strong genetic linkage, i.e., a "strong linkage disequilibrium.

Example 110

For individuals with colorectal cancer, the distribution of polymorphic alleles at position 158644585 of chromosome 6 was different from those without colorectal cancer (Table 110). The dominant test for risk associated with carrying the A allele had an empirical p-value based on permutation analysis of 0.002295, and the corresponding dominant odds ratio is 2.451 (Table 110). These data further suggest that this marker is associated with colorectal cancer risk and that the A allele at position 158644585 of chromosome 6 is associated with an increased risk of developing colorectal cancer.

Table 11OA indicates SNPs found to be in strong linkage disequilibrium with rs9364885. To generate this list, correlation coefficients (r2) were calculated between the index SNP and all neighboring SNPs cited in the June 2006 HapMap data set release. An r2 cut off of 0.50 was selected for inclusion as evidence for strong genetic linkage, i.e., a "strong linkage disequilibrium.

Example 111

For individuals with colorectal cancer, the distribution of polymorphic alleles at position 158841582 of chromosome 6, found within the TULP4 gene, was different from those without colorectal cancer (Table 111). The dominant test for risk associated with carrying the C allele had an empirical p-value based on permutation analysis of 0.003497, and the corresponding dominant odds ratio is 1.286 (Table 111). These data further suggest that this marker, located within the TULP4 gene, is associated with colorectal cancer risk and that the C allele at position 158841582 of chromosome 6 is associated with an increased risk of developing colorectal cancer.

Table H lA indicates SNPs found to be in strong linkage disequilibrium with rs341138. To generate this list, correlation coefficients (r2) were calculated between the index SNP and all neighboring SNPs cited in the June 2006 HapMap data set release. An r2 cut off of 0.50 was selected for inclusion as evidence for strong genetic linkage, i.e., a "strong linkage disequilibrium.

Example 112

For individuals with colorectal cancer, the distribution of polymorphic alleles at position 167066688 of chromosome 6 was different from those without colorectal cancer (Table 112). The recessive test for risk associated with carrying the T allele had an empirical p-value of 0.007959 based on permutation analysis, and the corresponding recessive odds ratio is 1.793 (Table 112). These data further suggest that this marker is associated with colorectal cancer risk and that the T allele at position 167066688 of chromosome 6 is associated with an increased risk of developing colorectal cancer.

Table 112A indicates SNPs found to be in strong linkage disequilibrium with rs 10484524. To generate this list, correlation coefficients (r2) were calculated between the index SNP and all neighboring SNPs cited in the June 2006 HapMap data set release. An r2 cut off of 0.50 was selected for inclusion as evidence for strong genetic linkage, i.e., a "strong linkage disequilibrium.

Example 113

For individuals with colorectal cancer, the distribution of polymorphic alleles at position 2993500 of chromosome 7 was different from those without colorectal cancer (Table 113).

The trend test for risk associated with carrying the C allele had an empirical p-value of

0.003906 based on permutation analysis, and the corresponding Mantel-Haenszel odds ratio for trend is 1.197 (Table 113). These data further suggest that this marker is associated with colorectal cancer risk and that the C allele at position 2993500 of chromosome 7 is associated with an increased risk of developing colorectal cancer.

Table 113A indicates SNPs found to be in strong linkage disequilibrium with rs 10241890. To generate this list, correlation coefficients (r2) were calculated between the index SNP and all neighboring SNPs cited in the June 2006 HapMap data set release. An r2 cut off of 0.50 was selected for inclusion as evidence for strong genetic linkage, i.e., a "strong linkage disequilibrium.

Example 114

For individuals with colorectal cancer, the distribution of polymorphic alleles at position 13938981 of chromosome 7 was different from those without colorectal cancer (Table 114). The dominant test for risk associated with carrying the T allele had an empirical p- value based on permutation analysis of 0.088324, and the corresponding dominant odds ratio is 1.432 (Table 114). These data further suggest that this marker is associated with colorectal cancer risk and that the T allele at position 13938981 of chromosome 7 is associated with an increased risk of developing colorectal cancer.

Table 114A indicates SNPs found to be in strong linkage disequilibrium with rsl0486058. To generate this list, correlation coefficients (r2) were calculated between the index SNP and all neighboring SNPs cited in the June 2006 HapMap data set release. An r2 cut off of 0.50 was selected for inclusion as evidence for strong genetic linkage, i.e., a "strong linkage disequilibrium.

Example 115

For individuals with colorectal cancer, the distribution of polymorphic alleles at position 20613496 of chromosome 7 was different from those without colorectal cancer (Table 115). The trend test for risk associated with carrying the G allele had an empirical p-value of 0.005162 based on permutation analysis, and the corresponding Mantel-Haenszel odds ratio for trend is 1.27 (Table 115). These data further suggest that this marker is associated with colorectal cancer risk and that the G allele at position 20613496 of chromosome 7 is associated with an increased risk of developing colorectal cancer.

Table 115A indicates SNPs found to be in strong linkage disequilibrium with rs2058076. To generate this list, correlation coefficients (r2) were calculated between the index SNP and all neighboring SNPs cited in the June 2006 HapMap data set release. An r2 cut off of 0.50 was selected for inclusion as evidence for strong genetic linkage, i.e., a "strong linkage disequilibrium.

Table 115A Linked SNPs

SNP r2 Position on chr7 SEQ ID NO rs2058076 - 20613496 3146

Example 116 For individuals with colorectal cancer, the distribution of polymorphic alleles at position 21799066 of chromosome 7 was different from those without colorectal cancer (Table 116). The recessive test for risk associated with carrying the A allele had an empirical p-value of 0.002002 based on permutation analysis, and the corresponding recessive odds ratio is 1.435 (Table 116). These data further suggest that this marker is associated with colorectal cancer risk and that the A allele at position 21799066 of chromosome 7 is associated with an increased risk of developing colorectal cancer.

Table 116A indicates SNPs found to be in strong linkage disequilibrium with rslO15818. To generate this list, correlation coefficients (r2) were calculated between the index SNP and all neighboring SNPs cited in the June 2006 HapMap data set release. An r2 cut off of 0.50 was selected for inclusion as evidence for strong genetic linkage, i.e., a "strong linkage disequilibrium.

Example 117

For individuals with colorectal cancer, the distribution of polymorphic alleles at position 21799157 of chromosome 7 was different from those without colorectal cancer (Table 117).

The trend test for risk associated with carrying the T allele had an empirical p-value of

0.000316 based on permutation analysis, and the corresponding Mantel-Haenszel odds ratio for trend is 1.318 (Table 117). These data further suggest that this marker is associated with colorectal cancer risk and that the T allele at position 21799157 of chromosome 7 is associated with an increased risk of developing colorectal cancer.

Table 117 rs no. 1174995

Table 117A indicates SNPs found to be in strong linkage disequilibrium with rs 1174995. To generate this list, correlation coefficients (r2) were calculated between the index SNP and all neighboring SNPs cited in the June 2006 HapMap data set release. An r2 cut off of 0.50 was selected for inclusion as evidence for strong genetic linkage, i.e., a "strong linkage disequilibrium.

Example 118

For individuals with colorectal cancer, the distribution of polymorphic alleles at position 21800306 of chromosome 7 was different from those without colorectal cancer (Table 118).

The dominant test for risk associated with carrying the T allele had an empirical p-value based on permutation analysis of 0.002277, and the corresponding dominant odds ratio is 1.322

(Table 118). These data further suggest that this marker is as&υciated with colorectal cancer risk and that the T allele at position 21800306 of chromosome 7 is associated with an increased risk of developing colorectal cancer.

Table 118A indicates SNPs found to be in strong linkage disequilibrium with rsl 174991. To generate this list, correlation coefficients (r2) were calculated between the index SNP and all neighboring SNPs cited in the June 2006 HapMap data set release. An r2 cut off of 0.50 was selected for inclusion as evidence for strong genetic linkage, i.e., a "strong linkage disequilibrium.

Example 119

For individuals with colorectal cancer, the distribution of polymorphic alleles at position 28279756 of chromosome 7, found within the CREB5 gene, was different from those without colorectal cancer (Table 119). The dominant test for risk associated with carrying the T allele had an empirical p- value based on permutation analysis of 0.013071, and the corresponding dominant odds ratio is 1.321 (Table 119). These data further suggest that this marker, located within the CREB5 gene, is associated with colorectal cancer risk and that the T allele at position 28279756 of chromosome 7 is associated with an increased risk of developing colorectal cancer.

Table 119A indicates SNPs found to be in strong linkage disequilibrium with rs6978323. To generate this list, correlation coefficients (r2) were calculated between the index SNP and all neighboring SNPs cited in the June 2006 HapMap data set release. An r2 cut off of 0.50 was selected for inclusion as evidence for strong genetic linkage, i.e., a "strong linkage disequilibrium.

Example 120

For individuals with colorectal cancer, the distribution of polymorphic alleles at position 33016928 of chromosome 7, found within the Bl gene, was different from those without colorectal cancer (Table 120). The dominant test for risk associated with carrying the T allele had an empirical p-value based on permutation analysis of 0.000967, and the corresponding dominant odds ratio is 1.38 (Table 120). These data further suggest that this marker, located within the Bl gene, is associated with colorectal cancer risk and that the T allele at position 33016928 of chromosome 7 is associated with an increased risk of developing colorectal cancer.

Table 120A indicates SNPs found to be in strong linkage disequilibrium with rsl7150810. To generate this list, correlation coefficients (r2) were calculated between the index SNP and all neighboring SNPs cited in the June 2006 HapMap data set release. An r2 cut off of 0.50 was selected for inclusion as evidence for strong genetic linkage, i.e., a "strong linkage disequilibrium.

Example 121

For individuals with colorectal cancer, the distribution of polymorphic alleles at position 39297161 of chromosome 7 was different from those without colorectal cancer (Table 121). The trend test for risk associated with carrying the G allele had an empirical p-value of 0.000985 based on permutation analysis, and the corresponding Mantel-Haenszel odds ratio for trend is 1.363 (Table 121). These data further suggest that this marker is associated with colorectal cancer risk and that the G allele at position 39297161 of chromosome 7 is associated with an increased risk of developing colorectal cancer.

Table 121 A indicates SNPs found to be in strong linkage disequilibrium with rs 17770077. To generate this list, correlation coefficients (r2) were calculated between the index SNP and all neighboring SNPs cited in the June 2006 HapMap data set release. An r2 cut off of 0.50 was selected for inclusion as evidence for strong genetic linkage, i.e., a "strong linkage disequilibrium.

Example 122

For individuals with colorectal cancer, the distribution of polymorphic alleles at position 47694028 of chromosome 7, found within the PKDlLl gene, was different from those without colorectal cancer (Table 122). The recessive test for risk associated with carrying the C allele had an empirical p-value of 0.00274 based on permutation analysis, and the corresponding recessive odds ratio is 1.325 (Table 122). These data further suggest that this marker, located within the PKDlLl gene, is associated with colorectal cancer risk and that the C allele at position 47694028 of chromosome 7 is associated with an increased risk of developing colorectal cancer.

Table 122A indicates SNPs found to be in strong linkage disequilibrium with rsl7131904. To generate this list, correlation coefficients (r2) were calculated between the index SNP and all neighboring SNPs cited in the June 2006 HapMap data set release. An r2 cut off of 0.50 was selected for inclusion as evidence for strong genetic linkage, i.e., a "strong linkage disequilibrium.

Example 123

For individuals with colorectal cancer, the distribution of polymorphic alleles at position 52815674 of chromosome 7, found within the LOC392027 gene, was different from those without colorectal cancer (Table 123). The dominant test for risk associated with carrying the G allele had an empirical p- value based on permutation analysis of 0.00129, and the corresponding dominant odds ratio is 1.337 (Table 123). These data further suggest that this marker, located within the LOC392027 gene, is associated with colorectal cancer risk and that the G allele at position 52815674 of chromosome 7 is associated with an increased risk of developing colorectal cancer.

Table 123A indicates SNPs found to be in strong linkage disequilibrium with rsl7556689. To generate this list, correlation coefficients (r2) were calculated between the index SNP and all neighboring SNPs cited in the June 2006 HapMap data set release. An r2 cut off of 0.50 was selected for inclusion as evidence for strong genetic linkage, i.e., a "strong linkage disequilibrium.

Example 124

For individuals with colorectal cancer, the distribution of polymorphic alleles at position 52927067 of chromosome 7 was different from those without colorectal cancer (Table 124). The dominant test for risk associated with carrying the C allele had an empirical p-value based on permutation analysis of 0.00171, and the corresponding dominant odds ratio is 1.656 (Table 124). These data further suggest that this marker is associated with colorectal cancer risk and that the C allele at position 52927067 of chromosome 7 is associated with an increased risk of developing colorectal cancer.

Table 124A indicates SNPs found to be in strong linkage disequilibrium with rs 10247706. To generate this list, correlation coefficients (r2) were calculated between the index SNP and all neighboring SNPs cited in the June 2006 HapMap data set release. An r2 cut off of 0.50 was selected for inclusion as evidence for strong genetic linkage, i.e., a "strong linkage disequilibrium.

Example 125

For individuals with colorectal cancer, the distribution of polymorphic alleles at position 75280891 of chromosome 7, found within the MK-STYX gene, was different from those without colorectal cancer (Table 125). The recessive test for risk associated with carrying the C allele had an empirical p-value of 0.007663 based on permutation analysis, and the corresponding recessive odds ratio is 1.272 (Table 125). These data further suggest that this marker, located within the MK-STYX gene, is associated with colorectal cancer risk and that the C allele at position 75280891 of chromosome 7 is associated with an increased risk of developing colorectal cancer.

Table 125A indicates SNPs found to be in strong linkage disequilibrium with rs6978677. To generate this list, correlation coefficients (r2) were calculated between the index SNP and all neighboring SNPs cited in the June 2006 HapMap data set release. An r2 cut off of 0.50 was selected for inclusion as evidence for strong genetic linkage, i.e., a "strong linkage disequilibrium.

Example 126

For individuals with colorectal cancer, the distribution of polymorphic alleles at position 80604131 of chromosome 7 was different from those without colorectal cancer (Table 126). The trend test for risk associated with carrying the C allele had an empirical p-value of 0.000752 based on permutation analysis, and the corresponding Mantel-Haenszel odds ratio for trend is 1.269 (Table 126). These data further suggest that this marker is associated with colorectal cancer risk and that the C allele at position 80604131 of chromosome 7 is associated with an increased risk of developing colorectal cancer.

Table 126 A indicates SNPs found to be in strong linkage disequilibrium with rs2040901. To generate this list, correlation coefficients (r2) were calculated between the index SNP and all neighboring SNPs cited in the June 2006 HapMap data set release. An r2 cut off of 0.50 was selected for inclusion as evidence for strong genetic linkage, i.e., a "strong linkage disequilibrium.

Example 127

For individuals with colorectal cancer, the distribution of polymorphic alleles at position 111946493 of chromosome 7 was different from those without colorectal cancer (Table 127). The dominant test for risk associated with carrying the A allele had an empirical p-value based on permutation analysis of 0.003908, and the corresponding dominant odds ratio is 2.432 (Table 127). These data further suggest that this marker is associated with colorectal cancer risk and that the A allele at position 111946493 of chromosome 7 is associated with an increased risk of developing colorectal cancer.

Table 127A indicates SNPs found to be in strong linkage disequilibrium with rslO244551. To generate this list, correlation coefficients (r2) were calculated between the index SNP and all neighboring SNPs cited in the June 2006 HapMap data set release. An r2 cut off of 0.50 was selected for inclusion as evidence for strong genetic linkage, i.e., a "strong linkage disequilibrium.

Example 128

For individuals with colorectal cancer, the distribution of polymorphic alleles at position 117246522 of chromosome 7 was different from those without colorectal cancer (Table 128). The trend test for risk associated with carrying the A allele had an empirical p-value of 0.004697 based on permutation analysis, and the corresponding Mantel-Haenszel odds ratio for trend is 1.204 (Table 128). These data further suggest that this marker is associated with colorectal cancer risk and that the A allele at position 117246522 of chromosome 7 is associated with an increased risk of developing colorectal cancer.

Table 128A indicates SNPs found to be in strong linkage disequilibrium with rsl0249457. To generate this list, correlation coefficients (r2) were calculated between the index SNP and all neighboring SNPs cited in the June 2006 HapMap data set release. An r2 cut off of 0.50 was selected for inclusion as evidence for strong genetic linkage, i.e., a "strong linkage disequilibrium.

Example 129

For individuals with colorectal cancer, the distribution of polymorphic alleles at position 126787618 of chromosome 7 was different from those witho"' ™'orεctal cancer (Table 129).

The dominant test for risk associated with carrying the G allele had an empirical p-value based on permutation analysis of 0.002724, and the corresponding dominant odds ratio is

1.401 (Table 129). These data further suggest that this marker is associated with colorectal cancer risk and that the G allele at position 126787618 of chromosome 7 is associated with an increased risk of developing colorectal cancer.

1 171 1 508 1 321 fl

Table 129A indicates SNPs found to be in strong linkage disequilibrium with rsl 1761076. To generate this list, correlation coefficients (r2) were calculated between the index SNP and all neighboring SNPs cited in the June 2006 HapMap data set release. An r2 cut off of 0.50 was selected for inclusion as evidence for strong genetic linkage, i.e., a "strong linkage disequilibrium.

Example 130

For individuals with colorectal cancer, the distribution of polymorphic alleles at position 6671547 of chromosome 8, found within the UNQ2754 gene, was different from those without colorectal cancer (Table 130). The recessive test for risk associated with carrying the T allele had an empirical p-value of 0.002645 based on permutation analysis, and the corresponding recessive odds ratio is 1.400 (Table 130). These data further suggest that this marker, located within the UNQ2754 gene, is associated with colorectal cancer risk and that the T allele at position 6671547 of chromosome 8 is associated with an increased risk of developing colorectal cancer.

Table 130A indicates SNPs found to be in strong linkage disequilibrium with rs2741083. To generate this list, correlation coefficients (r2) were calculated between the index SNP and all neighboring SNPs cited in the June 2006 HapMap data set release. An r2 cut off of 0.50 was selected for inclusion as evidence for strong genetic linkage, i.e., a "strong linkage disequilibrium.

Table 130A Linked SNPs

SNP r2 Position on chr8 SEQ ID NO rs2741083 - 6671547 3496

Example 131

For individuals with colorectal cancer, the distribution of polymorphic alleles at position 18699074 of chromosome 8, found within the PSD3 gene, was different from those without colorectal cancer (Table 131). The dominant test for risk associated with carrying the T allele had an empirical p- value based on permutation analysis of 0.012359, and the corresponding dominant odds ratio is 1.283 (Table 131). These data further suggest that this marker, located within the PSD3 gene, is associated with colorectal cancer risk and that the T allele at position 18699074 of chromosome 8 is associated with an increased risk of developing colorectal cancer.

Table 131A indicates SNPs found to be in strong linkage disequilibrium with rslO5O3636. To generate this list, correlation coefficients (r2) were calculated between the index SNP and all neighboring SNPs cited in the June 2006 HapMap data set release. An r2 cut off of 0.50 was selected for inclusion as evidence for strong genetic linkage, i.e., a "strong linkage disequilibrium.

Example 132

For individuals with colorectal cancer, the distribution of polymorphic alleles at position 74428819 of chromosome 8 was different from those without colorectal cancer (Table 132).

The dominant test for risk associated with carrying the A allele had an empirical p-value based on permutation analysis of 0.003255, and the corresponding dominant odds ratio is

1.316 (Table 132). These data further suggest that this marker is associated with colorectal cancer risk and that the A allele at position 74428819 of chromosome 8 is associated with an increased risk of developing colorectal cancer.

Table 132A indicates SNPs found to be in strong linkage disequilibrium with rslO957657. To generate this list, correlation coefficients (r2) were calculated between the index SNP and all neighboring SNPs cited in the June 2006 HapMap data set release. An r2 cut off of 0.50 was selected for inclusion as evidence for strong genetic linkage, i.e., a "strong linkage disequilibrium.

Example 133

For individuals with colorectal cancer, the distribution of polymorphic alleles at position 90213747 of chromosome 8 was different from those without colorectal cancer (Table 133). The recessive test for risk associated with carrying the G allele had an empirical p-value of 0.0328 based on permutation analysis, and the corresponding recessive odds ratio is 1.303 (Table 133). These data further suggest that this marker is associated with colorectal cancer risk and that the G allele at position 902137 '47 of chromosome 8 is associated with an increased risk of developing colorectal cancer.

Table 133 A indicates SNPs found to be in strong linkage disequilibrium with rs 1384747. To generate this list, correlation coefficients (r2) were calculated between the index SNP and all neighboring SNPs cited in the June 2006 HapMap data set release. An r2 cut off of 0.50 was selected for inclusion as evidence for strong genetic linkage, i.e., a "strong linkage disequilibrium.

Example 134

For individuals with colorectal cancer, the distribution of polymorphic alleles at position 104137053 of chromosome 8, found within the ATP6V1C1 gene, was different from those without colorectal cancer (Table 134). The dominant test for risk associated with carrying the A allele had an empirical p-value based on permutation analysis of 0.014254, and the corresponding dominant odds ratio is 1.273 (Table 134). These data further suggest that this marker, located within the ATP6V1C1 gene, is associated with colorectal cancer risk and that the A allele at position 104137053 of chromosome 8 is associated with an increased risk of developing colorectal cancer.

Table 134A indicates SNPs found to be in strong linkage disequilibrium with rs2253218. To generate this list, correlation coefficients (r2) were calculated between the index SNP and all neighboring SNPs cited in the June 2006 HapMap data set release. An r2 cut off of 0.50 was selected for inclusion as evidence for strong genetic linkage, i.e., a "strong linkage disequilibrium.

Example 135

For individuals with colorectal cancer, the distribution of polymorphic alleles at position 115951211 of chromosome 8 was different from those without colorectal cancer (Table 135). The trend test for risk associated with carrying the G allele had an empirical p-value of 0.000243 based on permutation analysis, and the corresponding Mantel-Haenszel odds ratio for trend is 1.389 (Table 135). These data further suggest that this marker is associated with colorectal cancer risk and that the G allele at position 115951211 of chromosome 8 is associated with an increased risk of developing colorectal cancer.

Table 135A indicates SNPs found to be in strong linkage disequilibrium with rs 17667338. To generate this list, correlation coefficients (r2) were calculated between the index SNP and all neighboring SNPs cited in the June 2006 HapMap data set release. An r2 cut off of 0.50 was selected for inclusion as evidence for . strong genetic linkage, i.e., a "strong linkage disequilibrium.

Example 136

For individuals with colorectal cancer, the distribution of polymorphic alleles at position 128490967 of chromosome 8 was different from those without colorectal cancer (Table 136). The trend test for risk associated with carrying the G allele had an empirical p-value of 0.001000 based on permutation analysis, and the corresponding Mantel-Haenszel odds ratio for trend is 1.208 (Table 136). These data further suggest that this marker is associated with colorectal cancer risk and that the G allele at position 12.8490967 of chromosome 8 is associated with an increased risk of developing colorectal cancer.

Table 136A indicates SNPs found to be in strong linkage disequilibrium with rs4871788. To generate this list, correlation coefficients (r2) were calculated between the index SNP and all neighboring SNPs cited in the June 2006 HapMap data set release. An r2 cut off of 0.50 was selected for inclusion as evidence for strong genetic linkage, i.e., a "strong linkage disequilibrium.

Example 137

For individuals with colorectal cancer, the distribution of polymorphic alleles at position 128493974 of chromosome 8 was different from those without colorectal cancer (Table 137). The recessive test for risk associated with carrying the A allele had an empirical p-value of 0.000300 based on permutation analysis, and the corresponding recessive odds ratio is 1.548 (Table 137). These data further suggest that this marker is associated with colorectal cancer risk and that the A allele at position 128493974 of chromosome 8 is associated with an increased risk of developing colorectal cancer.

Table 137A indicates SNPs found to be in strong linkage disequilibrium with rs7014346. To generate this list, correlation coefficients (r2) were calculated between the index SNP and all neighboring SNPs cited in the June 2006 HapMap data set release. An r2 cut off of 0.50 was selected for inclusion as evidence for strong genetic linkage, i.e., a "strong linkage disequilibrium.

Example 138

For individuals with colorectal cancer, the distribution of polymorphic alleles at position 128500876 of chromosome 8 was different from those without colorectal cancer (Table 138). The trend test for risk associated with carrying the G allele had an empirical p-value of 0.003906 based on permutation analysis, and the corresponding Mantel-Haenszel odds ratio for trend is 1.200 (Table 138). These data further suggest that this marker is associated with colorectal cancer risk and that the G allele at position 128500876 of chromosome 8 is associated with an increased risk of developing colorectal cancer.

Table 138A indicates SNPs found to be in strong linkage disequilibrium with rs7842552. To generate this list, correlation coefficients (r2) were calculated between the index SNP and all neighboring SNPs cited in the June 2006 HapMap data set release. An r2 cut off of 0.50 was selected for inclusion as evidence for strong genetic linkage, i.e., a "strong linkage disequilibrium.

Example 139

For individuals with colorectal cancer, the distribution of polymorphic alleles at position 134456489 of chromosome 8 was different from those without colorectal cancer (Table 139). The trend test for risk associated with carrying the G allele had an empirical p-value of 4.7e- 05 based on permutation analysis, and the corresponding Mantel-Haenszel odds ratio for trend is 1.31 (Table 139). These data further suggest that this marker is associated with colorectal cancer risk and that the G allele at position 134456489 of chromosome 8 is associated with an increased risk of developing colorectal cancer.

Table 139A indicates SNPs found to be in strong linkage disequilibrium with rs6980682. To generate this list, correlation coefficients (r2) were calculated between the index SNP and all neighboring SNPs cited in the June 2006 HapMap data set release. An r2 cut off of 0.50 was selected for inclusion as evidence for strong genetic linkage, i.e., a "strong linkage disequilibrium.

Example 140

For individuals with colorectal cancer, the distribution of polymorphic alleles at position 500862 of chromosome 9 was different from those without colorectal cancer (Table 140). The dominant test for risk associated with carrying the G allele had an empirical p-value based on permutation analysis of 0.004552, and the corresponding dominant odds ratio is 1.438 (Table 140). These data further suggest that this marker is associated with colorectal cancer risk and that the G allele at position 500862 of chromosome 9 is associated with an increased risk of developing colorectal cancer.

Table 140A indicates SNPs found to be in strong linkage disequilibrium with rs7874553. To generate this list, correlation coefficients (r2) were calculated between the index SNP and all neighboring SNPs cited in the June 2006 HapMap data set release. An r2 cut off of 0.50 was selected for inclusion as evidence for strong genetic linkage, i.e., a "strong linkage disequilibrium.

Example 141

For individuals with colorectal cancer, the distribution of polymorphic alleles at position 6685502 of chromosome 9 was different from those without colorectal cancer (Table 141). The dominant test for risk associated with carrying the T allele had an empirical p- value based on permutation analysis of 0.003846, and the corresponding dominant odds ratio is 2.08 (Table 141). These data further suggest that this marker is associated with colorectal cancer risk and that the T allele at position 6685502 of chromosome 9 is associated with an increased risk of developing colorectal cancer.

Table 14 IA indicates SNPs found to be in strong linkage disequilibrium with rs 1094040. To generate this list, correlation coefficients (r2) were calculated between the index SNP and all neighboring SNPs cited in the June 2006 HapMap data set release. An r2 cut off of 0.50 was selected for inclusion as evidence for strong genetic linkage, i.e., a "strong linkage disequilibrium.

Example 142

For individuals with colorectal cancer, the distribution of polymorphic alleles at position 15338120 of chromosome 9 was different from those without colorectal cancer (Table 142).

The trend test for risk associated with carrying the C allele had an empirical p-value of

0.000459 based on permutation analysis, and the corresponding Mantel-Haenszel odds ratio for trend is 1.291 (Table 142). These data further suggest that this marker is associated with colorectal cancer risk and that the C allele at position 15338120 of chromosome 9 is associated with an increased risk of developing colorectal cancer.

Table 142A indicates SNPs found to be in strong linkage disequilibrium with rs687381. To generate this list, correlation coefficients (r2) were calculated between the index SNP and all neighboring SNPs cited in the June 2006 HapMap data set release. An r2 cut off of 0.50 was selected for inclusion as evidence for strong genetic linkage, i.e., a "strong linkage disequilibrium.

Example 143

For individuals with colorectal cancer, the distribution of polymorphic alleles at position 16205744 of chromosome 9 was different from those without colorectal cancer (Table 143). The trend test for risk associated with carrying the C allele had an empirical p-value of 0.209228 based on permutation analysis, and the corresponding Mantel-Haenszel odds ratio for trend is 1.155 (Table 143). These data further suggest that this marker is associated with colorectal cancer risk and that the C allele at position 16205744 of chromosome 9 is associated with an increased risk of developing colorectal cancer.

Table 143 A indicates SNPs found to be in strong linkage disequilibrium with rs 16934264. To generate this list, correlation coefficients (r2) were calculated between the index SNP and all neighboring SNPs cited in the June 2006 HapMap data set release. An r2 cut off of 0.50 was selected for inclusion as evidence for strong genetic linkage, i.e., a "strong linkage disequilibrium.

Example 144

For individuals with colorectal cancer, the distribution of polymorphic alleles at position 80312169 of chromosome 9 was different from those without colorectal cancer (Table 144). The dominant test for risk associated with carrying the C allele had an empirical p-value based on permutation analysis of 0.002786, and the corresponding dominant odds ratio is 1.425 (Table 144). These data further suggest that this marker is associated with colorectal cancer risk and that the C allele at position 80312169 of chromosome 9 is associated with an increased risk of developing colorectal cancer.

1 Table 144 1

Table 144A indicates SNPs found to be in strong linkage disequilibrium with rs979468. To generate this list, correlation coefficients (r2) were calculated between the index SNP and all neighboring SNPs cited in the June 2006 HapMap data set release. An r2 cut off of 0.50 was selected for inclusion as evidence for strong genetic linkage, i.e., a "strong linkage disequilibrium.

Example 145

For individuals with colorectal cancer, the distribution of polymorphic alleles at position 95620787 of chromosome 9 was different from those without colorectal cancer (Table 145).

The trend test for risk associated with carrying the C allele had an empirical p-value of

0.017887 based on permutation analysis, and the corresponding Mantel-Haenszel odds ratio for trend is 1.214 (Table 145). These data further suggest that this marker is associated with colorectal cancer risk and that the C allele at position 95620787 of chromosome 9 is associated with an increased risk of developing colorectal cancer.

Table 145 rs no. 7047415

Table 145 A indicates SNPs found to be in strong linkage disequilibrium with rs7047415. To generate this list, correlation coefficients (r2) were calculated between the index SNP and all neighboring SNPs cited in the June 2006 HapMap data set release. An r2 cut off of 0.50 was selected for inclusion as evidence for strong genetic linkage, i.e., a "strong linkage disequilibrium.

Example 146

For individuals with colorectal cancer, the distribution of polymorphic alleles at position 108647178 of chromosome 9 was different from those without colorectal cancer (Table 146).

The trend test for risk associated with carrying the C allele had an empirical p-value of

0.010603 based on permutation analysis, and the corresponding Mantel-Haenszel odds ratio for trend is 1.268 (Table 146). These data further suggest that this marker is associated with colorectal cancer risk and that the C allele at position 108647178 of chromosome 9 is associated with an increased risk of developing colorectal cancer.

Table 146A indicates SNPs found to be in strong linkage disequilibrium with rs957235. To generate this list, correlation coefficients (r2) were calculated between the index SNP and all neighboring SNPs cited in the June 2006 HapMap data set release. An r2 cut off of 0.50 was selected for inclusion as evidence for strong genetic linkage, i.e., a "strong linkage disequilibrium.

Example 147

For individuals with colorectal cancer, the distribution of polymorphic alleles at position 110451236 of chromosome 9 was different from those without colorectal cancer (Table 147). The recessive test for risk associated with carrying the C allele had an empirical p-value of 0.000416 based on permutation analysis, and the corresponding recessive odds ratio is 2.441 (Table 147). These data further suggest that this marker is associated with colorectal cancer risk and that the C allele at position 110451236 of chromosome 9 is associated with an increased risk of developing colorectal cancer.

Table 147 A indicates SNPs found to be in strong linkage disequilibrium with rs 10817049. To generate this list, correlation coefficients (r2) were calculated between the index SNP and all neighboring SNPs cited in the June 2006 HapMap data set release. An r2 cut off of 0.50 was selected for inclusion as evidence for strong genetic linkage, i.e., a "strong linkage disequilibrium.

Example 148

For individuals with colorectal cancer, the distribution of polymorphic alleles at position 114484743 of chromosome 9, found within the C9orf91 gene, was different from those without colorectal cancer (Table 148). The trend test for risk associated with carrying the C allele had an empirical p-value of 0.002689 based on permutation analysis, and the corresponding Mantel-Haenszel odds ratio for trend is 1.254 (Table 148). These data further suggest that this marker, located within the C9orf91 gene, is associated with colorectal cancer risk and that the C allele at position 114484743 of chromosome 9 is associated with an increased risk of developing colorectal cancer.

Table 148A indicates SNPs found to be in strong linkage disequilibrium with rs7027937. To generate this list, correlation coefficients (r2) were calculated between the index SNP and all neighboring SNPs cited in the June 2006 HapMap data set release. An r2 cut off of 0.50 was selected for inclusion as evidence for strong genetic linkage, i.e., a "strong linkage disequilibrium.

Example 149

For individuals with colorectal cancer, the distribution of polymorphic alleles at position 129128218 of chromosome 9 was different from those without colorectal cancer (Table 149). The dominant test for risk associated with carrying the A allele had an empirical p-value based on permutation analysis of 0.002176, and the corresponding dominant odds ratio is 1.322 (Table 149). These data further suggest that this marker is associated with colorectal cancer risk and that the A allele at position 129128218 of chromosome 9 is associated with an increased risk of developing colorectal cancer.

Table 149A indicates SNPs found to be in strong linkage disequilibrium with rs4836648. To generate this list, correlation coefficients (r2) were calculated between the index SNP and all neighboring SNPs cited in the June 2006 H?pMap data set release. An r2 cut off of 0.50 was selected for inclusion as evidence for strong genetic linkage, i.e., a "strong linkage disequilibrium.

rs 10760603 0.884 129131288 3902

Example 150

For individuals with colorectal cancer, the distribution of polymorphic alleles at position 135749356 of chromosome 9, found within the GLTDCl gene, was different from those without colorectal cancer (Table 150). The dominant test for risk associated with carrying the T allele had an empirical p- value based on permutation analysis of 0.006619, and the corresponding dominant odds ratio is 1.593 (Table 150). These data further suggest that this marker, located within the GLTDCl gene, is associated with colorectal cancer risk and that the T allele at position 135749356 of chromosome 9 is associated with an increased risk of developing colorectal cancer.

Table 150A indicates SNPs found to be in strong linkage disequilibrium with rsl333233. To generate this list, correlation coefficients (r2) were calculated between the index SNP and all neighboring SNPs cited in the June 2006 HapMap data set release. An r2 cut off of 0.50 was selected for inclusion as evidence for strong genetic linkage, i.e., a "strong linkage disequilibrium.

Example 151

For individuals with colorectal cancer, the distribution of polymorphic alleles at position 5774364 of chromosome 10, found within the ClOorflδ gene, was different from those without colorectal cancer (Table 151). The dominant test for risk associated with carrying the A allele had an empirical p-value based on permutation analysis of 0.00092, and the corresponding dominant odds ratio is 1.773 (Table 151). These data further suggest that this marker, located within the ClOorflδ gene, is associated with colorectal cancer risk and that the A allele at position 5774364 of chromosome 10 is associated with an increased risk of developing colorectal cancer.

Table 15 IA indicates SNPs found to be in strong linkage disequilibrium with rs9423936. To generate this list, correlation coefficients (r2) were calculated between the index SNP and all neighboring SNPs cited in the June 2006 HapMap data set release. An r2 cut off of 0.50 was selected for inclusion as evidence for strong genetic linkage, i.e., a "strong linkage disequilibrium.

Example 152

For individuals with colorectal cancer, the distribution of polymorphic alleles at position 30211510 of chromosome 10 was different from those without colorectal cancer (Table 152). The recessive test for risk associated with carrying the C allele had an empirical p-value of 0.000735 based on permutation analysis, and the corresponding recessive odds ratio is 1.398 (Table 152). These data further suggest that this marker is associated with colorectal cancer risk and that the C allele at position 30211510 of chromosome 10 is associated with an increased risk of developing colorectal cancer.

Table 152A indicates SNPs found to be in strong linkage disequilibrium with rs914278. To generate this list, correlation coefficients (r2) were calculated between the index SNP and all neighboring SNPs cited in the June 2006 HapMap data set release. An r2 cut off of 0.50 was selected for inclusion as evidence for strong genetic linkage, i.e., a "strong linkage disequilibrium.

Example 153

For individuals with colorectal cancer, the distribution of polymorphic alleles at position 43467013 of chromosome 10 was different from those without colorectal cancer (Table 153).

The trend test for risk associated with carrying the C allele had an empirical p-value of

0.013944 based on permutation analysis, and the corresponding Mantel-Haenszel odds ratio for trend is 1.283 (Table 153). These data further suggest that this marker is associated with colorectal cancer risk and that the C allele at position 43467013 of chromosome 10 is associated with an increased risk of developing colorectal cancer.

Table 153 A indicates SNPs found to be in strong linkage disequilibrium with rs3128248. To generate this list, correlation coefficients (r2) were calculated between the index SNP and all neighboring SNPs cited in the June 2006 HapMap data set release. An r2 cut off of 0.50 was selected for inclusion as evidence for strong genetic linkage, i.e., a "strong linkage disequilibrium.

Table 153A Linked SNPs

SNP r2 Position on chrlO SEQ ID NO rs3128248 - 43467013 3926

Example 154

For individuals with colorectal cancer, the distribution of polymorphic alleles at position 44135054 of chromosome 10 was different from those without colorectal cancer (Table 154).

The dominant test for risk associated with carrying the T allele had an empirical p-value based on permutation analysis of 0.005806, and the corresponding dominant odds ratio is 2.589

(Table 154). These data further suggest that this marker is associated with colorectal cancer risk and that the T allele at position 44135054 of chromosome 10 is associated with an increased risk of developing colorectal cancer.

Table 154A indicates SNPs found to be in strong linkage disequilibrium with rs8OO31O. To generate this list, correlation coefficients (r2) were calculated between the index SNP and all neighboring SNPs cited in the June 2006 HapMap data set release. An r2 cut off of 0.50 was selected for inclusion as evidence foi strong genetic linkage, i.e., a "strong linkage disequilibrium.

Table 154A Linked SNPs

SNP r2 Position on chrlO SEQ ID NO rs4491167 0.631 44130826 3927

Example 155

For individuals with colorectal cancer, the distribution of polymorphic alleles at position 61680529 of chromosome 10, found within the ANK3 gene, was different from those without colorectal cancer (Table 155). The recessive test for risk associated with carrying the A allele had an empirical p-value of 0.002292 based on permutation analysis, and the corresponding recessive odds ratio is 1.768 (Table 155). These data further suggest that this marker, located within the ANK3 gene, is associated with colorectal cancer risk and that the A allele at position 61680529 of chromosome 10 is associated with an increased risk of developing colorectal cancer.

Table 155A indicates SNPs found to be in strong linkage disequilibrium with rsl2767186. To generate this list, correlation coefficients (r2) were calculated between the index SNP and all neighboring SNPs cited in the June 2006 HapMap data set release. An r2 cut off of 0.50 was selected for inclusion as evidence for strong genetic linkage, i.e., a "strong linkage disequilibrium.

Table 155A Linked SNPs

Example 156

For individuals with colorectal cancer, the distribution of polymorphic alleles at position 67146138 of chromosome 10 was different from those without colorectal cancer (Table 156). The recessive test for risk associated with carrying the A allele had an empirical p-value of 0.004653 based on permutation analysis, and the corresponding recessive odds ratio is 1.396 (Table 156). These data further suggest that this marker is associated with colorectal cancer risk and that the A allele at position 67146138 of chromosome 10 is associated with an increased risk of developing colorectal cancer.

Table 156A indicates SNPs found to be in strong linkage disequilibrium with rsl904723. To generate this list, correlation coefficients (r2) were calculated between the index SNP and all neighboring SNPs cited in the June 2006 HapMap data set release. An r2 cut off of 0.50 was selected for inclusion as evidence for strong genetic linkage, i.e., a "strong linkage disequilibrium.

Example 157

For individuals with colorectal cancer, the distribution of polymorphic alleles at position 77569191 of chromosome 10, found within the ClOorfll gene, was different from those without colorectal cancer (Table 157). The recessive test for risk associated with carrying the A allele had an empirical p-value of 0.002734 based on permutation analysis, and the corresponding recessive odds ratio is 1.446 (Table 157). These data further suggest that this marker, located within the ClOorfll gene, is associated with colorectal cancer risk and that the A allele at position 77569191 of chromosome 10 is associated with an increased risk of developing colorectal cancer.

Table 157 A indicates SNPs found to be in strong linkage disequilibrium with rs7101216. To generate this list, correlation coefficients (r2) were calculated between the index SNP and all neighboring SNPs cited in the June 2006 HapMap data set release. An r2 cut off of 0.50 was selected for inclusion as evidence for strong genetic linkage, i.e., a "strong linkage disequilibrium.

Example 158

For individuals with colorectal cancer, the distribution of polymorphic alleles at position 91205789 of chromosome 10, found within the LOC387700 gene, was different from those without colorectal cancer (Table 158). The recessive test for risk associated with carrying the

G allele had an empirical p-value of 0.001128 based on permutation analysis, and the corresponding recessive odds ratio is 1.947 (Table 158). These data further suggest that this marker, located within the LOC387700 gene, is associated with colorectal cancer risk and that the G allele at position 91205789 of chromosome 10 is associated with an increased risk of developing colorectal cancer.

Table 158A indicates SNPs found to be in strong linkage disequilibrium with rs3740029. To generate this list, correlation coefficients (r2) were calculated between the index SNP and all neighboring SNPs cited in the June 2006 HapMap data set release. An r2 cut off of 0.50 was selected for inclusion as evidence for strong genetic linkage, i.e., a "strong linkage disequilibrium.

Example 159

For individuals with colorectal cancer, the distribution of polymorphic alleles at position 91916839 of chromosome 10 was different from those without colorectal cancer (Table 159). The recessive test for risk associated with carrying the C allele had an empirical p-value of 0.001612 based on permutation analysis, and the corresponding recessive odds ratio is 1.723 (Table 159). These data further suggest that this marker is associated with colorectal cancer risk and that the C allele at position 91916839 of chromosome 10 is associated with an increased risk of developing colorectal cancer.

Table 159A indicates SNPs found to be in strong linkage disequilibrium with rsl 1186048. To generate this list, correlation coefficients (r2) were calculated between the index SNP and all neighboring SNPs cited in the June 2006 HapMap data set release. An r2 cut off of 0.50 was selected for inclusion as evidence for strong genetic linkage, i.e., a "strong linkage disequilibrium.

Example 160

For individuals with colorectal cancer, the distribution of polymorphic alleles at position 106897228 of chromosome 10, found within the SORCS3 gene, was different from those without colorectal cancer (Table 160). The recessive test for risk associated with carrying the G allele had an empirical p-value of 0.016428 based on permutation analysis, and the corresponding recessive odds ratio is 1.265 (Table 160). These data further suggest that this marker, located within the SORCS3 gene, is associated with colorectal cancer risk and that the G allele at position 106897228 of chromosome 10 is associated with an increased risk of developing colorectal cancer.

Table 160A indicates SNPs found to be in strong linkage disequilibrium with rs 10160134. To generate this list, correlation coefficients (r2) were calculated between the index SNP and all neighboring SNPs cited in the June 2006 HapMap data set release. An r2 cut off of 0.50 was selected for inclusion as evidence for strong genetic linkage, i.e., a "strong linkage disequilibrium.

Example 161

For individuals with colorectal cancer, the distribution of polymorphic alleles at position 7233719 of chromosome 11, found within the SYT9 gene, was different from those without colorectal cancer (Table 161). The trend test for risk associated with carrying the C allele had an empirical p-value of 0.008553 based on permutation analysis, and the corresponding Mantel-Haenszel odds ratio for trend is 1.206 (Table 161). These data further suggest that this marker, located within the SYT9 gene, is associated with colorectal cancer risk and that the C allele at position 7233719 of duomosome 11 is associated with an incieased risk of developing colorectal cancer.

Table 161 A indicates SNPs found to be in strong linkage disequilibrium with rs7126337. To generate this list, correlation coefficients (r2) were calculated between the index SNP and all neighboring SNPs cited in the June 2006 HapMap data set release. An r2 cut off of 0.50 was selected for inclusion as evidence for strong genetic linkage, i.e., a "strong linkage disequilibrium.

Example 162

For individuals with colorectal cancer, the distribution of polymorphic alleles at position 24098348 of chromosome 11 was different from those without colorectal cancer (Table 162). The dominant test for risk associated with carrying the A allele had an empirical p-value based on permutation analysis of 0.001873, and the corresponding dominant odds ratio is 1.706 (Table 162). These data further suggest that this marker is associated with colorectal cancer risk and that the A allele at position 24098848 of chromosome 11 is associated with an increased risk of developing colorectal cancer.

Table 162A indicates SNPs found to be in strong linkage disequilibrium with rs4922675. To generate this list, correlation coefficients (r2) were calculated between the index SNP and all neighboring SNPs cited in the June 2006 HapMap data set release. An r2 cut off of 0.50 was selected for inclusion as evidence for strong genetic linkage, i.e., a "strong linkage disequilibrium.

Example 163

For individuals with colorectal cancer, the distribution of polymorphic alleles at position 37072232 of chromosome 11 was different from those without colorectal cancer (Table 163). The recessive test for risk associated with carrying the T allele had an empirical p-value of 0.002367 based on permutation analysis, and the corresponding recessive odds ratio is 1.322 (Table 163). These data further suggest that this marker is associated with colorectal cancer risk and that the T allele at position 37072232 of chromosome 11 is associated with an increased risk of developing colorectal cancer.

Table 163 A indicates SNPs found to be in strong linkage disequilibrium with rsl512369. To generate this list, correlation coefficients (r2) were calculated between the index SNP and all neighboring SNPs cited in the June 2006 HapMap data set release. An r2 cut off of 0.50 was selected for inclusion as evidence for strong genetic linkage, i.e., a "strong linkage disequilibrium.

Example 164 For individuals with colorectal cancer, the distribution of polymorphic alleles at position 43228838 of chromosome 11 was different from those without colorectal cancer (Table 164). The dominant test for risk associated with carrying the G allele had an empirical p-value based on permutation analysis of 0.002749, and the corresponding dominant odds ratio is 1.449 (Table 164). These data further suggest that this marker is associated with colorectal cancer risk and that the G allele at position 43228838 of chromosome 11 is associated with an increased risk of developing colorectal cancer.

Table 164A indicates SNPs found to be in strong linkage disequilibrium with rs4755702. To generate this list, correlation coefficients (r2) were calculated between the index SNP and all neighboring SNPs cited in the June 2006 HapMap data set release. An r2 cut off of 0.50 was selected for inclusion as evidence for strong genetic linkage, i.e., a "strong linkage disequilibrium.

Example 165

For individuals with colorectal cancer, the distribution of polymorphic alleles at position 44571754 of chromosome 11, found within the KAIl gene, was different from those without colorectal cancer (Table 165). The recessive test for risk associated with carrying the A allele had an empirical p- value of 0.000281 based on permutation analysis, and the corresponding recessive odds ratio is 4.971 (Table 165). These data further suggest that this marker, located within the KAIl gene, is associated with colorectal cancer risk and that the A allele at position 44571754 of chromosome 11 is associated with an increased risk of developing colorectal cancer.

Table 165 A indicates SNPs found to be in strong linkage disequilibrium with rsl 7613700. To generate this list, correlation coefficients (r2) were calculated between the index SNP and all neighboring SNPs cited in the June 2006 HapMap data set release. An r2 cut off of 0.50 was selected for inclusion as evidence for strong genetic linkage, i.e., a "strong linkage disequilibrium.

Example 166

For individuals with colorectal cancer, the distribution of polymorphic alleles at position 44754354 of chromosome 11 was different from those without colorectal cancer (Table 166). The dominant test for risk associated with carrying the G allele had an empirical p-value based on permutation analysis of 0.005073, and the corresponding dominant odds ratio is 1.297 (Table 166). These data further suggest that this marker is associated with colorectal cancer risk and that the G allele at position 44754354 of chromosome 11 is associated with an increased risk of developing colorectal cancer.

Table 166A indicates SNPs found to be in strong linkage disequilibrium with rs750348. To generate this list, correlation coefficients (r2) were calculated between the index SNP and all neighboring SNPs cited in the June 2006 HapMap data set release. An r2 cut off of 0.50 was selected for inclusion as evidence for strong genetic linkage, i.e., a "strong linkage disequilibrium.

Example 167

For individuals with colorectal cancer, the distribution of polymorphic alleles at position 107635922 of chromosome 11, found within the ATM gene, was different from those without colorectal cancer (Table 167). The dominant test for risk associated with carrying the A allele had an empirical p- value based on permutation analysis of 0.006101, and the corresponding dominant odds ratio is 1.487 (Table 167). These data further suggest that this marker, located within the ATM gene, is associated with colorectal cancer risk and that the A allele at position 107635922 of chromosome 11 is associated with an increased risk of developing colorectal cancer.

Table 167 A indicates SNPs found to be in strong linkage disequilibrium with rs 11212570. To generate this list, correlation coefficients (r2) were calculated between the index SNP and all neighboring SNPs cited in the June 2006 HapMap data set release. An r2 cut off of 0.50 was selected for inclusion as evidence for strong genetic linkage, i.e., a "strong linkage disequilibrium.

Example 168

For individuals with colorectal cancer, the distribution of polymorphic alleles at position 110676919 of chromosome 11, found within the LOC 120376 gene, was different from those without colorectal cancer (Table 168). The trend test for risk associated with carrying the C allele had an empirical p-value of 0.000600 based on permutation analysis, and the corresponding Mantel-Haenszel odds ratio for trend is 1.237 (Table 168). These data further suggest that this marker, located within the LOC 120376 gene, is associated with colorectal cancer risk and that the C allele at position 110676919 of chromosome 11 is associated with an increased risk of developing colorectal cancer.

Table 168A indicates SNPs found to be in strong linkage disequilibrium with rs3802842. To generate this list, correlation coefficients (r2) were calculated between the index SNP and all neighboring SNPs cited in the June 2006 HapMap data set release. An r2 cut off of 0.50 was selected for inclusion as evidence for strong genetic linkage, i.e., a "strong linkage disequilibrium.

Example 169 For individuals with colorectal cancer, the distribution of polymorphic alleles at position 118330846 of chromosome 11, found within the UPK2 gene, was different from those without colorectal cancer (Table 169). The recessive test for risk associated with carrying the G allele had an empirical p-value of 0.003202 based on permutation analysis, and the corresponding recessive odds ratio is .1.348 (Table 169). These data further suggest that this marker, located within the UPK2 gene, is associated with colorectal cancer risk and that the G allele at position 118330846 of chromosome 11 is associated with an increased risk of developing colorectal cancer.

Table 169A indicates SNPs found to be in strong linkage disequilibrium with rsl790191. To generate this list, correlation coefficients (r2) were calculated between the index SNP and all neighboring SNPs cited in the June 2006 HapMap data set release. An r2 cut off of 0.50 was selected for inclusion as evidence for strong genetic linkage, i.e., a "strong linkage disequilibrium.

Example 170

For individuals with colorectal cancer, the distribution of polymorphic alleles at position 119277053 of chromosome 11 was different from those without colorectal cancer (Table 170). The recessive test for risk associated with caTying the C allele had an empirical p-value of 0.000819 based on permutation analysis, and the corresponding recessive odds ratio is 2.440 (Table 170). These data further suggest that this marker is associated with colorectal cancer risk and that the C allele at position 119277053 of chromosome 11 is associated with an increased risk of developing colorectal cancer.

Table 170A indicates SNPs found to be in strong linkage disequilibrium with rs518932. To generate this list, correlation coefficients (r2) were calculated between the index SNP and all neighboring SNPs cited in the June 2006 HapMap data set release. An r2 cut off of 0.50 was selected for inclusion as evidence for strong genetic linkage, i.e., a "strong linkage disequilibrium.

Example 171

For individuals with colorectal cancer, the distribution of polymorphic alleles at position 123067607 of chromosome 11 was different from those without colorectal cancer (Table 171). The recessive test for risk associated with carrying the T allele had an empirical p-value of 0.00212 based on permutation analysis, and the corresponding recessive odds ratio is 1.660 (Table 171). These data further suggest that this marker is associated with colorectal cancer risk and that the T allele at position 123067607 of chromosome 11 is associated with an increased risk of developing colorectal cancer.

Table 17 IA indicates SNPs found to be in strong linkage disequilibrium with rs3901231. To generate this list, correlation coefficients (r2) were calculated between the index SNP and all neighboring SNPs cited in the June 2006 HapMap data set release. An r2 cut off of 0.50 was selected for inclusion as evidence for strong genetic linkage, i.e., a "strong linkage disequilibrium.

Example 172

For individuals with colorectal cancer, the distribution of polymorphic alleles at position 123132878 of chromosome 11 was different from those without colorectal cancer (Table 172). The trend test for risk associated with carrying the A allele had an empirical p- value of 0.001103 based on permutation analysis, and the corresponding Mantel-Haenszel odds ratio for trend is 1.238 (Table 172). These data further suggest that this marker is associated with colorectal cancer risk and that the A allele at position 123132878 of chromosome 11 is associated with an increased risk of developing colorectal cancer.

Table 172A indicates SNPs found to be in strong linkage disequilibrium with rslO5O227O. To generate this list, correlation coefficients (r2) were calculated between the index SNP and all neighboring SNPs cited in the June 2006 HapMap data set release. An r2 cut off of 0.50 was selected for inclusion as evidence for strong genetic linkage, i.e., a "strong linkage disequilibrium.

I rsl939915 | 1 0.507 I I 123221459 I 4337 I

Example 173

For individuals with colorectal cancer, the distribution of polymorphic alleles at position 13348818 of chromosome 12 was different from those without colorectal cancer (Table 173). The dominant test for risk associated with carrying the T allele had an empirical p-value based on permutation analysis of 0.002243, and the corresponding dominant odds ratio is 1.32 (Table 173). These data further suggest that this marker is associated with colorectal cancer risk and that the T allele at position 13348818 of chromosome 12 is associated with an increased risk of developing colorectal cancer.

Table 173A indicates SNPs found to be in strong linkage disequilibrium with rsl2822216. To generate this list, correlation coefficients (r2) were calculated between the index SNP and all neighboring SNPs cited in the June 2006 HapMap data set release. An r2 cut off of 0.50 was selected for inclusion as evidence for strong genetic linkage, i.e., a "strong linkage disequilibrium.

Example 174

For individuals with colorectal cancer, the distribution of polymorphic alleles at position 49166483 of chromosome 12 was different from those without colorectal cancer (Table 174). The recessive test for risk associated with carrying the T allele had an empirical ρ-vaiue of 0.000416 based on permutation analysis, and the corresponding recessive odds ratio is 1.615 (Table 174). These data further suggest that this marker is associated with colorectal cancer risk and that the T allele at position 49166483 of chromosome 12 is associated with an increased risk of developing colorectal cancer.

Table 174A indicates SNPs found to be in strong linkage disequilibrium with rs7136702. To generate this list, correlation coefficients (r2) were calculated between the index SNP and all neighboring SNPs cited in the June 2006 HapMap data set release. An r2 cut off of 0.50 was selected for inclusion as evidence for strong genetic linkage, i.e., a "strong linkage disequilibrium.

Example 175

For individuals with colorectal cancer, the distribution of polymorphic alleles at position 51488647 of chromosome 12, found within the KRT4 gene, was different from those without colorectal cancer (Table 175). The dominant tesi for risk associated with carrying the C allele had an empirical p-value based on permutation analysis of 0.006799, and the corresponding dominant odds ratio is 1.535 (Table 175). These data further suggest that this marker, located within the KRT4 gene, is associated with colorectal cancer risk and that the C allele at position 51488647 of chromosome 12 is associated with an increased risk of developing colorectal cancer.

Table 175A indicates SNPs found to be in strong linkage disequilibrium with rs2307028. To generate this list, correlation coefficients (r2) were calculated between the index SNP and all neighboring SNPs cited in the June 2006 HapMap data set release. An r2 cut off of 0.50 was selected for inclusion as evidence for strong genetic linkage, i.e., a "strong linkage disequilibrium.

Example 176

For individuals with colorectal cancer, the distribution of polymorphic alleles at position 76791055 of chromosome 12, found within the NAV3 gene, was different from those without colorectal cancer (Table 176). The dominant test for risk associated with carrying the C allele had an empirical p- value based on permutation analysis of 0.003971, and the corresponding dominant odds ratio is 1.554 (Table 176). These data further suggest that this marker, located within the NAV3 gene, is associated with colorectal cancer risk and that the C allele at position 76791055 of chromosome 12 is associated with an increased risk of developing colorectal cancer.

Table 176A indicates SNPs found to be in strong linkage disequilibrium with rs2045989. To generate this list, correlation coefficients (r2) were calculated between the index SNP and all neighboring SNPs cited in the June 2006 HapMap data set release. An r2 cut off of 0.50 was selected for inclusion as evidence for strong genetic linkage, i.e., a "strong linkage disequilibrium.

Example 177

For individuals with colorectal cancer, the distribution of polymorphic alleles at position 88113076 of chromosome 12 was different from those without colorectal cancer (Table 177). The trend test for risk associated with carrying the G allele had an empirical p-value of 0.002542 based on permutation analysis, and the corresponding Mantel-Haenszel odds ratio for trend is 1.286 (Table 177). These data further suggest that this marker is associated with colorectal cancer risk and that the G allele at position 88113076 of chromosome 12 is associated with an increased risk of developing colorectal cancer.

1 I G 21 238 673 I

Table 177 A indicates SNPs found to be in strong linkage disequilibrium with rs 10506966. To generate this list, correlation coefficients (r2) were calculated between the index SNP and all neighboring SNPs cited in the June 2006 HapMap data set release. An r2 cut off of 0.50 was selected for inclusion as evidence for strong genetic linkage, i.e., a "strong linkage disequilibrium.

Example 178

For individuals with colorectal cancer, the distribution of polymorphic alleles at position 101473743 of chromosome 12 was different from those without colorectal cancer (Table

178). The recessive test for risk associated with carrying the G allele had an empirical p-value of 0.000215 based on permutation analysis, and the corresponding recessive odds ratio is 1.55

(Table 178). These data further suggest that this marker is associated with colorectal cancer risk and that the G allele at position 101473743 of chromosome 12 is associated with an increased risk of developing colorectal cancer.

Table 178A indicates SNPs found to be in strong linkage disequilibrium with rslO778179. To generate this list, correlation coefficients (r2) were calculated between the index SNP and all neighboring SNPs cited in the June 2006 HapMap data set release. An r2 cut off of 0.50 was selected for inclusion as evidence for strong genetic linkage, i.e., a "strong linkage disequilibrium.

Example 179

For individuals with colorectal cancer, the distribution of polymorphic alleles at position 104974668 of chromosome 12, found within the ARK5 gene, was different from those without colorectal cancer (Table 179). The dominant test for risk associated with carrying the C allele had an empirical p- value based on permutation analysis of 0.001572, and the corresponding dominant odds ratio is 2.068 (Table 179). These data further suggest that this marker, located within the ARK5 gene, is associated with colorectal cancer risk and that the C allele at position 104974668 of chromosome 12 is associated with an increased risk of developing colorectal cancer.

Table 179A indicates SNPs found to be in strong linkage disequilibrium with rsl7038085. To generate this list, correlation coefficients (r2) were calculated between the index SNP and all neighboring SNPs cited in the June 2006 HapMap data set release. An r2 cut off of 0.50 was selected for inclusion as evidence for strong genetic linkage, i.e., a "strong linkage disequilibrium.

Example 180

For individuals with colorectal cancer, the distribution of polymorphic alleles at position 114397478 of chromosome 12 was different from those without colorectal cancer (Table

180). The dominant test for risk associated with carrying the O allele had an empirical p- value based on permutation analysis of 0.005135, and the corresponding dominant odds ratio is

1.553 (Table 180). These data further suggest that this marker is associated with colorectal cancer risk and that the G allele at position 114397478 of chromosome 12 is associated with an increased risk of developing colorectal cancer.

Table 180A indicates SNPs found to be in strong linkage disequilibrium with rs 10850526. To generate this list, correlation coefficients (r2) were calculated between the index SNP and all neighboring SNPs cited in the June 2006 HapMap data set release. An r2 cut off of 0.50 was selected for inclusion as evidence for strong genetic linkage, i.e., a "strong linkage disequilibrium.

Example 181

For individuals with colorectal cancer, the distribution of polymorphic alleles at position 39876966 of chromosome 13 was different from those without colorectal cancer (Table 181). The trend test for risk associated with carrying the C allele had an empirical p-value of 0.002406 based on permutation analysis, and the corresponding Mantel-Haenszel odds ratio for trend is 1.368 (Table 181). These data further suggest that this marker is associated with colorectal cancer risk and that the C allele at position 39876966 of chromosome 13 is associated with an increased risk of developing colorectal cancer.

Table 181A indicates SNPs found to be in strong linkage disequilibrium with rsl751852. To generate this list, correlation coefficients (r2) were calculated between the index SNP and all neighboring SNPs cited in the June 2006 HapMap data set release. An r2 cut off of 0.50 was selected for inclusion as evidence for strong genetic linkage, i.e., a "strong linkage disequilibrium.

Example 182

For individuals with colorectal cancer, the distribution of polymorphic alleles at position 49833923 of chromosome 13 was different from those without colorectal cancer (Table 182). The trend test for risk associated with carrying the C allele had an empirical p-value of 0.000299 based on permutation analysis, and the corresponding Mantel-Haenszel odds ratio for trend is 1.62 (Table 182). These data further suggest that this marker is associated with colorectal cancer risk and that the C allele at position 49833923 of chromosome 13 is associated with an increased risk of developing colorectal cancer.

Table 182A indicates SNPs found to be in strong linkage disequilibrium with rs 12874278. To generate this list, correlation coefficients (r2) were calculated between the index SNP and all neighboring SNPs cited in the June 2006 HapMap data set release. An r2 cut off of 0.50 was selected for inclusion as evidence for strong genetic linkage, i.e., a "strong linkage disequilibrium.

Example 183

For individuals with colorectal cancer, the distribution of polymorphic alleles at position 73798631 of chromosome 13 was different from those without colorectal cancer (Table 183). The dominant test for risk associated with carrying the A allele had an empirical p-value based on permutation analysis of 0.002624, and the corresponding dominant odds ratio is 1.329 (Table 183). These data further suggest that this marker is associated with colorectal cancer risk and that the A allele at position 73798631 of chromosome 13 is associated with an increased risk of developing colorectal cancer.

Table 183A indicates SNPs found to be in strong linkage disequilibrium with rs9592985. To generate this list, correlation coefficients (r2) were calculated between the index SNP and all neighboring SNPs cited in the June 2006 HapMap data set release. An r2 cut off of 0.50 was selected for inclusion as evidence for strong genetic linkage, i.e., a "strong linkage disequilibrium.

Example 184

For individuals with colorectal cancer, the distribution of polymorphic alleles at position 74467066 of chromosome 13 was different from those without colorectal cancer (Table 184). The trend test for risk associated with carrying the C allele had an empirical p-value of 0.006401 based on permutation analysis, and the corresponding Mantel-Haenszel odds ratio for trend is 1.201 (Table 184). These data further suggest that this marker is associated with colorectal cancer risk and that the C allele at position 74467066 of chromosome 13 is associated with an increased risk of developing colorectal cancer.

Table 184

Table 184A indicates SNPs found to be in strong linkage disequilibrium with rs9543827. To generate this list, correlation coefficients (r2) were calculated between the index SNP and all neighboring SNPs cited in the June 2006 HapMap data set release. An r2 cut off of 0.50 was selected for inclusion as evidence for strong genetic linkage, i.e., a "strong linkage disequilibrium.

Example 185

For individuals with colorectal cancer, the distribution of polymorphic alleles at position 106131423 of chromosome 13 was different from those without colorectal cancer (Table 185). The trend test for risk associated with carrying the C allele had an empirical p-value of 0.009856 based on permutation analysis, and the corresponding Mantel-Haenszel odds ratio for trend is 1.296 (Table 185). These data further suggest that this marker is associated with colorectal cancer risk and that the C allele at position 106131423 of chromosome 13 is associated with an increased risk of developing colorectal cancer.

Table 185 A indicates SNPs found to be in strong linkage disequilibrium with rs 17548667. To generate this list, correlation coefficients (r2) were calculated between the index SNP and all neighboring SNPs cited in the June 2006 HapMap data set release. An r2 cut off of 0.50 was selected for inclusion as evidence for strong genetic linkage, i.e., a "strong linkage disequilibrium.

Example 186

For individuals with colorectal cancer, the distribution of polymorphic alleles at position 109042402 of chromosome 13 was different from those without colorectal cancer (Table 186). The recessive test for risk associated with carrying the G allele had an empirical p- value of 0.008447 based on permutation analysis, and the corresponding recessive odds ratio is 1.370 (Table 186). These data further suggest that this marker is associated with colorectal cancer risk and that the G allele at position 109042402 of chromosome 13 is associated with an increased risk of developing colorectal cancer.

Table 186A indicates SNPs found to be in strong linkage disequilibrium with rsl 1069790. To generate this list, correlation coefficients (r2) were calculated between the index SNP and all neighboring SNPs cited in the June 2006 HapMap data set release. An r2 cut off of 0.50 was selected for inclusion as evidence for strong genetic linkage, i.e., a "strong linkage disequilibrium.

Table 186A Linked SNPs

SNP r2 Position on chrl3 SEQ ID NO rsl 1069790 - 109042402 4629

Example 187

For individuals with colorectal cancer, the distribution of polymorphic alleles at position 109175464 of chromosome 13 was different from those without colorectal cancer (Table 187). The dominant test for risk associated with carrying the G allele had an empirical p-value based on permutation analysis of 0.000642, and the corresponding dominant odds ratio is 1.681 (Table 187). These data further suggest that this marker is associated with colorectal cancer risk and that the G allele at position 109175464 cf chromosome 13 is associated with an increased risk of developing colorectal cancer.

Table 187A indicates SNPs found to be in strong linkage disequilibrium with rs7319633. To generate this list, correlation coefficients (r2) were calculated between the index SNP and all neighboring SNPs cited in the June 2006 HapMap data set release. An r2 cut off of 0.50 was selected for inclusion as evidence for strong genetic linkage, i.e., a "strong linkage disequilibrium.

Example 188

For individuals with colorectal cancer, the distribution of polymorphic alleles at position 32814428 of chromosome 14, found within the NPAS3 gene, was different from those without colorectal cancer (Table 188). The trend test for risk associated with carrying the C allele had an empirical p-value of 0.000843 based on permutation analysis, and the corresponding Mantel-Haenszel odds ratio for trend is 1.255 (Table 188). These data further suggest that this marker, located within the NPAS3 gene, is associated with colorectal cancer risk and that the C allele at position 32814428 of chromosome 14 is associated with an increased risk of developing colorectal cancer.

Table 188A indicates SNPs found to be in strong linkage disequilibrium with rs7152037. To generate this list, correlation coefficients (r2) were calculated between the index SNP and all neighboring SNPs cited in the June 2006 HapMap data set release. An r2 cut off of 0.50 was selected for inclusion as evidence for strong genetic linkage, i.e., a "strong linkage disequilibrium.

Example 189

For individuals with colorectal cancer, the distribution of polymorphic alleles at position 32929909 of chromosome 14 was different from those without colorectal cancer (Table 189).

The dominant test for risk associated with carrying the G allele had an empirical p-value based on permutation analysis of 0.003507, and the corresponding dominant odds ratio is

11.090 (Table 189). These data further suggest that this marker is associated with colorectal cancer risk and that the G allele at position 32929909 of chromosome 14 is associated with an increased risk of developing colorectal cancer.

Table 189A indicates SNPs found to be in strong linkage disequilibrium with rs 17100933. To generate this list, correlation coefficients (r2) were calculated between the index SNP and all neighboring SNPs cited in the June 2006 HapMap data set release. An r2 cut off of 0.50 was selected for inclusion as evidence for strong genetic linkage, i.e., a "strong linkage disequilibrium.

Table 189A Linked SNPs

SNP r2 Position on chrl4 SEQ ID NO rsl7100933 - 32929909 4651

Example 190

For individuals with colorectal cancer, the distribution of polymorphic alleles at position 38722249 of chromosome 14 was different from those without colorectal cancer (Table 190). The recessive test for risk associated with carrying the G allele had an empirical p-value of 0.001239 based on permutation analysis, and the corresponding recessive odds ratio is 5.637 (Table 190). These data further suggest that this marker is associated with colorectal cancer risk and that the G allele at position 38722249 of chromosome 14 is associated with an increased risk of developing colorectal cancer.

Table 190A indicates SNPs found to be in strong linkage disequilibrium with rs 10135561. To generate this list, correlation coefficients (r2) were calculated between the index SNP and all neighboring SNPs cited in the June 2006 HapMap data set release. An r2 cut off of 0.50 was selected for inclusion as evidence for strong genetic linkage, i.e., a "strong linkage disequilibrium.

Example 191

For individuals with colorectal cancer, the distribution of polymorphic alleles at position 84254314 of chromosome 14 was different from those without colorectal cancer (Table 191). The recessive test for risk associated with carrying the T allele had an empirical p-value of 0.000192 based on permutation analysis, and the corresponding recessive odds ratio is 2.116 (Table 191). These data further suggest that this marker ic associated with colorectal cancer risk and that the T allele at position 84254314 of chromosome 14 is associated with an increased risk of developing colorectal cancer.

Table 191A indicates SNPs found to be in strong linkage disequilibrium with rs2623142. To generate this list, correlation coefficients (r2) were calculated between the index SNP and all neighboring SNPs cited in the June 2006 HapMap data set release. An r2 cut off of 0.50 was selected for inclusion as evidence for strong genetic linkage, i.e., a "strong linkage disequilibrium.

Example 192

For individuals with colorectal cancer, the distribution of polymorphic alleles at position 85233147 of chromosome 14 was different from those without colorectal cancer (Table 192). The trend test for risk associated with carrying the A allele had an empirical p-value of 0.005274 based on permutation analysis, and the corresponding Mantel-Haenszel odds ratio for trend is 1.198 (Table 192). These data further suggest that this marker is associated with colorectal cancer risk and that the A allele at position 85233147 of chromosome 14 is associated with an increased risk of developing colorectal cancer.

Table 192 A indicates SNPs found to be in strong linkage disequilibrium with rs6574840. To generate this list, correlation coefficients (r2) were calculated between the index SNP and all neighboring SNPs cited in the June 2006 HapMap data set release. An r2 cut off of 0.50 was selected for inclusion as evidence for strong genetic linkage, i.e., a "strong linkage disequilibrium.

Example 193

For individuals with colorectal cancer, the distribution of polymorphic alleles at position 51245627 of chromosome 15 was different from those without colorectal cancer (Table 193). The dominant test for risk associated with carrying the C allele had an empirical p-value based on permutation analysis of 0.000158, and the corresponding dominant odds ratio is 1.739 (Table 193). These data further suggest that this marker is associated with colorectal cancer risk and that the C allele at position 51245627 of chromosome 15 is associated with an increased risk of developing colorectal cancer.

Table 193A indicates SNPs found to be in strong linkage disequilibrium with rslO51871O. To generate this list, correlation coefficients (r2) were calculated between the index SNP and all neighboring SNPs cited in the June 2006 HapMap data set release. An r2 cut off of 0.50 was selected for inclusion as evidence for strong genetic linkage, i.e., a "strong linkage disequilibrium.

Example 194

For individuals with colorectal cancer, the distribution of polymorphic alleles at position 69387794 of chromosome 15 was different from those without colorectal cancer (Table 194). The dominant test for risk associated with carrying the T allele had an empirical p-value based on permutation analysis of 0.00157, and the corresponding dominant odds ratio is 1.332 (Table 194). These data further suggest that this marker is associated with colorectal cancer risk and that the T allele at position 69387794 of chromosome 15 is associated with an increased risk of developing colorectal cancer.

Table 194A indicates SNPs found to be in strong linkage disequilibrium with rs7174619. To generate this list, correlation coefficients (r2) were calculated between the index SNP and all neighboring SNPs cited in the June 2006 HapMap data set release. An r2 cut off of 0.50 was selected for inclusion as evidence for strong genetic linkage, i.e., a "strong linkage disequilibrium.

Example 195

For individuals with colorectal cancer, the distribution of polymorphic alleles at position 76871863 of chromosome 15, found within the ADAMTS7 gene, was different from those without colorectal cancer (Table 195). The dominant test for risk associated with carrying the

C allele had an empirical p-value based on permutation analysis of 0.001537, and the corresponding dominant odds ratio is 1.843 (Table 195). These data further suggest that this marker, located within the ADAMTS7 gene, is associated with colorectal cancer risk and that the C allele at position 76871863 of chromosome 15 is associated with an increased risk of developing colorectal cancer.

Table 195A indicates SNPs found to be in strong linkage disequilibrium with rs 1564499. To generate this list, correlation coefficients (r2) were calculated between the index SNP and all neighboring SNPs cited in the June 2006 HapMap data set release. An r2 cut off of 0.50 was selected for inclusion as evidence for strong genetic linkage, i.e., a "strong linkage disequilibrium.

Example 196

For individuals with colorectal cancer, the distribution of polymorphic alleles at position 93232312 of chromosome 15 was different from those without colorectal cancer (Table 196).

The trend test for risk associated with carrying the C allele had an empirical p-value of

0.00053 based on permutation analysis, and the corresponding Mantel-Haenszel odds ratio for trend is 1.295 (Table 196). These data further suggest that this marker is associated with colorectal cancer risk and that the C allele at position 93232312 of chromosome 15 is associated with an increased risk of developing colorectal cancer.

Table 196 rs no. 6496061

Table 196A indicates SNPs found to be in strong linkage disequilibrium with rs6496061. To generate this list, correlation coefficients (r2) were calculated between the index SNP and all neighboring SNPs cited in the June 2006 HapMap data set release. An r2 cut off of 0.50 was selected for inclusion as evidence for strong genetic linkage, i.e., a "strong linkage disequilibrium.

Example 197

For individuals with colorectal cancer, the distribution of polymorphic alleles at position 97473570 of chromosome 15, found within the DMN gene, was different from those without colorectal cancer (Table 197). The dominant test for risk associated with carrying the T allele had an empirical p-value based on permutation analysis of 2e-06, and the corresponding dominant odds ratio is 1.564 (Table 197). These data further suggest that this marker, located within the DMN gene, is associated with colorectal cancer risk and that the T allele at position 97473570 of chromosome 15 is associated with an increased risk of developing colorectal cancer.

Table 197 A indicates SNPs found to be in strong linkage disequilibrium with rs 1965866. To generate this list, correlation coefficients (r2) were calculated between the index SNP and all neighboring SNPs cited in the June 2006 HapMap data set release. An r2 cut off of 0.50 was selected for inclusion as evidence for strong genetic linkage, i.e., a "strong linkage disequilibrium.

Example 198

For individuals with colorectal cancer, the distribution of polymorphic alleles at position 98637371 of chromosome 15, found within the ADAMTS 17 gene, was different from those without colorectal cancer (Table 198). The trend test for risk associated with carrying the G allele had an empirical p-value of 0.002684 based on permutation analysis, and the corresponding Mantel-Haenszel odds ratio for trend is 1.236 (Table 198). These data further suggest that this marker, located within the ADAMTS 17 gene, is associated with colorectal cancer risk and that the G allele at position 98637371 of chromosome 15 is associated with an increased risk of developing colorectal cancer.

Table 198 A indicates SNPs found to be in strong linkage disequilibrium with rsl 1247180. To generate this list, correlation coefficients (r2) were calculated between the index SNP and all neighboring SNPs cited in the June 2006 HapMap data set release. An r2 cut off of 0.50 was selected for inclusion as evidence for strong genetic linkage, i.e., a "strong linkage disequilibrium.

Example 199

For individuals with colorectal cancer, the distribution of polymorphic alleles at position 99771450 of chromosome 15, found within the PCSK6 gene, was different from those without colorectal cancer (Table 199). The recessive test for risk associated with carrying the C allele had an empirical p-value of 0.010102 based on permutation analysis, and the corresponding recessive odds ratio is 1.298 (Table 199). These data further suggest that this marker, located within the PCSK6 gene, is associated with colorectal cancer risk and that the C allele at position 99771450 of chromosome 15 is associated with an increased risk of developing colorectal cancer.

Table 199A indicates SNPs found to be in strong linkage disequilibrium with rsl 495273. To generate this list, correlation coefficients (r2) were calculated between the index SNP and all neighboring SNPs cited in the June 2006 HapMap data set release. An r2 cut off of 0.50 was selected for inclusion as evidence for strong genetic linkage, i.e., a "strong linkage disequilibrium.

Table 199A Linked SNPs

Example 200

For individuals with colorectal cancer, the distribution of polymorphic alleles at position 1803521 of chromosome 16, found within the HAGH gene, was different from those without colorectal cancer (Table 200). The dominant test for risk associated with carrying the T allele had an empirical p-value based on permutation analysis of 0.001725, and the corresponding dominant odds ratio is 2.111 (Table 200). These data further suggest that this marker, located within the HAGH gene, is associated with colorectal cancer risk and that the T allele at position 1803521 of chromosome 16 is associated with an increased risk of developing colorectal cancer.

Table 200A indicates SNPs found to be in strong linkage disequilibrium with rs2575357. To generate this list, correlation coefficients (r2) were calculated between the index SNP and all neighboring SNPs cited in the June 2006 HapMap data set release. An r2 cut off of 0.50 was selected for inclusion as evidence for strong genetic linkage, i.e., a "strong linkage disequilibrium.

Example 201

For individuals with colorectal cancer, the distribution of polymorphic alleles at position 5809618 of chromosome 16 was different from those without colorectal cancer (Table 201). The trend test for risk associated with carrying the C allele had an empirical p-value of 0.015641 based on permutation analysis, and the corresponding Mantel-Haenszel odds ratio for trend is 1.177 (Table 201). These data further suggest that this marker is associated with colorectal cancer risk and that the C allele at position 5809618 of chromosome 16 is associated with an increased risk of developing colorectal cancer.

Table 201A indicates SNPs found to be in strong linkage disequilibrium with rs7200468. To generate this list, correlation coefficients (r2) were calculated between the index SNP and all neighboring SNPs cited in the June 2006 HapMap data set release. An r2 cut off of 0.50 was selected for inclusion as evidence for strong genetic linkage, i.e., a "strong linkage disequilibrium.

Example 202

For individuals with colorectal cancer, the distribution of polymorphic alleles at position

52441905 of chromosome 16, found within the FTO gene, was different from those without colorectal cancer (Table 202). The trend test for risk associated with carrying the G allele had an empirical p-value of 0.000866 based on permutation analysis, and the corresponding Mantel-Haenszel odds ratio for trend is 1.306 (Table 202). These data further suggest that this marker, located within the FTO gene, is associated with colorectal cancer risk and that the G allele at position 52441905 of chromosome 16 is associated with an increased risk of developing colorectal cancer.

Table 202A indicates SNPs found to be in strong linkage disequilibrium with rs 10521306. To generate this list, correlation coefficients (r2) were calculated between the index SNP and all neighboring SNPs cited in the June 2006 HapMap data set release. An r2 cut off of 0.50 was selected for inclusion as evidence for strong genetic linkage, i.e., a "strong linkage disequilibrium.

Example 203 For individuals with colorectal cancer, the distribution of polymorphic alleles at position 67331784 of chromosome 16, found within the CDHl gene, was different from those without colorectal cancer (Table 203). The recessive test for risk associated with carrying the T allele had an empirical p-value of 0.003602 based on permutation analysis, and the corresponding recessive odds ratio is 1.297 (Table 203). These data further suggest that this marker, located within the CDHl gene, is associated with colorectal cancer risk and that the T allele at position 67331784 of chromosome 16 is associated with an increased risk of developing colorectal cancer.

Table 203 A indicates SNPs found to be in strong linkage disequilibrium with rsl 1865026. To generate this list, correlation coefficients (r2) were calculated between the index SNP and all neighboring SNPs cited in the June 2006 HapMap data set release. An r2 cut off of 0.50 was selected for inclusion as evidence for strong genetic linkage, i.e., a "strong linkage disequilibrium.

Example 204

For individuals with colorectal cancer, the distribution of polymorphic alleles at position 76102583 of chromosome 16 was different from those without colorectal cancer (Table 204). The trend test for risk associated with carrying the G allele had an empirical p-value of 0.004492 based on permutation analysis, and the corresponding Mantel-Haenszel odds ratio for trend is 1.194 (Table 204). These data further suggest that this marker is associated with colorectal cancer risk and that the G allele at position 76102583 of chromosome 16 is associated with an increased risk of developing colorectal cancer.

Table 204A indicates SNPs found to be in strong linkage disequilibrium with rs 1493892. To generate this list, correlation coefficients (r2) were calculated between the index SNP and all neighboring SNPs cited in the June 2006 HapMap data set release. An r2 cut off of 0.50 was selected for inclusion as evidence for strong genetic linkage, i.e., a "strong linkage disequilibrium.

Table 204A Linked SNPs

SNP r2 Position on chrlό SEQ ID NO rs 1493892 - 76102583 5091

Example 205

For individuals with colorectal cancer, the distribution of polymorphic alleles at position 77795011 of chromosome 16, found within the WWOX gene, was different from those without colorectal cancer (Table 205). The trend test for risk associated with carrying the C allele had an empirical p-value of 0.000708 based on permutation analysis, and the corresponding Mantel-Haenszel odds ratio for trend is 1.265 (Table 205). These data further suggest that this marker, located within the WWOX gene, is associated with colorectal cancer risk and that the C allele at position 77795011 of chromosome 16 is associated with an increased risk of developing colorectal cancer.

Table 205 A indicates SNPs found to be in strong linkage disequilibrium with rs 1813526. To generate this list, correlation coefficients (r2) were calculated between the index SNP and all neighboring SNPs cited in the June 2006 HapMap data set release. An r2 cut off of 0.50 was selected for inclusion as evidence for strong genetic linkage, i.e., a "strong linkage disequilibrium.

Example 206

For individuals with colorectal cancer, the distribution of polymorphic alleles at position 7853 ICIO of chromosome 16 was different from those without colorectal cancer (Table 206). The dominant test for risk associated with carrying the G allele had an empirical p-value based on permutation analysis of 0.001871, and the corresponding dominant odds ratio is 1.33 (Table 206). These data further suggest that this marker is associated with colorectal cancer risk and that the G allele at position 78531040 of chromosome 16 is associated with an increased risk of developing colorectal cancer.

Table 206A indicates SNPs found to be in strong linkage disequilibrium with rs 13335346. To generate this list, correlation coefficients (r2) were calculated between the index SNP and all neighboring SNPs cited in the June 2006 HapMap data set release. An r2 cut off of 0.50 was selected for inclusion as evidence for strong genetic linkage, i.e., a "strong linkage disequilibrium.

Example 207

For individuals with colorectal cancer, the distribution of polymorphic alleles at position 2666091 of chromosome 17, found within the GARNL4 gene, was different from those withoui colorectal cancer (Table 207). The dominant test for risk associated with carrying the T allele had an empirical p-value based on permutation analysis of 0.00258, and the corresponding dominant odds ratio is 1.315 (Table 207). These data further suggest that this marker, located within the GARNL4 gene, is associated with colorectal cancer risk and that the T allele at position 2666091 of chromosome 17 is associated with an increased risk of developing colorectal cancer.

Table 207A indicates SNPs found to be in strong linkage disequilibrium with rs8080237. To generate this list, correlation coefficients (r2) were calculated between the index SNP and all neighboring SNPs cited in the June 2006 HapMap data set release. An r2 cut off of 0.50 was selected for inclusion as evidence for strong genetic linkage, i.e., a "strong linkage disequilibrium.

Example 208

For individuals with colorectal cancer, the distribution of polymorphic alleles at position 22877777 of chromosome 17 was different from those without colorectal cancer (Table 208). The trend test for risk associated with carrying the G allele had an empirical p-value of 0.001648 based on permutation analysis, and the corresponding Mantel-Haenszel odds ratio for trend is 1.222 (Table 208). These data further suggest that this marker is associated with colorectal cancer risk and that the G allele at position 22877777 of chromosome 17 is associated with an increased risk of developing colorectal cancer.

Table 208A indicates SNPs found to be in strong linkage disequilibrium with rs2945379. To generate this list, correlation coefficients (r2) were calculated between the index SNP and all neighboring SNPs cited in the June 2006 HapMap data set release. An r2 cut off of 0.50 was selected for inclusion as evidence for strong genetic linkage, i.e., a "strong linkage disequilibrium.

Example 209

For individuals with colorectal cancer, the distribution of polymorphic alleles at position 28921210 of chromosome 17, found within the LOC147004 gene, was different from those without colorectal cancer (Table 209). The dominant test for risk associated with carrying the G allele had an empirical p-value based on permutation analysis of 0.00244, and the corresponding dominant odds ratio is 2.332 (Table 209). These data further suggest that this marker, located within the LOC 147004 gene, is associated with colorectal cancer risk and that the G allele at position 28921210 of chromosome 17 is associated with an increased risk of developing colorectal cancer.

Table 209A indicates SNPs found to be in strong linkage disequilibrium with rsl 2453488. To generate this list, correlation coefficients (r2) were calculated between the index SNP and all neighboring SNPs cited in the June 2006 HapMap data set release. An r2 cut off of 0.50 was selected for inclusion as evidence for strong genetic linkage, i.e., a "strong linkage disequilibrium.

Example 210

For individuals with colorectal cancer, the distribution of polymorphic alleles at position 30403780 of chromosome 17, found within the LOCI 17584 gene, was different from those without colorectal cancer (Table 210). The dominant test for risk associated with carrying the T allele had an empirical p- value based on permutation analysis of 0.001778, and the corresponding dominant odds ratio is 1.442 (Table 210). These data further suggest that this marker, located within the LOCI 17584 gene, is associated with colorectal cancer risk and that the T allele at position 30403780 of chromosome 17 is associated with an increased risk of developing colorectal cancer.

Table 210A indicates SNPs found to be in strong linkage disequilibrium with rs9303681. To generate this list, correlation coefficients (r2) were calculated between the index SNP and all neighboring SNPs cited in the June 2006 HapMap data set release. An r2 cut off of 0.50 was selected for inclusion as evidence for strong genetic linkage, i.e., a "strong linkage disequilibrium.

Example 211

For individuals with colorectal cancer, the distribution of polymorphic alleles at position 3209591 of chromosome 18, found within the MYOMl gene, was different from those without colorectal cancer (Table 211). The trend test for risk associated with carrying the A allele had an empirical p-value of 0.003444 based on permutation analysis, and the corresponding Mantel-Haenszel odds ratio for trend is 1.283 (Table 211). These data further suggest that this marker, located within the MYOMl gene, is associated with colorectal cancer risk and that the A allele at position 3209591 of chromosome 18 is associated with an increased risk of developing colorectal cancer.

Table 21 IA indicates SNPs found to be in strong linkage disequilibrium with rs4507002. To generate this list, correlation coefficients (r2) were calculated between the index SNP and all neighboring SNPs cited in the June 2006 HapMap data set release. An r2 cut off of 0.50 was selected for inclusion as evidence for strong genetic linkage, i e., a "strong linkage disequilibrium.

Table 211A Linked SNPs

SNP r2 Position on chrlδ SEQ ID NO rs4340411 0 .623 3199224 5247

Example 212

For individuals with colorectal cancer, the distribution of polymorphic alleles at position 4960506 of chromosome 18 was different from those without colorectal cancer (Table 212). The recessive test for risk associated with carrying the C allele had an empirical p-value of 0.002818 based on permutation analysis, and the corresponding recessive odds ratio is 1.341 (Table 212). These data further suggest that this marker is associated with colorectal cancer risk and that the C allele at position 4960506 of chromosome 18 is associated with an increased risk of developing colorectal cancer.

Table 212A indicates SNPs found to be in strong linkage disequilibrium with rsl466882. To generate this list, correlation coefficients (r2) were calculated between the index SNP and all neighboring SNPs cited in the June 2006 HapMap data set release. An r2 cut off of 0.50 was selected for inclusion as evidence for strong genetic linkage, i.e., a "strong linkage disequilibrium.

Example 213

For individuals with colorectal cancer, the distribution of polymorphic alleles at position 18318589 of chromosome 18, found within the LOC441815 gene, was different from those without colorectal cancer (Table 213). The dominant test for risk associated with carrying the G allele had an empirical p-value based on permutation analysis of 0.011284, and the corresponding dominant odds ratio is 1.396 (Table 213). These data further suggest that this marker, located within the LOC441815 gene, is associated with colorectal cancer risk and that the G allele at position 18318589 of chromosome 18 is associated with an increased risk of developing colorectal cancer.

Table 213A indicates SNPs found to be in strong linkage disequilibrium with rs 177994. To generate this list, correlation coefficients (r2) were calculated between the index SNP and all neighboring SNPs cited in the June 2006 HapMap data set release. An r2 cut off of 0.50 was selected for inclusion as evidence for strong genetic linkage, i.e., a "strong linkage disequilibrium.

Example 214

For individuals with colorectal cancer, the distribution of polymorphic alleles at position 37705863 of chromosome 18 was different from those without colorectal cancer (Table 214). The trend test for risk associated with carrying the C allele had an empirical p-value of 0.003686 based on permutation analysis, and the corresponding Mantel-Haenszel odds ratio for trend is 1.218 (Table 214). These data further suggest that this marker is associated with colorectal cancer risk and that the C allele at position 37705863 of chromosome 18 is associated with an increased risk of developing colorectal cancer.

Table 214A indicates SNPs found to be in strong linkage disequilibrium with rs930189. To generate this list, correlation coefficients (r2) were calculated between the index SNP and all neighboring SNPs cited in the June 2006 HapMap data set release. An r2 cut off of 0.50 was selected for inclusion as evidence for strong genetic linkage, i.e., a "strong linkage disequilibrium.

Example 215

For individuals with colorectal cancer, the distribution of polymorphic alleles at position 41627762 of chromosome 18 was different from those without colorectal cancer (Table 215).

The recessive test for risk associated with carrying the A allele had an empirical p-value of 0.011576 based on permutation analysis, and the corresponding recessive odds ratio is 1.267 (Table 215). These data further suggest that this marker is associated with colorectal cancer risk and that the A allele at position 41627762 of chromosome 18 is associated with an increased risk of developing colorectal cancer.

Table 215 A indicates SNPs found to be in strong linkage disequilibrium with rs4362470. To generate this list, correlation coefficients (r2) were calculated between the index SNP and all neighboring SNPs cited in the June 2006 HapMap data set release. An r2 cut off of 0.50 was selected for inclusion as evidence for strong genetic linkage, i.e., a "strong linkage disequilibrium.

Example 216

For individuals with colorectal cancer, the distribution of polymorphic alleles at position 6050771O of chromosome 18 was different from those without colorectal cancer (Table 216). The trend test for risk associated with carrying the G allele had an empirical p-value of 0.002912 based on permutation analysis, and the corresponding Mantel-Haenszel odds ratio for trend is 1.271 (Table 216). These data further suggest that this marker is associated with colorectal cancer risk and that the G allele at position 60507710 of chromosome 18 is associated with an increased risk of developing colorectal cancer.

Table 216 rs no. 11151137

Chromosome; Position 18; 60507710

Gene Name unknown

Genotype; Phenotype n=G; increased risk

Hardy-Weinberg 0.40723

Case Flag | Allele B | AA I AB I BB I Model | p-Value | Odds Ratio

Table 216A indicates SNPs found to be in strong linkage disequilibrium with rsl 1151137. To generate this list, correlation coefficients (r2) were calculated between the index SNP and all neighboring SNPs cited in the June 2006 HapMap data set release. An r2 cut off of 0.50 was selected for inclusion as evidence for strong genetic linkage, i.e., a "strong linkage disequilibrium.

Example 217

For individuals with colorectal cancer, the distribution of polymorphic alleles at position 68444594 of chromosome 18 was different from those without colorectal cancer (Table 217).

The trend test for risk associated with carrying the G allele had an empirical p-value of

0.00588 based on permutation analysis, and the corresponding Mantel-Haenszel odds ratio for trend is 1.527 (Table 217). These data further suggest that this marker is associated with colorectal cancer risk and that the G allele at position 68444594 of chromosome 18 is associated with an increased risk of developing colorectal cancer.

Table 217A indicates SNPs found to be in strong linkage disequilibrium with rsl7086215. To generate this list, correlation coefficients (r2) were calculated between the index SNP and all neighboring SNPs cited in the June 2006 HapMap data set release. An r2 cut off of 0.50 was selected for inclusion as evidence for strong genetic linkage, i.e., a "strong linkage disequilibrium.

Example 218

For individuals with colorectal cancer, the distribution of polymorphic alleles at position 34356661 of chromosome 19 was different from those without colorectal cancer (Table 218).

The trend test for risk associated with carrying the A allele had an empirical p-value of

0.000157 based on permutation analysis, and the corresponding Mantel-Haenszel odds ratio for trend is 1.280 (Table 218). These data further suggest that this marker is associated with colorectal cancer risk and that the A allele at position 34356661 of chromosome 19 is associated with an increased risk of developing colorectal ca..cer.

Table 218A indicates SNPs found to be in strong linkage disequilibrium with rs2160740. To generate this list, correlation coefficients (r2) were calculated between the index SNP and all neighboring SNPs cited in the June 2006 HapMap data set release. An r2 cut off of 0.50 was selected for inclusion as evidence for strong genetic linkage, i.e., a "strong linkage disequilibrium.

Example 219

For individuals with colorectal cancer, the distribution of polymorphic alleles at position 59509847 of chromosome 19, found within the LIR9 gene, was different from those without colorectal cancer (Table 219). The dominant test for risk associated with carrying the G allele had an empirical p-value based on permutation analysis of 0.035346, and the corresponding dominant odds ratio is 2.979 (Table 219). These data further suggest that this marker, located within the LIR9 gene, is associated with colorectal cancer risk and that the G allele at position 59509847 of chromosome 19 is associated with an ^aeased risk of developing coloiectal cancer.

2008/000424

Table 219A indicates SNPs found to be in strong linkage disequilibrium with rsl761450. To generate this list, correlation coefficients (r2) were calculated between the index SNP and all neighboring SNPs cited in the June 2006 HapMap data set release. An r2 cut off of 0.50 was selected for inclusion as evidence for strong genetic linkage, i.e., a "strong linkage disequilibrium.

Table 219A Linked SNPs

SNP r2 Position on chrl9 SEQ ID NO rsl761450 - 59509847 5436

Example 220

For individuals with colorectal cancer, the distribution of polymorphic alleles at position 2503157 of chromosome 20, found within the TMC2 gene, was different from those without colorectal cancer (Table 220). The recessive test for risk associated with carrying the C allele had an empirical p-value of 0.00014 based on permutation analysis, and the corresponding recessive odds ratio is 1.544 (Table 220). These data further suggest that this marker, located within the TMC2 gene, is associated with colorectal cancer risk and that the C allele at position 2503157 of chromosome 20 is associated with an increased risk of developing colorectal cancer.

Table 220A indicates SNPs found to be in strong linkage disequilibrium with rs6050260. To generate this list, correlation coefficients (r2) were calculated between the index SNP and ail neighboring SNPs cited in the June 2006 HapMap data set release. An r2 cut off of 0.50 was selected for inclusion as evidence for strong genetic linkage, i.e., a "strong linkage disequilibrium.

Example 221

For individuals with colorectal cancer, the distribution of polymorphic alleles at position 10589575 of chromosome 20, found within the JAGl gene, was different from those without colorectal cancer (Table 221). The trend test for risk associated with carrying the C allele had an empirical p-value of 0.027093 based on permutation analysis, and the corresponding Mantel-Haenszel odds ratio for trend is 1.407 (Table 221). These data further suggest that this marker, located within the JAGl gene, is associated with colorectal cancer risk and that the C allele at position 10589575 of chromosome 20 is associated with an increased risk of developing colorectal cancer.

Table 221A indicates SNPs found to be in strong linkage disequilibrium with rs3748478. To generate this list, correlation coefficients (r2) were calculated between the index SNP and all neighboring SNPs cited in the June 2006 HapMap data set release. An r2 cut off of 0.50 was selected for inclusion as evidence for strong genetic linkage, i.e., a "strong linkage disequilibrium.

Example 222

For individuals with colorectal cancer, the distribution of polymorphic alleles at position 38556196 of chromosome 20 was different from those without colorectal cancer (Table 222).

The dominant test for risk associated with carrying the T allele had an empirical p-value based on permutation analysis of 0.00633, and the corresponding dominant odds ratio is 1.281

(Table 222). These data further suggest that this marker is associated with colorectal cancer risk and that the T allele at position 38556196 of chromosome 20 is associated with an increased risk of developing colorectal cancer.

Table 222A indicates SNPs found to be in strong linkage disequilibrium with rs2207135. To generate this list, correlation coefficients (r2) were calculated between the index SNP and all neighboring SNPs cited in the June 2006 HapMap data set release. An r2 cut off of 0.50 was selected for inclusion as evidence for strong genetic linkage, i.e., a "strong linkage disequilibrium.

Example 223

For individuals with colorectal cancer, the distribution of polymorphic alleles at position 42151350 of chromosome 20 was different from those without colorectal cancer (Table 223).

The trend test for risk associated with carrying the C allele had an empirical p-value of

0.00353 based on permutation analysis, and the corresponding Mantel-Haenszel odds ratio for trend is 1.205 (Table 223). These data further suggest that this marker is associated with colorectal cancer risk and that the C aliele at position 42151350 of chromosome 20 is associated with an increased risk of developing colorectal cancer.

Table 223 A indicates SNPs found to be in strong linkage disequilibrium with rs 16988700. To generate this list, correlation coefficients (r2) were calculated between the index SNP and all neighboring SNPs cited in the June 2006 HapMap data set release. An r2 cut off of 0.50 was selected for inclusion as evidence for strong genetic linkage, i.e., a "strong linkage disequilibrium.

Example 224

For individuals with colorectal cancer, the distribution of polymorphic alleles at position 42460924 of chromosome 20 was different from those without colorectal cancer (Table 224). The recessive test for risk associated with carrying the G allele had an empirical p-value of 0.000722 based on permutation analysis, and the corresponding recessive odds ratio is 1.407 (Table 224). These data further suggest that this marker is associated with colorectal cancer risk and that the G allele at position 42460924 of chromosome 20 is associated with an increased risk of developing colorectal cancer.

Table 224A indicates SNPs found to be in strong linkage disequilibrium with rs2425639. To generate this list, correlation coefficients (r2) were calculated between the index SNP and all neighboring SNPs cited in the June 2006 HapMap data set release. An r2 cut off of 0.50 was selected for inclusion as evidence for strong genetic linkage, i.e., a "strong linkage disequilibrium.

Example 225

For individuals with colorectal cancer, the distribution of polymorphic alleles at position 60036888 of chromosome 20, found within the TAF4 gene, was different from those without colorectal cancer (Table 225). The recessive test for risk associated with carrying the T allele had an empirical p- value of 0.021306 based on permutation analysis, and the corresponding recessive odds ratio is 4.462 (Table 225). These data further suggest that this marker, located within the TAF4 gene, is associated with colorectal cancer risk and that the T allele at position 60036888 of chromosome 20 is associated with an increased risk of developing colorectal cancer.

Table 225 A indicates SNPs found to be in strong linkage disequilibrium with rs6142925. To generate this list, correlation coefficients (r2) were calculated between the index SNP and all neighboring SNPs cited in the June 2006 HapMap data set release. An r2 cut off of 0.50 was selected for inclusion as evidence for strong genetic linkage, i.e., a "strong linkage disequilibrium.

Example 226

For individuals with colorectal cancer, the distribution of polymorphic alleles at position 18809897 of chromosome 21 was different from those without colorectal cancer (Table 226).

The recessive test for risk associated with carrying the C allele had an empirical p-value of

0.00326 based on permutation analysis, and the corresponding recessive odds ratio is 3.152

(Table 226). These data further suggest that this marker is associated with colorectal cancer risk and that the C allele at position 18809897 of chromosome 21 is associated with an increased risk of developing colorectal cancer.

Table 226

Table 226A indicates SNPs found to be in strong linkage disequilibrium with rs2824888. To generate this list, correlation coefficients (r2) were calculated between the index SNP and all neighboring SNPs cited in the June 2006 HapMap data set release. An r2 cut off of 0.50 was selected for inclusion as evidence for strong genetic linkage, i.e., a "strong linkage disequilibrium.

Example 227

For individuals with colorectal cancer, the distribution of polymorphic alleles at position 20282727 of chromosome 21 was different from those without colorectal cancer (Table 227).

The recessive test for risk associated with carrying the C allele had an empirical p-value of

0.001142 based on permutation analysis, and the corresponding recessive odds ratio is 1.409

(Table 227). These data further suggest that this marker is associated with colorectal cancer risk and that the C allele at position 20282727 of chromosome 21 is associated with an increased risk of developing colorectal cancer.

Table 227A indicates SNPs found to be in strong linkage disequilibrium with rsl2482714. To generate this list, correlation coefficients (r2) were calculated between the index SNP and all neighboring SNPs cited in the June 2006 HapMap data set release. An r2 cut off of 0.50 was selected for inclusion as evidence for strong genetic linkage, i.e., a "strong linkage disequilibrium.

Example 228

For individuals with colorectal cancer, the distribution of polymorphic alleles at position 25192249 of chromosome 21 was different from those without colorectal cancer (Table 228). The recessive test for risk associated with carrying the C allele had an empirical p-value of 0.001184 based on permutation analysis, and the corresponding recessive odds ratio is 1.654 (Table 228). These data further suggest that this marker is associated with colorectal cancer risk and that the C allele at position 25192249 of chromosome 21 is associated with an increased risk of developing colorectal cancer.

Table 228 A indicates SNPs found to be in strong linkage disequilibrium with rs2250059. To generate this list, correlation coefficients (r2) were calculated between the index SNP and all neighboring SNPs cited in the June 2006 HapMap data set release. An r2 cut off of 0.50 was selected for inclusion as evidence for strong genetic linkage, i.e., a "strong linkage disequilibrium.

Example 229

For individuals with colorectal cancer, the distribution of polymorphic alleles at position 40477600 of chromosome 21, found within the DSCAM gene, was different from those without colorectal cancer (Table 229). The trend test for risk associated with carrying the C allele had an empirical p-value of 0.000652 based on permutation analysis, and the corresponding Mantel-Haenszel odds ratio for trend is 1.249 (Table 229). These data further suggest that this marker, located within the DSCAM gene, is associated with colorectal cancer risk and that the C allele at position 40477600 of chromosome 21 is associated with an increased risk of developing colorectal cancer.

Table 229 A indicates SNPs found to be in strong linkage disequilibrium with rs 1000371. To generate this list, correlation coefficients (r2) were calculated between the index SNP and all neighboring SNPs cited in the June 2006 HapMap data set release. An r2 cut off of 0.50 was selected for inclusion as evidence for strong genetic linkage, i.e., a "strong linkage disequilibrium.

Example 230

For individuals with colorectal cancer, the distribution of polymorphic alleles at position 17935876 of chromosome 22 was different from those without colorectal cancer (Table 230). The trend test for risk associated with carrying the G allele had an empirical p-value of 0.001457 based on permutation analysis, and the corresponding Mantel-Haenszel odds ratio for trend is 1.259 (Table 230). These data further suggest that this marker is associated with colorectal cancer risk and that the G allele at position 17935876 of chromosome 22 is associated with an increased risk of developing colorectal cancer.

Table 230A indicates SNPs found to be in strong linkage disequilibrium with rs7286951. To generate this list, correlation coefficients (r2) were calculated between the index SNP and all neighboring SNPs cited in the June 2006 HapMap data set release. An r2 cut off of 0.50 was selected for inclusion as evidence for strong genetic linkage, i.e., a "strong linkage disequilibrium.

Another aspect of the invention is a method of diagnosing colorectal cancer in an individual, or determining whether the individual is at altered risk for colorectal cancer, by detecting polymorphism in a subject by treating a tissue sample from the subject with an antibody to a polymorphic genetic variant of the present invention and detecting binding of said antibody. A person of skill in the art would know how to produce such an antibody (see, for instance, Harlow, E. and Lane, eds., 1988, "Antibodies: A Laboratory Manual", Cold Spring Harbor Press, Cold Spring Harbor). Such antibodies may include, but are not limited to polyclonal antibodies, monoclonal antibodies (mAbs), humanized or chimeric antibodies, single chain antibodies, Fab fragments, F(ab')2 fragments, fragments produced by a Fab expression library, anti-idiotypic (anti-Id) antibodies and epitope-binding fragments of any of the above. The present invention also provides an animal model to study colorectal cancer and susceptibility to colorectal cancer. Such studies can be performed using transgenic animals. For example, one can produce transgenic mice, which contain a specific allelic variant of a containing any of the SNPs disclosed herein. These mice can be created, e.g., by replacing their wild-type gene with an allele containing a SNP disclosed herein, or of the corresponding human gene containing such a SNP.

In a preferred embodiment, the present invention provides a transgenic mammalian animal, said animal having cells incorporating a recombinant expression system adapted to express a gene containing a SNP disclosed herein (preferably the human gene containing a SNP disclosed herein). Generally, the recombinant expression system will be stably integrated into the genome of the transgenic animal and will thus be heritable so that the offspring of such a transgenic animal may themselves contain the transgene. Transgenic animals can be engineered by introducing the a nucleic acid molecule containing only the coding portion of the gene into the genome of animals of interest, using standard techniques for producing transgenic animals. Animals that can serve as a target for transgenic manipulation include, without limitation, mice, rats, rabbits, guinea pigs, sheep, goats, pigs, and non-human primates, e.g. baboons, chimpanzees and monkeys. Techniques known in the art to introduce a transgene into such animals include pronucleic microinjection (U.S. Pat. No. 4,873,191); retro virus-mediated gene transfer into germ lines (e.g. Van der Putten et al. 1985, Proc. Natl. Acad. Sci. USA 82: 6148-6152); gene targeting in embryonic stem cells (Thompson et al, Cell 56 (1989), 313-321); electroporation of embryos and sperm-mediated gene transfer (for a review, see for example, U.S. Pat. No. 4,736,866). For the purpose of the present invention, transgenic animals include those that carry the recombinant molecule only in part of their cells ("mosaic animals"). The molecule can be integrated either as a single transgene, or in concatamers. Selective introduction of a nucleic acid molecule into a particular cell type is also possible by following, for example, the technique of Lasko et al., Proc. Natl. Acad. Sci. USA 89 (1992): 6232-6236. Particular cells could also be targeted for molecular incorporation with tissue-specific enhancers. The expression of the integrated molecule can be monitored by standard techniques such as in situ hybridization, Northern Blot analysis, PCR or immunocytochemistry. Transgenic animals that include a copy of such a nucleic acid molecule introduced into the germ line of the animal at an embryonic stage can be used to examine the effect of increased expression of DNA encoding the corresponding protein. In accordance with this facet of the invention, an animal is treated with the reagent and a reduced incidence of the pathological condition, compared to untreated animals bearing the transgene, would indicate a potential therapeutic intervention for the pathological condition.

The present invention has been described in detail by way of illustration and example in order to acquaint others skilled in the art with the invention, its principles and its practical application. Particular formulations and processes of the present invention are not limited to the descriptions of the specific embodiments presented, but rather the descriptions and examples should be viewed in terms of the claims that follow and their equivalents. While some of the examples and descriptions above include some conclusions about the way the invention may function, the inventors do not intend to be bound by those conclusions and functions, but put them forth only as possible explanations.

It is to be further understood that the specific embodiments of the present invention as set forth are not intended as being exhaustive or limiting of the invention, and that many alternatives, modifications and variations will be apparent to those of ordinary skill in the art in light of the foregoing examples and detailed description. Accordingly, this invention is intended to embrace all such alternatives, modifications and variations that fall within the spirit and scope of the following claims.

Reference List

All publications mentioned in the specification are herein incorporated by reference to the same extent as if each individual publication was specifically and individually indicated to be incorporated by reference herein.

(1999) Current Protocols in Molecular Biology. Wiley, New York.

(2005) Remington's Pharmaceutical Sciences. Mack.

Abderrahmani A, Steinmann M, Plaisance V, Niederhauser G, Haefliger J A, Mooser V, Bonny C, Nicod P and Waeber G (2001) The Transcriptional Repressor REST Determines the Cell-Specific Expression of the Human MAPK8BP1 Gene Encoding IBl (JIP-I). MoI Cell Biol 21: pp 7256-7267.

Abecasis GR, Noguchi E, Heinzmann A, Traherne J A, Bhattacharyya S, Leaves N I, Anderson G G, Zhang Y, Lench N J, Carey A, Cardon L R, Moffatt M F and Cookson W O (2001) Extent and Distribution of Linkage Disequilibrium in Three Genomic Regions. Am J Hum Genet 68: pp 191-197.

Agresti A (2001) Exact Inference for Categorical Data: Recent Advances and Continuing Controversies. Stat Med 20: pp 2709-2722.

Ansell RJ, Kriz D and Mosbach K (1996) Molecularly Imprinted Polymers for Bioanalysis: Chromatography, Binding Assays and Biomimetic Sensors. Curr Opin Biotechnol 7: pp 89- 94.

Banerji J, Olson L and Schaffner W (1983) A Lymphocyte-Specific Cellular Enhancer Is

Located Downstream of the Joining Region in Immunoglobulin Heavy Chain Genes. Cell 33: pp 729-740.

Bartel DP and Szostak J W (1993) Isolation of New Ribozymes From a Large Pool of Random Sequences. Science 261: pp 1411-1418.

Bartel P, Chien C T, Sternglanz R and Fields S (1993) Elimination of False Positives That Arise in Using the Two-Hybrid System. Biotechniques 14: pp 920-924. Beidler CB, Ludwig J R, Cardenas J, Phelps J, Papworth C G, Melcher E, Sierzega M, Myers L J, Unger B W, Fisher M and . (1988) Cloning and High Level Expression of a Chimeric Antibody With Specificity for Human Carcinoembryonic Antigen. J Immunol 141: pp 4053- 4060.

Better M, Chang C P, Robinson R R and Horwitz A H (1988) Escherichia CoIi Secretion of an Active Chimeric Antibody Fragment. Science 240: pp 1041-1043.

Bhattacharya-Chatterjee M and Foon K A (1998) Anti-Idiotype Antibody Vaccine Therapies of Cancer. Cancer Treat Res 94:51-68.: pp 51-68.

Bosher JM and Labouesse M (2000) RNA Interference: Genetic Wand and Genetic Watchdog. Nat Cell Biol 2: pp E31-E36.

Byrne GW and Ruddle F H (1989) Multiplex Gene Regulation: a Two-Tiered Approach to Transgene Regulation in Transgenic Mice. Proc Natl Acad Sci U S A M: pp 5473-5477.

Calame K and Eaton S (1988) Transcriptional Controlling Elements in the Immunoglobulin and T Cell Receptor Loci. Adv Immunol 43:235-75.: pp 235-275.

Camper SA and Tilghman S M (1989) Postnatal Repression of the Alpha-Fetoprotein Gene Is Enhancer Independent. Genes Dev 3: pp 537-546.

Caplen NJ, Parrish S, Imani F, Fire A and Morgan R A (2001a) Specific Inhibition of Gene Expression by Small Double-Stranded RNAs in Invertebrate and Vertebrate Systems. Proc Natl Acad Sci USA 9S: pp 9742-9747.

Caplen NJ, Parrish S, Imani F, Fire A and Morgan R A (2001b) Specific Inhibition of Gene Expression by Small Double-Stranded RNAs in Invertebrate and Vertebrate Systems. Proc Natl Acad Sci U SA 98: pp 9742-9747.

Carstensen B, Soll-Johanning H, Villadsen E, Sondergaard J O and Lynge E (1996) Familial Aggregation of Colorectal Cancer in the General Population. Int J Cancer 68: pp 428-435.

Chen SH, Shine H D, Goodman J C, Grossman R G and Woo S L (1994) Gene Therapy for Brain Tumors: Regression of Experimental Gliomas by Adenovirus-Mediated Gene Transfer in Vivo. Proc Natl Acad Sci U S A 91: pp 3054-3057. Cho CY, Moran E J, Cherry S R, Stephans J Cs Fodor S P, Adams C L, Sundaram A, Jacobs J W and Schultz P G (1993) An Unnatural Biopolymer. Science 261: pp 1303-1305.

Clark AG, Weiss K M, Nickerson D A, Taylor S L, Buchanan A, Stengard J, Salomaa V, Vartiainen E, Perola M, Boerwinkle E and Sing C F (1998) Haplotype Structure and Population Genetic Inferences From Nucleotide-Sequence Variation in Human Lipoprotein Lipase. Am J Hum Genet 63: pp 595-612.

Colcher D, Pavlinkova G, Beresford G, Booth B J and Batra S K (1999) Single-Chain Antibodies in Pancreatic Cancer. Ann N Y Acad Sci 880:263-80.: pp 263-280.

Collins FS, Brooks L D and Chakravarti A (1998) A DNA Polymorphism Discovery Resource for Research on Human Genetic Variation. Genome Res 8: pp 1229-1231.

Cotton RG, Rodrigues N R and Campbell R D (1988) Reactivity of Cytosine and Thymine in Single-Base-Pair Mismatches With Hydroxylamine and Osmium Tetroxide and Its Application to the Study of Mutations. Proc Natl Acad Sci U SA S5: pp 4397-4401.

Cronin MT, Fucini R V, Kim S M, Masino R S, Wespi R M and Miyada C G (1996) Cystic Fibrosis Mutation Detection by Hybridization to Light-Generated DNA Probe Arrays. Hum Mutat 7: pp 244-255.

Crow JF (1995) Spontaneous Mutation As a Risk Factor. Exp CHn Immunogenet 12: pp 121- 128.

Cruikshank WW, Doctrow S R, Falvo M S, Huffman K, Maciaszek J. Viglianti G. Raina J, Komfeld H and Malfroy B ( 1997) A Lipidated Anti-Tat Antibody Enters Living Cells and Blocks HΓV-1 Viral Replication. J Acquir Immune Defic Syndr Hum Retrovirol 14: pp 193- 203.

Cull MG, Miller J F and Schatz P J (1992) Screening for Receptor Ligands Using Large Libraries of Peptides Linked to the C Terminus of the Lac Repressor. Proc Natl Acad Sci U S A 89: pp 1865-1869.

Cwirla SE, Peters E A, Barrett R W and Dower W J (1990) Peptides on Phage: a Vast Library of Peptides for Identifying Ligands. Proc Natl Acad Sci U SA 87: pp 6378-6382. Daly MJ, Rioux J D, Schaffner S F, Hudson T J and Lander E S (2001) High-Resolution Haplotype Structure in the Human Genome. Nat Genet 29: pp 229-232.

Dawson E, Abecasis G R, Bumpstead S, Chen Y, Hunt S, Beare D M, Pabial J, Dibling T, Tinsley E, Kirby S, Carter D, Papaspyridonos M, Livingstone S, Ganske R, Lohmussaar E, Zernant J, Tonisson N, Remm M, Magi R, Puurand T, ViIo J, Kurg A, Rice K, Deloukas P, Mott R, Metspalu A, Bentley D R, Cardon L R and Dunham I (2002) A First-Generation Linkage Disequilibrium Map of Human Chromosome 22. Nature 418: pp 544-548.

de Leon MP, Pedroni M, Benatti P, Percesepe A, Di Gregorio C, Foroni M, Rossi G, Genuardi M, Neri G, Leonardi F, Viel A, Capozzi E, Boiocchi M and Roncucci L (1999) Hereditary Colorectal Cancer in the General Population: From Cancer Registration to Molecular Diagnosis. Gut 45: pp 32-38.

Devlin JJ, Panganiban L C and Devlin P E (1990) Random Peptide Libraries: a Source of Specific Protein Binding Molecules. Science 249: pp 404-406.

DeWitt SH, Kiely J S, Stankovic C J, Schroeder M C, Cody D M and Pavia M R (1993) "Diversomers": an Approach to Nonpeptide, Nonoligomeric Chemical Diversity. Proc Natl Acad Sci U SA 90: pp 6909-6913.

Dunning AM, Durocher F, Healey C S, Teare M D, McBride S E, Carlomagno F, Xu C F, Dawson E, Rhodes S, Ueda S, Lai E, Luben R N, Van Rensburg E J, Mannermaa A, Kataja V, Rennart G, Dunham I, Purvis I, Easton D and Ponder B A (2000) The Extent of Linkage Disequilibrium in Four Populations With Distinct Demographic Histories. Am J Hum Genet 67: pp 1544-1554.

Edlund T, Walker M D, Barr P J and Rutter W J (1985) Cell-Specific Expression of the Rat Insulin Gene: Evidence for Role of Two Distinct 5' Flanking Elements. Science 230: pp 912- 916.

Elbashir SM, Harborth J, Weber K and Tuschl T (2002) Analysis of Gene Function in Somatic Mammalian Cells Using Small Interfering RNAs. Methods 26: pp 199-213.

Erb E, Janda K D and Brenner S (1994) Recursive Decon volution of Combinatorial Chemical Libraries. Proc Natl Acad Sci U SA 91: pp 11422-11426. Felici F. Castagnoli L, Musacchio A, Jappelli R and Cesareni G (1991) Selection of Antibody Ligands From a Large Library of Oligopeptides Expressed on a Multivalent Exposition Vector. J MoI Biol 111: pp 301-310.

Fodor SP, Rava R P, Huang X C, Pease A C, Holmes C P and Adams C L (1993) Multiplexed Biochemical Assays With Biological Chips. Nature 364: pp 555-556.

Gabriel SB, Schaffner S F, Nguyen H, Moore J M, Roy J, Blumenstiel B, Higgins J, DeFelice M, Lochner A, Faggart M, Liu-Cordero S N, Rotimi C, Adeyemo A, Cooper R, Ward R, Lander E S, Daly M J and Altshuler D (2002) The Structure of Haplotype Blocks in the Human Genome. Science 296: pp 2225-2229.

Gallop MA, Barrett R W, Dower W J, Fodor S P and Gordon E M (1994) Applications of Combinatorial Technologies to Drug Discovery. 1. Background and Peptide Combinatorial Libraries. J Med Chem 37: pp 1233-1251.

Gautier C, Morvan F, Rayner B, Huynh-Dinh T, Igolen J, Imbach J L, Paoletti C and Paoletti J (1987) Alpha-DNA. IV: Alpha- Anomeric and Beta-Anomeric Tetrathymidylates Covalently Linked to Intercalating Oxazolopyridocarbazole. Synthesis, Physicochemical Properties and Poly (RA) Binding. Nucleic Acids Res 15: pp 6625-6641.

Goeddel DV (1990) Systems for Heterologous Gene Expression. Methods Enzymol 185:3-7.: pp 3-7.

Gottesman S (1990) Minimizing Proteolysis in Escherichia CoIi: Genetic Solutions. Methods Enzymol 185:119-29.: pp 119-129.

Hage DS and Tweed S A (1997) Recent Advances in Chromatographic and Electrophoretic Methods for the Study of Drug-Protein Interactions. J Chromatogr B Biomed Sci Appl 699: pp 499-525.

Haseloff J and Gerlach W L (1988) Simple RNA Enzymes With New and Highly Specific Endoribonuclease Activities. Nature 334: pp 585-591.

Heegaard NH (1998) Capillary Electrophoresis for the Study of Affinity Interactions. J MoI Recognit 11: pp 141-148. Helene C (1991) The Anti-Gene Strategy: Control of Gene Expression by Triplex-Forming- Oligonucleotides. Anticancer Drug Des 6: pp 569-584.

Helene C, Thuong N T and Harel-Bellan A (1992) Control of Gene Expression by Triple Helix-Forming Oligonucleotides. The Antigene Strategy. Ann N Y Acad Sci 660:27-36.: pp 27-36.

Herlyn D and Birebent B (1999) Advances in Cancer Vaccine Development. Ann Med 31: pp 66-78.

Herzog TJ (2003) New approaches for the management of cervical cancer. Gynecol Oncol. (3 Pt 2):S22-7.

Houghten RA, Appel J R, Blondelle S E, Cuervo J H, Dooley C T and Pinilla C (1992) The Use of Synthetic Peptide Combinatorial Libraries for the Identification of Bioactive Peptides. Biotechniques 13: pp 412-421.

Hyrup B and Nielsen P E (1996) Peptide Nucleic Acids (PNA): Synthesis, Properties and Potential Applications. Bioorg Med Chem 4: pp 5-23.

Inoue H, Hayase Y, Imura A, Iwai S, Miura K and Ohtsuka E (1987a) Synthesis and

Hybridization Studies on Two Complementary Nona (2'-O-Methyl)Ribonucleotides. Nucleic Acids Res 15: pp 6131-6148.

Inoue H, Hayase Y, Iwai S and Ohtsuka E (1987b) Sequence-Dependent Hydrolysis of RNA Using Modified Oligonucleotide Splints and RNase H. FEBS Lett 215: pp 327-330.

Iwabuchi K, Li B, Bartel P and Fields S (1993) Use of the Two-Hybrid System to Identify the Domain of P53 Involved in Oligomerization. Oncogene 8: pp 1693-1696.

Jespers LS, Roberts A, Mahler S M, Winter G and Hoogenboom H R (1994) Guiding the Selection of Human Antibodies From Phage Display Repertoires to a Single Epitope of an Antigen. Biotechnology (N Y) U: pp 899-903.

Kessel M and Grass P (1990) Murine Developmental Control Genes. Science 249: pp 374- 379. Kikuchi T, Daigo Y, Katagiri T, Tsunoda T, Okada K, Kakiυchi S, Zembutsu H, Furukawa Y, Kawamura M, Kobayashi K, Imai K and Nakamura Y (2003) Expression Profiles of Non- Small Cell Lung Cancers on CDNA Microarrays: Identification of Genes for Prediction of Lymph-Node Metastasis and Sensitivity to Anti-Cancer Drugs. Oncogene 22: pp 2192-2205.

Kondrashov AS (1995) Contamination of the Genome by Very Slightly Deleterious Mutations: Why Have We Not Died 100 Times Over? J Theor Biol 175: pp 583-594.

Kozal MJ, Shah N, Shen N, Yang R, Fucini R, Merigan T C, Richman D D, Morris D, Hubbell E, Chee M and Gingeras T R (1996) Extensive Polymorphisms Observed in HIV-I Clade B Protease Gene Using High-Density Oligonucleotide Arrays. Nat Med 2: pp 753-759.

Lam KS (1997) Application of Combinatorial Library Methods in Cancer Research and Drug Discovery. Anticancer Drug Des 12: pp 145-167.

Lam KS, Salmon S E, Hersh E M, Hruby V J, Kazmierski W M and Knapp R J (1991) A New Type of Synthetic Peptide Library for Identifying Ligand-Binding Activity. Nature 354: pp 82-84.

Lemaitre M, Bayard B and Lebleu B (1987) Specific Antiviral Activity of a Poly (L-Lysine)- Conjugated Oligodeoxyribonucleotide Sequence Complementary to Vesicular Stomatitis Virus N Protein MRNA Initiation Site. Proc Natl Acad Sci U SA M: pp 648-652.

Letsinger RL, Zhang G R, Sun D K, flceuchi T and Sarin P S (1989) Cholesteryl-Conjugated Oligonucleotides: Synthesis, Properties, and Activity As Inhibitors of Replication of Human Immunodeficiency Virus in Cell Culture. Proc Natl Acad Sci U SA 86: pp 6553-6556.

Liu AY, Robinson R R, Hellstrom K E, Murray E D, Jr., Chang C P and Hellstrom I (1987a) Chimeric Mouse-Human IgGl Antibody That Can Mediate Lysis of Cancer Cells. Proc Natl Acad Sci U SA S4: pp 3439-3443.

Liu AY, Robinson R R, Murray E D, Jr., Ledbetter J A, Hellstrom I and Hellstrom K E (1987b) Production of a Mouse-Human Chimeric Monoclonal Antibody to CD20 With Potent Fc-Dependent Biologic Activity. J Immunol 139: pp 3521-3526. Liu N, Sawyer S L, Mukherjee N, Pakstϊs A J, Kidd J R, Kidd K K, Brookes A J and Zhao H (2004) Haplotype Block Structures Show Significant Variation Among Populations. Genet Epidemiol 27: pp 385-400.

Lonberg N and Huszar D (1995) Human Antibodies From Transgenic Mice. lnt Rev Immunol 13: pp 65-93.

Lynch HT and de La C A (2003) Hereditary Colorectal Cancer. N Engl J Med 348: pp 919- 932.

Madura K, Dohmen R J and Varshavsky A (1993) N-Recognin/Ubc2 Interactions in the N- End Rule Pathway. J Biol Chem 268: pp 12046-12054.

Maher LJ, m (1992) DNA Triple-Helix Formation: an Approach to Artificial Gene Repressors? Bioessays 14: pp 807-815.

Malik F, Delgado C, Knusli C, Irvine A E, Fisher D and Francis G E (1992) Polyethylene Glycol (PEG)-Modified Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) With Conserved Biological Activity. Exp Hematol 20: pp 1028-1035.

Marasco WA, Haseltine W A and Chen S Y (1993) Design, Intracellular Expression, and Activity of a Human Anti-Human Immunodeficiency Virus Type 1 Gp 120 Single-Chain Antibody. Proc Natl Acad Sci USA 90: pp 7889-7893.

McConnell HM, Owicki J C, Parce J W, Miller D L, Baxter G T, Wada H G and Pitchford S (1992) The Cytosensor Microphysiometer: Biological Applications of Silicon Technology. Science 257: pp 1906-1912.

Morrison SL (1985) Transfectomas Provide Novel Chimeric Antibodies. Science 229: pp 1202-1207.

Myers RM, Larin Z and Maniatis T (1985) Detection of Single Base Substitutions by Ribonuclease Cleavage at Mismatches in RNA:DNA Duplexes. Science 230: pp 1242-1246.

Nishimura Y, Yokoyama M, Araki K, Ueda R, Kudo A and Watanabe T (1987) Recombinant Human-Mouse Chimeric Monoclonal Antibody Specific for Common Acute Lymphocytic Leukemia Antigen. Cancer Res 47: pp 999-1005. Osbome SE, Matsumura I and Ellington A D (1997) Aptamers As Therapeutic and Diagnostic Reagents: Problems and Prospects. Curr Opin Chem Biol 1: pp 5-9.

Patel DJ (1997) Structural Analysis of Nucleic Acid Aptamers. Curr Opin Chem Biol 1: pp 32-46.

Perry-O'Keefe H, Yao X W, Coull J M, Fuchs M and Egholm M (1996) Peptide Nucleic Acid Pre-Gel Hybridization: an Alternative to Southern Hybridization. Proc Natl Acad Sci USA 93: pp 14670-14675.

Pinkert CA, Ornitz D M, Brinster R L and Palmiter R D (1987) An Albumin Enhancer Located 10 Kb Upstream Functions Along With Its Promoter to Direct Efficient, Liver- Specific Expression in Transgenic Mice. Genes Dev 1: pp 268-276.

Queen C and Baltimore D (1983) Immunoglobulin Gene Transcription Is Activated by Downstream Sequence Elements. Cell 33: pp 741-748.

Reich DE, Cargill M, BoIk S, Ireland J, Sabeti P C, Richter D J, Lavery T, Kouyoumjian R, Farhadian S F, Ward R and Lander E S (2001) Linkage Disequilibrium in the Human Genome. Nature 411: pp 199-204.

Reiter Y and Pastan I (1996) Antibody Engineering of Recombinant Fv Immunotoxins for Improved Targeting of Cancer: Disulfide-Stabilized Fv Immunotoxins. CHn Cancer Res 2: pp

245-252.

Rioux JD, Daly M J, Silverberg M S, Lindblad K, Steinhart H, Cohen Z, Delmonte T, Kocher K, Miller K, Guschwan S, Kulbokas E J, O'Leary S, Winchester E, Dewar K, Green T, Stone V, Chow C, Cohen A, Langelier D, Lapointe G, Gaudet D, Faith J, Branco N, Bull S B, McLeod R S, Griffiths A M, Bitton A, Greenberg G R, Lander E S, Siminovitch K A and Hudson T J (2001) Genetic Variation in the 5q31 Cytokine Gene Cluster Confers Susceptibility to Crohn Disease. Nat Genet 29: pp 223-228.

Rivas G and Minton A P (1993) New Developments in the Study of Biomolecular Associations Via Sedimentation Equilibrium. Trends Biochem Sci 18: pp 284-287.

Sachidanandam R, Weissman D, Schmidt S C, Kakol J M, Stein L D, Marth G, Sherry S, Mullikin J C, Mortimore B J, Willey D L, Hunt S E, Cole C G, Coggill P C, Rice C M, Ning Z, Rogers J, Bentley D R, Kwok P Y, Mardis E R, Yeh R T, Schultz B, Cook L, Davenport R, Dante M, Fulton L, Hillier L, Waterston R H, McPherson J D, Gilman B, Schaffner S, Van Etten W J, Reich D, Higgins J, Daly M J, Blumenstiel B, Baldwin J, Stange-Thomann N, Zody M C, Linton L, Lander E S and Altshuler D (2001) A Map of Human Genome Sequence Variation Containing 1.42 Million Single Nucleotide Polymorphisms. Nature 409: pp 928- 933.

Saiki RK, Bugawan T L, Horn G T, Mullis K B and Erlich H A (1986) Analysis of Enzymatically Amplified Beta-Globin and HLA-DQ Alpha DNA With Allele-Specific Oligonucleotide Probes. Nature 324: pp 163-166.

Sasieni D P (1997) From Genotypes to Genes: Doubling the Sample Size. Biometrics V.53,(4) 1253-1261.

Scott JK and Smith G P (1990) Searching for Peptide Ligands With an Epitope Library. Science 249: pp 386-390.

Shaw DR, Khazaeli M B and LoBuglio A F (1988) Mouse/Human Chimeric Antibodies to a Tumor-Associated Antigen: Biologic Activity of the Four Human IgG Subclasses. J Natl Cancer Inst 80: pp 1553-1559.

Sjolander S and Urbaniczky C (1991) Integrated Fluid Handling System for Biomolecular Interaction Analysis. Anal Chem 63: pp 2338-2345.

Smith & Johnson (1988) Single-step purification of polypeptides expressed in Escherichia coli as fusions with glutathione S-transf erase. Gene 67: 31-40.

Sun LK, Curtis P, Rakowicz-Szulczynska E, Ghrayeb J, Chang N, Morrison S L and Koprowski H (1987) Chimeric Antibody With Human Constant Regions and Mouse Variable Regions Directed Against Carcinoma-Associated Antigen 17-1A. Proc Natl Acad Sci USA 84: pp 214-218.

Szabo A, Stolz L and Granzow R (1995) Surface Plasmon Resonance and Its Use in Biomolecular Interaction Analysis (BIA). Curr Opin Struct Biol 5: pp 699-705.

Taillon-Miller P, Piernot E E and Kwok P Y (1999) Efficient Approach to Unique Single- Nucleotide Polymorphism Discovery. Genome Res 9: pp 499-505. van der Krol AR, MoI J N and Stuitje A R (1988) Modulation of Eukaryotic Gene Expression by Complementary RNA or DNA Sequences. Biotechniques 6: pp 958-976.

Verhoeyen M, Milstein C and Winter G (1988) Reshaping Human Antibodies: Grafting an Antilysozyme Activity. Science 239: pp 1534-1536.

Vlatakis G, Andersson L I, Muller R and Mosbach K (1993) Drug Assay Using Antibody Mimics Made by Molecular Imprinting. Nature 361: pp 645-647.

Wada K, Wada Y, Ishibashi F, Gojobori T and Ikemura T (1992) Codon Usage Tabulated From the GenBank Genetic Sequence Data. Nucleic Acids Res 20 Suppl:2111-8.: pp 2111- 2118.

Wang DG, Fan J B, Siao C J, Berno A, Young P, Sapolsky R, Ghandour G, Perkins N,

Winchester E, Spencer J, Kruglyak L, Stein L, Hsie L, Topaloglou T, Hubbell E, Robinson E, Mittmann M, Morris M S, Shen N, Kilburn D, Rioux J, Nusbaum C, Rozen S, Hudson T J, Lipshutz R, Chee M and Lander E S (1998) Large-Scale Identification, Mapping, and Genotyping of Single-Nucleotide Polymorphisms in the Human Genome. Science 280: pp 1077-1082.

Winoto A and Baltimore D (1989) A Novel, Inducible and T Cell-Specific Enhancer Located at the 3' End of the T Cell Receptor Alpha Locus. EMBO J 8: pp 729-733.

Wood CR, Boss M A, Kenten J H, CaI vert J E, Roberts N A and Emtage J S (1985) The Synthesis and in Vivo Assembly of Functional Antibodies in Yeast. Nature 314: pp 446-449.

Zervos AS, Gyuris J and Brent R (1993) Mxi 1 , a Protein That Specifically Interacts With Max to Bind Myc-Max Recognition Sites. Cell 72: pp 223-232.

Zon G (1988) Oligonucleotide Analogues As Potential Chemotherapeutic Agents. Pharm Res 5: pp 539-549.

Zuckermann RN, Martin E J, Spellmeyer D C, Stauber G B, Shoemaker K R, Kerr J M, Figliozzi G M, Goff D A. Siani M A, Simon R J and . ( 1994) Discovery of Nanomolar Ligands for 7-Transmembrane G-Protein-Coupled Receptors From a Diverse N- (Substituted)Glycine Peptoid Library. J Med Chem 37: pp 2678-2685.

CLAIMS

1. A method for identifying an individual who has an altered risk for developing colorectal cancer, comprising detecting a single nucleotide polymorphism (SNP) in any one or more of the following nucleotide bases: a base located at position 5643494 to position 5653688 on human chromosome 1 ; a base located at position 17384494 to position 17419907 on human chromosome 1; a base located at position 18484832 to position 18512119 on human chromosome 1; a base located at position 20628809 to position 20628828 on human chromosome 1 ; a base located at position 20805662 to position 21149959 on human chromosome 1; a base located at position 21994187 to position 22090953 on human chromosome 1; a base located at position 33594198 to position 33676601 on human chromosome 1; a base located at position 40754887 to position 40801318 on human chromosome 1; a base located at position 82399075 to position 82511041 on human chromosome 1; a base located at position 95488809 to position 95530617 on human chromosome 1; a base located at position 118561559 to position 118664662 on human chromosome 1; a base located at position 142933600 to position 143043494 on human chromosome 1; a base located at position 154354010 to position 154507828 on human chromosome 1; a base located at position 166392439 to position 166577414 on human chromosome 1; a base located at position 182256575 to position 182285181 on human chromosome 1; a base located at position 187082093 to position 187337861 on human chromosome 1; a base located at position 200499985 to position 200698626 on human chromosome 1 ; a base located at position 211255378 to position 211297540 on human chromosome 1; a base located at position 214639829 to position 214641707 on human chromosome 1; a base located at position 228779667 to position 228793128 on human chromosome 1; a base located at position 228780820 to position 228815730 on human chromosome 1 ; a base located at position 229740644 to position 229802303 on human chromosome 1; a base located at position 236665853 on human chromosome 1; a base located at position 1981076 to position 2154044 on human chromosome 2; a base located at position 6787971 to position 6837215 on human chromosome 2; a base located at position 10447542 to position 104^9016 on human chromosome 2; a base located at position 14717418 to position 14979189 on human chromosome 2; a base located at position 16423966 to position 16466591 on human chromosome 2; a base located at position 16444388 to position 16470091 on human chromosome 2; a base located at position 19192227 to position 19222754 on human chromosome 2; a base located at position 45105940 to position 45108790 on human chromosome 2; a base located at position 49157212 to position 49335916 on human chromosome 2; a base located at position 51253921 to position 51372576 on human chromosome 2; a base located at position 51581044 to position 51670971 on human chromosome 2; a base located at position 51728639 to position 51860492 on human chromosome 2; a base located at position 54600331 to position 54875672 on human chromosome 2; a base located at position 57681639 to position 57818569 on human chromosome 2; a base located at position 59392191 to position 59515351 on human chromosome 2; a base located at position 66140052 to position 66217596 on human chromosome 2; a base located at position 76569557 to position 76657927 on human chromosome 2; a base located at position 79509214 to position 79543671 on human chromosome 2; a base located at position 101306757 to position 101496373 on human chromosome 2; a base located at position 101830649 to position 102016032 on human chromosome 2; a base located at position 116932933 to position 117089137 on human chromosome 2; a base located at position 136894809 to position 136995795 on human chromosome 2; a base located at position 148275544 to position 148547339 on human chromosome 2; a base located at position 166017910 to position 166180918 on human chromosome 2; a base located at position 166311863 to position 166466082 on human chromosome 2; a base located at position 182829393 to position 182977270 on human chromosome 2; a base located at position 186710420 to position 186944471 on human chromosome 2; a base located at position 190190056 to position 190257783 on human chromosome 2; a base located at position 192530205 on human chromosome 2; a base located at position 200935729 to position 201079462 on human chromosome 2; a base located at position 201393474 to position 201394505 on human chromosome 2; a base located at position 15972853 to position 16045510 on human chromosome 3; a base located at position 25124423 to position 25182177 on human chromosome 3; a base located at position 25169305 to position 25300483 on human chromosome 3; a base located at position 32100486 to position 32163010 on human chromosome 3; a base located at position 36532521 to position 36630641 on human chromosome 3; a base located at position 95535589 to position 95612334 on human chromosome 3; a base located at position 112901691 to position 112988303 on human chromosome 3; a base located at position 115100733 to position 115129347 on human chromosome 3; a base located at position 119908152 to position 120003649 on human chromosome 3; a base located at position 135273298 to position 135475438 on human chromosome 3; a base located at position 150158635 to position 150161751 on human chromosome 3; a base located at position 171012778 to position 171079610 on human chromosome 3; a base located at position 185023187 to position 185107149 on human chromosome 3; a base located at position 189622331 to position 189651573 on human chromosome 3; a base located at position 17011072 to position 17058442 on human chromosome 4; a base located at position 84499813 to position 84578598 on human chromosome 4; a base located at position 96577385 to position 96651424 on human chromosome 4; a base located at position 99799667 to position 99884270 on human chromosome 4; a base located at position 126362489 to position 126495757 on human chromosome 4; a base located at position 136880552 to position 136902550 on human chromosome 4; a base located at position 141738039 to position 141849181 on human chromosome 4; a base located at position 174180260 to position 174243021 on human chromosome 4; a base located at position 33068424 to position 33230214 on human chromosome 5; a base located at position 34794058 to position 34830429 on human chromosome 5; a base located at position 53410335 to position 53420578 on human chromosome 5; a base located at position 53646736 to position 53708606 on human chromosome 5; a base located at position 88021051 to position 88179782 on human chromosome 5; a base located at position 94538098 to position 94756096 on human chromosome 5; a base located at position 98670568 to position 98971488 on human chromosome 5; a base located at position 100010191 to position 100111425 on human chromosome 5; a base located at position 106697845 to position 106793738 on human chromosome 5; a base located at position 113500176 to position 113631667 on human chromosome 5; a base located at position 114713355 to position 114773293 on human chromosome 5; a base located at position 128919467 to position 129075899 on human chromosome 5; a base located at position 145262302 to position 145285959 on human chromosome 5; a base located at position 153338419 to position 153474121 on human chromosome 5; a base located at position 155746109 to position 155811196 on human chromosome 5; a base located at position 166726668 on human chromosome 5; a base located at position 172412942 to position 172513472 on human chromosome 5; a base located at position 3421102 to position 3445838 on human chromosome 6; a base located at position 8930286 to position 8944645 on human chromosome 6; a base located at position 10955923 to position 10994571 on human chromosome 6; a base located at position 12403489 on human chromosome 6; a base located at position 12512974 to position 12532953 on human chromosome 6; a base located at position 20091192 to position 20111445 on human chromosome 6; a base located at position 23519068 to position 23545252 on human chromosome 6; a base located at position 39396512 to position 39399785 on human chromosome 6; a base located at position 50369349 to position 50402402 on human chromosome 6; a base located at position 82950808 to position 83170215 on human chromosome 6; a base located at position 82950808 to position 83172329 on human chromosome 6; a base located at position 93549999 to position 93655110 on human chromosome 6; a base located at position 129859646 to position 129880427 on human chromosome 6; a base located at position 131737411 to position 131772200 on human chromosome 6; a base located at position 133771457 to position 133828176 on human chromosome 6; a base located at position 158369411 to position 158383241 on human chromosome 6; a base located at position 158619762 to position 158751844 on human chromosome 6; a base located at position 158836596 to position 158880182 on human chromosome 6; a base located at position 167053307 to position 167066688 on human chromosome 6; a base located at position 2977418 to position 3009317 on human chromosome 7; a base located at position 13931478 to position 13947845 on human chromosome 7; a base located at position 20613496 on human chromosome 7; a base located at position 21780211 to position 21805889 on human chromosome 7; a base located at position 21793279 to position 21810373 on human chromosome 7; a base located at position 21794549 to position 21800306 on human chromosome 7; a base located at position 28277806 to position 28290456 on human chromosome 7; a base located at position 32928625 to position 33262968 on human chromosome 7; a base located at position 39239867 to position 39373108 on human chromosome 7; a base located at position Al '679607 to position 47694028 on human chromosome 7; a base located at position 52786119 to position 52892643 on human chromosome 7; a base located at position 52912062 to position 52940292 on human chromosome 7; a base located at position 75255800 to position 75477789 on human chromosome 7; a base located at position 80554980 to position 80611094 on human chromosome 7; a base located at position 111854629 to position 112181364 on human chromosome 7 ; a base located at position 117236203 to position 117301830 on human chromosome 7; a base located at position 126749490 to position 126805426 on human chromosome 7; a base located at position 6671547 on human chromosome 8; a base located at position 18698758 to position 18712961 on human chromosome 8; a base located at position 74427949 to position 74432043 on human chromosome 8; a base located at position 90069996 to position 90274542 on human chromosome 8; a base located at position 104118573 to position 104139431 on human chromosome 8; a base located at position 115941011 to position 116094281 on human chromosome 8; a base located at position 128476372 to position 128495575 on human chromosome 8; a base located at position 128476372 to position 128500876 on human chromosome 8; a base located at position 128484074 to position 128500876 on human chromosome 8; a base located at position 134432616 to position 134519724 on human chromosome 8; a base located at position 483247 to position 536432 on human chromosome 9; a base located at position 6655097 to position 6685502 on human chromosome 9; a base located at position 15332046 to position 15360575 on human chromosome 9; a base located at position 16205744 to position 16220898 on human chromosome 9; a base located at position 80306838 to position 80349311 on human chromosome 9; a base located at position 95620787 to position 95624530 on human chromosome 9; a base located at position 108607941 to position 108705645 on human chromosome 9; a base located at position 110451147 to position 110499314 on human chromosome 9; a base located at position 114439269 to position 114500765 on human chromosome 9; a base located at position 129102032 to position 129131288 on human chromosome 9; a base located at position 135743798 to position 135753601 on human chromosome 9; a base located at position 5763668 to position 5774364 on human chromosome 10; a base located at position 30205989 to position 30211510 on human chromosome 10; a base located at position 43467013 on human chromosome 10; a base located at position 44130826 to position 44152160 on human chromosome 10; a base located at position 61627647 to position 61717600 on human chromosome 10; a base located at position 67129869 to position 67203466 on human chromosome 10; a base located at position 77559267 to position 77578908 on human chromosome 10; a base located at position 91204084 to position 91207882 on human chromosome 10; a base located at position 91726020 to position 91931446 on human chromosome 10; a base located at position 106848543 to position 106931514 on human chromosome 10; a base located at position 7232814 to position 7287335 on human chromosome 11 ; a base located at position 24089131 to position 24138593 on human chromosome 11; a base located at position 37042702 to position 37072441 on human chromosome 11; a base located at position 43127290 to position 43471106 on human chromosome 11; a base located at position 44564466 to position 44572616 on human chromosome 11; a base located at position 44744162 to position ^4773663 on human chromosome 11; a base located at position 107416661 to position 107635922 on human chromosome 11; a base located at position 110624904 to position 110685841 on human chromosome 11; a base located at position 118321563 to position 118361701 on human chromosome 11; a base located at position 119266187 to position 119283754 on human chromosome 11 ; a base located at position 123046828 to position 123071807 on human chromosome 11; a base located at position 123090819 to position 123221459 on human chromosome 11; a base located at position 13348818 to position 13356632 on human chromosome 12; a base located at position 48922631 to position 49376001 on human chromosome 12; a base located at position 51485831 to position 51495953 on human chromosome 12; a base located at position 76786901 to position 76849556 on human chromosome 12; a base located at position 88008483 to position 88113076 on human chromosome 12; abase located at position 101472403 to position 101540195 on human chromosome 12; a base located at position 104963405 to position 105004141 on human chromosome 12; a base located at position 114354123 to position 114412595 on human chromosome 12; a base located at position 39852882 to position 39894067 on human chromosome 13; a base located at position 49731880 to position 49858379 on human chromosome 13; a base located at position 73791516 to position 73830873 on human chromosome 13; a base located at position 74291176 to position 74482470 on human chromosome 13; a base located at position 106128657 to position 106146991 on human chromosome 13; a base located at position 109042402 on human chromosome 13; a base located at position 109154406 to position 109175464 on human chromosome 13; a base located at position 32813779 to position 32844778 on human chromosome 14; a base located at position 32929909 on human chromosome 14; a base located at position 38479068 to position 38755290 on human chromosome 14; a base located at position 84192776 to position 84311538 on human chromosome 14; a base located at position 85206930 to position 85255860 on human chromosome 14; a base located at position 51189302 to position 51322236 on human chromosome 15; a base located at position 69382722 to position 69431235 on human chromosome 15; a base located at position 76733918 to position 76960060 on human chromosome 15; a base located at position 93195638 to position 93279847 on human chromosome 15; a base located at position 97471189 to position 97560036 on human chromosome 15; a base located at position 98596360 to position 98655850 on human chromosome 15; a base located at position 99771450 to position 99780246 on human chromosome 15; a base located at position 1791149 to position 1865280 on human chromosome 16; a base located at position 5796152 to position 5830572 on human chromosome 16; a base located at position 52439872 to position 52444943 on human chromosome 16; a base located at position 67246920 to position 67394997 on human chromosome 16; a base located at position 76102583 on human chromosome 16; a base located at position 77795011 to position 77795260 on human chromosome 16; a base located at position 78507029 to position 78602515 on human chromosome 16; a base located at position 2658514 to position 2673087 on human chromosome 17; a base located at position 22820896 to position 22897438 on human chromosome 17; a base located at position 28890180 to position 28944267 on human chromosome 17; a base located at position 30321178 to position 30467328 on human chromosome 17; a base located at position 3199224 to position 3218815 on human chromosome 18; a base located at position 4923689 to position 5039243 on human chromosome 18; a base located at position 18312106 to position 18380432 on human chromosome 18; a base located at position 37702718 to position 37719111 on human chromosome 18; a base located at position 41563909 to position 41663873 on human chromosome 18; a base located at position 60452260 to position 60554118 on human chromosome 18; a base located at position 68423906 to position 68444594 on human chromosome 18; a base located at position 34276329 to position 34364983 on human chromosome 19; a base located at position 59509847 on human chromosome 19; a base located at position 2488701 to position 2533770 on human chromosome 20; a base located at position 10523782 to position 10591091 on human chromosome 20; a base located at position 38527211 to position 38561992 on human chromosome 20; a base located at position 42147372 to position 42174528 on human chromosome 20; a base located at position 42457255 to position 42460924 on human chromosome 20; a base located at position 59989629 to position 60058583 on human chromosome 20; a base located at position 18771052 to position 18820035 on human chromosome 21; a base located at position 20218657 to position 20308050 on human chromosome 21; a base located at position 25132923 to position 25262070 on human chromosome 21; a base located at position 40467923 to position 40496156 on human chromosome 21; and a base located at position 17935876 to position 17944549 on human chromosome 22; or a base in strong linkage disequilibrium with at least one of the foregoing bases.

2. The method of claim 1, which comprises detecting a single nucleotide polymorphism

(SNP) in any one or more of the following nucleotide bases: a base located at position 5643494 to position 5653688 on human chromosome 1; a base located at position 17384494 to position 17419907 on human chromosome 1; a base located at position 18484832 to position 18512119 on human chromosome 1; a base located at position 20628809 to position 20628828 on human chromosome 1 ; a base located at position 20805662 to position 21149959 on human chromosome 1; a base located at position 21994187 to position 22090953 on human chromosome 1; a base located at position 33594198 to position 33676601 on human chromosome 1; a base located at position 40754887 to position 40801318 on human chromosome 1; a base located at position 82399075 to position 82511041 on human chromosome 1; a base located at position 95488809 to position 95530617 on human chromosome 1; a base located at position 118561559 to position 118664662 on human chromosome 1; a base located at position 142933600 to position 143043494 on human chromosome 1; a base located at position 154354010 to position 154507828 on human chromosome 1; a base located at position 166392439 to position 166577414 on human chromosome 1; a base located at position 182256575 to position 182285181 on human chromosome 1; a base located at position 187082093 to position 187337861 on human chromosome 1; a base located at position 200499985 to position 200698626 on human chromosome 1 ; a base located at position 211255378 to position 211297540 on human chromosome 1; a base located at position 214639829 to position 214641707 on human chromosome 1; a base located at position 228779667 to position 228793128 on human chromosome 1; a base located at position 228780820 to position 228815730 on human chromosome 1; a base located at position 229740644 to position 229802303 on human chromosome 1 ; a base located at position 236665853 on human chromosome 1 ; a base located at position 1981076 to position 2154044 on human chromosome 2; a base located at position 6787971 to position 6837215 on human chromosome 2; a base located at position 10447542 to position 10449016 on human chromosome 2; a base located at position 14717418 to position 14979189 on human chromosome 2; a base located at position 16423966 to position 16466591 on human chromosome 2; a base located at position 16444388 to position 16470091 on human chromosome 2; a base located at position 19192227 to position 19222754 on human chromosome 2; a base located at position 45105940 to position 45108790 on human chromosome 2; a base located at position 49157212 to position 49335916 on human chromosome 2; a base located at position 51253921 to position 51372576 on human chromosoms 2; a base located at position 51581044 to position 51670971 on human chromosome 2; a base located at position 51728639 to position 51860492 on human chromosome 2; a base located at position 54600331 to position 54875672 on human chromosome 2; a base located at position 57681639 to position 57818569 on human chromosome 2; a base located at position 59392191 to position 59515351 on human chromosome 2; a base located at position 66140052 to position 66217596 on human chromosome 2; a base located at position 76569557 to position 76657927 on human chromosome 2; a base located at position 79509214 to position 79543671 on human chromosome 2; a base located at position 101306757 to position 101496373 on human chromosome 2; a base located at position 101830649 to position 102016032 on human chromosome 2; a base located at position 116932933 to position 117089137 on human chromosome 2; a base located at position 136894809 to position 136995795 on human chromosome 2; a base located at position 148275544 to position 148547339 on human chromosome 2; a base located at position 166017910 to position 166180918 on human chromosome 2; a base located at position 166311863 to position 166466082 on human chromosome 2; a base located at position 182829393 to position 182977270 on human chromosome 2; a base located at position 186710420 to position 186944471 on human chromosome 2; a base located at position 190190056 to position 190257783 on human chromosome 2; a base located at position 192530205 on human chromosome 2; a base located at position 200935729 to position 201079462 on human chromosome 2; a base located at position 201393474 to position 201394505 on human chromosome 2; a base located at position 15972853 to position 16045510 on human chromosome 3; a base located at position 25124423 to position 25182177 on human chromosome 3; a base located at position 25169305 to position 25300483 on human chromosome 3; a base located at position 32100486 to position 32163010 on human chromosome 3; a base located at position 36532521 to position 36630641 on human chromosome 3; a base located at position 95535589 to position 95612334 on human chromosome 3; a base located at position 112901691 to position 112988303 on human chromosome 3; a base located at position 115100733 to position 115129347 on human chromosome 3; a base located at position 119908152 to position 120003649 on human chromosome 3; a base located at position 135273298 to position 135475438 on human chromosome 3; a base located at position 150158635 to position 150161751 on human chromosome 3; a base located at position 171012778 to position 171079610 on human chromosome 3; a base located at position 185023187 to position 185107149 on human chromosome 3; a base located at position 189622331 to position 189651573 on human chromosome 3; a base located at position 17011072 to position 17058442 on human chromosome 4; a base located at position 84499813 to position 84578598 on human chromosome 4; a base located at position 96577385 to position 96651424 on human chromosome 4; a base located at position 99799667 to position 99884270 on human chromosome 4; a base located at position 126362489 to position 126495757 on human chromosome 4; a base located at position 136880552 to position 136902550 on human chromosome 4; a base located at position 141738039 to position 141849181 on human chromosome 4; a base located at position 174180260 to position 174243021 on human chromosome 4; a base located at position 33068424 to position 33230214 on human chromosome 5; a base located at position 34794058 to position 34830429 on human chromosome 5; a base located at position 53410335 to position 53420578 on human chromosome 5; a base located at position 53646736 to position 53708606 on human chromosome 5; a base located at position 88021051 to position 88179782 on human chromosome 5; a base located at position 94538098 to position 94756096 on human chromosome 5; a base located at position 98670568 to position 98971488 on human chromosome 5; a base located at position 100010191 to position 100111425 on human chromosome 5; a base located at position 106697845 to position 106793738 on human chromosome 5; a base located at position 113500176 to position 113631667 on human chromosome 5; a base located at position 114713355 to position 114773293 on human chromosome 5; a base located at position 128919467 to position 129075899 on human chromosome 5; a base located at position 145262302 to position 145285959 on human chromosome 5; a base located at position 153338419 to position 153474121 on human chromosome 5; a base located at position 155746109 to position 155811196 on human chromosome 5; a base located at position 166726668 on human chromosome 5; a base located at position 172412942 to position 172513472 on human chromosome 5; a base located at position 3421102 to position 3445838 on human chromosome 6; a base located at position 8930286 to position 8944645 on human chromosome 6; a base located at position 10955923 to position 10994571 on human chromosome 6; a base located at position 12403489 on human chromosome 6; a base located at position 12512974 to position 12532953 on human chromosome 6; a base located at position 20091192 to position 20111445 on human chromosome 6; a base located at position 23519068 to position 23545252 on human chromosome 6; a base located at position 39396512 to position 39399785 on human chromosome 6; a base located at position 50369349 to position 50402402 on human chromosome 6; a base located at position 82950808 to position 83170215 on human chromosome 6; a base located at position 82950808 to position 83172329 on human chromosome 6; a base located at position 93549999 to position 93655110 on human chromosome 6; a base located at position 129859646 to position 129880427 on human chromosome 6; a base located at position 131737411 to position 131772200 on human chromosome 6; a base located at position 133771457 to position 133828176 on human chromosome 6; a base located at position 158369411 to position 158383241 on human chromosome 6; a base located at position 158619762 to position 158751844 on human chromosome 6; a base located at position 158836596 to position 158880182 on human chromosome 6; a base located at position 167053307 to position 167066688 on human chromosome 6; a base located at position 2977418 to position 3009317 on human chromosome 7; a base located at position 13931478 to position 13947845 on human chromosome 7; a base located at position 20613496 on human chromosome 7; a base located at position 21780211 to position 21805889 on human chromosome 7; a base located at position 21793279 to position 21810373 on human chromosome 7; a base located at position 21794549 to position 21800306 on human chromosome 7; a base located at position 28277806 to position 28290456 on human chromosome 7; a base located at position 32928625 to position 33262968 on human chromosome 7; a base located at position 39239867 to position 39373108 on human chromosome 7; a base located at position 47679607 to position 47694028 on human chromosome 7; a base located at position 52786119 to position 52892643 on human chromosome 7; a base located at position 52912062 to position 52940292 on human chromosome 7; a base located at position 75255800 to position 75477789 on human chromosome 7; a base located at position 80554980 to position 80611094 on human chromosome 7; a base located at position 111854629 to position 112181364 on human chromosome 7; a base located at position 117236203 to position 117301830 on human chromosome 7; a base located at position 126749490 to position 126805426 on human chromosome 7; a base located at position 6671547 on human chromosome 8; a base located at position 18698758 to position 18712961 on human chromosome 8; a base located at position 74427949 to position 74432043 on human chromosome 8; a base located at position 90069996 to position 90274542 on human chromosome 8; a base located at position 104118573 to position 104139431 on human chromosome 8; a base located at position 115941011 to position 116094281 on human chromosome 8; a base located at position 128476372 to position 128495575 on human chromosome 8; a base located at position 128476372 to position 128500876 on human chromosome 8; a base located at position 128484074 to position 128500876 on human chromosome 8; a base located at position 134432616 to position 134519724 on human chromosome 8; a base located at position 483247 to position 536432 on human chromosome 9; a base located at position 6655097 to position 6685502 on human chromosome 9; a base located at position 15332046 to position 15360575 on human chromosome 9; a base located at position 16205744 to position 16220898 on human chromosome 9; a base located at position 80306838 to position 80349311 on human chromosome 9; a base located at position 95620787 to position 95624530 on human chromosome 9; a base located at position 108607941 to position 108705645 on human chromosome 9; a base located at position 110451147 to position 110499314 on human chromosome 9; a base located at position 114439269 to position 114500765 on human chromosome 9; a base located at position 129102032 to position 129131288 on human chromosome 9; a base located at position 135743798 to position 135753601 on human chromosome 9; a base located at position 5763668 to position 5774364 on human chromosome 10; a base located at position 30205989 to position 30211510 on human chromosome 10; a base located at position 43467013 on human chromosome 10; a base located at position 44130826 to position 44152160 on human chromosome 10; a base located at position 61627647 to position 61717600 on human chromosome 10; a base located at position 67129869 to position 67203466 on human chromosome 10; a base located at position 77559267 to position 77578908 on human chromosome 10; a base located at position 91204084 to position 91207882 on human chromosome 10; a base located at position 91726020 to position 91931446 on human chromosome 10; a base located at position 106848543 to position 106931514 on human chromosome 10; a base located at position 7232814 to position 7287335 on human chromosome 11; a base located at position 24089131 to position 24138593 on human chromosome 11; a base located at position 37042702 to position 37072441 on human chromosome 11; a base located at position 43127290 to position 43471106 on human chromosome 11 ; a base located at position 44564466 to position 44572616 on human chromosome 11; a base located at position 44744162 to position 44773663 on human chromosome 11; a base located at position 107416661 to position 107635922 on human chromosome 11; a base located at position 110624904 to position 110685841 on human chromosome 11; a base located at position 118321563 to position 118361701 on human chromosome 11; a base located at position 119266187 to position 119283754 on human chromosome 11 ; a base located at position 123046828 to position 123071807 on human chromosome 11; a base located at position 123090819 to position 123221459 on human chromosome 11; a base located at position 13348818 to position 13356632 on human chromosome 12; a base located at position 48922631 to position 49376001 on human chromosome 12; a base located at position 51485831 to position 51495953 on human chromosome 12; a base located at position 76786901 to position 76849556 on human chromosome 12; a base located at position 88008483 to position 88113076 on human chromosome 12; a base located at position 101472403 to position 101540195 on human chromosome 12; a base located at position 104963405 to position 105004141 on human chromosome 12; a base located at position 114354123 to position 114412595 on human chromosome 12; a base located at position 39852882 to position 39894067 on human chromosome 13; a base located at position 49731880 to position 49858379 on human chromosome 13; a base located at position 73791516 to position 73830873 on human chromosome 13; a base located at position 74291176 to position 74482470 on human chromosome 13; a base located at position 106128657 to position 106146991 on human chromosome 13; a base located at position 109042402 on human chromosome 13; a base located at position 109154406 to position 109175464 on human chromosome 13; a base located at position 32813779 to position 32844778 on human chromosome 14; a base located at position 32929909 on human chromosome 14; a base located at position 38479068 to position 38755290 on human chromosome 14; a base located at position 84192776 to position 84311538 on human chromosome 14; a base located at position 85206930 to position 85255860 on human chromosome 14; a base located at position 51189302 to position 51322236 on human chromosome 15; a base located at position 69382722 to position 69431235 on human chromosome 15; a base located at position 76733918 to position 76960060 on human chromosome 15; a base located at position 93195638 to position 93279847 on human chromosome 15; a base located at position 97471189 to position 97560036 on human chromosome 15; a base located at position 98596360 to position 98655850 on human chromosome 15; a base located at position 99771450 to position 99780246 on human chromosome 15; a base located at position 1791149 to position 1865280 on human chromosome 16; a base located at position 5796152 to position 5830572 on human chromosome 16; a base located at position 52439872 to position 52444943 on human chromosome 16; a base located at position 67246920 to position 67394997 on human chromosome 16; a base located at position 76102583 on human chromosome 16; a base located at position 77795011 to position 77795260 on human chromosome 16; a base located at position 78507029 to position 78602515 on human chromosome 16; a base located at position 2658514 to position 2673087 on human chromosome 17; a base located at position 22820896 to position 22897438 on human chromosome 17; a base located at position 28890180 to position 28944267 on human chromosome 17; a base located at position 30321178 to position 30467328 on human chromosome 17; a base located at position 3199224 to position 3218815 on human chromosome 18; a base located at position 4923689 to position 5039243 on human chromosome 18; a base located at position 18312106 to position 18380432 on human chromosome 18; a base located at position 37702718 to position 37719111 on human chromosome 18; a base located at position 41563909 to position 41663873 on human chromosome 18; a base located at position 60452260 to position 60554118 on human chromosome 18; a base located at position 68423906 to position 68444594 on human chromosome 18; a base located at position 34276329 to position 34364983 on human chromosome 19; a base located at position 59509847 on human chromosome 19; a base located at position 2488701 to position 2533770 on human chromosome 20; a base located at position 10523782 to position 10591091 on human chromosome 20; a base located at position 38527211 to position 38561992 on human chromosome 20; a base located at position 42147372 to position 42174528 on human chromosome 20; a base located at position 42457255 to position 42460924 on human chromosome 20; a base located at position 59989629 to position 60058583 on human chromosome 20; a base located at position 18771052 to position 18820035 on human chromosome 21; a base located at position 20218657 to position 20308050 on human chromosome 21 ; a base located at position 25132923 to position 25262070 on human chromosome 21; a base located at position 40467923 to position 40496156 on human chromosome 21; and a base located at position 17935876 to position 17944549 on human chromosome 22; or a base in strong linkage disequilibrium with at least one of the foregoing bases.

3. The method of claim 2, wherein said base is in strong linkage disequilibrium with at least one of the nucleotide bases located as follows: at position 5643494, 5645572, 5645696, 5645913, 5647097, 5647280, 5647550, 5647811, 5650870, 5650899, 5651404, 5651654, 5651818, 5651847, 5652214, 5652282, 5652680, 5652840,5653015,5653688, 17384494, 17386090, 17388878, 17391832, 17392000, 17396536, 17396934, 17402627, 17404594, 17411445, 17411632, 17412020, 17414282, 17419907, 18484832, 18484852, 18484976, 18485834, 18485839, 18492401, 18494907, 18495737, 18496318, 18496396, 18496810, 18497170, 18498465, 18499756, 18500442, 18501831, 18502267, 18503492, 18504683, 18506717, 18506806, 18508721, 18512119, 20628809, 20628828, 20805662, 20807307, 20812307, 20814435, 20833262, 20834778, 20835387, 20843033, 20843089, 20843172, 20845152, 20851322, 20859722, 20860139, 20866984, 20868329, 20869596, 20871652, 20873726, 20885691, 20890966, 20897686, 20897690, 20897946, 20900501, 20901973, 20902168, 20910482, 20912408, 20922516, 20925487, 20925556, 20927846, 20931914, 20934009, 20935818, 20937929, 20939816, 20943571, 20945070, 20945280, 20945717, 20949204, 20949302, 20951449, 20955075, 20958577, 20959014, 20960041, 20965681, 20965980, 20966007, 20969559, 20972644, 20980229, 20984365, 20986738, 20993250, 20994909, 20997023, 20999899, 21000095, 21000981, 21004018, 21006394, 21010403, 21016114, 21022160, 21024702, 21028251, 21033244, 21035367, 21035826, 21040905, 21041170, 21044669, 21050902, 21051467, 21055398, 21062830, 21063762, 21068091, 21068874, 21069797, 21072609, 21078118, 21082461, 21082628, 21084950, 21101147, 21106482, 21107684, 21112807, 21114874, 21120116, 21120469, 21121210, 21127511, 21131101, 21136620, 21137181, 21140439, 21140663, 21141522, 21141902, 21142192, 21145524, 21149959, 21994187, 22003045, 22010599, 22017145, 22028977, 22033247, 22033774, 22035462, 22037572, 22039203, 22040172, 22040277, 22051221, 22054010, 22057214, 22066093, 22066856, 22067235. 22070236, 22073585, 22081426, 22090399, 22090953, 33594198, 33594270, 33595060, 33596139, 33605440, 33610121, 33616560, 33651889, 33652136, 33654063, 33654926, 33660788, 33661463, 33670428, 33676444, 33676601, 40754887, 40755019, 40757670, 40762923, 40771174, 40775136, 40776959, 40777187, 40778790, 40779764, 40780164, 40781063, 40781288, 40797069, 40798090, 40801268, 40801318, 82399075, 82401753, 82402027, 82402309, 82404022, 82404407, 82406375, 82406489, 82406720, 82408523, 82411232, 82413745, 82416733, 82417487, 82417910, 82418308, 82418330, 82418366, 82419538, 82420496, 82420704, 82421197, 82422197, 82422368, 82423727, 82424134, 82424150, 82424914, 82424975, 82425243, 82426612, 82427690, 82434461, 82435415, 82439143, 82439471, 82444631, 82444660, 82447710, 82448718, 82449218, 82449749,

82449774, 82452506, 82452647, 82453300, 82453338, 82453515, 82453539, 82453848, 82453927, 82454106, 82455294, 82455776, 82456621, 82456752, 82456889, 82456912, 82457399, 82457424, 82457468, 82457982, 82458227, 82458977, 82459886, 82460521, 82460840, 82466546, 82466878, 82474430, 82476963, 82478914, 82480981, 82481004, 82484336, 82484391, 82484596, 82484930, 82485259, 82486216, 82487128, 82487294, 82488099, 82489906, 82489977, 82490942, 82490987, 82492500, 82492549, 82499839, 82505085, 82505197, 82505473, 82506578, 82506826, 82508028, 82508044, 82509654, 82510272, 82511041, 95488809, 95491103, 95493443, 95494480, 95498250, 95501385, 95530617, 118561559, 118562029, 118562981, 118564656, 118564859, 118566872, 118566892, 118570326, 118571091, 118571342, 118571646, 118575513, 118578029, 118578119, 118578309, 118579425, 118580020, 118581538, 118581975, 118585388, 118585550, 118589180, 118596956, 118600709, 118601663, 118610570, 118615020, 118619695, 118621071, 118628630, 118640477, 118641626, 118664662, 142933600, 142994415, 142996870, 143024965, 143037007, 143039966, 143040559, 143043494, 154354010, 154354638, 154354747, 154355118, 154355147, 154355235, 154355289, 154356819, 154356951, 154358120, 154359419, 154361742, 154362243, 154363430, 154363490, 154366090, 154379092, 154384794, 154397374, 154408258, 154409264, 154409463, 154419367, 154420450, 154423513, 154426410, 154432962, 154440037, 154450003, 154461171, 154479409, 154492764, 154492856, 154493187, 154494971, 154498579, 154498812, 154500310, 154501115, 154501714, 154503542, 154507828, 166392439, 166394400, 166394636, 166397209, 166397290, 166398255, 166398645, 166401473, 166408144, 166411211, 166440044, 166451495, 166457690, 166534614, 166555318, 166556037, 166569936, 166577414, 182256575, 182257700, 182264962, 182272275, 182275532, 182284803, 182285181, 187082093, 187174628, 187199686, 187205762, 187227358, 187229616, 187235623, 187245840, 187257909, 187259731, 187260102, 187262889, 187265357, 187265802, 187270060, 187271578, 187271664, 187272352, 187282856, 187294343, 187298692, 187306394, 187311887, 187316314, 187319957, 187337861, 200499985, 200501189, 200501548, 200506450, 200508966, 200509456, 200516826, 200519147, 200524239, 200527354, 200551097, 200565332, 200569854, 200588556, 200636760, 200644895, 200645480, 200645637, 200653088, 200677055, 200680317, 200687498, 200688166, 200698626, 211255378, 211257304, 211261122, 211262732, 211262877, 211263362, 211272121, 211276776, 211279482, 211283002, 211297540, 214639829, 214640087, 214640676, 214641707, 228779667, 228780820, 228781610, 228781647, 228784137, 228787987, 228791128, 228792077, 228792350, 228792421, 228793128, 228795562, 228796991, 228798772, 228798840, 228802209, 228802332, 228803037, 228803110, 228804365, 228804648, 228805071, 228812020, 228815730, 229740644, 229740798, 229741584, 229742681, 229742852, 229743138, 229772462, 229775255, 229775633, 229775685, 229775732, 229776204, 229776296, 229776889, 229777047, 229779187, 229781272, 229782916, 229783979, 229788385, 229798172, 229802303, or 236665853 on human chromosome 1; atposition 1981076, 1997590, 2000240, 2041790, 2095003, 2135816, 2137239, 2138961, 2141402, 2143625, 2144206, 2145868, 2146474, 2148224, 2148955, 2149477, 2151490, 2154044, 6787971, 6788719, 6791928, 6795452, 6797609, 6803426, 6807649, 6816663, 6817235, 6817416, 6817511, 6820094, 6824454, 6824649, 6825691, 6832251, 6833027, 6834747, 6836618, 6837215, 10447542, 10447613, 10449016, 14717418, 14730427, 14730636, 14733739, 14734664, 14736069, 14741491, 14741776, 14747763, 14759875, 14762397, 14765208, 14766106, 14782636, 14784332, 14791609, 14803091, 14805637, 14807512, 14811732, 14811975, 14813784, 14815996, 14817501, 14817638, 14818554, 14818772, 14819080, 14819413, 14819616, 14820033, 14820204, 14821252, 14821469, 14821774, 14822113, 14822372, 14823215, 14823397, 14824206, 14824355, 14824669, 14825477, 14825491, 14825515, 14825579, 14825843, 14825988, 14826533, 14826982, 14827692, 14828251, 14828478, 14828602, 14828866, 14829175, 14830288, 14830415, 14832593, 14832767, 14835129, 14836747, 14837340, 14841532, 14841955, 14842480, 14843205, 14847211, 14847384, 14848466, 14849112, 14850007, 14850241, 14854674, 14856969, 14857019, 14857404, 14858596, 14859653, 14861777, 14865257, 14867233, 14884637, 14885952, 14886528, 14889421, 14890602, 14891629, 14891836, 14893918, 14895761, 14895898, 14896644, 14897874, 14898959, 14901340, 14902171, 14902258, 14902695, 14902783, 14903803, 14904181, 14906178, 14906940, 14908749, 14913424, 14919179, 14921640, 14921971, 14924120, 14925890, 14927435, 14927984, 14928014, 14955346, 14975692, 14979189, 16423966, 16429905, 16436415, 16436634, 16438849, 16441253, 16444388, 16445618, 16449154, 16449252, 16452489, 16452960, 16453191, 16453401, 16456670, 16456858, 16456971, 16457143, 16457924, 16458608, 16460229, 16460397, 16462574, 16462884, 16463084, 16465684, 16466591, 16469303, 16470091, 19192227, 19196921, 19199416, 19200437, 19200850, 19202694, 19206904, 19207725, 19208019, 19208571, 19209828, 19220355, 19220680, 19222754, 45105940, 45108790, 49157212, 49159483, 49163446, 49169518, 49180455, 49183068, 49184463, 49185265, 49186995, 49187101, 49187893, 49189474, 49190619, 49191171, 49204882, 49228799, 49242409, 49244528, 49244583, 49311997, 49319087, 49329514, 49329682, 49332761,

49335916, 51253921, 51282582, 51283998, 51292542, 51292816, 51293152, 51295469, 51295990, 51296316, 51296923, 51299142, 51299895, 51301729, 51302018, 51302766, 51308652, 51309069, 51310020, 51310044, 51310173, 51310771, 51311259, 51311482, 51312641, 51312847, 51312996, 51313386, 51314939, 51322555, 51336913, 51337143, 51337268, 51350473, 51350968, 51352442, 51359648, 51366391, 51368581, 51372576, 51581044, 51581245, 51581381, 51581793, 51582624, 51582698, 51582708, 51583049, 51583586, 51585227, 51585680, 51585798, 51586102, 51586672, 51586849, 51586986, 51587119, 51588006, 51588334, 51588675, 51588954, 51589200, 51589275, 51591307, 51591566, 51591990, 51592343, 51592536, 51592586, 51592716, 51592732, 51593258, 51593383, 51593808, 51593873, 51594068, 51594415, 51594505, 51595017, 51595132, 51595138, 51595162, 51595217, 51595686, 51596013, 51596427, 51596503, 51596924, 51598188, 51604192, 51604653, 51606466, 51612697, 51616113, 51616175, 51616622, 51618694, 51620262, 51621249, 51621558, 51623474, 51624825, 51627047, 51629369, 51629761, 51630099, 51630541, 51631175, 51631495, 51632351, 51634094, 51634284, 51634299, 51634564, 51639966, 51641156, 51641476, 51641840, 51641866, 51642637, 51642841, 51643067, 51643284, 51645247, 51646327, 51646730, 51646785, 51646789, 51647145, 51647506, 51648328, 51648645, 51649654, 51649807, 51650133, 51651094, 51651372, 51651532, 51651671, 51652648, 51652748, 51654053, 51654167, 51654512, 51654644, 51655509, 51655749, 51656169, 51656563, 51656610, 51656620, 51656944, 51657505, 51657783, 51657787, 51658048, 51658435, 51659770, 51662636, 51663024, 51663466, 51664734, 51666133, 51666155, 51667730, 51668201, 51668300, 51668763, 51670217, 51670971, 51728639, 51733559, 51734157, 51736163, 51736904, 51737857, 51744922, 51745502, 51746490, 51749051, 51753451, 51761022, 51763530, 51763744, 51764024, 51764406, 51765606, 51772482, 51777123, 51778134, 51778197, 51778908, 51779815, 51781192, 51782154, 51782992, 51783172, 51783597, 51785250, 51785797, 51785854, 51785974, 51786209, 51786351, 51786438, 51788047, 51788314, 51789376, 51789672, 51791905, 51796180, 51799588, 51800143, 51800330, 51800670, 51801927, 51802093, 51805779, 51805870, 51810856, 51811445, 51811704, 51812416, 51812487, 51812736, 51814002, 51814655, 51814894, 51816235, 51816249, 51816496, 51816919, 51817159, 51817748, 51820864, 51821404, 51821994, 51822333, 51822667, 51822862, 51825960, 51826065, 51832068, 51832308, 51832588, 51833854, 51836275, 51838112, 51839346, 51839857, 51841311, 51841526, 51841815, 51842300, 51843180, 51843615, 51843781, 51844459, 51844998, 51845560, 51846399, 51846977, 51847151, 51847495, 51848463, 51857814, 51860363, 51860492, 54600331, 54602615, 54610296, 54617743,

54620579, 54625770, 54626013, 54628472, 54629673, 54630772, 54634922, 54635392, 54636684, 54642867, 54649884, 54666880, 54667529, 54677809, 54681294, 54682974, 54699927, 54709360, 54709449, 54711779, 54713242, 54713507, 54713857, 54714165, 54714347, 54715322, 54715467, 54716869, 54717060, 54717238, 54717400, 54717427, 54717505, 54718930, 54719243, 54719308, 54719973, 54719991, 54720155, 54720496, 54720805, 54722143, 54722413, 54723568, 54724373, 54725589, 54726891, 54729104, 54730546, 54735797, 54736000, 54736047, 54736466, 54738652, 54741247, 54742322, 54743526, 54744402, 54744731, 54749028, 54750510, 54753715, 54753953, 54753968, 54756577, 54756768, 54757349, 54760379, 54766556, 54767105, 54770315, 54771054, 54775681, 54777211, 54779147, 54780932, 54788797, 54793127, 54794032, 54798256, 54800800, 54802668, 54810284, 54822523, 54830810, 54855293, 54861436, 54869067, 54869424, 54870481, 54870743, 54871341, 54871513, 54872331, 54874003, 54874374, 54875672, 57681639, 57687588, 57688449, 57691658, 57693363, 57709282, 57732596, 57735950, 57760058, 57763417, 57777936, 57808407, 57817557, 57818569, 59392191, 59399670, 59400093, 59408778, 59414243, 59415406, 59416427, 59420806, 59434692, 59457067, 59515351, 66140052, 66140190, 66217596, 76569557, 76591689, 76598770, 76599140, 76605013, 76618308, 76626555, 76631872, 76642367, 76646916, 76656753, 76657927, 79509214, 79510568, 79510789, 79511670, 79511757, 79512105, 79512569, 79512603, 79512655, 79512928, 79512978, 79512993, 79513076, 79513154, 79513396, 79513965, 79514583, 79514706, 79514895, 79515184, 79517131, 79517413, 79517850, 79518056, 79518922, 79519021, 79519484, 79520546, 79520657, 79521051, 79534569, 79534859, 79535220, 79535301, 79536353, 79537326, 79538240, 79538284, 79539437, 79539489, 79539540, 79539593, 79539826, 79541573, 79543059, 79543363, 79543671, 101306757, 101341564, 101346009, 101375883, 101424556, 101430850, 101444879, 101450992, 101476330, 101477396, 101478319, 101487446, 101487791, 101488066, 101494973, 101496373, 101830649, 101841611, 101902560, 101904245, 101992400, 101992755, 101999859, 102001205, 102016032, 116932933, 116933474, 116933613, 116937194, 116940960, 116942210, 116944233, 116946663, 117009893, 117010156, 117037549, 117037756, 117037869, 117052785, 117052962, 117058333, 117058442, 117063781, 117065974, 117066033, 117073189, 117073629, 117076708, 117080977, 117089137, 136894809, 136895491, 136899042, 136907864, 136914881, 136919330, 136921389, 136925001, 136933309, 136995795, 148275544, 148291308, 148294679, 148296596, 148306979, 148314459, 148315182, 148316634, 148317180, 148317795, 148324588, 148326077, 148331075, 148337515, 148338194, 148339660, 148339727,

148341027, 148343988, 148344362, 148346096, 148354462, 148370793, 148378520, 148408061, 148445260, 148461128, 148461782, 148467668, 148471194, 148476850, 148492327, 148500567, 148509460, 148521463, 148524988, 148547339, 166017910, 166084924, 166089262, 166090523, 166092398, 166093832, 166097172, 166098152, 166098465, 166104522, 166105514, 166110486, 166142208, 166144081, 166144295, 166144830, 166145243, 166147508, 166152395, 166157163, 166158108, 166158192, 166158291, 166166091, 166180918, 166311863, 166329442, 166331473, 166335348, 166338881, 166341227, 166343885, 166346767, 166364549, 166379544, 166383017, 166402463, 166402996, 166403621, 166408648, 166408751, 166422864, 166426553, 166428594, 166430517, 166431307, 166431434, 166433253, 166438750, 166440084, 166440286, 166441062, 166443769, 166446143, 166448105, 166466082, 182829393, 182855824, 182856997, 182860054, 182868726, 182869042, 182869069, 182870183, 182872106, 182874475, 182888394, 182890477, 182894958, 182911506, 182912900, 182915858, 182919107, 182922252, 182927388, 182932776, 182933991, 182935866, 182935924, 182938657, 182954748, 182977270, 186710420, 186711372, 186722263, 186724122, 186729521, 186740943, 186746224, 186746951, 186748482, 186749691, 186752544, 186753368, 186754123, 186754244, 186754964, 186756686, 186759677, 186762379, 186762957, 186763380, 186765243, 186767243, 186771130, 186774634, 186779933, 186782889, 186783677, 186783723, 186786323, 186786345, 186787592, 186788152, 186788675, 186790815, 186795703, 186795981, 186797056, 186797101, 186797572, 186799104, 186799574, 186801145, 186802740, 186804008, 186804743, 186808518, 186811816, 186814495, 186816642, 186817077, 186817164, 186817449, 186818961, 186820366, 186821302, 186821580, 186821687, 186821697, 186821729, 186822277, 186822318, 186822413, 186822456, 186822924, 186823239, 186826582, 186830554, 186832300, 186835982, 186839354, 186840321, 186841731, 186854278, 186854406, 186856196, 186869233, 186870116, 186873391, 186873805, 186876760, 186944471, 190190056, 190192330, 190192563, 190193864, 190194497, 190196792, 190197228, 190198425, 190201274, 190201295, 190201999, 190202876, 190203400, 190203827, 190203877, 190204668, 190205948, 190207286, 190207749, 190207999, 190212085, 190212749, 190212993, 190213950, 190215226, 190215309, 190220632, 190222165, 190227029, 190227235, 190229743, 190237883, 190248653, 190249291, 190255683, 190257783, 192530205, 200935729, 200938958, 200956630, 200961649, 200965467, 200966508, 200975546, 200985494, 201021108, 201037222, 201038297, 201039577, 201050143, 201062851, 201065463, 201071056, 201072985, 201073286, 201079275, 201079462, 201393474, 201393875, 201393939, or201394505 on human chromosome 2; at position 15972853, 15979492, 15981630, 15984048, 15984372, 15984808, 15985480, 15985719, 15986206, 15986712, 15987135, 15987195, 15989624, 15989740, 15989773, 15989863, 15992669, 15992909, 16003374, 16003757, 16037627, 16041215, 16043358, 16045510, 25124423, 25124551, 25124975, 25139227, 25139810, 25143644, 25146657, 25155292, 25157766, 25169305, 25170688, 25182177, 25184366, 25188663, 25194200, 25205423, 25207827, 25211158, 25211837, 25235457, 25238040, 25239011, 25239845, 25243914, 25244762, 25244932, 25245547, 25250478, 25264520, 25265009, 25269521, 25273091, 25273425, 25274083, 25275052, 25277488, 25279386, 25280012, 25280571, 25283486, 25283965, 25284812, 25285067, 25287098, 25287161, 25288171, 25291318, 25291410, 25295964, 25300483, 32100486, 32103807, 32107036, 32107687, 32116971, 32123720, 32126831, 32127741, 32128616, 32129426, 32129512, 32130347, 32130743, 32131531, 32132631, 32132792, 32133557, 32134166, 32134835, 32135918, 32139992, 32146121, 32161901, 32162884, 32162947, 32163010, 36532521, 36539606, 36542082, 36546788, 36556181, 36561025, 36561276, 36561684, 36563172, 36563891, 36566407, 36566673, 36567042, 36567136, 36567376, 36567812, 36568926, 36571384, 36572905, 36575321, 36583646, 36588086, 36597648, 36598879, 36599138, 36599474, 36603785, 36609993, 36610151, 36611158, 36612106, 36618463, 36618485, 36622465, 36622754, 36623372, 36624146, 36625495, 36630641, 95535589, 95536563, 95537539, 95538497, 95541066, 95541356, 95541430, 95542046, 95542127, 95548256, 95550760, 95556822, 95557275, 95558516, 95560239, 95561173, 95561492, 95561508, 95561574, 95562468, 95562542, 95562592, 95563503, 95565070, 95565527, 95565570, 95565633, 95566063, 95566678, 95566835, 95568434, 95569562, 95575150, 95576084, 95578194, 95579991, 95580731, 95581248, 95585252, 95594541, 95595165, 95595774, 95595981, 95596068, 95596238, 95597788, 95598005, 95598035, 95599070, 95599229, 95599466, 95600272, 95600700,95601126,95604167,95609193,95612334, 112901691, 112911217, 112911456, 112914281, 112914508, 112923379, 112929749, 112933794, 112934718, 112934733, 112936579, 112937535, 112941527, 112944650, 112945600, 112946224, 112949845, 112950789, 112952064, 112953158, 112953907, 112960326, 112960464, 112961319, 112964465, 112964757, 112964847, 112966546, 112967692, 112968039, 112968240, 112970271, 112975773, 112977534, 112978250, 112979487, 112980486, 112983462, 112988303, 115100733, 115101297, 115109335, 115114470, 115129347, 119908152,

119908174, 119911858, 119913615, 119915026, 119915448, 119925257, 119928987, 119929073, 119931670, 119934191, 119943730, 119953482, 119953633, 119983099, 119992658, 119993533, 119993770, 119993980, 119996400, 120003493, 120003649, 135273298, 135277326, 135288644, 135288700, 135288916, 135289731, 135290724, 135292254, 135292422, 135296364, 135296455, 135296818, 135303500, 135305323, 135305589, 135305973, 135306205, 135306463, 135306633, 135307476, 135307512, 135308026, 135312328, 135313451, 135315131, 135324810, 135334692, 135337322, 135339567, 135341358, 135346670, 135347977, 135349426, 135351177, 135352909, 135357264, 135357936, 135365759, 135378819, 135379339, 135388075, 135388784, 135394123, 135402607, 135408504, 135410561, 135413833, 135417147, 135424018, 135425014, 135426703, 135427812, 135431040, 135439963, 135439977, 135473124, 135473446, 135475438, 150158635, 150158710, 150160849, 150161057, 150161649, 150161751, 171012778, 171017968, 171019339, 171021314, 171023099, 171028354, 171033461, 171035083, 171036200, 171036786, 171036831, 171036966, 171040727, 171041075, 171041413, 171041523, 171041936, 171045499, 171046152, 171046225, 171048273, 171048792, 171048949, 171049943, 171050818, 171051194, 171051212, 171051372, 171052943, 171057167, 171062673, 171064925, 171076328, 171076812, 171078187, 171079610, 185023187, 185033825, 185037776, 185041104, 185044978, 185045230, 185049644, 185050091, 185051283, 185052327, 185054365, 185059302, 185060606, 185063452, 185076469, 185078886, 185080700, 185084200, 185090462, 185095158, 185098798, 185103116, 185103429, 185107149, 189622331, 189623355, 189629883, 189629976, 189631928, 189632288, 189633762, 189635008, 189639419, 189644408, 189648322, 189651406, or 189651573 on human chromosome 3; atposition 17011072, 17011296, 17011857, 17012061, 17012868, 17013194, 17020761, 17028536, 17029094, 17031066, 17032854, 17036401, 17036875, 17037383, 17038178, 17038456, 17040989, 17041183, 17042057, 17049030, 17051325, 17056406, 17057986, 17058442, 84499813, 84500768, 84500972, 84501804, 84503554, 84508606, 84510152, 84511612, 84519523, 84519694, 84525763, 84525832, 84526533, 84527258, 84527315, 84528586, 84529026, 84529399, 84529437, 84529578, 84530283, 84530423, 84531290, 84534358, 84536250, 84536659, 84536797, 84536876, 84539894, 84541948, 84547048, 84547093, 84548210, 84549347, 84570798, 84574120, 84578598, 96577385, 96582377, 96582519, 96583132, 96584178, 96592699, 96599702, 96651424, 99799667, 99801210, 99801320, 99803666, 99807848, 99807964, 99809387, 99814723, 99816706, 99819712, 99821167, 99823508, 99823684, 99825745, 99833465, 99833656, 99833736, 99834522,

99834590, 99835934, 99836081, 99836862, 99837966, 99839510, 99840416, 99844135, 99845490, 99845547, 99846346, 99847490, 99848365, 99851756, 99854723, 99355858, 99861413, 99861813, 99866311, 99867457, 99867911, 99878073, 99884270, 126362489, 126379394, 126396940, 126407660, 126409942, 126416826, 126418374, 126430383, 126487544, 126490716, 126493527, 126495757, 136880552, 136881968, 136883623, 136885451, 136886076, 136887132, 136889055, 136889443, 136890103, 136890876, 136893449, 136897722, 136900288, 136900741, 136901146, 136902550, 141738039, 141743060, 141745922, 141757671, 141759797, 141760063, 141761604, 141761653, 141762517, 141766929, 141767297, 141767342, 141767856, 141769735, 141775917, 141776879, 141818775, 141826174, 141849181, 174180260, 174197301, 174197751, 174198513, 174199345, 174207198, 174216579, 174218180, 174223753, 174224227, 174225158, 174232525, 174234640, 174238245, 174239858, or 174243021 on human chromosome 4; at position 33068424, 33073250, 33074880, 33075144, 33079303, 33079972, 33085376, 33085473, 33085951, 33086064, 33086350, 33087719, 33088172, 33088550, 33089676, 33089910, 33091405, 33091437, 33091499, 33114163, 33115099, 33115311, 33117602, 33118498, 33121271, 33122149, 33142786, 33155568, 33155668, 33174152, 33180167, 33189004, 33204171, 33205864, 33212781, 33213163, 33214982, 33226224, 33226311, 33230214, 34794058, 34797450, 34807222, 34830429, 53410335, 53410896, 53415059, 53418196, 53419665, 53420578, 53646736, 53648433, 53650336, 53652843, 53655784, 53656359, 53663936, 53665145, 53665388, 53667813, 53667954, 53672705, 53672811, 53674961, 53675669, 53675732, 53676101, 53676619, 53676736, 53677045, 53677338, 53678841, 53679109, 53680093, 53681052, 53683397, 53690381, 53695238, 53695715, 53707299, 53708606, 88021051, 88028332, 88028954, 88031926, 88037725, 88039159, 88039857, 88040372, 88042649, 88045349, 88046895, 88051301, 88055503, 88056075, 88057283, 88062626, 88062658, 88062905, 88066426, 88074146, 88074601, 88078052, 88079412, 88082346, 88083755, 88083827, 88084213, 88084523, 88090048, 88090519, 88091517, 88099768, 88144330, 88146094, 88150232, 88154614, 88156944, 88170066, 88171218, 88173798, 88179782, 94538098, 94550044, 94552156, 94553824, 94557181, 94558969, 94560801, 94567006, 94570526, 94576732, 94576925, 94577064, 94584565, 94587700, 94588747, 94596642, 94597032, 94599413, 94600202, 94600278, 94602702, 94605148, 94606353, 94611677, 94612551, 94613368, 94614685, 94618904, 94618955, 94619294, 94622424, 94623398, 94626513, 94628342, 94629140, 94629619, 94629816, 94631128, 94631232, 94631493, 94632003, 94632116, 94632425, 94632936, 94633120,

94633445, 94634399, 94634443, 94634456, 94634684, 94635668, 94636517, 94636785, 94641576, 94649002, 94649379, 94651147, 94651360, 94655931, 94657922, 94659495, 94659853, 94660088, 94660336, 94662854, 94663216, 94663373, 94663538, 94663672, 94664367, 94665060, 94666072, 94666129, 94666213, 94666924, 94667001, 94668029, 94668309, 94670433, 94671181, 94671416, 94672434, 94672474, 94672558, 94672606, 94673344, 94675660, 94676060, 94676295, 94676914, 94677635, 94678233, 94678458, 94678505, 94678894, 94679052, 94679562, 94679943, 94680414, 94680899, 94681136, 94681313, 94681983, 94685578, 94705236, 94712319, 94713792, 94715934, 94719045, 94724163, 94724943, 94733999, 94734306, 94740898, 94745024, 94745037, 94746001, 94750979, 94753834, 94756096, 98670568, 98672074, 98672967, 98696360, 98699369, 98702111, 98702589, 98709592, 98716622, 98721832, 98722748, 98723571, 98728423, 98729312, 98738383, 98749771, 98752890, 98754788, 98763319, 98770275, 98771905, 98952846, 98953245, 98953580, 98958585, 98958615, 98960421, 98965980, 98970968, 98971488, 100010191, 100010673, 100013867, 100014052, 100014436, 100016776, 100017865, 100018294, 100020010, 100020379, 100021853, 100025750, 100027357, 100028226, 100029865, 100030250, 100033114, 100033220, 100034262, 100043746, 100047287, 100048359, 100050177, 100053551, 100053597, 100055142, 100056049, 100057119, 100057973, 100058783, 100059543, 100060234, 100060833, 100073261, 100073357, 100073717, 100074002, 100080943, 100088049, 100088312, 100090637, 100095967, 100099693, 100111425, 106697845, 106741517, 106753230, 106757891, 106765747, 106765944, 106766858, 106773421, 106777589, 106780213, 106782654, 106786583, 106790074, 106791596, 106792191, 106793738, 113500176, 113502800, 113506634, 113511198, 113511406, 113511998, 113512057, 113512451, 113514918, 113515203, 113516722, 113516744, 113526961, 113527088, 113528435, 113528450. 113528466, 113531301, 113531506, 113535625, 113541152, 113550101, 113550750, 113553376, 113566741, 113570824, 113572234, 113581019, 113582603, 113583525, 113584197, 113585159, 113585933, 113586234, 113586796, 113587246, 113589665, 113590586, 113591021, 113591649, 113591904, 113592887, 113595823, 113596126, 113597745, 113598192, 113601411, 113602505, 113604903, 113606206, 113606361, 113611679, 113611816, 113612491, 113612556, 113614669, 113617288, 113618525, 113623513, 113623601, 113624557, 113624918, 113625176, 113626407, 113626740, 113626945, 113627153, 113627251, 113627646, 113628416, 113630061, 113631575, 113631667, 114713355, 114713440, 114713519, 114718052, 114718222, 114718659, 114719100, 114719186, 114724952, 114727927, 114728598, 114729838, 114731087,

114736973, 114737036, 114737437, 114738244, 114739954, 114742587, 114742608, 114742827, 114743461, 114743518, 114743558, 114743695, 114743979, 114743998, 114744008, 114744237, 114744809, 114745180, 114745898, 114745943, 114752244, 114773293, 128919467, 128922333, 128985111, 128987981, 128988214, 128989963, 128997514, 129005875, 129005908, 129008002, 129010670, 129027429, 129031240, 129031881, 129050355, 129072554, 129075353, 129075899, 145262302, 145263992, 145265351, 145265645, 145266116, 145266325, 145272216, 145274560, 145280161, 145285959, 153338419, 153340423, 153343527, 153344333, 153345557, 153345621, 153346796, 153346998, 153347489, 153348358, 153350759, 153351656, 153352718, 153353811, 153356765, 153357791, 153365426, 153369105, 153369974, 153370547, 153370609, 153371902, 153385278, 153385607, 153385847, 153386769, 153386837, 153387180, 153387590, 153390413, 153391127, 153392378, 153392722, 153393038, 153393583, 153395675, 153395890, 153396325, 153396559, 153397914, 153399535, 153400001, 153400926, 153402128, 153403791, 153405274, 153405394, 153406146, 153407489, 153409362, 153409380, 153410180, 153411651, 153411662, 153412323, 153413163, 153414600, 153414636, 153415931, 153419001, 153419234, 153425143, 153426527, 153427018, 153430830, 153431481, 153432195, 153434373, 153435197, 153436129, 153436445, 153436517, 153437000, 153437979, 153438869, 153439598, 153440236, 153441242, 153442726, 153442901, 153444620, 153445645, 153446433, 153448388, 153449213, 153451930, 153452902, 153452947, 153453656, 153453887, 153456852, 153457015, 153458370, 153462976, 153464693, 153464854, 153466019, 153470369, 153470551, 153470971, 153472870, 153474121, 155746109, 155751856, 155752850, 155755167, 155759118, 155767497, 155767700, 155769361, 155769420, 155794803, 155797045, 155811196, 166726668, 172412942, 172414424, 172419724. 172425055, 172433181, 172434579, 172434592, 172436070, 172443943, 172448249, 172463083, 172463167, 172467286, 172476423, 172481315, 172490802, 172510009, or 172513472 on human chromosome 5; atposition 3421102, 3422474, 3426661, 3427976, 3428061, 3428441, 3428863, 3432929, 3433624, 3433664, 3435785, 3437612, 3438187, 3439001, 3439774, 3440198, 3445838, 8930286, 8932904, 8934563, 8935206, 8936885, 8939853, 8944645, 10955923, 10965632, 10970876, 10971311, 10973858, 10985853, 10987982, 10994571, 12403489, 12512974, 12513387, 12514506, 12517402, 12517609, 12517893, 12519141, 12520304, 12522290, 12525249, 12532953, 20091192, 20095790, 20096424, 20096632, 20099425, 20100741, 20103710, 20104787, 20107101, 20107989, 20109678, 20109906, 20110042, 20111136,

20111283, 20111445, 23519068, 23520173, 23521765, 23521908, 23524354, 23527622, 23528304, 23528945, 23529348, 23531094, 23531190, 23533945, 23544837, 23545252, 39396512, 39396865, 39397142, 39397439, 39397492, 39397628, 39397853, 39398178, 39398631, 39399085, 39399130, 39399396, 39399587, 39399731, 39399785, 50369349, 50369837, 50370105, 50371633, 50371644, 50372103, 50374024, 50374995, 50375792, 50376777, 50377121, 50379448, 50379554, 50383265, 50385551, 50385874, 50387443, 50402079, 50402402, 82950808, 83037702, 83052756, 83052893, 83059529, 83059811, 83063355, 83065585, 83065715, 83066965, 83067321, 83079412, 83086171, 83086772, 83087733, 83088471, 83089659, 83092525, 83092537, 83094274, 83094499, 83094576, 83095347, 83095565, 83095939, 83096974, 83097004, 83097222, 83098262, 83098329, 83098352, 83100260, 83101000, 83103870, 83104741, 83105428, 83113039, 83114887, 83120523, 83122607, 83126442, 83127291, 83129590, 83131084, 83137358, 83140060, 83144954, 83146375, 83146661, 83147795, 83150543, 83150571, 83153296, 83155501, 83162032, 83163350, 83165082, 83165771, 83166290, 83167427, 83167802, 83168404, 83169083, 83169297, 83169493, 83170215, 83170490, 83170598, 83172329, 93549999, 93550988, 93574060, 93574522, 93574540, 93574573, 93575648, 93576176, 93576560, 93576978, 93577084, 93577313, 93577607, 93577840, 93577997, 93578092, 93578445, 93578855, 93579206, 93579392, 93579470, 93579873, 93580591, 93581103, 93581640, 93583843, 93584500, 93587421, 93587478, 93587745, 93588743, 93588760, 93611698, 93614915, 93617324, 93617727, 93617871, 93618465, 93618592, 93618621, 93618956, 93619679, 93619875, 93619969, 93620707, 93620981, 93621417, 93621503, 93621875, 93622542, 93623082, 93626943, 93627153, 93631417, 93632051, 93633298, 93633564, 93639815, 93641321, 93641611, 93643621, 93644555, 93644941, 93647163, 93649192, 93650622, 93653196,93655110, 129859646, 129880427, 131737411, 131738018, 131738569, 131740637, 131740693, 131747407, 131748781, 131749219, 131749871, 131749981, 131750606, 131750761, 131751136, 131751408, 131751505, 131752090, 131752582, 131753351, 131753446, 131753744, 131754312, 131754361, 131755156, 131755195, 131755663, 131756431, 131756778, 131756962, 131757296, 131757526, 131758263, 131758274, 131759702, 131762896, 131762912, 131772200, 133771457, 133782576, 133786144, 133788718, 133795518, 133796900, 133797315, 133798398, 133799240, 133803356, 133805598, 133806056, 133808124, 133810497, 133812159, 133817050, 133817187, 133817805, 133817815, 133820602, 133820854, 133823646, 133824778, 133828176, 158369411, 158371127, 158375718, 158381773, 158382054, 158382593, 158382907, 158382973, 158383089, 158383241, 158619762, 158629271,

158644585, 158656118, 158664938, 158666456, 158678327, 158679231, 158684979, 158705285, 158707220, 158714406, 158725711, 158751844, 158836596, 158837583, 158838606, 158839027, 158839757, 158841582, 158843785, 158847544, 158848341, 158848475, 158849467, 158850042, 158850353, 158852173, 158853638, 158855871, 158855941, 158856167, 158856424, 158856437, 158857267, 158857400, 158857924, 158858138, 158859464, 158859975, 158860490, 158861234, 158861301, 158862362, 158863997, 158865566, 158866045, 158866068, 158866415, 158866736, 158867185, 158873590, 158880182, 167053307, 167054179, 167054274, 167059431, 167066262, or 167066688 on human chromosome 6; at position 2977418, 2977464, 2977762, 2991128, 2993500, 2993528,2994231, 2994650, 2997087, 2997243, 2998042, 3001408, 3001529, 3001814, 3002285, 3002516, 3003589, 3006048, 3007382, 3007489, 3009317, 13931478, 13932104, 13932169, 13932242, 13934583, 13934671, 13934737, 13935047, 13935765, 13937514, 13938132, 13938981, 13940664, 13942792, 13942872, 13942919, 13944165, 13945372, 13945465, 13946973, 13947845, 20613496, 21780211, 21780543, 21784331, 21784532, 21786289, 21788166, 21790652, 21791661, 21793018, 21793279, 21794549, 21795827, 21799066, 21799157, 21800082, 21800306, 21802722, 21802782, 21803073, 21803300, 21804191, 21804531, 21804566, 21805889, 21807152, 21810373, 28277806, 28279391, 28279756, 28281476, 28290456, 32928625, 32933759, 32939310, 32940969, 32942900, 32943344, 32944087, 32944960, 32945212, 32945390, 32946130, 32949114, 32950845, 32951429, 32955379, 32955441, 32957280, 32957798, 32958023, 32958251, 32958275, 32958849, 32959593, 32960134, 32960166, 32960433, 32960455, 32960519, 32960597, 32961789; 32962173, 32963033, 32963688, 32963831, 32965041, 32965406, 32965742, 32965831, 32966381, 32967211, 32967947, 32969056, 32969499, 32969594, 32969674, 32969804, 32969877, 32970088, 32970601, 33004114, 33006462, 33012764, 33016000, 33016928, 33021918, 33024359, 33024415, 33035629, 33045795, 33048294, 33057978, 33063374, 33067474, 33069447, 33074723, 33077347, 33077458, 33082095, 33095678, 33098280, 33110661, 33119685, 33126190, 33137722, 33141753, 33145919, 33159695, 33161953, 33162479, 33165620, 33166205, 33166726, 33169992, 33171273, 33172356, 33182072, 33190360, 33191358, 33202574, 33211276, 33213259, 33223131, 33225242, 33226384, 33226951, 33231775, 33232397, 33232771, 33233013, 33233420, 33233576, 33239234, 33241070, 33250591, 33256485, 33258223, 33260686, 33261502, 33262968, 39239867, 39278070, 39287022, 39295021, 39297161, 39299486, 39299583, 39299867, 39301253, 39301518, 39305022, 39310867, 39310887, 39311290, 39373108, 47679607, 47679905, 47680454,

47683435, 47685516, 47687238, 47687910, 47688210, 47688891, 47690190, 47690200, 47690735, 47690849, 47691497, 47694028, 52786119, 52786434, 52786490, 52786506, 52786523, 52786586, 52786722, 52786809, 52787074, 52787829, 52787880, 52788089, 52790199, 52794025, 52795336, 52800574, 52812096, 52815674, 52845865, 52892643, 52912062, 52916477, 52923342, 52923891, 52924855, 52926517, 52927067, 52927138, 52927592, 52927807, 52929540, 52932108, 52935372, 52939229, 52940292, 75255800, 75274925, 75276348, 75280891, 75296316, 75304466, 75307854, 75321667, 75325745, 75328232, 75330219, 75333274, 75333605, 75338614, 75338730, 75341071, 75341257, 75346379, 75348741, 75359534, 75361432, 75362746, 75375310, 75377930, 75378857, 75383536, 75390517, 75394345, 75399509, 75399790, 75406541, 75410614, 75413700, 75415623, 75416043, 75417529, 75418111, 75420661, 75426287, 75432068, 75434843, 75435056, 75438056, 75444284, 75455124, 75459792, 75465934, 75477789, 80554980, 80555039, 80557066, 80561799, 80565840, 80576038, 80576490, 80581391, 80581806, 80582384, 80588940, 80590056, 80591254, 80591572, 80592168, 80592300, 80598123, 80598700, 80599149, 80599892, 80600669, 80602726, 80603448, 80604131, 80607249, 80610073,80611094, 111854629, 111882881, 111883063, 111889885, 111900831, 111903611, 111904149, 111907159, 111915260, 111915329, 111925747, 111928896, 111946493, 111947263, 111947391, 111954397, 111954620, 111960606, 111961809, 111967947, 111973027, 111975331, 111978691, 111980734, 111987543, 112014023, 112037492, 112038044, 112053603, 112063624, 112086263, 112104088, 112132329, 112145486, 112146988, 112148281, 112158715, 112178255, 112181364, 117236203, 117242170, 117246522, 117249531, 117250217, 117254934, 117256949, 117257050, 117262034, 117262186, 117298657, 117299244, 117301830, 126749490, 126752308, 126760821, 126763848, 126768699, 126772113, 126776259, 126784188, 126787618, 126789189, 126797202, 126797527, 126798589, 126798795, 126804970, 126805362, or 126805426 on human chromosome 7; at position 6671547, 18698758, 18699074, 18701373, 18701730, 18701912, 18701941, 18702265, 18702287, 18702626, 18703230, 18709772, 18709990, 18712763, 18712961, 74427949, 74428819, 74432043, 90069996, 90082194, 90093695, 90096817, 90102446, 90116445, 90116543, 90116612, 90116964, 90117638, 90117943, 90118638, 90118914, 90119048, 90119921, 90121222, 90121663, 90122479, 90122660, 90123078, 90123412, 90123540, 90123958, 90124160, 90125410, 90125681, 90126798, 90128134, 90128856, 90129393, 90130637, 90130783, 90130886, 90131334, 90132757, 90133487, 90133515, 90134733, 90135712, 90135793, 90136435, 90136511, 90136571, 90136589, 90139036,

90139083, 90139731, 90140123, 90141269, 90143122, 90147313, 90147560, 90148953, 90149005, 90149411, 90151810, 90154883, 9015764?, 90159452, 90162703, 90163700, 90171355, 90171916, 90172229, 90172384, 90174078, 90174091, 90174273, 90175501, 90175512, 90176580, 90177417, 90178513, 90178626, 90178888, 90183461, 90184062, 90185119, 90185254, 90187149, 90187573, 90187807, 90187901, 90189629, 90191813, 90192035, 90197641, 90197668, 90198621, 90199925, 90200120, 90201518, 90202503, 90208095, 90212847, 90213345, 90213747, 90215450, 90216613, 90220298, 90223006, 90227167, 90228222, 90230508, 90254539, 90259357, 90274542, 104118573, 104120734, 104131909, 104137053, 104137952, 104139321, 104139431, 115941011, 115947906, 115950427, 115951211, 115951650, 115953160, 115959680, 115960577, 115961336, 115961783, 115962230, 115962978, 115963234, 115980114, 115986100, 116020380, 116020490, 116020927, 116020928, 116021044, 116021489, 116021533, 116022733, 116023006, 116025054, 116031725, 116033693, 116033814, 116034628, 116042186, 116053060, 116094281, 128476372, 128476625, 128477298, 128478414, 128478693, 128482329, 128482487, 128483680, 128484074, 128486686, 128489299, 128490967, 128492309, 128492523, 128492580, 128492832, 128492999, 128493974, 128495575, 128500876, 134432616, 134432757, 134432928, 134432990, 134433076, 134433095, 134433727, 134433749, 134433831, 134434340, 134434438, 134435278, 134435857, 134436910, 134437896, 134438488, 134438565, 134439148, 134439299, 134439791, 134443264, 134444101, 134446144, 134448268, 134448538, 134450865, 134456489, 134458401, 134470691, 134471389, 134471415, 134497425, 134502792, 134504289, 134505548, 134514422, or 134519724 on human chromosome 8; at position 483247, 485701, 489516, 490810, 490979, 499526, 500546, 500700, 500862, 502589, 503222, 519916, 523804, 536432, 6655097, 6660062, 6666953, 6667167, 6667316, 6685502, 15332046, 15333613, 15333709, 15337518, 15338120, 15360575, 16205744, 16220898, 80306838, 80307042, 80311525, 80312169, 80317346, 80320677, 80325743, 80331697, 80334157, 80334175, 80334382, 80334645, 80338207, 80342972, 80349311, 95620787,95624467,95624530, 108607941, 108608314, 108614898, 108622382, 108624140, 108625578, 108626003, 108629314, 108629372, 108630098, 108630233, 108630899, 108631155, 108632694, 108632869, 108634304, 108635627, 108637954, 108640963, 108641599, 108641744, 108642955, 108643132, 108643426, 108647178, 108650142, 108651401, 108651424, 108652066, 108652126, 108652441, 108690689, 108696373, 108705645, 110451147, 110451236, 110451582, 110452183, 110452978, 110453857, 110454978, 110455578, 110458344, 110460448, 110463553, 110464331,

110468467, 110469102, 110470498, 110481490, 110494530, 110499314, 114439269, 114469145, 114469854, 114470231, 114471776, 114472191, 114472320, 114472639, 114473222, 114473288, 114473290, 114473459, 114473613, 114473646, 114474149, 114474377, 114474781, 114474977, 114475435, 114475791, 114476128, 114476211, 114476301, 114477754, 114480873, 114484105, 114484743, 114485935, 114486155, 114487477, 114487655, 114488549, 114489090, 114490069, 114490974, 114491201, 114491308, 114493381, 114493913, 114494535, 114495666, 114496737, 114496976, 114498283, 114500765, 129102032, 129102320, 129102342, 129109422, 129110241, 129110692, 129111391, 129111978, 129112191, 129112271, 129113020, 129113208, 129113258, 129113284, 129113314, 129115006, 129116578, 129116733, 129116849, 129117885, 129120723, 129121160, 129121539, 129122056, 129122431, 129122712, 129122745, 129123924, 129124138, 129124492, 129124887, 129125597, 129125755, 129125927, 129126045, 129126179, 129128058, 129128218, 129128883, 129129396, 129129994, 129130142, 129131288, 135743798, 135745305, 135748752, 135748820, 135749277, 135749356, 135749712, 135749845, 135753036, 135753175, or 135753601 on human chromosome 9; at position 5763668, 5774364, 30205989, 30206553, 30207015, 30207760, 30208850, 30210493, 30210638, 30210790, 30211023, 30211510, 43467013, 44130826, 44133744, 44134342, 44135054, 44136288, 44137425, 44140163, 44141103, 44143798, 44146090, 44146547, 44146739, 44147170, 44149523, 44152160, 61627647, 61634954, 61635015, 61635194, 61636447, 61655634, 61668066, 61673395, 61678714, 61680529, 61698803, 61700731, 61705507, 61717600, 67129869, 67136480, 67137478, 67138672, 67139962, 67140692, 67141195, 67143178, 67144395, 67145017, 67146138, 67146941, 67147970, 67148082, 67149357, 67151405, 67151574, 67152738, 67156720, 67163419, 67166761, 67173087, 67181098, 67187472, 67203466, 77559267, 77561874, 77563836, 77569191, 77570952, 77571486, 77578908, 91204084, 91204301, 91204341, 91205354, 91205789, 91207882, 91726020, 91728805, 91728947, 91734313, 91734664, 91735353, 91766646, 91772708, 91789010, 91790046, 91799004, 91808309, 91836719, 91849522, 91859823, 91875901, 91891310, 91898654, 91902473, 91910394, 91916839, 91917176, 91917383, 91917555, 91918021, 91918169, 91923057, 91923465, 91931446, 106848543, 106850608, 106855945, 106864786, 106865273, 106871024, 106871459, 106872309, 106873958, 106873995, 106874053, 106876621, 106876775, 106877150, 106877212, 106877222, 106878097, 106878228, 106879167, 106882519, 106882778, 106883225, 106883404, 106884538, 106884893, 106885032, 106885186, 106885275, 106886776, 106887206,

106888505, 106888711, 106888756, 106889411, 106889697, 106890564, 106892268, 106892543, 106893623, 106893754, 106894112, 106896436, 106896479, 106896648, 106897228, 106897310, 106897430, 106897576, 106898251, 106898407, 106898794, 106898906, 106899092, 106899518, 106899623, 106899926, 106900061, 106900891, 106901647, 106901893, 106903034, 106903267, 106905498, 106905575, 106906037, 106906641, 106911603, 106925199, or 106931514 on human chromosome 10; at position 7232814, 7233719, 7237726, 7237862, 7239747, 7239825, 7240874, 7240933, 7241450, 7244036, 7244394, 7244594, 7245461, 7245654, 7245750, 7246861, 7247945, 7248795, 7253622, 7253763, 7254352, 7255272, 7255327, 7257738, 7266085, 7267343, 7268139, 7270442, 7270749, 7273151, 7274316, 7274631, 7276742, 7277233, 7282771, 7287335, 24089131, 24089229, 24089447, 24092928, 24093822, 24094484, 24094782, 24097201, 24097409, 24098510, 24098848, 24100430, 24100862, 24100992, 24102924, 24109245, 24109319, 24111445, 24112412, 24112847, 24112871, 24113496, 24114341, 24114984, 24116149, 24116272, 24116855, 24117965, 24119117, 24119517, 24120332, 24123708, 24124710, 24125456, 24125609, 24125671, 24125905, 24126100, 24126781, 24127266, 24127403, 24128116, 24128287, 24128608, 24129346, 24131622, 24131757, 24131911, 24131999, 24133658, 24133976, 24134063, 24134710, 24135792, 24136299, 24138593, 37042702, 37045562, 37047075, 37047761, 37053096, 37057317, 37059039, 37059996, 37060928, 37064906, 37065299, 37067111, 37069674, 37072232, 37072419, 37072441, 43127290, 43132253, 43132366, 43149325, 43153863, 43157926, 43158213, 43165780, 43166809, 43175000, 43178115, 43192637, 43193331, 43196380, 43199163, 43200251, 43200962, 43201482, 43203251, 43210738, 43215573, 43221085, 43223410, 43225225, 43227459,43228838, 43234838, 43236249, 43244292, 43246639, 43254839, 43290052, 43310734, 43364995, 43383522, 43471106, 44564466, 44566250, 44571754, 44572391, 44572616, 44744162, 44744691, 44745118, 44754062, 44754354, 44766236, 44773663, 107416661, 107419601, 107424109, 107443390, 107488748, 107549301, 107635922, 110624904, 110625908, 110630722, 110638215, 110640955, 110645253, 110657706, 110659282, 110662046, 110665963, 110667901, 110672767, 110676856, 110676919, 110677389, 110678500, 110685600, 110685841, 118321563, 118328358, 118330846, 118337034, 118342323, 118351676, 118351692, 118351784, 118357291, 118357347, 118361701, 119266187, 119270528, 119274702, 119277053, 119277178, 119279435, 119281021, 119282613, 119283754, 123046828, 123048853, 123050340, 123050953, 123051795, 123053512, 123053929, 123053963, 123054200, 123055812, 123056170, 123056379, 123057038, 123057305, 123067607, 123069434, 123071807,

123090819, 123098217, 123103014, 123103830, 123105685, 123107126, 123107409, 123108095, 123108155, 123111147, 123113791, 123114574, 123121666, 123122086, 123123687, 123125107, 123126375, 123127296, 123127542, 123128342, 123128353, 123131946, 123132878, 123137082, 123143910, 123153805, 123157735, or 123221459 on human chromosome 11; at position 13348818, 13350296, 13356632, 48922631, 48923562, 48927839, 48933021, 48933491, 48936831, 48939196, 48951494, 48952213, 48954805, 48957637, 48961020, 48963773, 48965685, 48967806, 48970012, 48976252, 48991982, 49010260, 49012232, 49016725, 49025275, 49030386, 49030438, 49031020, 49033184, 49035561, 49036738, 49040830, 49043895, 49048756, 49049682, 49050978, 49166483, 49172107, 49221198, 49226074, 49227250, 49233222, 49250373, 49297523, 49318682, 49326664, 49329157, 49337618, 49350331, 49359790, 49360466, 49361140, 49367207, 49372542, 49373198, 49375554, 49376001, 51485831, 51486150, 51488647, 51491024, 51492024, 51495953, 76786901, 76789099, 76791055, 76791279, 76793783, 76794372, 76796043, 76801081, 76806276, 76808214, 76809284, 76817549, 76820402, 76829607, 76830502, 76832719, 76834381, 76835231, 76841266, 76849493, 76849556, 88008483, 88016229, 88027520, 88034297, 88070765, 88081450, 88092416, 88106387, 88112458, 88113076, 101472403, 101473743, 101474537, 101476912, 101477573, 101480992, 101481273, 101481557, 101481686, 101486942, 101487851, 101488216, 101488991, 101489523, 101490105, 101492514, 101493497, 101494144, 101495278, 101514547, 101514769, 101520667, 101524864, 101540195, 104963405, 104974668, 104979631, 104979656, 104981558, 104983503, 104984052, 104999313, 105001063, 105004141, 114354123, 114356910, 114366770, 114366778, 114366985, 114376278, 114384238, 114391160, 114391604, 114391640, 114391911, 114392159, 114392743, 114393208, 114394665, 114394992, 114395239, 114395254, 114395347, 114395381, 114395828, 114395927, 114396720, 114397478, 114398044, 114400822, 114403841, 114403983, 114404378, 114406627, 114407356, 114407741, 114410621, 114411153, 114411612, 114411620, 114412048, or 114412595 on human chromosome 12; at position 39852882, 39864768, 39867438, 39874034, 39874507, 39876966, 39877240, 39878019, 39878687, 39882912, 39894067, 49731880, 49740441, 49753024, 49798737, 49811875, 49820774, 49822449, 49827390, 49829566, 49832893, 49833923, 49847949, 49858379, 73791516, 73793561, 73795648, 73796232, 73797634, 73798631, 73817057, 73817643, 73830873, 74291176, 74294283, 74296869, 74297059, 74299032, 74301925, 74305801, 74306967, 74307954, 74312063, 74315191, 74317380, 74323828, 74332962, 74333453, 74334367, 74341095, 74344149, 74344843, 74345635, 74348089, 74348524, 74349020, 74350680, 74355403, 74360517, 74364541, 74365406, ^4368477, 74368981, 74369007, 74369270, 74369460, 74370135, 74370622, 74372407, 74372494, 74372780, 74374712, 74375084, 74375502, 74381956, 74388471, 74389001, 74389625, 74389659, 74389818, 74390032, 74392110, 74393228, 74401178, 74403542, 74405161, 74409627, 74412048, 74412374, 74423025, 74423460, 74425012, 74425568, 74431719, 74439614, 74445545, 74445738, 74446187, 74447569, 74447610, 74448949, 74450132, 74452030, 74453192, 74454071, 74454950, 74456183, 74460869, 74463899, 74463969, 74464048, 74464138, 74465245, 74467066, 74467730, 74469281, 74469343, 74472663, 74474385, 74477599,74481389,74482470, 106128657, 106131423, 106146991, 109042402, 109154406, 109158183, 109159306, 109162594, 109165751, 109168465, 109168563, 109175309, or 109175464 onhuman chromosome 13; at position 32813779, 32814180, 32814215, 32814236, 32814428, 32814490, 32828643, 32835686, 32840593, 32841577, 32842241, 32844778, 32929909, 38479068, 38480457, 38485844, 38486966, 38496308, 38508662, 38509514, 38509542, 38510038, 38510255, 38510675, 38512241, 38513475, 38513837, 38515181, 38516976, 38521446, 38521998, 38522050, 38522195, 38523473, 38524018, 38530214, 38533854, 38548144, 38562908, 38576104, 38583982, 38589166, 38613732, 38625936, 38629795, 38646046, 38646321, 38664129, 38684472, 38702727, 38714523, 38715209, 38720575, 38720675, 38722249, 38724104, 38743742, 38755290, 84192776, 84206728, 84208183, 84210737, 84214008, 84222923, 84253556, 84254314, 84268666, 84274612, 84276002, 84277594, 84291919, 84302496, 84304684, 84307393, 84311538, 85206930, 85209412, 85213915, 85214634, 85215088, 85216336, 85216501, 85218011, 85219650, 85220146, 85220562, 85220666, 85220676, 85221016, 85221418, 85221577, 85221813, 85222179, 85223990, 85224180. 85224501, 85224735, 85226794, 85231886, 85233147, 85233774, 85234265, 85234635, 85235063, 85235438, 85240904, 85243452, 85246148, 85246661, 85246923, 85247699, or 85255860 on human chromosome 14; at position 51189302, 51190324, 51190404, 51194001, 51195489, 51195545, 51195790, 51197700, 51214080, 51214304, 51214796, 51225339, 51225655, 51234395, 51238288, 51240801, 51243958, 51245627, 51260182, 51268982, 51270770, 51272844, 51275052, 51279348, 51279653, 51279938, 51280500, 51280606, 51285677, 51288845, 51294397, 51305758, 51322236, 69382722, 69387305, 69387523, 69387794, 69391304, 69408616, 69408932, 69409840, 69412176, 69415310, 69415401, 69415913, 69431235, 76733918, 76743393, 76751049, 76751417, 76761600, 76833546, 76867361, 76869419, 76871863,

76873154, 76876062, 76886081, 76886593, 76892161, 76893275, 76954658, 76959821, 76960060, 93195638, 93202040, 93217814, 93271398, 93222123, 93226669, 93229804, 93231817, 93232312, 93233505, 93238457, 93261273, 93263139, 93264699, 93265029, 93266435, 93266453, 93267466, 93274496, 93277598, 93279847, 97471189, 97472403, 97473570, 97475137, 97475852, 97477041, 97480753, 97481697, 97482559, 97483852, 97483971, 97500514, 97505717, 97510252, 97518402, 97519380, 97524820, 97527318, 97527904, 97530400, 97537568, 97538182, 97556377, 97557412, 97560036, 98596360, 98604209, 98605328, 98610870, 98612143, 98612927, 98622005, 98623294, 98623847, 98623951, 98624069, 98624169, 98624867, 98625471, 98625685, 98626523, 98627275, 98627413, 98627999, 98628117, 98628565, 98637371, 98637952, 98638227, 98655850, 99771450, or99780246 on human chromosome 15; atposition 1791149, 1794541, 1794649, 1796441, 1798950, 1799433, 1799851, 1800806, 1802725, 1803521, 1805095, 1806272, 1806363, 1806665, 1808555, 1811231, 1811330, 1817559, 1826234, 1826523, 1826610, 1826967, 1826982, 1827575, 1829646, 1829822, 1830057, 1833344, 1833810, 1834962, 1837495, 1838377, 1839951, 1840036, 1841479, 1841810, 1841845, 1841894, 1842890, 1843652, 1843935, 1843939, 1844323, 1844546, 1844557, 1844588, 1844641, 1844812, 1844960, 1845007, 1845764, 1845875, 1847224, 1847303, 1847653, 1847701, 1847947, 1848219, 1848257, 1848340, 1848501, 1848669, 1848750, 1848888, 1849108, 1849841, 1850374, 1854890, 1855035, 1855056, 1855459, 1856104, 1857175, 1859452, 1860317, 1860630, 1860679, 1860741, 1860758, 1860793, 1865280, 5796152, 5796463, 5796692, 5796802, 5796895, 5798935, 5801007, 5801769, 5801792, 5802165, 5802892, 5803453, 5803764, 5804132, 5805957, 5806056, 5806139, 5806149, 5806269, 5806359, 5806460, 5807386, 5807689, 5808267, 5808466, 5808524, 5808701, 5808730, 5809059, 5809618, 5809651, 5810450, 5812560, 5813426, 5819886, 5828787, 5830572, 52439872, 52440158, 52440360, 52440534, 52440953, 52441905, 52444943, 67246920, 67256387, 67264434, 67268238, 67271231, 67271324, 67273680, 67276251, 67278841, 67282987, 67283284, 67284570, 67284631, 67286112, 67286439, 67286477, 67286613, 67287026, 67288866, 67290478, 67293793, 67301601, 67307030, 67307164, 67307691, 67311813, 67328535, 67331784, 67332301, 67335958, 67336497, 67342088, 67346410, 67347895, 67348003, 67348807, 67355394, 67357953, 67358578, 67359783, 67360437, 67361569, 67361818, 67361843, 67364009, 67364040, 67366708, 67366774, 67367100, 67367141, 67368424, 67372003, 67372091, 67372327, 67372449, 67372501, 67373050, 67373339, 67373761, 67374940, 67375746, 67375891, 67376404, 67376508, 67377115, 67378447, 67378627, 67378772, 67379842, 67380100, 67381509, 67386522, 67388012, 67389915, 67390251, 67390444, 67391657, 67394997, 76102583, 77795011, 77795109, 77795260, 78507029, 78508980, 78509723, 78509863, 78510460, 78511718, 78513035, 78513627, 78514644, 78514790, 78514927, 78517960, 78518612, 78518831, 78521396, 78522990, 78523633, 78524456, 78524825, 78526291, 78526600, 78527579, 78528001, 78528364, 78528542, 78530026, 78530348, 78530449, 78531040, 78531210, 78531810, 78532892, 78533723, 78534887, 78535701, 78535735, 78535956, 78536589, 78536893, 78537257, 78537469, 78537911, 78537926, 78538384, 78538583, 78538630, 78539037, 78539131, 78541336, 78543143, 78544051, 78548517, 78550378, 78550728, 78551293, 78551701, 78554765, 78554834, 78556053, 78559824, 78562596, 78563468, 78564910, 78565362, 78567471, 78568860, 78572842, 78580575, 78582528, 78592084, 78595960, 78597066, or78602515 on human chromosome 16; at position 2658514, 2661001, 2665103, 2665118, 2666091, 2673087, 22820896, 22823395, 22824689, 22825137, 22830498, 22832527, 22833055, 22836140, 22839015, 22840839, 22843340, 22846791, 22846832, 22847173, 22847504, 22850255, 22856541, 22861817, 22864080, 22869931, 22873444, 22874985, 22875818, 22876070, 22877777, 22878315, 22882194, 22883192, 22883607, 22883806, 22884337, 22884838, 22885655, 22885716, 22890677, 22892455, 22893135, 22894092, 22896216, 22896312, 22897438, 28890180, 28894872, 28905348, 28910497, 28911274, 28921210, 28925064, 28925255, 28928070, 28928118, 28931247, 28935710, 28944267, 30321178, 30337424, 30339558, 30342425, 30350130, 30350893, 30361524, 30362560, 30363396, 30371625, 30373383, 30403780, 30410974, 30414282, 30416800, 30427093, 30428955, 30457600, or 30467328 on human chromosome 17; atposition 3199224, 3209591, 3210857, 3218815, 4923689, 4926147, 4926402, 4934685, 4936422, 4936562, 4937183, 4937365, 4938110, 4938253, 4938671, 4939304, 4941575, 4948939, 4950581, 4959766, 4959964, 4960506, 4963174, 4969612, 4970659, 4974601, 4979314, 4981745, 4993537, 5002433, 5004084, 5004339, 5004366, 5004748, 5006279, 5007428, 5008786, 5011644, 5039243, 18312106, 18313143, 18315385, 18317202, 18318589, 18319478, 18320153, 18321043, 18322157, 18323697, 18324589, 18338815, 18351412, 18351907, 18351955, 18355664, 18359560, 18361520, 18362154, 18373649, 18375382, 18379689, 18379848, 18380080, 18380432, 37702718, 37703149, 37703215, 37703488, 37703966, 37704734, 37705863, 37708590, 37709295, 37709510, 37710264, 37711607, 37713054, 37713702, 37714980, 37715153, 37716013, 37716214, 37716277, 37717458, 37718102, 37718127, 37718470, 37719111, 41563909, 41570268, 41571247, 41577622, 41581292, 41582293, 41582632, 41582748, 41583196, 41583308, 41588324,

41588803, 41589256, 41589691, 41589897, 41593219, 41594516, 41595420, 41595770, 41595792, 41596131, 41597080, 41597415, 41597628, 41597987, 41598280, 41613925, 41614138, 41617419, 41618120, 41623325, 41623910, 41624961, 41626853, 41627762, 41633410, 41634834, 41635463, 41635510, 41635799, 41636812, 41637703, 41638223, 41639267, 41641545, 41643303, 41644754, 41648373, 41648521, 41653433, 41663873, 60452260, 60477510, 60488119, 60490204, 60490280, 60496339, 60507710, 60511196, 60517518, 60520125, 60522027, 60522514, 60524571, 60525741, 60533668, 60534962, 60548441, 60548679, 60554118, 68423906, 68426604, 68427893, 68441726, or 68444594 on human chromosome 18; atposition 34276329, 34276495, 34277090, 34277961, 34279795, 34281209, 34283109, 34283740, 34285910, 34288722, 34294949, 34298201, 34301022, 34302834, 34309273, 34314346, 34330168, 34332628, 34333479, 34335698, 34344182, 34344849, 34353570, 34356661, 34364519, 34364983, or 59509847 on human chromosome 19; at position 2488701, 2489084, 2490747, 2491144, 2493219, 2494225, 2495597, 2497008, 2498579, 2500926, 2502907, 2503157, 2507778, 2510604, 2510708, 2526935, 2528772, 2531652, 2533770, 10523782, 10586327, 10586424, 10587222, 10587841, 10589470, 10589575, 10590389, 10591091, 38527211, 38528818, 38529666, 38532337, 38534109, 38536785, 38539932, 38541748, 38541918, 38544403, 38546263, 38549619, 38550978, 38551409, 38556196, 38556633, 38557455, 38557463, 38561992, 42147372, 42147941, 42148380, 42148459, 42148669, 42149347, 42151350, 42151833, 42152019, 42155679, 42155996, 42156826, 42158000, 42159296, 42159619, 42160904, 42162052, 42162344, 42162545, 42165258, 42165548, 42165767, 42166601, 42167016, 42167261, 42167414, 42169375, 42170362, 42170805, 42170908, 42172004, 42173722, 42174113, 42174528, 42457255, 42457463, 42459198, 42460030, 42460924, 59989629, 60009225, 60014082, 60017343, 60017467, 60017755, 60019004, 60020185, 60021444, 60026791, 60028281, 60029814, 60031018, 60033821, 60034898, 60035259, 60036888, 60046156, or 60058583 on human chromosome 20; at position 18771052, 18791084, 18809897, 18820035, 20218657, 20222308, 20226492, 20228734, 20232506, 20243479, 20257959, 20261725, 20272988, 20274521, 20274865, 20279236, 20282727, 20308050, 25132923, 25139728, 25142953, 25144269, 25149891, 25150796, 25154439, 25157062, 25158001, 25158027, 25162631, 25163382, 25164231, 25172000, 25174725, 25179102, 25181676, 25184885, 25188509, 25190795, 25192249, 25194942, 25195327, 25202797, 25203906, 25205864, 25216178, 25219492, 25220024, 25262070, 40467923, 40468825, 40469751, 40470121, 40471529, 40473045, 40477600, 40478284, 40478922, 40485092, 40485283, 40487282, 40487855, 40487938, 40488679, 40488748, 40488921, 40489274, 40489378, 40489417, 40489901, 40491419, 4O194077,

40494926, 40495261, or 40496156 on human chromosome 21; or at position 17935876, 17941703, or 17944549 on human chromosome 22.

4. The method of claim 3, wherein: when the base at position 5643494 on human chromosome 1 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 5645572 on human chromosome 1 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 5645696 on human chromosome 1 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 5645913 on human chromosome 1 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 5647097 on human chromosome 1 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 5647280 on human chromosome 1 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 5647550 on human chromosome 1 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 5647811 on human chromosome 1 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 5650870 on human chromosome 1 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 5650899 on human chromosome 1 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 5651404 on human chromosome 1 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 5651654 on human chromosome 1 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 5651818 on human chromosome 1 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 5651847 on human chromosome 1 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 5652214 on human chromosome 1 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 5652282 on human chromosome 1 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 5652840 on human chromosome 1 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 5653015 on human chromosome 1 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 5653688 on human chromosome 1 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 17384494 on human chromosome 1 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 17386090 on human chromosome 1 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 17388878 on human chromosome 1 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 17392000 on human chromosome 1 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 17396536 on human chromosome 1 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 17396934 on human chromosome 1 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 17402627 on human chromosome 1 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 17404594 on human chromosome 1 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 17411445 on human chromosome 1 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 17411632 on human chromosome 1 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 17412020 on human chromosome 1 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 17414282 on human chromosome 1 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 17419907 on human chromosome 1 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 18484832 on human chromosome 1 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 18484852 on human chromosome 1 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 18484976 on human chromosome 1 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 18485834 on human chromosome 1 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 18485839 on human chromosome 1 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 18492401 on human chromosome 1 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 18494907 on human chromosome 1 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 18495737 on human chromosome 1 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 18496318 on human chromosome 1 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 18496396 on human chromosome 1 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 18496810 on human chromosome 1 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 18497170 on human chromosome 1 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 18498465 on human chromosome 1 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 18499756 on human chromosome 1 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 18500442 on human chromosome 1 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 18501831 on human chromosome 1 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 18502267 on human chromosome 1 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 18503492 on human chromosome 1 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 18504683 on human chromosome 1 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 18506717 on human chromosome 1 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 18506806 on human chromosome 1 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 18508721 on human chromosome 1 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 20628828 on human chromosome 1 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 20805662 on human chromosome 1 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 20807307 on human chromosome 1 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 20812307 on human chromosome 1 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 20814435 on human chromosome 1 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 20833262 on human chromosome 1 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 20834778 on human chromosome 1 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 20835387 on human chromosome 1 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 20843033 on human chromosome 1 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 20843089 on human chromosome 1 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 20843172 on human chromosome 1 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 20845152 on human chromosome 1 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 20851322 on human chromosome 1 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 20859722 on human chromosome 1 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 20860139 on human chromosome 1 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 20866984 on human chromosome 1 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 20868329 on human chromosome 1 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 20869596 on human chromosome 1 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 20871652 on human chromosome 1 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 20873726 on human chromosome 1 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 20885691 on human chromosome 1 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 20890966 on human chromosome 1 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 20897686 on human chromosome 1 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 20897690 on human chromosome 1 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 20897946 on human chromosome 1 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 20900501 on human chromosome 1 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 20902168 on human chromosome 1 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 20910482 on human chromosome 1 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 20912408 on human chromosome 1 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 20922516 on human chromosome 1 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 20925487 on human chromosome 1 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 20925556 on human chromosome 1 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 20927846 on human chromosome 1 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 20931914 on human chromosome 1 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 20934009 on human chromosome 1 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 20935818 on human chromosome 1 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 20937929 on human chromosome 1 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 20939816 on human chromosome 1 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 20943571 on human chromosome 1 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 20945070 on human chromosome 1 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 20945280 on human chromosome 1 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 20945717 on human chromosome 1 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 20949204 on human chromosome 1 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 20949302 on human chromosome 1 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 20951449 on human chromosome 1 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 20955075 on human chromo- ome 1 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 20958577 on human chromosome 1 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 20959014 on human chromosome 1 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 20960041 on human chromosome 1 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 20965681 on human chromosome 1 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 20965980 on human chromosome 1 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 20966007 on human chromosome 1 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 20969559 on human chromosome 1 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 20972644 on human chromosome 1 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 20980229 on human chromosome 1 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 20984365 on human chromosome 1 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 20986738 on human chromosome 1 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 20993250 on human chromosome 1 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 20994909 on human chromosome 1 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 20997023 on human chromosome 1 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 20999899 on human chromosome 1 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 21000095 on human chromosome 1 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 21000981 on human chromosome 1 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 21004018 on human chromosome 1 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 21006394 on human chromosome 1 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 21010403 on human chromosome 1 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 21016114 on human chromosome 1 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 21022160 on human chromosome 1 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 21024702 on human chromosome 1 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 21028251 on human chromosome 1 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 21033244 on human chromosome 1 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 21035367 on human chromosome 1 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 21035826 on human chromosome 1 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 21040905 on human chromosome 1 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 21041170 on human chromosome 1 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 21044669 on human chromosome 1 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 21050902 on human chromosome 1 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 21051467 on human chromosome 1 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 21055398 on human chromosome 1 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 21062830 on human chromosome 1 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 21063762 on human chromosome 1 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 21068091 on human chromosome 1 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 21068874 on human chromosome 1 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 21069797 on human chromosome 1 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 21072609 on human chromosome 1 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 21078118 on human chromosome 1 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 21082461 on human chromosome 1 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 21082628 on human chromosome 1 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 21084950 on human chromosome 1 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 21101147 on human chromosome 1 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 21106482 on human chromosome 1 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 21107684 on human chromosome 1 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 21112807 on human chromosome 1 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 21114874 on human chromosome 1 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 21120116 on human chromosome 1 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 21120469 on human chromosome 1 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 21121210 on human chromosome 1 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 21127511 on human chromosome 1 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 21131101 on human chromosome 1 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 21136620 on human chromosome 1 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 21137181 on human chromosome 1 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 21140439 on human chromosome 1 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 21140663 on human chromosome 1 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 21141522 on human chromosome 1 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 21141902 on human chromosome 1 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 21142192 on human chromosome 1 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 21145524 on human chromosome 1 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 21149959 on human chromosome 1 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 21994187 on human chromosome 1 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 22003045 on human chromosome 1 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 22010599 on human chromosome 1 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 22017145 on human chromosome 1 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 22028977 on human chromosome 1 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 22033247 on human chromosome 1 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 22033774 on human chromosome 1 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 22035462 on human chromosome 1 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 22037572 on human chromosome 1 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 22039203 on human chromosome 1 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 22040172 on human chromosome 1 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 22040277 on human chromosome 1 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 22051221 on human chromosome 1 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 22054010 on human chromosome 1 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 22057214 on human chromosome 1 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 22066093 on human chromosome 1 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 22066856 on human chromosome 1 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 22067235 on human chromosome 1 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 22070236 on human chromosome 1 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 22073585 on human chromosome 1 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 22081426 on human chromosome 1 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 22090953 on human chromosome 1 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 33594198 on human chromosome 1 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 33594270 on human chromosome 1 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 33595060 on human chromosome 1 is C or is in strong disequilibrium linkage therewith, then said base exeits a increased risk; when the base at position 33596139 on human chromosome 1 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 33605440 on human chromosome 1 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 33610121 on human chromosome 1 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 33616560 on human chromosome 1 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 33651889 on human chromosome 1 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 33652136 on human chromosome 1 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 33654063 on human chromosome 1 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 33654926 on human chromosome 1 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 33660788 on human chromosome 1 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 33661463 on human chromosome 1 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 33670428 on human chromosome 1 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 33676601 on human chromosome 1 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 40754887 on human chromosome 1 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 40755019 on human chromosome 1 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 40757670 on human chromosome 1 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 40762923 on human chromosome 1 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 40771174 on human chromosome 1 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 40775136 on human chromosome 1 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 40776959 on human chromosome 1 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 40777187 on human chromosome 1 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 40778790 on human chromosome 1 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 40779764 on human chromosome 1 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 40780164 on human chromosome 1 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 40781288 on human chromosome 1 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 40797069 on human chromosome 1 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 40798090 on human chromosome 1 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 40801268 on human chromosome 1 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 40801318 on human chromosome 1 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 82399075 on human chromosome 1 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 82401753 on human chromosome 1 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 82402027 on human chromosome 1 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 82402309 on human chromosome 1 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 82404022 on human chromosome 1 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 82404407 on human chromosome 1 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 82406375 on human chromosome 1 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 82406489 on human chromosome 1 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 82406720 on human chromosome 1 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 82408523 on human chromosome 1 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 82411232 on human chromosome 1 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 82413745 on human chromosome 1 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 82416733 on human chromosome 1 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 82417487 on human chromosome 1 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 82417910 on human chromosome 1 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 82418308 on human chromosome 1 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 82418330 on human chromosome 1 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 82418366 on human chromosome 1 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 82419538 on human chromosome 1 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 82420496 on human chromosome 1 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 82420704 on human chromosome 1 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 82421197 on human chromosome 1 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 82422368 on human chromosome 1 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 82423727 on human chromosome 1 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 82424134 on human chromosome 1 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 82424150 on human chromosome 1 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 82424914 on human chromosome 1 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 82424975 on human chromosome 1 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 82425243 on human chromosome 1 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 82426612 on human chromosome 1 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 82427690 on human chromosome 1 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 82434461 on human chromosome 1 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 82435415 on human chromosome 1 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 82439143 on human chromosome 1 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 82439471 on human chromosome 1 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 82444631 on human chromosome 1 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 82444660 on human chromosome 1 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 82447710 on human chromosome 1 i? A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 82448718 on human chromosome 1 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 82449218 on human chromosome 1 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 82449749 on human chromosome 1 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 82449774 on human chromosome 1 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 82452506 on human chromosome 1 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 82452647 on human chromosome 1 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 82453300 on human chromosome 1 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 82453338 on human chromosome 1 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 82453515 on human chromosome 1 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 82453539 on human chromosome 1 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 82453848 on human chromosome 1 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 82453927 on human chromosome 1 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 82454106 on human chromosome 1 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 82455294 on human chromosome 1 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 82455776 on human chromosome 1 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 82456621 on human chromosome 1 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 82456752 on human chromosome 1 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 82456889 on human chromosome 1 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 82456912 on human chromosome 1 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 82457399 on human chromosome 1 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 82457424 on human chromosome 1 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 82457468 on human chromosome 1 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 82457982 on human chromosome 1 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 82458227 on human chromosome 1 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 82458977 on human chromosome 1 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 82459886 on human chromosome 1 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 82460521 on human chromosome 1 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 82460840 on human chromosome 1 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 82466546 on human chromosome 1 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 82466878 on human chromosome 1 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 82474430 on human chromosome 1 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 82476963 on human chromosome 1 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 82478914 on human chromosome 1 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 82480981 on human chromosome 1 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 82481004 on human chromosome 1 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 82484336 on human chromosome 1 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 82484391 on human chromosome 1 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 82484596 on human chromosome 1 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 82484930 on human chromosome 1 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 82485259 on human chromosome 1 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 82486216 on human chromosome 1 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 82487128 on human chromosome 1 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 82487294 on human chromosome 1 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 82488099 on human chromosome 1 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 82489906 on human chromosome 1 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 82489977 on human chromosome 1 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 82490942 on human chromosome 1 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 82490987 on human chromosome 1 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 82492500 on human chromosome 1 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 82492549 on human chromosome 1 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 82499839 on human chromosome 1 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 82505085 on human chromosome 1 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 82505197 on human chromosome 1 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 82505473 on human chromosome 1 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 82506578 on human chromosome 1 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 82506826 on human chromosome 1 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 82508028 on human chromosome 1 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 82508044 on human chromosome 1 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 82509654 on human chromosome 1 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 82510272 on human chromosome 1 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 82511041 on human chromosome 1 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 95488809 on human chromosome 1 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 95491103 on human chromosome 1 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 95493443 on human chromosome 1 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 95498250 on human chromosome 1 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 95501385 on human chromosome 1 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 95530617 on human chromosome 1 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 118561559 on human chromosome 1 is C or is in εtrong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 118562029 on human chromosome 1 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 118564656 on human chromosome 1 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 118564859 on human chromosome 1 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 118566872 on human chromosome 1 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 118566892 on human chromosome 1 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 118570326 on human chromosome 1 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 118571091 on human chromosome 1 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 118571342 on human chromosome 1 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 118571646 on human chromosome 1 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 118575513 on human chromosome 1 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 118578029 on human chromosome 1 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 118578119 on human chromosome 1 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 118578309 on human chromosome 1 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 118579425 on human chromosome 1 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 118580020 on human chromosome 1 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 118581538 on human chromosome 1 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 118581975 on human chromosome 1 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 118585388 on human chromosome 1 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 118585550 on human chromosome 1 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 118589180 on human chromosome 1 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 118596956 on human chromosome 1 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 118600709 on human chromosome 1 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 118601663 on human chromosome 1 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 118610570 on human chromosome 1 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 118615020 on human chromosome 1 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 118619695 on human chromosome 1 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 118621071 on human chromosome 1 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 118628630 on human chromosome 1 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 118640477 on human chromosome 1 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 118641626 on human chromosome 1 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 118664662 on human chromosome 1 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 142933600 on human chromosome 1 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 142994415 on human chromosome 1 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 142996870 on human chromosome 1 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 143024965 on human chromosome 1 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 143037007 on human chromosome 1 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 143039966 on human chromosome 1 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 143040559 on human chromosome 1 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 154354010 on human chromosome 1 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 154354638 on human chromosome 1 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 154354747 on human chromosome 1 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 154355118 on human chromosome 1 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 154355147 on human chromosome 1 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 154355235 on human chromosome 1 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 154355289 on human chromosome 1 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 154356819 on human chromosome 1 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 154356951 on human chromosome 1 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 154358120 on human chromosome 1 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 154359419 on human chromosome 1 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 154361742 on human chromosome 1 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 154362243 on human chromosome 1 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 154363430 on human chromosome 1 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 154363490 on human chromosome 1 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 154366090 on human chromosome 1 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 154379092 on human chromosome 1 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 154384794 on human chromosome 1 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 154397374 on human chromosome 1 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 154408258 on human chromosome 1 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 154409264 on human chromosome 1 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 154409463 on human chromosome 1 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 154419367 on human chromosome 1 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 154423513 on human chromosome 1 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 154426410 on human chromosome 1 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 154432962 on human chromosome 1 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 154440037 on human chromosome 1 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 154450003 on human chromosome 1 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 154461171 on human chromosome 1 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 154479409 on human chromosome 1 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 154492764 on human chromosome 1 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 154492856 on human chromosome 1 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 154493187 on human chromosome 1 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 154494971 on human chromosome 1 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 154498579 on human chromosome 1 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 154498812 on human chromosome 1 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 154500310 on human chromosome 1 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 154501115 on human chromosome 1 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 154501714 on human chromosome 1 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 154503542 on human chromosome 1 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 154507828 on human chromosome 1 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 166392439 on human chromosome 1 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 166394400 on human chromosome 1 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 166394636 on human chromosome 1 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 166397209 on human chromosome 1 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 166397290 on human chromosome 1 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 166398255 on human chromosome 1 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 166398645 on human chromosome 1 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 166401473 on human chromosome 1 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 166411211 on human chromosome 1 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 166440044 on human chromosome 1 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 166451495 on human chromosome 1 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 166457690 on human chromosome 1 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 166534614 on human chromosome 1 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 166555318 on human chromosome 1 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 166556037 on human chromosome 1 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 166569936 on human chromosome 1 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 166577414 on human chromosome 1 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 182257700 on human chromosome 1 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 182264962 on human chromosome 1 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 182272275 on human chromosome 1 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 182275532 on human chromosome 1 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 182284803 on human chromosome 1 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 182285181 on human chromosome 1 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 187082093 on human chromosome 1 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 187174628 on human chromosome 1 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 187199686 on human chromosome 1 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 187205762 on human chromosome 1 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 187227358 on human chromosome 1 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 187229616 on human chromosome 1 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 187235623 on human chromosome 1 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 187245840 on human chromosome 1 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 187257909 on human chromosome 1 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 187259731 on human chromosome 1 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 187262889 on human chromosome 1 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 187265357 on human chromosome 1 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 187265802 on human chromosome 1 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 187270060 on human chromosome 1 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 187271578 on human chromosome 1 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 187271664 on human chromosome 1 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 187272352 on human chromosome 1 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 187282856 on human chromosome 1 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 187294343 on human chromosome 1 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 187298692 on human chromosome 1 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 187306394 on human chromosome 1 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 187311887 on human chromosome 1 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 187316314 on human chromosome 1 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 187319957 on human chromosome 1 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 187337861 on human chromosome 1 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 200499985 on human chromosome 1 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 200501189 on human chromosome 1 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 200501548 on human chromosome 1 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 200506450 on human chromosome 1 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 200508966 on human chromosome 1 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 200509456 on human chromosome 1 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 200516826 on human chromosome 1 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 200519147 on human chromosome 1 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 200524239 on human chromosome 1 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 200527354 on human chromosome 1 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 200551097 on human chromosome 1 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 200565332 on human chromosome 1 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 200569854 on human chromosome 1 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 200588556 on human chromosome 1 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 200636760 on human chromosome 1 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 200644895 on human chromosome 1 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 200645480 on human chromosome 1 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 200645637 on human chromosome 1 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 200653088 on human chromosome 1 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 200677055 on human chromosome 1 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 200687498 on human chromosome 1 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 200688166 on human chromosome 1 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 200698626 on human chromosome 1 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 211255378 on human chromosome 1 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 211257304 on human chromosome 1 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 211261122 on human chromosome 1 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 211262732 on human chromosome 1 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 211262877 on human chromosome 1 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 211263362 on human chromosome 1 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 211272121 on human chromosome 1 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 211279482 on human chromosome 1 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 211283002 on human chromosome 1 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 211297540 on human chromosome 1 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 214639829 on human chromosome 1 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 214640676 on human chromosome 1 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 214641707 on human chromosome 1 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 228780820 on human chromosome 1 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 228781610 on human chromosome 1 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 228781647 on human chromosome 1 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 228784137 on human chromosome 1 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 228787987 on human chromosome 1 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 228791128 on human chromosome 1 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 228792077 on human chromosome 1 ;s G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 228792350 on human chromosome 1 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 228792421 on human chromosome 1 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 228793128 on human chromosome 1 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 228795562 on human chromosome 1 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 228796991 on human chromosome 1 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 228798772 on human chromosome 1 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 228802209 on human chromosome 1 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 228802332 on human chromosome 1 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 228803037 on human chromosome 1 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 228803110 on human chromosome 1 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 228804365 on human chromosome 1 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 228804648 on human chromosome 1 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 228805071 on human chromosome 1 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 228812020 on human chromosome 1 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 228815730 on human chromosome 1 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 229740644 on human chromosome 1 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 229740798 on human chromosome 1 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 229741584 on human chromosome 1 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 229742681 on human chromosome 1 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 229742852 on human chromosome 1 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 229743138 on human chromosome 1 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 229772462 on human chromosome 1 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 229775633 on human chromosome 1 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 229775685 on human chromosome 1 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 229775732 on human chromosome 1 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 229776204 on human chromosome 1 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 229776296 on human chromosome 1 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 229776889 on human chromosome 1 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 229777047 on human chromosome 1 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 229779187 on human chromosome 1 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 229781272 on human chromosome 1 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 229782916 on human chromosome 1 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 229783979 on human chromosome 1 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 229788385 on human chromosome 1 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 229798172 on human chromosome 1 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 229802303 on human chromosome 1 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 1981076 on human chromosome 2 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 1997590 on human chromosome 2 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 2000240 on human chromosome 2 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 2041790 on human chromosome 2 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 2095003 on human chromosome 2 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 2135816 on human chromosome 2 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 2137239 on human chromosome 2 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 2138961 on human chromosome 2 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 2141402 on human chromosome 2 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 2144206 on human chromosome 2 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 2145868 on human chromosome 2 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 2146474 on human chromosome 2 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 2148224 on human chromosome 2 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 2148955 on human chromosome 2 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 2149477 on human chromosome 2 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 2151490 on human chromosome 2 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 2154044 on human chromosome 2 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 6787971 on human chromosome 2 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 6788719 on human chromosome 2 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 6791928 on human chromosome 2 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 6795452 on human chromosome 2 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 6797609 on human chromosome 2 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 6803426 on human chromosome 2 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 6807649 on human chromosome 2 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 6816663 on human chromosome 2 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 6817235 on human chromosome 2 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 6817416 on human chromosome 2 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 6820094 on human chromosome 2 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 6824454 on human chromosome 2 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 6824649 on human chromosome 2 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 6825691 on human chromosome 2 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 6832251 on human chromosome 2 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 6833027 on human chromosome 2 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 6834747 on human chromosome 2 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 6836618 on human chromosome 2 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 6837215 on human chromosome 2 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 10447542 on human chromosome 2 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 10447613 on human chromosome 2 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 14717418 on human chromosome 2 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 14730427 on human chromosome 2 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 14730636 on human chromosome 2 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 14733739 on human chromosome 2 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 14734664 on human chromosome 2 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 14736069 on human chromosome 2 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 14741491 on human chromosome 2 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 14741776 on human chromosome 2 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 14747763 on human chromosome 2 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 14759875 on human chromosome 2 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 14762397 on human chromosome 2 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 14765208 on human chromosome 2 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 14766106 on human chromosome 2 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 14782636 on human chromosome 2 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 14784332 on human chromosome 2 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 14791609 on human chromosome 2 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 14803091 on human chromosome 2 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 14805637 on human chromosome 2 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 14807512 on human chromosome 2 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 14811732 on human chromosome 2 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 14811975 on human chromosome 2 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 14813784 on human chromosome 2 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 14815996 on human chromosome 2 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 14817501 on human chromosome 2 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 14817638 on human chromosome 2 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 14818554 on human chromosome 2 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 14818772 on human chromosome 2 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 14819080 on human chromosome 2 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 14819413 on human chromosome 2 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 14820033 on human chromosome 2 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 14820204 on human chromosome 2 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 14821252 on human chromosome 2 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 14821469 on human chromosome 2 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 14821774 on human chromosome 2 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 14822113 on human chromosome 2 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 14822372 on human chromosome 2 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 14823215 on human chromosome 2 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 14823397 on human chromosome 2 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 14824206 on human chromosome 2 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 14824355 on human chromosome 2 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 14824669 on human chromosome 2 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 14825477 on human chromosome 2 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 14825491 on human chromosome 2 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 14825515 on human chromosome 2 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 14825579 on human chromosome 2 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 14825843 on human chromosome 2 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 14825988 on human chromosome 2 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 14826533 on human chromosome 2 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 14826982 on human chromosome 2 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 14827692 on human chromosome 2 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 14828251 on human chromosome 2 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 14828478 on human chromosome 2 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 14828602 on human chromosome 2 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 14828866 on human chromosome 2 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 14829175 on human chromosome 2 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 14830288 on human chromosome 2 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 14830415 on human chromosome 2 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 14832593 on human chromosome 2 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 14832767 on human chromosome 2 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 14835129 on human chromosome 2 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 14836747 on human chromosome 2 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 14837340 on human chromosome 2 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 14841532 on human chromosome 2 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 14841955 on human chromosome 2 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 14842480 on human chromosome 2 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 14843205 on human chromosome 2 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 14847211 on human chromosome 2 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 14847384 on human chromosome 2 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 14848466 on human chromosome 2 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 14849112 on human chromosome 2 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 14850007 on human chromosome 2 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 14850241 on human chromosome 2 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 14854674 on human chromosome 2 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 14856969 on human chromosome 2 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 14857019 on human chromosome 2 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 14857404 on human chromosome 2 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 14858596 on human chromosome 2 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 14859653 on human chromosome 2 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 14861777 on human chromosome 2 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 14865257 on human chromosome 2 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 14867233 on human chromosome 2 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 14884637 on human chromosome 2 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 14885952 on human chromosome 2 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 14886528 on human chromosome 2 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 14889421 on human chromosome 2 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 14890602 on human chromosome 2 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 14891629 on human chromosome 2 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 14891836 on human chromosome 2 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 14893918 on human chromosome 2 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 14895761 on human chromosome 2 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 14895898 on human chromosome 2 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 14896644 on human chromosome 2 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 14897874 on human chromosome 2 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 14898959 on human chromosome 2 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 14901340 on human chromosome 2 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 14902171 on human chromosome 2 is> G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 14902258 on human chromosome 2 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 14902695 on human chromosome 2 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 14902783 on human chromosome 2 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 14903803 on human chromosome 2 is C or is in strong disequilibriμm linkage therewith, then said base exerts a increased risk; when the base at position 14904181 on human chromosome 2 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 14906178 on human chromosome 2 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 14906940 on human chromosome 2 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 14908749 on human chromosome 2 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 14913424 on human chromosome 2 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 14919179 on human chromosome 2 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 14921640 on human chromosome 2 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 14921971 on human chromosome 2 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 14924120 on human chromosome 2 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 14925890 on human chromosome 2 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 14927435 on human chromosome 2 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 14927984 on human chromosome 2 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 14928014 on human chromosome 2 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 14955346 on human chromosome 2 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 14975692 on human chromosome 2 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 14979189 on human chromosome 2 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 16423966 on human chromosome 2 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 16436415 on human chromosome 2 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 16436634 on human chromosome 2 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 16438849 on human chromosome 2 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 16441253 on human chromosome 2 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 16444388 on human chromosome 2 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 16445618 on human chromosome 2 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 16449154 on human chromosome 2 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 16449252 on human chromosome 2 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 16452489 on human chromosome 2 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 16452960 on human chromosome 2 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 16453191 on human chromosome 2 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 16453401 on human chromosome 2 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 16456670 on human chromosome 2 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 16456858 on human chromosome 2 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 16456971 on human chromosome 2 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 16457143 on human chromosome 2 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 16457924 on human chromosome 2 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 16458608 on human chromosome 2 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 16460229 on human chromosome 2 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 16460397 on human chromosome 2 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 16462574 on human chromosome 2 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 16462884 on human chromosome 2 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 16463084 on human chromosome 2 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 16466591 on human chromosome 2 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 16469303 on human chromosome 2 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 16470091 on human chromosome 2 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 19192227 on human chromosome 2 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 19196921 on human chromosome 2 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 19199416 on human chromosome 2 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 19200437 on human chromosome 2 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 19200850 on human chromosome 2 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 19202694 on human chromosome 2 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 19206904 on human chromosome 2 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 19208019 on human chromosome 2 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 19208571 on human chromosome 2 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 19209828 on human chromosome 2 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 19220355 on human chromosome 2 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 19220680 on human chromosome 2 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 19222754 on human chromosome 2 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 45105940 on human chromosome 2 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 49157212 on human chromosome 2 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 49159483 on human chromosome 2 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 49163446 on human chromosome 2 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 49169518 on human chromosome 2 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 49183068 on human chromosome 2 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 49184463 on human chromosome 2 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 49185265 on human chromosome 2 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 49186995 on human chromosome 2 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 49187101 on human chromosome 2 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 49187893 on human chromosome 2 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 49189474 on human chromosome 2 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 49190619 on human chromosome 2 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 49191171 on human chromosome 2 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 49204882 on human chromosome 2 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 49228799 on human chromosome 2 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 49242409 on human chromosome 2 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 49244528 on human chromosome 2 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 49244583 on human chromosome 2 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 49311997 on human chromosome 2 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 49319087 on human chromosome 2 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 49329514 on human chromosome 2 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 49329682 on human chromosome 2 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 49332761 on human chromosome 2 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 49335916 on human chromosome 2 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 51253921 on human chromosome 2 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 51282582 on human chromosome 2 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 51283998 on human chromosome 2 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 51292542 on human chromosome 2 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 51292816 on human chromosome 2 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 51293152 on human chromosome 2 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 51295469 on human chromosome 2 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 51295990 on human chromosome 2 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 51296316 on human chromosome 2 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 51296923 on human chromosome 2 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 51299142 on human chromosome 2 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 51299895 on human chromosome 2 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 51301729 on human chromosome 2 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 51302018 on human chromosome 2 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 51302766 on human chromosome 2 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 51308652 on human chromosome 2 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 51309069 on human chromosome 2 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 51310044 on human chromosome 2 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 51310173 on human chromosome 2 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 51310771 on human chromosome 2 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 51311259 on human chromosome 2 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 51311482 on human chromosome 2 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 51312641 on human chromosome 2 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 51312847 on human chromosome 2 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 51312996 on human chromosome 2 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 51313386 on human chromosome 2 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 51314939 on human chromosome 2 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 51322555 on human chromosome 2 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 51336913 on human chromosome 2 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 51337143 on human chromosome 2 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 51337268 on human chromosome 2 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 51350473 on human chromosome 2 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 51350968 on human chromosome 2 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 51352442 on human chromosome 2 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 51359648 on human chromosome 2 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 51366391 on human chromosome 2 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 51368581 on human chromosome 2 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 51372576 on human chromosome 2 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 51581044 on human chromosome 2 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 51581245 on human chromosome 2 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 51581381 on human chromosome 2 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 51581793 on human chromosome 2 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 51582624 on human chromosome 2 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 51582698 on human chromosome 2 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 51582708 on human chromosome 2 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 51583049 on human chromosome 2 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 51583586 on human chromosome 2 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 51585227 on human chromosome 2 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 51585680 on human chromosome 2 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 51585798 on human chromosome 2 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 51586672 on human chromosome 2 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 51586849 on human chromosome 2 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 51586986 on human chromosome 2 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 51587119 on human chromosome 2 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 51588006 on human chromosome 2 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 51588334 on human chromosome 2 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 51588675 on human chromosome 2 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 51588954 on human chromosome 2 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 51589200 on human chromosome 2 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 51589275 on human chromosome 2 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 51591307 on human chromosome 2 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 51591566 on human chromosome 2 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 51591990 on human chromosome 2 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 51592343 on human chromosome 2 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 51592536 on human chromosome 2 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 51592586 on human chromosome 2 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 51592716 on human chromosome 2 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 51592732 on human chromosome 2 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 51593258 on human chromosome 2 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 51593383 on human chromosome 2 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 51593808 on human chromosome 2 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 51594068 on human chromosome 2 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 51594415 on human chromosome 2 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 51594505 on human chromosome 2 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 51595017 on human chromosome 2 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 51595132 on human chromosome 2 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 51595138 on human chromosome 2 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 51595162 on human chromosome 2 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 51595217 on human chromosome 2 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 51595686 on human chromosome 2 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 51596013 on human chromosome 2 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 51596427 on human chromosome 2 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 51596503 on human chromosome 2 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 51596924 on human chromosome 2 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 51598188 on human chromosome 2 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 51604192 on human chromosome 2 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 51604653 on human chromosome 2 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 51606466 on human chromosome 2 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 51612697 on human chromosome 2 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 51616113 on human chromosome 2 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 51616175 on human chromosome 2 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 51616622 on human chromosome 2 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 51618694 on human chromosome 2 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 51620262 on human chromosome 2 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 51621249 on human chromosome 2 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 51621558 on human chromosome 2 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 51623474 on human chromosome 2 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 51624825 on human chromosome 2 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 51627047 on human chromosome 2 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 51629369 on human chromosome 2 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 51629761 on human chromosome 2 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 51630099 on human chromosome 2 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 51630541 on human chromosome 2 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 51631175 on human chromosome 2 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 51631495 on human chromosome 2 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 51632351 on human chromosome 2 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 51634284 on human chromosome 2 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 51634299 on human chromosome 2 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 51634564 on human chromosome 2 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 51639966 on human chromosome 2 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 51641156 on human chromosome 2 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 51641476 on human chromosome 2 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 51641840 on human chromosome 2 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 51641866 on human chromosome 2 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 51642841 on human chromosome 2 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 51643067 on human chromosome 2 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 51643284 on human chromosome 2 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 51645247 on human chromosome 2 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 51646327 on human chromosome 2 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 51646730 on human chromosome 2 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 51646785 on human chromosome 2 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 51646789 on human chromosome 2 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 51647145 on human chromosome 2 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 51647506 on human chromosome 2 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 51648328 on human chromosome 2 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 51648645 on human chromosome 2 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 51649654 on human chromosome 2 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 51649807 on human chromosome 2 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 51650133 on human chromosome 2 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 51651094 on human chromosome 2 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 51651372 on human chromosome 2 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 51651532 on human chromosome 2 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 51651671 on human chromosome 2 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 51652648 on human chromosome 2 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 51652748 on human chromosome 2 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 51654053 on human chromosome 2 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 51654167 on human chromosome 2 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 51654512 on human chromosome 2 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 51654644 on human chromosome 2 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 51655509 on human chromosome 2 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 51655749 on human chromosome 2 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 51656169 on human chromosome 2 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 51656563 on human chromosome 2 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 51656610 on human chromosome 2 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 51656620 on human chromosome 2 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 51656944 on human chromosome 2 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 51657505 on human chromosome 2 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 51657783 on human chromosome 2 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 51657787 on human chromosome 2 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 51658048 on human chromosome 2 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 51658435 on human chromosome 2 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 51659770 on human chromosome 2 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 51662636 on human chromosome 2 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 51663466 on human chromosome 2 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 51664734 on human chromosome 2 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 51666133 on human chromosome 2 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 51666155 on human chromosome 2 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 51667730 on human chromosome 2 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 51668201 on human chromosome 2 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 51668300 on human chromosome 2 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 51668763 on human chromosome 2 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 51670217 on human chromosome 2 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 51670971 on human chromosome 2 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 51728639 on human chromosome 2 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 51733559 on human chromosome 2 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 51734157 on human chromosome 2 is C or is in strong • disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 51736163 on human chromosome 2 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 51736904 on human chromosome 2 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 51737857 on human chromosome 2 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 51744922 on human chromosome 2 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 51745502 on human chromosome 2 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 51746490 on human chromosome 2 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 51749051 on human chromosome 2 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 51753451 on human chromosome 2 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 51761022 on human chromosome 2 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 51763530 on human chromosome 2 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 51763744 on human chromosome 2 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 51764024 on human chromosome 2 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 51764406 on human chromosome 2 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 51765606 on human chromosome 2 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 51772482 on human chromosome 2 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 51777123 on human chromosome 2 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 51778197 on human chromosome 2 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 51778908 on human chromosome 2 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 51779815 on human chromosome 2 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 51781192 on human chromosome 2 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 51782154 on human chromosome 2 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 51782992 on human chromosome 2 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 51783172 on human chromosome 2 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 51783597 on human chromosome 2 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 51785250 on human chromosome 2 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 51785797 on human chromosome 2 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 51785854 on human chromosome 2 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 51785974 on human chromosome 2 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 51786209 on human chromosome 2 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 51786351 on human chromosome 2 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 51786438 on human chromosome 2 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 51788047 on human chromosome 2 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 51788314 on human chromosome 2 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 51789376 on human chromosome 2 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 51789672 on human chromosome 2 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 51791905 on human chromosome 2 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 51796180 on human chromosome 2 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 51799588 on human chromosome 2 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 51800143 on human chromosome 2 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 51800330 on human chromosome 2 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 51800670 on human chromosome 2 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 51801927 on human chromosome 2 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 51802093 on human chromosome 2 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 51805779 on human chromosome 2 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 51805870 on human chromosome 2 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 51810856 on human chromosome 2 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 51811445 on human chromosome 2 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 51811704 on human chromosome 2 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 51812416 on human chromosome 2 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 51812487 on human chromosome 2 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 51812736 on human chromosome 2 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 51814002 on human chromosome 2 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 51814655 on human chromosome 2 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 51814894 on human chromosome 2 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 51816235 on human chromosome 2 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 51816249 on human chromosome 2 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 51816496 on human chromosome 2 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 51816919 on human chromosome 2 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 51817159 on human chromosome 2 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 51817748 on human chromosome 2 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 51820864 on human chromosome 2 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 51821404 on human chromosome 2 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 51821994 on human chromosome 2 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 51822333 on human chromosome 2 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 51822667 on human chromosome 2 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 51822862 on human chromosome 2 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 51825960 on human chromosome 2 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 51826065 on human chromosome 2 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 51832068 on human chromosome 2 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 51832308 on human chromosome 2 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 51832588 on human chromosome 2 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 51833854 on humar chromosome 2 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 51836275 on human chromosome 2 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 51838112 on human chromosome 2 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 51839346 on human chromosome 2 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 51839857 on human chromosome 2 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 51841311 on human chromosome 2 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 51841526 on human chromosome 2 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 51841815 on human chromosome 2 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 51842300 on human chromosome 2 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 51843180 on human chromosome 2 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 51843615 on human chromosome 2 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 51843781 on human chromosome 2 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 51844459 on human chromosome 2 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 51844998 on human chromosome 2 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 51845560 on human chromosome 2 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 51846399 on human chromosome 2 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 51846977 on human chromosome 2 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 51847151 on human chromosome 2 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 51847495 on human chromosome 2 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 51857814 on human chromosome 2 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 51860363 on human chromosome 2 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 51860492 on human chromosome 2 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 54600331 on human chromosome 2 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 54602615 on human chromosome 2 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 54610296 on human chromosome 2 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 54617743 on human chromosome 2 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 54620579 on human chromosome 2 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 54625770 on human chromosome 2 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 54626013 on human chromosome 2 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 54628472 on human chromosome 2 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 54629673 on human chromosome 2 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 54630772 on human chromosome 2 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 54635392 on human chromosome 2 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 54636684 on human chromosome 2 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 54642867 on human chromosome 2 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 54649884 on human chromosome 2 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 54666880 on human chromosome 2 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 54667529 on human chromosome 2 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 54677809 on human chromosome 2 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 54681294 on human chromosome 2 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 54682974 on human chromosome 2 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 54699927 on human chromosome 2 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 54709360 on human chromosome 2 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 54709449 on human chromosome 2 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 54711779 on human chromosome 2 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 54713242 on human chromosome 2 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 54713507 on human chromosome 2 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 54713857 on human chromosome 2 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 54714165 on human chromosome 2 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 54714347 on human chromosome 2 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 54715322 on human chromosome 2 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 54715467 on human chromosome 2 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 54716869 on human chromosome 2 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 54717060 on human chromosome 2 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 54717238 on human chromosome 2 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 54717400 on human chromosome 2 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 54717427 on human chromosome 2 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 54717505 on human chromosome 2 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 54718930 on human chromosome 2 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 54719243 on human chromosome 2 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 54719308 on human chromosome 2 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 54719973 on human chromosome 2 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 54719991 on human chromosome 2 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 54720155 on human chromosome 2 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 54720496 on human chromosome 2 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 54720805 on human chromosome 2 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 54722143 on human chromosome 2 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 54722413 on human chromosome 2 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 54723568 on human chromosome 2 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 54724373 on human chromosome 2 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 54725589 on human chromosome 2 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 54726891 on human chromosome 2 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 54729104 on human chromosome 2 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 54730546 on human chromosome 2 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 54735797 on human chromosome 2 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 54736000 on human chromosome 2 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 54736047 on human chromosome 2 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 54736466 on human chromosome 2 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 54738652 on human chromosome 2 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 54741247 on human chromosome 2 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 54742322 on human chromosome 2 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 54743526 on human chromosome 2 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 54744402 on human chromosome 2 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 54744731 on human chromosome 2 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 54749028 on human chromosome 2 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 54750510 on hnman chromosome 2 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 54753715 on human chromosome 2 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 54753953 on human chromosome 2 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 54753968 on human chromosome 2 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 54756577 on human chromosome 2 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 54756768 on human chromosome 2 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 54757349 on human chromosome 2 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 54760379 on human chromosome 2 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 54766556 on human chromosome 2 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 54767105 on human chromosome 2 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 54770315 on human chromosome 2 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 54771054 on human chromosome 2 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 54775681 on human chromosome 2 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 54777211 on human chromosome 2 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 54779147 on human chromosome 2 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 54780932 on human chromosome 2 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 54788797 on human chromosome 2 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 54793127 on human chromosome 2 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 54794032 on human chromosome 2 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 54798256 on human chromosome 2 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 54800800 on human chromosome 2 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 54802668 on human chromosome 2 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 54810284 on human chromosome 2 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 54822523 on human chromosome 2 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 54830810 on human chromosome 2 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 54855293 on human chromosome 2 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 54861436 on human chromosome 2 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 54869067 on human chromosome 2 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 54869424 on human chromosome 2 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 54870481 on human chromosome 2 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 54870743 on human chromosome 2 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 54871341 on human chromosome 2 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 54871513 on human chromosome 2 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 54872331 on human chromosome 2 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 54874003 on human chromosome 2 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 54874374 on human chromosome 2 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 54875672 on human chromosome 2 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 57681639 on human chromosome 2 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 57687588 on human chromosome 2 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 57688449 on human chromosome 2 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 57691658 on human chromosome 2 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 57693363 on human chromosome 2 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 57709282 on human chromosome 2 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 57732596 on human chromosome 2 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 57760058 on human chromosome 2 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 57763417 on human chromosome 2 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 57777936 on human chromosome 2 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 57808407 on human chromosome 2 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 57817557 on human chromosome 2 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 57818569 on human chromosome 2 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 59392191 on human chromosome 2 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 59399670 on human chromosome 2 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 59400093 on human chromosome 2 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 59408778 on human chromosome 2 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 59414243 on human chromosome 2 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 59415406 on human chromosome 2 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 59416427 on human chromosome 2 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 59420806 on human chromosome 2 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 59434692 on human chromosome 2 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 59515351 on human chromosome 2 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 66140052 on human chromosome 2 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 66140190 on human chromosome 2 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 76569557 on human chromosome 2 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 76591689 on human chromosome 2 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 76598770 on human chromosome 2 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 76599140 on human chromosome 2 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 76618308 on human chromosome 2 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 76626555 on human chromosome 2 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 76631872 on human chromosome 2 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 76642367 on human chromosome 2 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 76646916 on human chromosome 2 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 76656753 on human chromosome 2 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 76657927 on human chromosome 2 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 79509214 on human chromosome 2 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 79510568 on human chromosome 2 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 79510789 on human chromosome 2 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 79511670 on human chromosome 2 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 79511757 on human chromosome 2 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 79512105 on human chromosome 2 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 79512569 on human chromosome 2 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 79512603 on human chromosome 2 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 79512655 on human chromosome 2 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 79512928 on human chromosome 2 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 79512978 on human chromosome 2 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 79512993 on human chromosome 2 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 79513076 on human chromosome 2 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 79513154 on human chromosome 2 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 79513396 on human chromosome 2 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 79513965 on human chromosome 2 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 79514583 on human chromosome 2 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 79514706 on human chromosome 2 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 79515184 on human chromosome 2 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 79517131 on human chromosome 2 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 79517413 on human chromosome 2 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 79517850 on human chromosome 2 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 79518056 on human chromosome 2 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 79518922 on human chromosome 2 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 79519021 on human chromosome 2 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 79519484 on human chromosome 2 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 79520546 on human chromosome 2 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 79520657 on human chromosome 2 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 79521051 on human chromosome 2 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 79534569 on human chromosome 2 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 79534859 on human chromosome 2 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 79535220 on human chromosome 2 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 79535301 on human chromosome 2 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 79536353 on human chromosome 2 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 79537326 on human chromosome 2 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 79538240 on human chromosome 2 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 79538284 on human chromosome 2 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 79539437 on human chromosome 2 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 79539489 on human chromosome 2 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 79539540 on human chromosome 2 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 79539593 on human chromosome 2 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 79539826 on human chromosome 2 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 79541573 on human chromosome 2 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 79543059 on human chromosome 2 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 79543363 on human chromosome 2 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 79543671 on human chromosome 2 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 101306757 on human chromosome 2 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 101341564 on human chromosome 2 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 101346009 on human chromosome 2 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 101375883 on human chromosome 2 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 101424556 on human chromosome 2 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 101430850 on human chromosome 2 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 101450992 on human chromosome 2 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 101476330 on human chromosome 2 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 101477396 on human chromosome 2 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 101478319 on human chromosome 2 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 101487446 on human chromosome 2 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 101487791 on human chromosome 2 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 101488066 on human chromosome 2 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 101494973 on human chromosome 2 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 101496373 on human chromosome 2 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 101830649 on human chromosome 2 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 101841611 on human chromosome 2 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 101902560 on human chromosome 2 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 101904245 on human chromosome 2 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 101992400 on human chromosome 2 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 101992755 on human chromosome 2 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 101999859 on human chromosome 2 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 102016032 on human chromosome 2 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 116932933 on human chromosome 2 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 116933474 on human chromosome 2 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 116933613 on human chromosome 2 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 116937194 on human chromosome 2 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 116940960 on human chromosome 2 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 116942210 on human chromosome 2 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 116944233 on human chromosome 2 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 116946663 on human chromosome 2 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 117010156 on human chromosome 2 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 117037549 on human chromosome 2 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 117037756 on human chromosome 2 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 117037869 on human chromosome 2 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 117052785 on human chromosome 2 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 117052962 on human chromosome 2 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 117058333 on human chromosome 2 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 117058442 on human chromosome 2 is C or is in strong disequilibrium linkage therewith; then said base exerts a increased risk; when the base at position 117063781 on human chromosome 2 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 117065974 on human chromosome 2 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 117066033 on human chromosome 2 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 117073189 on human chromosome 2 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 117073629 on human chromosome 2 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 117076708 on human chromosome 2 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 117080977 on human chromosome 2 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 117089137 on human chromosome 2 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 136894809 on human chromosome 2 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 136895491 on human chromosome 2 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 136899042 on human chromosome 2 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 136907864 on human chromosome 2 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 136914881 on human chromosome 2 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 136919330 on human chromosome 2 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 136921389 on human chromosome 2 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 136933309 on human chromosome 2 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 136995795 on human chromosome 2 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 148275544 on human chromosome 2 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 148291308 on human chromosome 2 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 148294679 on human chromosome 2 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 148296596 on human chromosome 2 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 148306979 on human chromosome 2 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 148314459 on human chromosome 2 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 148315182 on human chromosome 2 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 148317180 on human chromosome 2 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 148317795 on human chromosome 2 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 148324588 on human chromosome 2 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 148326077 on human chromosome 2 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 148331075 on human chromosome 2 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 148337515 on human chromosome 2 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 148338194 on human chromosome 2 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 148339660 on human chromosome 2 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 148339727 on human chromosome 2 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 148341027 on human chromosome 2 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 148343988 on human chromosome 2 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 148344362 on human chromosome 2 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 148346096 on human chromosome 2 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 148354462 on human chromosome 2 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 148370793 on human chromosome 2 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 148378520 on human chromosome 2 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 148408061 on human chromosome 2 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 148445260 on human chromosome 2 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 148461128 on human chromosome 2 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 148461782 on human chromosome 2 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 148467668 on human chromosome 2 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 148471194 on human chromosome 2 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 148476850 on human chromosome 2 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 148492327 on human chromosome 2 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 148500567 on human chromosome 2 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 148509460 on human chromosome 2 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 148521463 on human chromosome 2 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 148524988 on human chromosome 2 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 148547339 on human chromosome 2 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 166017910 on human chromosome 2 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 166089262 on human chromosome 2 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 166090523 on human chromosome 2 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 166092398 on human chromosome 2 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 166093832 on human chromosome 2 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 166097172 on human chromosome 2 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 166098152 on human chromosome 2 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 166098465 on human chromosome 2 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 166104522 on human chromosome 2 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 166105514 on human chromosome 2 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 166110486 on human chromosome 2 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 166142208 on human chromosome 2 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 166144081 on human chromosome 2 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 166144295 on human chromosome 2 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 166144830 on human chromosome 2 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 166145243 on human chromosome 2 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 166147508 on human chromosome 2 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 166152395 on human chromosome 2 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 166157163 on human chromosome 2 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 166158108 on human chromosome 2 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 166158192 on human chromosome 2 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 166158291 on human chromosome 2 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 166166091 on human chromosome 2 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 166180918 on human chromosome 2 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 166311863 on human chromosome 2 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 166329442 on human chromosome 2 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 166331473 on human chromosome 2 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 166335348 on human chromosome 2 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 166338881 on human chromosome 2 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 166341227 on human chromosome 2 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 166343885 on human chromosome 2 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 166346767 on human chromosome 2 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 166364549 on human chromosome 2 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 166379544 on human chromosome 2 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 166383017 on human chromosome 2 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 166402996 on human chromosome 2 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 166403621 on human chromosome 2 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 166408648 on human chromosome 2 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 166408751 on human chromosome 2 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 166422864 on human chromosome 2 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 166426553 on human chromosome 2 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 166428594 on human chromosome 2 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 166430517 on human chromosome 2 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 166431307 on human chromosome 2 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 166431434 on human chromosome 2 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 166433253 on human chromosome 2 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 166438750 on human chromosome 2 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 166440084 on human chromosome 2 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 166440286 on human chromosome 2 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 166441062 on human chromosome 2 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 166443769 on human chromosome 2 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 166446143 on human chromosome 2 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 166448105 on human chromosome 2 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 166466082 on human chromosome 2 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 182829393 on human chromosome 2 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 182855824 on human chromosome 2 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 182856997 on human chromosome 2 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 182860054 on human chromosome 2 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 182868726 on human chromosome 2 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 182869042 on human chromosome 2 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 182869069 on human chromosome 2 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 182870183 on human chromosome 2 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 182872106 on human chromosome 2 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 182874475 on human chromosome 2 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 182888394 on human chromosome 2 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 182890477 on human chromosome 2 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 182894958 on human chromosome 2 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 182911506 on human chromosome 2 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 182912900 on human chromosome 2 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 182915858 on human chromosome 2 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 182919107 on human chromosome 2 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 182922252 on human chromosome 2 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 182927388 on human chromosome 2 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 182932776 on human chromosome 2 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 182933991 on human chromosome 2 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 182935866 on human chromosome 2 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 182935924 on human chromosome 2 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 182954748 on human chromosome 2 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 182977270 on human chromosome 2 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 186710420 on human chromosome 2 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 186711372 on human chromosome 2 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 186722263 on human chromosome 2 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 186724122 on human chromosome 2 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 186729521 on human chromosome 2 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 186740943 on human chromosome 2 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 186746224 on human chromosome 2 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 186746951 on human chromosome 2 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 186748482 on human chromosome 2 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 186749691 on human chromosome 2 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 186752544 on human chromosome 2 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 186753368 on human chromosome 2 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 186754123 on human chromosome 2 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 186754244 on human chromosome 2 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 186754964 on human chromosome 2 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 186756686 on human chromosome 2 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 186759677 on human chromosome 2 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 186762379 on human chromosome 2 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 186762957 on human chromosome 2 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 186763380 on human chromosome 2 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 186765243 on human chromosome 2 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 186767243 on human chromosome 2 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 186771130 on human chromosome 2 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 186774634 on human chromosome 2 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 186779933 on human chromosome 2 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 186782889 on human chromosome 2 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 186783677 on human chromosome 2 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 186783723 on human chromosome 2 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 186786323 on human chromosome 2 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 186786345 on human chromosome 2 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 186787592 on human chromosome 2 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 186788152 on human chromosome 2 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 186788675 on human chromosome 2 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 186790815 on human chromosome 2 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 186795703 on human chromosome 2 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 186795981 on human chromosome 2 is A or is in strong disequilibrium linkage therewith, then said base extrts a increased risk; when the base at position 186797056 on human chromosome 2 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 186797101 on human chromosome 2 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 186797572 on human chromosome 2 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 186799104 on human chromosome 2 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 186799574 on human chromosome 2 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 186801145 on human chromosome 2 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 186802740 on human chromosome 2 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 186804008 on human chromosome 2 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 186804743 on human chromosome 2 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 186808518 on human chromosome 2 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 186811816 on human chromosome 2 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 186814495 on human chromosome 2 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 186816642 on human chromosome 2 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 186817164 on human chromosome 2 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 186817449 on human chromosome 2 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 186818961 on human chromosome 2 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 186820366 on human chromosome 2 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 186821302 on human chromosome 2 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 186821580 on human chromosome 2 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 186821687 on human chromosome 2 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 186821697 on human chromosome 2 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 186821729 on human chromosome 2 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 186822277 on human chromosome 2 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 186822318 on human chromosome 2 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 186822413 on human chromosome 2 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 186822456 on human chromosome 2 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 186822924 on human chromosome 2 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 186823239 on human chromosome 2 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 186826582 on human chromosome 2 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 186830554 on human chromosome 2 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 186832300 on human chromosome 2 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 186835982 on human chromosome 2 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 186839354 on human chromosome 2 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 186840321 on human chromosome 2 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 186841731 on human chromosome 2 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 186854278 on human chromosome 2 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 186854406 on human chromosome 2 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 186856196 on human chromosome 2 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 186869233 on human chromosome 2 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 186870116 on human chromosome 2 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 186873391 on human chromosome 2 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 186873805 on human chromosome 2 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 186876760 on human chromosome 2 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 186944471 on human chromosome 2 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 190190056 on human chromosome 2 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 190192330 on human chromosome 2 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 190192563 on human chromosome 2 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 190193864 on human chromosome 2 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 190194497 on human chromosome 2 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 190196792 on human chromosome 2 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 190197228 on human chromosome 2 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 190198425 on human chromosome 2 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 190201274 on human chromosome 2 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 190201295 on human chromosome 2 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 190201999 on human chromosome 2 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 190202876 on human chromosome 2 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 190203400 on human chromosome 2 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 190203827 on human chromosome 2 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 190203877 on human chromosome 2 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 190204668 on human chromosome 2 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 190207286 on human chromosome 2 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 190207749 on human chromosome 2 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 190207999 on human chromosome 2 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 190212085 on human chromosome 2 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 190212749 on human chromosome 2 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 190212993 on human chromosome 2 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 190213950 on human chromosome 2 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 190215226 on human chromosome 2 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 190215309 on human chromosome 2 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 190220632 on human chromosome 2 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 190222165 on human chromosome 2 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 190227029 on human chromosome 2 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 190227235 on human chromosome 2 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 190229743 on human chromosome 2 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 190237883 on human chromosome 2 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 190248653 on human chromosome 2 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 190249291 on human chromosome 2 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 190255683 on human chromosome 2 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 190257783 on human chromosome 2 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 200935729 on human chromosome 2 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 200938958 on human chromosome 2 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 200956630 on human chromosome 2 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 200961649 on human chromosome 2 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 200965467 on human chromosome 2 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 200966508 on human chromosome 2 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 200975546 on human chromosome 2 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 200985494 on human chromosome 2 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 201021108 on human chromosome 2 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 201037222 on human chromosome 2 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 201038297 on human chromosome 2 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 201039577 on human chromosome 2 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 201050143 on human chromosome 2 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 201065463 on human chromosome 2 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 201071056 on human chromosome 2 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 201072985 on human chromosome 2 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 201073286 on human chromosome 2 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 201079275 on human chromosome 2 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 201079462 on human chromosome 2 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 201393875 on human chromosome 2 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 201393939 on human chromosome 2 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 201394505 on human chromosome 2 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 15972853 on human chromosome 3 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 15979492 on human chromosome 3 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 15981630 on human chromosome 3 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 15984048 on human chromosome 3 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 15984372 on human chromosome 3 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 15984808 on human chromosome 3 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 15985719 on human chromosome 3 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 15986206 on human chromosome 3 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 15986712 on human chromosome 3 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 15987135 on human chromosome 3 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 15987195 on human chromosome 3 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 15989624 on human chromosome 3 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 15989740 on human chromosome 3 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 15989773 on human chromosome 3 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 15989863 on human chromosome 3 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 15992669 on human chromosome 3 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 15992909 on human chromosome 3 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; , when the base at position 16003374 on human chromosome 3 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 16003757 on human chromosome 3 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 16037627 on human chromosome 3 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 16041215 on human chromosome 3 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 16043358 on human chromosome 3 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 16045510 on human chromosome 3 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 25124423 on human chromosome 3 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 25124551 on human chromosome 3 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 25124975 on human chromosome 3 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 25139227 on human chromosome 3 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 25143644 on human chromosome 3 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 25146657 on human chromosome 3 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 25155292 on human chromosome 3 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 25157766 on human chromosome 3 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 25169305 on human chromosome 3 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 25182177 on human chromosome 3 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 25184366 on human chromosome 3 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 25188663 on human chromosome 3 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 25194200 on human chromosome 3 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 25205423 on human chromosome 3 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 25207827 on human chromosome 3 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 25211158 on human chromosome 3 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 25211837 on human chromosome 3 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 25235457 on human chromosome 3 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 25238040 on human chromosome 3 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 25239011 on human chromosome 3 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 25239845 on human chromosome 3 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 25243914 on human chromosome 3 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 25244762 on human chromosome 3 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 25244932 on human chromosome 3 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 25245547 on human chromosome 3 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 25250478 on human chromosome 3 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 25264520 on human chromosome 3 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 25265009 on human chromosome 3 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 25269521 on human chromosome 3 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 25273091 on human chromosome 3 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 25273425 on human chromosome 3 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 25274083 on human chromosome 3 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 25275052 on human chromosome 3 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 25277488 on human chromosome 3 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 25279386 on human chromosome 3 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 25280012 on human chromosome 3 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 25280571 on human chromosome 3 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 25283486 on human chromosome 3 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 25283965 on human chromosome 3 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 25284812 on human chromosome 3 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 25285067 on human chromosome 3 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 25287098 on human chromosome 3 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 25287161 on human chromosome 3 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 25288171 on human chromosome 3 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 25291318 on human chromosome 3 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 25291410 on human chromosome 3 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 25295964 on human chromosome 3 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 25300483 on human chromosome 3 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 32100486 on human chromosome 3 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 32103807 on human chromosome 3 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 32107036 on human chromosome 3 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 32107687 on human chromosome 3 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 32116971 on human chromosome 3 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 32123720 on human chromosome 3 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 32126831 on human chromosome 3 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 32127741 on human chromosome 3 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 32128616 on human chromosome 3 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 32129426 on human chromosome 3 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 32129512 on human chromosome 3 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 32130347 on human chromosome 3 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 32130743 on human chromosome 3 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 32131531 on human chromosome 3 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 32132631 on human chromosome 3 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 32132792 on human chromosome 3 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 32133557 on human chromosome 3 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 32134835 on human chromosome 3 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 32135918 on human chromosome 3 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 32139992 on human chromosome 3 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 32146121 on human chromosome 3 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 32161901 on human chromosome 3 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 32162884 on human chromosome 3 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 32162947 on human chromosome 3 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 32163010 on human chromosome 3 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 36532521 on human chromosome 3 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 36539606 on human chromosome 3 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 36542082 on human chromosome 3 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 36546788 on human chromosome 3 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 36556181 on human chromosome 3 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 36561276 on human chromosome 3 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 36561684 on human chromosome 3 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 36563172 on human chromosome 3 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 36563891 on human chromosome 3 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 36566407 on human chromosome 3 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 36566673 on human chromosome 3 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 36567042 on human chromosome 3 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 36567136 on human chromosome 3 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 36567376 on human chromosome 3 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 36567812 on human chromosome 3 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 36568926 on human chromosome 3 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 36571384 on human chromosome 3 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 36572905 on human chromosome 3 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 36575321 on human chromosome 3 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 36583646 on human chromosome 3 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 36588086 on human chromosome 3 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 36597648 on human chromosome 3 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 36598879 on human chromosome 3 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 36599138 on human chromosome 3 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 36599474 on human chromosome 3 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 36603785 on human chromosome 3 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 36609993 on human chromosome 3 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 36610151 on human chromosome 3 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 36611158 on human chromosome 3 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 36612106 on human chromosome 3 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 36618463 on human chromosome 3 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 36618485 on human chromosome 3 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 36622465 on human chromosome 3 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 36622754 on human chromosome 3 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 36623372 on human chromosome 3 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 36624146 on human chromosome 3 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 36625495 on human chromosome 3 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 36630641 on human chromosome 3 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 95535589 on human chromosome 3 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 95536563 on human chromosome 3 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 95537539 on human chromosome 3 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 95538497 on human chromosome 3 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 95541066 on human chromosome 3 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 95541356 on human chromosome 3 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 95542046 on human chromosome 3 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 95542127 on human chromosome 3 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 95548256 on human chromosome 3 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 95550760 on human chromosome 3 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 95556822 on human chromosome 3 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 95557275 on human chromosome 3 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 95558516 on human chromosome 3 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 95560239 on human chromosome 3 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 95561173 on human chromosome 3 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 95561492 on human chromosome 3 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 95561508 on human chromosome 3 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 95561574 on human chromosome 3 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 95562468 on human chromosome 3 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 95562542 on human chromosome 3 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 95562592 on human chromosome 3 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 95563503 on human chromosome 3 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 95565070 on human chromosome 3 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 95565527 on human chromosome 3 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 95565570 on human chromosome 3 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 95565633 on human chromosome 3 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 95566063 on human chromosome 3 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 95566678 on human chromosome 3 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 95566835 on human chromosome 3 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 95568434 on human chromosome 3 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 95569562 on human chromosome 3 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 95575150 on human chromosome 3 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 95576084 on human chromosome 3 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 95578194 on human chromosome 3 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 95579991 on human chromosome 3 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 95580731 on human chromosome 3 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 95581248 on human chromosome 3 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 95585252 on human chromosome 3 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 95594541 on human chromosome 3 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 95595165 on human chromosome 3 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 95595774 on human chromosome 3 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 95595981 on human chromosome 3 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 95596068 on human chromosome 3 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 95596238 on human chromosome 3 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 95597788 on human chromosome 3 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 95598005 on human chromosome 3 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 95598035 on human chromosome 3 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 95599070 on human chromosome 3 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 95599229 on human chromosome 3 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 95599466 on human chromosome 3 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 95600272 on human chromosome 3 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 95600700 on human chromosome 3 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 95601126 on human chromosome 3 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 95604167 on human chromosome 3 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 95609193 on human chromosome 3 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 95612334 on human chromosome 3 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 112901691 on human chromosome 3 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 112911217 on human chromosome 3 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 112911456 on human chromosome 3 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 112914281 on human chromosome 3 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 112914508 on human chromosome 3 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 112923379 on human chromosome 3 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 112929749 on human chromosome 3 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 112933794 on human chromosome 3 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 112934718 on human chromosome 3 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 112934733 on human chromosome 3 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 112936579 on human chromosome 3 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 112937535 on human chromosome 3 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 112944650 on human chromosome 3 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 112945600 on human chromosome 3 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 112946224 on human chromosome 3 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 112949845 on human chromosome 3 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 112950789 on human chromosome 3 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 112952064 on human chromosome 3 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 112953158 on human chromosome 3 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 112953907 on human chromosome 3 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 112960326 on human chromosome 3 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 112960464 on human chromosome 3 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 112961319 on human chromosome 3 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 112964465 on human chromosome 3 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 112964757 on human chromosome 3 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 112964847 on human chromosome 3 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 112966546 on human chromosome 3 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 112967692 on human chromosome 3 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 112968039 on human chromosome 3 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 112968240 on human chromosome 3 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 112970271 on human chromosome 3 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 112975773 on human chromosome 3 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 112977534 on human chromosome 3 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 112978250 on human chromosome 3 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 112979487 on human chromosome 3 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 112980486 on human chromosome 3 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 112983462 on human chromosome 3 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 112988303 on human chromosome 3 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 115100733 on human chromosome 3 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 115101297 on human chromosome 3 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 115109335 on human chromosome 3 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 115114470 on human chromosome 3 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 119908174 on human chromosome 3 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 119911858 on human chromosome 3 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 119913615 on human chromosome 3 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 119915026 on human chromosome 3 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 119915448 on human chromosome 3 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 119925257 on human chromosome 3 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 119928987 on human chromosome 3 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 119929073 on human chromosome 3 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 119931670 on human chromosome 3 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 119934191 on human chromosome 3 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 119943730 on human chromosome 3 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 119953482 on human chromosome 3 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 119953633 on human chromosome 3 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 119983099 on human chromosome 3 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 119992658 on human chromosome 3 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 119993533 on human chromosome 3 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 119993770 on human chromosome 3 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 119993980 on human chromosome 3 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 119996400 on human chromosome 3 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 120003493 on human chromosome 3 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 120003649 on human chromosome 3 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 135273298 on human chromosome 3 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 135277326 on human chromosome 3 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 135288644 on human chromosome 3 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 135288700 on human chromosome 3 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 135288916 on human chromosome 3 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 135289731 on human chromosome 3 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 135290724 on human chromosome 3 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 135292254 on human chromosome 3 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 135292422 on human chromosome 3 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 135296364 on human chromosome 3 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 135296455 on human chromosome 3 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 135296818 on human chromosome 3 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 135303500 on human chromosome 3 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 135305589 on human chromosome 3 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 135305973 on human chromosome 3 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 135306205 on human chromosome 3 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 135306463 on human chromosome 3 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 135306633 on human chromosome 3 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 135307476 on human chromosome 3 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 135307512 on human chromosome 3 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 135308026 on human chromosome 3 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 135312328 on human chromosome 3 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 135313451 on human chromosome 3 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 135315131 on human chromosome 3 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 135324810 on human chromosome 3 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 135334692 on human chromosome 3 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 135337322 on human chromosome 3 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 135339567 on human chromosome 3 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 135341358 on human chromosome 3 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 135346670 on human chromosome 3 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 135347977 on human chromosome 3 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 135349426 on human chromosome 3 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 135351177 on human chromosome 3 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 135352909 on human chromosome 3 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 135357264 on human chromosome 3 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 135357936 on human chromosome 3 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 135365759 on human chromosome 3 is T or is in strong disequilibrium linkage therewith, then said base exerts a incieased risk; when the base at position 135378819 on human chromosome 3 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 135379339 on human chromosome 3 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 135388075 on human chromosome 3 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 135388784 on human chromosome 3 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 135394123 on human chromosome 3 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 135402607 on human chromosome 3 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 135408504 on human chromosome 3 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 135410561 on human chromosome 3 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 135413833 on human chromosome 3 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 135417147 on human chromosome 3 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 135424018 on human chromosome 3 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 135425014 on human chromosome 3 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 135426703 on human chromosome 3 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 135427812 on human chromosome 3 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 135431040 on human chromosome 3 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 135439963 on human chromosome 3 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 135439977 on human chromosome 3 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 135473124 on human chromosome 3 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 135473446 on human chromosome 3 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 135475438 on human chromosome 3 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 150158710 on human chromosome 3 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 150160849 on human chromosome 3 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 150161057 on human chromosome 3 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 150161649 on human chromosome 3 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 150161751 on human chromosome 3 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 171012778 on human chromosome 3 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 171017968 on human chromosome 3 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 171019339 on human chromosome 3 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 171021314 on human chromosome 3 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 171023099 on human chromosome 3 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 171028354 on human chromosome 3 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 171035083 on human chromosome 3 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 171036200 on human chromosome 3 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 171036786 on human chromosome 3 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at pqsition 171036831 on human chromosome 3 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 171036966 on human chromosome 3 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 171040727 on human chromosome 3 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 171041075 on human chromosome 3 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 171041413 on human chromosome 3 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 171041523 on human chromosome 3 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 171041936 on human chromosome 3 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 171045499 on human chromosome 3 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 171046152 on human chromosome 3 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 171046225 on human chromosome 3 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 171048273 on human chromosome 3 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 171048792 on human chromosome 3 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 171048949 on human chromosome 3 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 171049943 on human chromosome 3 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 171050818 on human chromosome 3 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 171051194 on human chromosome 3 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 171051212 on human chromosome 3 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 171051372 on human chromosome 3 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 171052943 on human chromosome 3 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 171057167 on human chromosome 3 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 171062673 on human chromosome 3 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 171064925 on human chromosome 3 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 171076328 on human chromosome 3 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 171076812 on human chromosome 3 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 171078187 on human chromosome 3 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 171079610 on human chromosome 3 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 185023187 on human chromosome 3 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 185033825 on human chromosome 3 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 185037776 on human chromosome 3 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 185041104 on human chromosome 3 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 185044978 on human chromosome 3 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 185045230 on human chromcsome 3 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 185049644 on human chromosome 3 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 185050091 on human chromosome 3 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 185051283 on human chromosome 3 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 185052327 on human chromosome 3 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 185054365 on human chromosome 3 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 185059302 on human chromosome 3 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 185060606 on human chromosome 3 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 185063452 on human chromosome 3 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 185076469 on human chromosome 3 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; ' when the base at position 185080700 on human chromosome 3 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 185084200 on human chromosome 3 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 185090462 on human chromosome 3 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 185095158 on human chromosome 3 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 185098798 on human chromosome 3 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 185103116 on human chromosome 3 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 185103429 on human chromosome 3 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 185107149 on human chromosome 3 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 189623355 on human chromosome 3 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 189629883 on human chromosome 3 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 189629976 on human chromosome 3 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 189631928 on human chromosome 3 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 189632288 on human chromosome 3 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 189633762 on human chromosome 3 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 189635008 on human chromosome 3 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 189639419 on human chromosome 3 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 189644408 on human chromosome 3 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 189648322 on human chromosome 3 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 189651406 on human chromosome 3 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 189651573 on human chromosome 3 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 17011296 on human chromosome 4 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 17011857 on human chromosome 4 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 17012061 on human chromosome 4 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 17012868 on human chromosome 4 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 17013194 on human chromosome 4 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 17020761 on human chromosome 4 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 17028536 on human chromosome 4 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 17029094 on human chromosome 4 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 17031066 on human chromosome 4 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 17032854 on human chromosome 4 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 17036401 on human chromosome 4 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 17036875 on human chromosome 4 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 17037383 on human chromosome 4 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 17038178 on human chromosome 4 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 17038456 on human chromosome 4 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 17040989 on human chromosome 4 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 17041183 on human chromosome 4 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 17042057 on human chromosome 4 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 17049030 on human chromosome 4 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 17051325 on human chromosome 4 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 17056406 on human chromosome 4 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 17057986 on human chromosome 4 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 17058442 on human chromosome 4 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 84499813 on human chromosome 4 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 84500768 on human chromosome 4 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 84500972 on human chromosome 4 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 84501804 on human chromosome 4 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 84503554 on human chromosome 4 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 84508606 on human chromosome 4 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 84510152 on human chromosome 4 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 84511612 on human chromosome 4 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 84519523 on human chromosome 4 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 84519694 on human chromosome 4 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 84525763 on human chromosome 4 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 84525832 on human chromosome 4 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 84527258 on human chromosome 4 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 84527315 on human chromosome 4 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 84528586 on human chromosome 4 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 84529026 on human chromosome 4 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 84529399 on human chromosome 4 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 84529437 on human chromosome 4 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 84529578 on human chromosome 4 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 84530283 on human chromosome 4 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 84530423 on human chromosome 4 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 84531290 on human chromosome 4 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 84534358 on human chromosome 4 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 84536250 on human chromosome 4 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 84536659 on human chromosome 4 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 84536797 on human chromosome 4 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 84536876 on human chromosome 4 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 84539894 on human chromosome 4 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 84541948 on human chromosome 4 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 84547048 on human chromosome 4 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 84547093 on human chromosome 4 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 84548210 on human chromosome 4 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 84549347 on human chromosome 4 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 84570798 on human chromosome 4 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 84574120 on human chromosome 4 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 84578598 on human chromosome 4 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 96577385 on human chromosome 4 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 96582377 on human chromosome 4 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 96583132 on human chromosome 4 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 96584178 on human chromosome 4 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 96592699 on human chromosome 4 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 96599702 on human chromosome 4 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 96651424 on human chromosome 4 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 99799667 on human chromosome 4 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 99801210 on human chromosome 4 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 99801320 on human chromosome 4 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 99803666 on human chromosome 4 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 99807848 on human chromosome 4 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 99807964 on human chromosome 4 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 99809387 on human chromosome 4 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 99814723 on human chromosome 4 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 99816706 on human chromosome 4 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 99819712 on human chromosome 4 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 99821167 on human chromosome 4 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 99823508 on human chromosome 4 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 99823684 on human chromosome 4 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 99825745 on human chromosome 4 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 99833465 on human chromosome 4 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 99833656 on human chromosome 4 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 99833736 on human chromosome 4 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 99834522 on human chromosome 4 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 99834590 on human chromosome 4 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 99835934 on human chromosome 4 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 99836081 on human chromosome 4 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 99836862 on human chromosome 4 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 99837966 on human chromosome 4 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 99839510 on human chromosome 4 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 99840416 on human chromosome 4 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 99844135 on human chromosome 4 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 99845490 on human chromosome 4 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 99845547 on human chromosome 4 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 99846346 on human chromosome 4 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 99847490 on human chromosome 4 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 99848365 on human chromosome 4 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 99851756 on human chromosome 4 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 99854723 on human chromosome 4 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 99855858 on human chromosome 4 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 99861413 on human chromosome 4 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 99861813 on human chromosome 4 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 99866311 on human chromosome 4 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 99867457 on human chromosome 4 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 99878073 on human chromosome 4 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 99884270 on human chromosome 4 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 126362489 on human chromosome 4 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 126379394 on human chromosome 4 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 126396940 on human chromosome 4 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 126407660 on human chromosome 4 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 126416826 on human chromosome 4 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 126418374 on human chromosome 4 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 126430383 on human chromosome 4 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 126487544 on human chromosome 4 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 126490716 on human chromosome 4 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 126493527 on human chromosome 4 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 126495757 on human chromosome 4 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 136880552 on human chromosome 4 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 136881968 on human chromosome 4 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 136883623 on human chromosome 4 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 136885451 on human chromosome 4 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 136886076 on human chromosome 4 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 136889055 on human chromosome 4 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 136889443 on human chromosome 4 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 136890103 on human chromosome 4 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 136890876 on human chromosome 4 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 136893449 on human chromosome 4 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 136897722 on human chromosome 4 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 136900288 on human chromosome 4 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 136900741 on human chromosome 4 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 136901146 on human chromosome 4 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 136902550 on human chromosome 4 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 141738039 on human chromosome 4 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 141743060 on human chromosome 4 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 141757671 on human chromosome 4 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 141759797 on human chromosome 4 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 141760063 on human chromosome 4 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 141761604 on human chromosome 4 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 141761653 on human chromosome 4 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 141762517 on human chromosome 4 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 141766929 on h^man chromosome 4 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 141767297 on human chromosome 4 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 141767342 on human chromosome 4 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 141767856 on human chromosome 4 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 141769735 on human chromosome 4 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 141775917 on human chromosome 4 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 141776879 on human chromosome 4 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 141818775 on human chromosome 4 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 141826174 on human chromosome 4 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 141849181 on human chromosome 4 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 174180260 on human chromosome 4 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 174197301 on human chromosome 4 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 174197751 on human chromosome 4 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 174198513 on human chromosome 4 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 174199345 on human chromosome 4 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 174216579 on human chromosome 4 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 174218180 on human chromosome 4 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 174223753 on human chromosome 4 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 174224227 on human chromosome 4 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 174225158 on human chromosome 4 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 174232525 on human chromosome 4 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 174234640 on human chromosome 4 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 174238245 on human chromosome 4 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 174239858 on human chromosome 4 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 174243021 on human chromosome 4 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 33068424 on human chromosome 5 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 33073250 on human chromosome 5 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 33074880 on human chromosome 5 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 33075144 on human chromosome 5 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 33079303 on human chromosome 5 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 33079972 on human chromosome 5 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 33085376 on human chromosome 5 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 33085473 on human chromosome 5 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 33085951 on human chromosome 5 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 33086064 on human chromosome 5 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 33087719 on human chromosome 5 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 33088172 on human chromosome 5 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 33088550 on human chromosome 5 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 33089676 on human chromosome 5 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 33089910 on human chromosome 5 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 33091405 on human chromosome 5 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 33091437 on human chromosome 5 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 33091499 on human chromosome 5 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 33114163 on human chromosome 5 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 33115099 on human chromosome 5 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 33115311 on human chromosome 5 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 33117602 on human chromosome 5 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 33118498 on human chromosome 5 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 33121271 on human chromosome 5 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 33122149 on human chromosome 5 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 33142786 on human chromosome 5 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 33155568 on human chromosome 5 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 33155668 on human chromosome 5 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 33174152 on human chromosome 5 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 33180167 on human chromosome 5 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 33189004 on human chromosome 5 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 33204171 on human chromosome 5 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 33205864 on human chromosome 5 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 33212781 on human chromosome 5 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 33213163 on human chromosome 5 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 33214982 on human chromosome 5 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 33226224 on human chromosome 5 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 33226311 on human chromosome 5 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 33230214 on human chromosome 5 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 34794058 on human chromosome 5 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 34797450 on human chromosome 5 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 34807222 on human chromosome 5 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 53410335 on human chromosome 5 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 53410896 on human chromosome 5 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 53415059 on human chromosome 5 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 53418196 on human chromosome 5 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 53420578 on human chromosome 5 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 53646736 on human chromosome 5 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 53648433 on human chromosome 5 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 53650336 on human chromosome 5 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 53652843 on human chromosome 5 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 53655784 on human chromosome 5 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 53656359 on human chromosome 5 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 53663936 on human chromosome 5 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 53665145 on human chromosome 5 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 53665388 on human chromosome 5 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 53667813 on human chromosome 5 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 53667954 on human chromosome 5 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 53672705 on human chromosome 5 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 53672811 on human chromosome 5 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 53674961 on human chromosome 5 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 53675669 on human chromosome 5 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 53675732 on human chromosome 5 is T or is in strong disequilibrium linkage therewith, then said base exeits a increased risk; when the base at position 53676101 on human chromosome 5 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 53676619 on human chromosome 5 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 53676736 on human chromosome 5 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; • when the base at position 53677045 on human chromosome 5 is G or is in strong disequilibrium linkage therewith, then said base exeits a increased risk; when the base at position 53677338 on human chromosome 5 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 53678841 on human chromosome 5 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 53679109 on human chromosome 5 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 53680093 on human chromosome 5 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 53681052 on human chromosome 5 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 53683397 on human chromosome 5 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 53690381 on human chromosome 5 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 53695238 on human chromosome 5 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 53695715 on human chromosome 5 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 53707299 on human chromosome 5 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 88021051 on human chromosome 5 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 88028332 on human chromosome 5 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 88028954 on human chromosome 5 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 88031926 on human chromosome 5 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 88037725 on human chromosome 5 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 88039159 on human chromosome 5 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 88039857 on human chromosome 5 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 88040372 on human chromosome 5 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 88042649 on human chromosome 5 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 88046895 on human chromosome 5 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 88051301 on human chromosome 5 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 88055503 on human chromosome 5 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 88056075 on human chromosome 5 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 88057283 on human chromosome 5 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 88062626 on human chromosome 5 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 88062658 on human chromosome 5 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 88062905 on human chromosome 5 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 88066426 on human chromosome 5 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 88074146 on human chromosome 5 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 88074601 on human chromosome 5 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 88078052 on human chromosome 5 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 88079412 on human chromosome 5 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 88082346 on human chromosome 5 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 88083755 on human chromosome 5 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 88083827 on human chromosome 5 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 88084213 on human chromosome 5 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 88084523 on human chromosome 5 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 88090048 on human chromosome 5 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 88090519 on human chromosome 5 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 88091517 on human chromosome 5 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 88099768 on human chromosome 5 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 88144330 on human chromosome 5 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 88146094 on human chromosome 5 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 88150232 oh human chromosome 5 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 88154614 on human chromosome 5 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 88156944 on human chromosome 5 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 88170066 on human chromosome 5 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 88171218 on human chromosome 5 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 88173798 on human chromosome 5 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 88179782 on human chromosome 5 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 94538098 on human chromosome 5 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 94550044 on human chromosome 5 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 94552156 on human chromosome 5 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 94553824 on human chromosome 5 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 94557181 on human chromosome 5 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 94558969 on human chromosome 5 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 94560801 on human chromosome 5 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 94567006 on human chromosome 5 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 94570526 on human chromosome 5 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 94576732 on human chromosome 5 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 94576925 on human chromosome 5 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 94577064 on human chromosome 5 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 94584565 on human chromosome 5 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 94587700 on human chromosome 5 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 94588747 on human chromosome 5 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 94596642 on human chromosome 5 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 94597032 on human chromosome 5 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 94599413 on human chromosome 5 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 94600202 on human chromosome 5 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 94600278 on human chromosome 5 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 94602702 on human chromosome 5 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 94605148 on human chromosome 5 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 94606353 on human chromosome 5 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 94611677 on human chromosome 5 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 94612551 on human chromosome 5 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 94613368 on human chromosome 5 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 94614685 on human chromosome 5 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 94618904 on human chromosome 5 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 94618955 on human chromosome 5 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 94619294 on human chromosome 5 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 94622424 on human chromosome 5 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 94623398 on human chromosome 5 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 94626513 on human chromosome 5 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 94628342 on human chromosome 5 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 94629140 on human chromosome 5 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 94629619 on human chromosome 5 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 94629816 on human chromosome 5 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 94631128 on human chromosome 5 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 94631232 on human chromosome 5 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 94631493 on human chromosome 5 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 94632003 on human chromosome 5 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 94632116 on human chromosome 5 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 94632425 on human chromosome 5 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 94632936 on human chromosome 5 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 94633120 on human chromosome 5 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 94633445 on human chromosome 5 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 94634399 on human chromosome 5 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 94634443 on human chromosome 5 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 94634456 on human chromosome 5 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 94634684 on human chromosome 5 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 94635668 on human chromosome 5 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 94636517 on human chromosome 5 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 94636785 on human chromosome 5 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 94641576 on human chromosome 5 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 94649002 on human chromosome 5 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 94649379 on human chromosome 5 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 94651147 on human chromosome 5 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 94651360 on human chromosome 5 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 94657922 on human chromosome 5 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 94659495 on human chromosome 5 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 94659853 on human chromosome 5 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 94660088 on human chromosome 5 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 94660336 on human chromosome 5 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 94662854 on human chromosome 5 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 94663216 on human chromosome 5 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 94663373 on human chromosome 5 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 94663538 on human chromosome 5 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 94663672 on human chromosome 5 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 94664367 on human chromosome 5 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 94665060 on human chromosome 5 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 94666072 on human chromosome 5 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 94666129 on human chromosome 5 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 94666213 on human chromosome 5 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 94666924 on human chromosome 5 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 94667001 on human chromosome 5 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 94668029 on human chromosome 5 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 94668309 on human chromosome 5 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 94670433 on human chromosome 5 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 94671181 on human chromosome 5 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 94671416 on human chromosome 5 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 94672434 on human chromosome 5 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 94672474 on human chromosome 5 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 94672558 on human chromosome 5 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 94672606 on human chromosome 5 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 94673344 on human chromosome 5 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 94675660 on human chromosome 5 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 94676060 on human chromosome 5 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 94676295 on human chromosome 5 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 94676914 on human chromosome 5 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 94677635 on human chromosome 5 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 94678233 on human chromosome 5 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 94678458 on human chromosome 5 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 94678505 on human chromosome 5 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 94678894 on human chromosome 5 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 94679052 on human chromosome 5 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 94679562 on human chromosome 5 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 94679943 on human chromosome 5 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 94680414 on human chromosome 5 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 94680899 on human chromosome 5 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 94681136 on human chromosome 5 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 94681313 on human chromosome 5 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 94681983 on human chromosome 5 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 94685578 on human chromosome 5 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 94705236 on human chromosome 5 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 94712319 on human chromosome 5 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 94713792 on human chromosome 5 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 94715934 on human chromosome 5 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 94719045 on human chromosome 5 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 94724163 on human chromosome 5 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 94724943 on human chromosome 5 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 94733999 on human chromosome 5 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 94734306 on human chromosome 5 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 94740898 on human chromosome 5 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 94745024 on human chromosome 5 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 94745037 on human chromosome 5 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 94746001 on human chromosome 5 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 94750979 on human chromosome 5 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 94753834 on human chromosome 5 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 94756096 on human chromosome 5 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 98670568 on human chromosome 5 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 98672074 on human chromosome 5 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 98672967 on human chromosome 5 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 98696360 on human chromosome 5 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 98699369 on human chromosome 5 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 98702111 on human chromosome 5 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 98702589 on human chromosome 5 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 98709592 on human chromosome 5 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 98716622 on human chromosome 5 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 98721832 on human chromosome 5 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 98723571 on human chromosome 5 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 98728423 on human chromosome 5 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 98729312 on human chromosome 5 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 98738383 on human chromosome 5 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 98749771 on human chromosome 5 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 98752890 on human chromosome 5 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 98754788 on human chromosome 5 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 98763319 on human chromosome 5 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 98770275 on human chromosome 5 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 98771905 on human chromosome 5 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 98952846 on human chromosome 5 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 98953245 on human chromosome 5 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 98953580 on human chromosome 5 is C or is in strong . disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 98958585 on human chromosome 5 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 98958615 on human chromosome 5 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 98960421 on human chromosome 5 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 98965980 on human chromosome 5 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 98970968 on human chromosome 5 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 98971488 on human chromosome 5 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 100010191 on human chromosome 5 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 100010673 on human chromosome 5 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 100013867 on human chromosome 5 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 100014436 on human chromosome 5 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 100016776 on human chromosome 5 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 100017865 on human chromosome 5 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 100018294 on human chromosome 5 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 100020010 on human chromosome 5 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 100020379 on human chromosome 5 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 100021853 on human chromosome 5 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 100025750 on human chromosome 5 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 100027357 on human chromosome 5 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 100028226 on human chromosome 5 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 100029865 on human chromosome 5 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 100030250 on human chromosome 5 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 100033114 on human chromosome 5 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 100033220 on human chromosome 5 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 100034262 on human chromosome 5 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 100043746 on human chromosome 5 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 100047287 on human chromosome 5 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 100048359 on human chromosome 5 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 100050177 on human chromosome 5 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 100053551 on human chromosome 5 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 100053597 on human chromosome 5 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 100055142 on human chromosome 5 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 100056049 on human chromosome 5 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 100057119 on human chromosome 5 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 100057973 on human chromosome 5 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 100058783 on human chromosome 5 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 100059543 on human chromosome 5 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 100060234 on human chromosome 5 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 100060833 on human chromosome 5 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 100073261 on human chromosome 5 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 100073357 on human chromosome 5 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 100073717 on human chromosome 5 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 100074002 on human chromosome 5 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 100080943 on human chromosome 5 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 100088049 on human chromosome 5 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 100088312 on human chromosome 5 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 100090637 on human chromosome 5 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 100095967 on human chromosome 5 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 100099693 on human chromosome 5 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 100111425 on human chromosome 5 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 106697845 on human chromosome 5 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 106753230 on human chromosome 5 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 106757891 on human chromosome 5 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 106765747 on human chromosome 5 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 106765944 on human chromosome 5 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 106766858 on human chromosome 5 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 106773421 on human chromosome 5 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 106777589 on human chromosome 5 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 106780213 on human chromosome 5 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 106782654 on human chromosome 5 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 106786583 on human chromosome 5 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 106790074 on human chromosome 5 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 106791596 on human chromosome 5 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 106792191 on human chromosome 5 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 106793738 on human chromosome 5 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 113500176 on human chromosome 5 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 113502800 on human chromosome 5 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 113506634 on human chromosome 5 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 113511198 on human chromosome 5 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 113511406 on human chromosome 5 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 113511998 on human chromosome 5 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 113512057 on human chromosome 5 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 113512451 on human chromosome 5 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 113514918 on human chromosome 5 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 113515203 on human chromosome 5 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 113516744 on human chromosome 5 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 113526961 on human chromosome 5 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 113527088 on human chromosome 5 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 113528435 on human chromosome 5 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 113528450 on human chromosome 5 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 113528466 on human chromosome 5 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 113531301 on human chromosome 5 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 113531506 on human chromosome 5 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 113535625 on human chromosome 5 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 113541152 on human chromosome 5 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 113550101 on human chromosome 5 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 113550750 on human chromosome 5 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 113553376 on human chromosome 5 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 113566741 on human chromosome 5 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 113570824 on human chromosome 5 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 113572234 on human chromosome 5 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 113581019 on human chromosome 5 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 113582603 on human chromosome 5 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 113583525 on human chromosome 5 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 113584197 on human chromosome 5 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 113585159 on human chromosome 5 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 113585933 on human chromosome 5 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 113586234 on human chromosome 5 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 113586796 on human chromosome 5 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 113587246 on human chromosome 5 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 113589665 on human chromosome 5 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 113590586 on human chromosome 5 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 113591021 on human chromosome 5 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 113591649 on human chromosome 5 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 113591904 on human chromosome 5 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 113592887 on human chromosome 5 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 113595823 on human chromosome 5 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 113596126 on human chromosome 5 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 113597745 on human chromosome 5 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 113598192 on human chromosome 5 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 113601411 on human chromosome 5 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 113602505 on human chromosome 5 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 113604903 on human chromosome 5 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 113606206 on human chromosome 5 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 113606361 on human chromosome 5 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 113611679 on human chromosome 5 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 113611816 on human chromosome 5 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 113612491 on human chromosome 5 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 113612556 on human chromosome 5 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 113614669 on human chromosome 5 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 113617288 on human chromosome 5 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 113618525 on human chromosome 5 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 113623513 on human chromosome 5 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 113623601 on human chromosome 5 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 113624557 on human chromosome 5 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 113624918 on human chromosome 5 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 113625176 on human chromosome 5 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 113626407 on human chromosome 5 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 113626740 on human chromosome 5 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 113626945 on human chromosome 5 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 113627153 on human chromosome 5 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 113627251 on human chromosome 5 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 113627646 on human chromosome 5 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 113628416 on human chromosome 5 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 113630061 on human chromosome 5 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 113631575 on human chromosome 5 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 113631667 on human chromosome 5 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 114713355 on human chromosome 5 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 114713440 on human chromosome 5 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 114713519 on human chromosome 5 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 114718052 on human chromosome 5 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 114718222 on human chromosome 5 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 114718659 on human chromosome 5 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 114719100 on human chromosome 5 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 114719186 on human chromosome 5 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 114724952 on human chromosome 5 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 114727927 on human chromosome 5 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 114728598 on human chromosome 5 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 114729838 on human chromosome 5 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 114731087 on human chromosome 5 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 114736973 on human chromosome 5 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 114737036 on human chromosome 5 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 114737437 on human chromosome 5 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 114738244 on human chromosome 5 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 114739954 on human chromosome 5 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 114742587 on human chromosome 5 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 114742608 on human chromosome 5 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 114742827 on human chromosome 5 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 114743461 on human chromosome 5 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 114743518 on human chromosome 5 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 114743558 on human chromosome 5 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 114743695 on human chromosome 5 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 114743979 on human chromosome 5 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 114743998 on human chromosome 5 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 114744008 on human chromosome 5 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 114744237 on human chromosome 5 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 114744809 on human chromosome 5 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 114745180 on human chromosome 5 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 114745943 on human chromosome 5 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 114752244 on human chromosome 5 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 114773293 on human chromosome 5 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 128919467 on human chromosome 5 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 128922333 on human chromosome 5 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 128985111 on human chromosome 5 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 128987981 on human chromosome 5 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 128988214 on human chromosome 5 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 128989963 on human chromosome 5 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 129005875 on human chromosome 5 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 129005908 on human chromosome 5 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 129008002 on human chromosome 5 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 129010670 on human chromosome 5 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 129027429 on human chromosome 5 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 129031240 on human chromosome 5 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 129031881 on human chromosome 5 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 129050355 on human chromosome 5 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 129072554 on human chromosome 5 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 129075353 on human chromosome 5 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 129075899 on human chromosome 5 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 145263992 on human chromosome 5 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 145265351 on human chromosome 5 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 145265645 on human chromosome 5 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 145266116 on human chromosome 5 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 145266325 on human chromosome 5 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 145272216 on iwαan chromosome 5 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 145274560 on human chromosome 5 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 145280161 on human chromosome 5 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 145285959 on human chromosome 5 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 153338419 on human chromosome 5 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 153340423 on human chromosome 5 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 153343527 on human chromosome 5 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 153345557 on human chromosome 5 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 153345621 on human chromosome 5 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 153346796 on human chromosome 5 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 153346998 on human chromosome 5 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 153347489 on human chromosome 5 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 153348358 on human chromosome 5 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 153350759 on human chromosome 5 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 153351656 on human chromosome 5 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 153352718 on human chromosome 5 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 153353811 on human chromosome 5 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 153356765 on human chromosome 5 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 153357791 on human chromosome 5 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 153365426 on human chromosome 5 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 153369105 on human chromosome 5 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 153369974 on human chromosome 5 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 153370547 on human chromosome 5 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 153370609 on human chromosome 5 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 153371902 on human chromosome 5 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 153385278 on human chromosome 5 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 153385607 on human chromosome 5 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 153385847 on human chromosome 5 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 153386769 on human chromosome 5 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 153386837 on human chromosome 5 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 153387180 on human chromosome 5 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 153387590 on human chromosome 5 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 153390413 on human chromosome 5 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 153391127 on human chromosome 5 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 153392378 on human chromosome 5 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 153392722 on human chromosome 5 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 153393038 on human chromosome 5 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 153393583 on human chromosome 5 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 153395675 on human chromosome 5 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 153395890 on human chromosome 5 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 153396325 on human chromosome 5 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 153396559 on human chromosome 5 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 153397914 on human chromosome 5 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 153399535 on human chromosome 5 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 153400001 on human chromosome 5 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 153400926 on human chromosome 5 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 153402128 on human chromosome 5 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 153403791 on human chromosome 5 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 153405274 on human chromosome 5 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 153405394 on human chromosome 5 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 153406146 on human chromosome 5 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 153407489 on human chromosome 5 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 153409362 on human chromosome 5 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 153409380 on human chromosome 5 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 153410180 on human chromosome 5 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 153411651 on human chromosome 5 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 153411662 on human chromosome 5 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 153412323 on human chromosome 5 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 153413163 on human chromosome 5 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 153414600 on human chromosome 5 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 153414636 on human chromosome 5 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 153415931 on human chromosome 5 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 153419001 on human chromosome 5 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 153419234 on human chromosome 5 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 153425143 on human chromosome 5 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 153426527 on human chromosome 5 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 153427018 on human chromosome 5 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 153430830 on human chromosome 5 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 153431481 on human chromosome 5 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 153432195 on human chromosome 5 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 153434373 on human chromosome 5 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 153435197 on human chromosome 5 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 153436129 on human chromosome 5 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 153436445 on human chromosome 5 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 153436517 on human chromosome 5 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 153437000 on human chromosome 5 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 153437979 on human chromosome 5 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 153438869 on human chromosome 5 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 153439598 on human chromosome 5 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 153440236 on human chromosome 5 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 153441242 on human chromosome 5 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 153442726 on human chromosome 5 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 153442901 on human chromosome 5 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 153444620 on human chromosome 5 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 153445645 on human chromosome 5 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 153446433 on human chromosome 5 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 153448388 on human chromosome 5 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 153449213 on human chromosome 5 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 153451930 on human chromosome 5 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 153452902 on human chromosome 5 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 153452947 on human chromosome 5 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 153453656 on human chromosome 5 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 153453887 on human chromosome 5 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 153456852 on human chromosome 5 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 153457015 on human chromosome 5 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 153458370 on human chromosome 5 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 153462976 on human chromosome 5 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 153464693 on human chromosome 5 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 153464854 on human chromosome 5 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 153466019 on human chromosome 5 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 153470369 on human chromosome 5 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 153470551 on human chromosome 5 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 153470971 on human chromosome 5 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 153472870 on human chromosome 5 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 153474121 on human chromosome 5 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 155746109 on human chromosome 5 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 155751856 on human chromosome 5 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 155752850 on human chromosome 5 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 155755167 on human chromosome 5 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 155759118 on human chromosome 5 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 155767497 on human chromosome 5 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 155767700 on human chromosome 5 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 155769361 on human chromosome 5 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 155769420 on human chromosome 5 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 155794803 on human chromosome 5 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 155811196 on human chromosome 5 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 172414424 on human chromosome 5 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 172419724 on human chromosome 5 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 172425055 on human chromosome 5 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 172433181 on human chromosome 5 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 172434579 on human chromosome 5 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 172434592 on human chromosome 5 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 172436070 on human chromosome 5 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 172443943 on human chromosome 5 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 172448249 on human chromosome 5 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 172463083 on human chromosome 5 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 172463167 on human chromosome 5 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 172467286 on human chromosome 5 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 172476423 on human chromosome 5 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 172481315 on human chromosome 5 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 172490802 on human chromosome 5 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 172510009 on human chromosome 5 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 172513472 on human chromosome 5 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 3421102 on human chromosome 6 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 3422474 on human chromosome 6 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 3426661 on human chromosome 6 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 3427976 on human chromosome 6 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 3428061 on human chromosome 6 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 3428441 on human chromosome 6 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 3428863 on human chromosome 6 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 3432929 on human chromosome 6 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 3433624 on human chromosome 6 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 3433664 on human chromosome 6 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 3435785 on human chromosome 6 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 3437612 on human chromosome 6 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 3438187 on human chromosome 6 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 3439001 on human chromosome 6 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 3439774 on human chromosome 6 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 3440198 on human chromosome 6 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 8930286 on human chromosome 6 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 8932904 on human chromosome 6 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 8934563 on human chromosome 6 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 8935206 on human chromosome 6 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 8936885 on human chromosome 6 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 8939853 on human chromosome 6 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 10955923 on human chromosome 6 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 10965632 on human chromosome 6 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 10971311 on human chromosome 6 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 10973858 on human chromosome 6 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 10985853 on human chromosome 6 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 10987982 on human chromosome 6 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 10994571 on human chromosome 6 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 12512974 on human chromosome 6 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 12513387 on human chromosome 6 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 12514506 on human chromosome 6 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 12517609 on human chromosome 6 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 12517893 on human chromosome 6 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 12519141 on human chromosome 6 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 12520304 on human chromosome 6 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 12522290 on human chromosome 6 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 12525249 on human chromosome 6 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 12532953 on human chromosome 6 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 20091192 on human chromosome 6 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 20095790 on human chromosome 6 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 20096424 on human chromosome 6 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 20096632 on human chromosome 6 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 20100741 on human chromosome 6 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 20103710 on human chromosome 6 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 20104787 on human chromosome 6 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 20107101 on human chromosome 6 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 20107989 on human chromosome 6 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 20109678 on human chromosome 6 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 20109906 on human chromosome 6 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 20110042 on human chromosome 6 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 20111136 on human chromosome 6 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 20111283 on human chromosome 6 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 20111445 on human chromosome 6 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 23519068 on human chromosome 6 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 23520173 on human chromosome 6 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 23521765 on human chromosome 6 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 23521908 on human chromosome 6 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 23524354 on human chromosome 6 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 23528304 on human chromosome 6 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 23528945 on human chromosome 6 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 23529348 on human chromosome 6 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 23531094 on human chromosome 6 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 23531190 on human chromosome 6 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 23533945 on human chromosome 6 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 23544837 on human chromosome 6 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 23545252 on human chromosome 6 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 39396865 on human chromosome 6 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 39397142 on human chromosome 6 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 39397439 on human chromosome 6 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 39397492 on human chromosome 6 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 39397628 on human chromosome 6 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 39397853 on human chromosome 6 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 39398178 on human chromosome 6 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 39398631 on human chromosome 6 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 39399085 on human chromosome 6 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 39399130 on human chromosome 6 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 39399396 on human chromosome 6 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 39399587 on human chromosome 6 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 39399731 on human chromosome 6 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 39399785 on human chromosome 6 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 50369349 on human chromosome 6 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 50369837 on human chromosome 6 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 50370105 on human chromosome 6 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 50371633 on human chromosome 6 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 50371644 on human chromosome 6 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 50372103 on human chromosome 6 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 50374024 on human chromosome 6 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 50374995 on human chromosome 6 ;s C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 50375792 on human chromosome 6 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 50376777 on human chromosome 6 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 50377121 on human chromosome 6 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 50379554 on human chromosome 6 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 50383265 on human chromosome 6 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 50385551 on human chromosome 6 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 50385874 on human chromosome 6 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 50387443 on human chromosome 6 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 50402079 on human chromosome 6 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 50402402 on human chromosome 6 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 82950808 on human chromosome 6 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 83037702 on human chromosome 6 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 83052756 on human chromosome 6 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 83052893 on human chromosome 6 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 83059529 on human chromosome 6 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 83059811 on human chromosome 6 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 83063355 on human chromosome 6 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 83065585 on human chromosome 6 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 83065715 on human chromosome 6 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 83066965 on human chromosome 6 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 83079412 on human chromosome 6 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 83086171 on human chromosome 6 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 83086772 on human chromosome 6 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 83087733 on human chromosome 6 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 83088471 on human chromosome 6 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 83089659 on human chromosome 6 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 83092525 on human chromosome 6 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 83092537 on human chromosome 6 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 83094274 on human chromosome 6 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 83094499 on human chromosome 6 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 83094576 on human chromosome 6 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 83095347 on human chromosome 6 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 83095565 on human chromosome 6 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk;

- 54] - when the base at position 83095939 on human chromosome 6 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 83096974 on human chromosome 6 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 83097004 on human chromosome 6 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 83097222 on human chromosome 6 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 83098262 on human chromosome 6 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 83098329 on human chromosome 6 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 83098352 on human chromosome 6 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 83100260 on human chromosome 6 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 83101000 on human chromosome 6 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 83103870 on human chromosome 6 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 83104741 on human chromosome 6 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 83105428 on human chromosome 6 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 83113039 on human chromosome 6 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 83114887 on human chromosome 6 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 83120523 on human chromosome 6 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 83122607 on human chromosome 6 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 83126442 on human chromosome 6 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 83127291 on human chromosome 6 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 83129590 on human chromosome 6 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 83131084 on human chromosome 6 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 83137358 on human chromosome 6 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 83140060 on human chromosome 6 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 83144954 on human chromosome 6 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 83146375 on human chromosome 6 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 83147795 on human chromosome 6 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 83150543 on human chromosome 6 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 83150571 on human chromosome 6 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 83153296 on human chromosome 6 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 83155501 on human chromosome 6 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 83162032 on human chromosome 6 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 83163350 on human chromosome 6 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 83165082 on human chromosome 6 is T or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 83165771 on human chromosome 6 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 83166290 on human chromosome 6 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 83167427 on human chromosome 6 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 83167802 on human chromosome 6 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 83168404 on human chromosome 6 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 83169083 on human chromosome 6 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 83169297 on human chromosome 6 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 83169493 on human chromosome 6 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 83170215 on human chromosome 6 is C or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 83170490 on human chromosome 6 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 83170598 on human chromosome 6 is G or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 83172329 on human chromosome 6 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 93549999 on human chromosome 6 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 93550988 on human chromosome 6 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at position 93574060 on human chromosome 6 is A or is in strong disequilibrium linkage therewith, then said base exerts a increased risk; when the base at